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Abstract 
The fibroblast growth factor (FGF) signalling pathway contributes to the regulation 
of a variety of cellular functions, affecting differentiation, migration, proliferation, 
and survival. Unsurprisingly, cancer cells can hijack this pathway for growth or 
survival advantages, through alterations in ligands, receptors or regulatory 
molecules. Sequencing consortia have highlighted how mutation, amplification, 
translocation or loss of elements in the FGF signalling network can contribute to 
tumourigenesis, and the pathway is a major clinical target. Many FGF receptor 
(FGFR) driven cancers develop resistance against commonly used receptor tyrosine 
kinase (RTK) targeted therapeutics and dissection of the mechanisms that underlie 
this, both in the cancer cell, and also via stromal crosstalk in the tumour 
microenvironment, is of utmost importance to the development of therapeutic 
approaches to treat FGFR-driven cancers. In this work, I focus on the mechanisms of 
FGF deregulation and the impact of stromal cells. I aim to identify the implications of 
FGFR2 aberrations on gastric and endometrial cancer, and FGFR1 aberrations on lung 
cancer. Furthermore, I aim to dissect the mechanisms by which targeted cells may 
develop drug resistance both in two-dimensional (2D) and in a more physiomimetic 
three-dimensional (3D) co-culture model. 
It was established that cancer cells with FGFR aberrations were sensitive towards 
FGFR inhibitors such as PD173074 (PD), AZD4547 (AZD) and BGJ398 (BGJ). Cancer 
cells could be killed with increasing concentration of these drugs and exhibited 
sensitivity to FGFR inhibitors by decreased p-AKT and p-ERK signalling. However, 
with prolonged exposure to FGFR inhibition, certain cells began to acquire resistance 
in 2D. To study drug resistance in a more physiomimetic environment, cells were 
grown alone or co-cultured with fibroblasts and treated with FGFR inhibitors PD, 
AZD or BGJ and imaged using fluorescent live cell imaging. These cultures were then 
fixed, paraffin embedded and immuno- or Haematoxylin and Eosin (H&E) stained. 
To study the emergence of drug resistance in 3D with and without stromal support, 
cells were seeded into Alvetex® scaffolds and treated with increasing concentrations 
of BGJ until resistant populations were observed via confocal fluorescence 
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microscopy. Cancer cells grown in co-culture with fibroblasts acquired resistance 
faster than monoculture cells. Significantly regulated genes between resistant and 
parental mono- and co-culture cells were identified using ribonucleic acid sequencing 
(RNA-Seq) and bioinformatics. The majority of significantly regulated pathways in 
FGFR2-amplifed gastric cancer cells, were metabolic pathways including retinol 
metabolism, starch and sucrose degradation, which was mainly driven by sucrose-
isomaltase (SI) and aldolase B (ALDOB), resulting in glucose generation. Targets were 
then modified using different approaches such as knockdown, overexpression and 
drug treatments to observe how this affects resistance of FGFR-driven cancers. 
Blockade of ALDOB resulted in lower cell numbers within 2D cultures in drug-
resistant gastric cancer cells, possibly by slowing down cell growth rather than 
inducing cell death. However, the effect of glucose or sucrose on cells is possibly 
through a SI-independent manner. When analysing gene expression in cells grown 
on 2D versus 3D substrates, expression levels varied considerably, and this underlines 
the importance of investigating biological processes in a physiomimetic in vivo-like 
setting. 
Drug resistance in cancer is an increasing issue for successful therapy and a number 
of interesting targets have been identified in FGFR2-amplified gastric cancer that 
could be responsible for drug resistance towards FGFR inhibitors. With stromal 
support, cancer cells acquired resistance faster, which highlights the influence of 
fibroblasts and the extracellular matrix (ECM) environment on resistance. It was 
shown that sugar metabolism plays a substantial part in resistance, together with the 
retinol pathway. Possibly, these genes and pathways are intertwined, ultimately 
aiding cancer cells to grow in presence of inhibition via cytoprotective mechanisms 
and also generation of metabolites to ensure sustained proliferation of cells. The 
importance of these genes and pathways need to be further evaluated. Therefore, 
drug combination therapy could be the pivotal way forward to hinder cancer cells 
from rewiring their pathways to overcome drug inhibition. 
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1.1 Fibroblast growth factors (FGF) and FGFR signalling 
Fibroblast growth factor (FGF) signalling plays critical roles in cellular crosstalk, 
proliferation, survival and migration (Tanner and Grose, 2016). It is essential during 
development and aberrant signalling can result in developmental defects (Coumoul 
and Deng, 2003). 
FGFs are small signalling molecules, which bind to receptor tyrosine kinases, FGF 
receptors (FGFR). In addition to receptor-based signalling, FGFRs can also directly 
migrate into the nucleus and exert their functions (Coleman et al., 2014). There are 22 
members of the FGF family with sizes ranging between 17-34 kDa (Ornitz and Itoh, 
2001). FGF11-14, also known as FGF homologous factors (FHF), share substantial 
structural identity with FGF family members, however are usually not considered 
true family members as they remain intracellular and therefore do not bind known 
FGFRs (Olsen et al., 2003). FGFs share homologous core regions but diverge in C- and 
N-termini. Most FGF family members, except FGF1 and 2, incorporate an N-terminal 
signal sequence peptide to be secreted via the endoplasmic reticulum (ER) and Golgi-
dependent secretory pathways. FGF1 and FGF2 are secreted via an ER-Golgi-
independent pathway (Mignatti et al., 1992). FGFs often signal between epithelium 
and mesenchyme in a paracrine manner and are expressed in almost all tissues, where 
they mediate essential cellular functions during embryonic development, 
homeostasis, metabolism and repair (Carter et al., 2015). When FGFs, in combination 
with heparan sulphate (HS), bind to an extracellular immunoglobulin domain of the 
receptor, dimerisation of the receptor is induced, followed by transphosphorylation 
of the kinase domain and recruitment of adaptor proteins to phosphotyrosine 
residues, leading to the activation of downstream signalling cascades (Furdui et al., 
2006; Turner and Grose, 2010) (Figure 1.1). There are seven signalling FGFRs encoded 
by four FGFR genes, FGFR1-FGFR4. FGFRL1 (also known as FGFR5) lacks kinase 
activity and might therefore be involved in negative regulation (Sleeman et al., 2001). 
FGFR1-4 all consist of three extracellular domains (D1-D3), a transmembrane and a 
cytoplasmic domain (Beenken and Mohammadi, 2009).   
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D1 is thought to be responsible for regulating receptor signalling via auto-inhibition, 
whilst D2 and D3 are crucial for ligand specificity and D3 can be alternatively spliced, 
leading to FGFRb and FGFRc isoforms for FGFR1-3. 
 
 
Figure 1.1. Schematic representation of FGFR.  
N, N terminus; C, C terminus 
 
1.2 FGF, FGFR and HS complex 
FGF signals are ubiquitously expressed in development, homeostasis and disease; 
therefore a tight regulation of the pathway is essential. Canonical FGFs have a high 
affinity for heparin and form tight bonds with heparin/heparan sulphate 
proteoglycans (HSPGs), to regulate specificity and affinity for FGFRs but also limit 
diffusion through the extracellular matrix (ECM) (Beenken and Mohammadi, 2009; 
Matsuo and Kimura-Yoshida, 2013; Ornitz, 2000; Sarrazin et al., 2011; Yayon et al., 
1991). HS is a highly sulphated polysaccharide that consists of 50-150 basic 
disaccharide repeats of uronic acid and D-glucosamine units (Bernfield et al., 1999). 
HSPGs play a crucial role in the formation of the FGF:FGFR:HS complex (Lindahl and 
Höök, 1978). Their appearance is similar to a sulphated saccharide chain that has 
acidic properties (Gambarini et al., 1993). For interaction with FGFs or FGFRs, the 
length of the molecule is important and, upon binding to FGF/FGFR, a 
conformational change is induced in the HS saccharide. FGFRs harbour highly 
conserved heparin-binding residues in the Immunoglobulin II loop (Schlessinger et 
al., 2000). However, in FGFs such residues are very diverse (Bellosta et al., 2001). 
Thus, for the ideal activity of FGFs, different lengths of chains and HS sulphation 
patterns are necessary, which have an effect on FGF:FGFR interaction and are thought 
to activate FGFR signalling (Gambarini et al., 1993). 
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1.3 FGF signalling pathways 
1.3.1 FGFR activation 
Fibroblast signalling begins with the formation of a ternary complex with two 1:1:1 
FGF, FGFR and HS molecules forming a functional signalling complex composed of 
a symmetrical dimer (Plotnikov et al., 2000; Schlessinger et al., 2000). The complex 
formation allows transphosphorylation of specific tyrosine residues of the 
intracellular kinase domains (Figure 1.2). The activated receptor recruits scaffolding 
or signalling molecules containing phosphotyrosine-binding src-homology 2 (SH2) 
domains which, thus activate further signal transducers and trigger downstream 
signalling cascades (Anderson et al., 1990; Moran et al., 1990; Pawson et al., 1993). 
Studies to further elucidate signalling cascades have typically involved FGFR1, 
revealing the existence of seven tyrosines that can be phosphorylated. From these 
tyrosine residues Tyr653, Tyr654 are essential for the catalytic activity of the receptor 
while Tyr463, Tyr583, Tyr585, Tyr730, Tyr766 are thought to serve as recognition sites for 
scaffolding proteins for downstream signalling (Mohammadi et al., 1996). 
 
 
 
Figure 1.2. Canonical FGFR activation. 
The classical model of FGFR activation involves the formation of a symmetrical complex composed of 
two HS chains, both ligands and the receptor monomers leading to receptor dimerisation (Schlessinger 
et al., 2000). This allows auto-phosphorylation and subsequent phosphorylation of downstream 
signalling molecules. Violet indicates the kinase domains, purple FGF ligands and the tyrosine 
phosphorylation sites are shown as red circles.  
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Four main signalling pathways can be activated: Mitogen-activated protein kinase 
(MAPK)/extracellular-signal-regulated kinase (ERK), Phosphoinositide 3-kinase 
(PI3K)/AKT, phospholipase γ (PLC γ) and Janus kinase (JAK)/signal transducer and 
activator of transcription (STAT) (Beenken and Mohammadi, 2009; Eswarakumar et 
al., 2005; Furdui et al., 2006; Goetz and Mohammadi, 2013; Turner and Grose, 2010). 
These pathways are involved in cellular proliferation, differentiation and survival. 
The different FGFRs target the same proteins, but differ in the strength of their kinase 
activity (Raffioni et al., 1999). It is therefore unclear if the diversity in FGFs and 
respective FGFRs enrich the extent of cellular signalling or merely provide further 
extracellular binding sites for the different FGFs. A pivotal study of FGFR2 signalling 
indicated that differential ligand binding can activate downstream pathways that 
lead to distinct downstream cellular processes (Francavilla et al., 2013). 
FGFR substrate 2 (FRS2) is a major FGFR kinase substrate and acts as an essential 
component for the assembly of multiprotein complexes, therefore mediating the 
initiation of multiple FGF-FGFR-induced pathways, such as PI3K and MAPK 
pathways. PLCγ and JAK/STAT pathways are mediated through mechanisms 
independent of the docking protein FRS2. It was identified as a 90 kDa protein that is 
anchored to the plasma membrane by a myristolated N-terminus and is constitutively 
associated with FGFR1 at the amino acids 407-433 of the intracellular juxtamembrane 
region (Kouhara et al., 1997; Mohammadi et al., 1996; Wang et al., 1996; Xu et al., 
1998). FRS2 binds to FGFR1 via a phosphotyrosine binding domain (PTB), which 
occurs without ligand stimulation (Ong et al., 1997). Activation of FGFR leads to 
FRS2α phosphorylation at tyrosine residues in the C-terminal region, and therefore 
creates binding sites for proteins containing SH2 domains, such as growth factor 
receptor-bound protein 2 (GRB2) and Src homology region 2-containing protein 
tyrosine phosphatase 2 (SHP2) (Kouhara et al., 1997; Ong et al., 1997). The formation 
of this complex then enables signal activation and further initiation of the PI3K and 
MAPK pathways (Lax et al., 2002; Wong et al., 2002) (Figure 1.3). 
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Figure 1.3. FGF induced downstream signalling of FGFR.  
Schematic representation of the FGF signalling pathway, where FGF binds to an extracellular domain of 
FGFR resulting in receptor dimerisation and transphosphorylation of the tyrosine kinase domain. This 
leads to the activation of four signalling cascades: MAPK, PLCγ, PI3K and STAT. The MAPK or ERK 
pathway acts on cellular proliferation, differentiation, apoptosis and migration (Dhillon et al., 2007). It 
can influence the cell cycle, for example via activation of the transcription factor c-MYC or by 
upregulation of Cyclin D1. The PI3K/AKT signalling pathway regulates cell survival, proliferation and 
angiogenesis through nuclear and cytoplasmic domains (Fruman et al., 1998; Gotoh, 2008). In the STAT 
pathway, STAT dimers bind to γ-activated site (GAS) enhancers in the nucleus where they activate or 
repress gene transcription (Darnell, 1997). Upon activation, these pathways lead to cellular responses 
such as proliferation, migration and survival. Negative regulators are shown in red boxes (adapted from 
Carter et al. 2015). 
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1.3.2 MAPK/ ERK pathway 
The next step in MAPK activation is the recruitment of the rat sarcoma (RAS) protein 
to the FGFR/FRS2/GRB2/son of sevenless (SOS) complex. GRB2 harbours an N-
terminal SH3 domain that can bind constitutively to proline-rich regions in the RAS-
guanine exchange factor SOS, which catalyses the exchange of guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP) on the membrane bound small 
GTPase protein RAS, resulting in its activation. The recruited SOS activates the RAS 
GTPase which initiates a serine/threonine kinase cascade by recruitment and 
activation of rapidly accelerated fibrosarcoma (RAF). RAF kinase then 
phosphorylates and activates MAPK kinase (MEK, MEK1 and MEK2), which results 
in mitogenic activity and cell survival (Eswarakumar et al., 2005). Phosphorylated 
MAPK then activates transcription factors in the nucleus, for example cellular 
homologue of v-MYC (c-MYC), thereby influencing the cell cycle. It is also involved 
in the regulation of cell proliferation, survival and migration and was found to be 
associated with resistance towards targeted treatment (Bockorny et al., 2018; 
McCubrey et al., 2007; Yadav et al., 2012). 
1.3.3 The PI3K/AKT signalling pathway 
The PI3K/AKT signalling pathway plays a role in anti-apoptotic signalling but also 
cell growth and proliferation (Dailey et al., 2005; Gotoh, 2008). Downstream of PI3K, 
an anti-apoptotic protein kinase (AKT) gets activated. Growth-factor mediated 
activation of AKT involves a PH-domain dependant membrane translocation step 
where AKT is recruited to the plasma membrane with the help of 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) generated by PI3K. Once at the 
membrane, AKT is phosphorylated by PDK1 at Thr308 and other kinases, including 
mTORC2, at Ser473. Thr308 phosphorylation partially activates AKT, while 
phosphorylation of both, Thr308 and Ser473, sites results in full activation (Scheid and 
Woodgett, 2003; Hanada et al., 2004). Once PIP3 levels decrease, AKT activity is 
attenuated through dephosphorlyation by serine/threonine phosphatases (Nicholson 
and Anderson, 2002). 
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GRB2 can also associate with GAB1 (GRB2-associated binder-1), which shows 
similarity to IRS-1 (insulin-receptor substrate-1) (Holgado-Madruga et al., 1996). 
Upon receptor activation, phosphorylated FRS2 forms a complex with SOS and GAB1 
binds to FRS2-activated GRB2 via its C-terminal SH3 domain, becomes 
phosphorylated in turn and forms a multi-complex with downstream effector 
proteins, including the p85 regulatory subunit of PI3K, hence activating the 
PI3K/AKT signalling pathway (Turner and Grose, 2010). 
PI3K is an important regulator of phosphoinositide lipids, which are a key component 
of the plasma membrane. Since their phosphorylation status is important in cellular 
signalling, it needs to be tightly regulated by kinases such as PI3K in response to 
FGFR activation (Balla, 2013). PI3K isoforms can be subdivided into three distinct 
classes: Class I, Class II and III, based on their structural characteristics and substrate 
specificity (Fruman et al., 1998). Class I is the best understood and is known to be 
activated upon receptor phosphorylation (Vanhaesebroeck et al., 2010). 
The class I isoforms are heterodimers consisting of a catalytic subunit (p110) and the 
adaptor/regulatory subunit p85 and can be further subdivided into class IA and IB. 
Class IA are activated by receptors with protein kinase activity whereas subclass IB 
is activated by receptors coupled to G proteins. Class IA has three potential catalytic 
subunits p110α (PI3CKA), p110β (PIK3CB), p110δ (PIK3CD) and five adaptor subunit 
isoforms generated by alternative splicing of p85α to p55α and p50α (PIK3R1), and 
p85β (PIK3R2) and p55γ (PIK3R3). Subunit p110α and 110β isoforms are ubiquitously 
expressed and have been shown to be crucial for normal development (Bi et al., 1999). 
In class IB PI3Ks, the catalytic subunit p110γ (PIK3CG) can bind two regulatory 
subunits, p101 and p87 (Thorpe et al., 2015), and is mainly expressed in leukocytes 
(Chantry et al., 1997). Therefore, four distinct PI3K class I isoforms exist: PI3Kα, 
PI3Kβ, PI3Kδ, PI3Kγ.  
The FRS2/GRB2/GAB1 complex recruits PI3K to the receptor with the p85 subunit, 
which causes a conformational change in the p110 subunit. The catalytically active 
PI3K can then phosphorylate the inositol ring of phosphoinositide lipids at the 3’-
position, converting phosphatidylinositol (4,5) bisphosphate (PIP2) to 
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phosphatidylinositol (3,4,5) trisphosphate (PIP3). Subsequently PIP3 recruits 
signalling molecules containing pleckstrin homology (PH) domains, including 
phosphoinositide-dependent kinase-1 (PDK1). This, in turn, phosphorylates and 
activates serine/threonine AKT (PKB) on threonine 308 (thr308) at the membrane 
(Alessi et al., 1997; Franke et al., 1995; Lietzke et al., 2000). 
AKT is further implicated with the mammalian target of rapamycin (mTOR) pathway 
via tuberous sclerosis complex (TSC). mTOR protein complexes can be subdivided 
into mTOR complex 1 and 2 (mTORC1, 2), depending on their constituent proteins. 
mTORC2 phosphorylates AKT at serine 473 (ser473), resulting in complete activation 
- meaning a five-fold increase of activity compared to the activity of phosphorylated 
protein at thr308 alone (Facchinetti et al., 2008; Sarbassov et al., 2005). AKT functions 
further by promoting cell survival via regulation of anti-apoptotic targets, such as B-
cell lymphoma 2 (BCL2), via mTORC1, through activation of ribosomal S6 kinase 
(S6K). The release of eukaryotic translation initiation factor 4E binding protein 1 
(EIF4EBP1) then leads to transcriptional repression and allows for translation of pro-
survival mediators (Wang et al., 2006). In addition, PI3K has been implicated in RAS 
activation, as PI3K was found to associate with GTP-bound RAS (Kodaki et al., 1994; 
Rodriguez-Viciana et al., 1994).  
Class II and III subfamilies are less studied than Class I and their functional 
importance remains unclear. Class II PI3K (PI3KC2) have three members in 
vertebrates, two of the three class II isoforms PI3KC2α and β are widely distributed 
throughout mammalian tissue however less is known about the third γ isoform. It is 
thought that class II PI3Ks interact with proteins that are involved in adaptor 
functions. PI3KC2α and β could be associated with clathrin-coated vesicles as they 
contain an N-terminal clathrin-binding (CB) domain (Gaidarov et al., 2001; Posor et 
al., 2013). The PI3KC2β N-terminus can also bind the scaffold protein intersectin, that 
is involved in the synthesis of PIP3 (Das et al., 2007). Less is known about PI3KC2γ 
and protein interactions have not been tested. Class II PI3Ks also contain a RAS-
binding domain (RBD), although this mechanism is not well characterised. All three 
members of the PI3KC2 subfamily own a unique C-terminal extension that carries a 
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C2 domain and a PX domain that binds favourably to PIP2 (Stahelin et al., 2006). The 
single class III PI3K, initially described as vacuolar protein sorting 34 (VPS34) and 
also known as PIK3C3 is conserved in all eukaryotes (Schu et al., 1993). VPS34 can 
bind to adaptor protein VPS15, which is myristoylated at the N-terminus, and forms 
an intracellular membrane-bound heterodimer controlling VPS34 catalytic activity 
that can influence cellular outcomes such as autophagy and endosomal trafficking by 
engaging with other key membrane proteins such as RAB5 GTPase (Backer, 2008; 
Christoforidis et al., 1999; Vanhaesebroeck et al., 2010).  
1.3.4 The PLCγ pathway 
The PLCγ pathway is initiated by auto-phosphorylation of Tyr766 of FGFR1 and 
FGFR2 and subsequent association of PLCγ to the phosphorylated site via its SH2 
domain, where it is itself phosphorylated and thus gains its catalytic activity (Burgess 
et al., 1990; Mohammadi et al., 1991; Spivak-Kroizman et al., 1994). PLCγ is a 
phosphodiesterase and is recruited to the membrane, where it cleaves PIP2, resulting 
in formation of inositol triphosphate (IP3) and diacylglycerol (DAG) (Carpenter and 
Ji, 1999; Klint and Claesson-Welsh, 1999). IP3 causes the release of calcium ions from 
the endoplasmic reticulum (Streb et al., 1983), which together with DAG induces the 
activation of protein kinase C (PKC) (Rameh et al., 1998; Yun et al., 2010). In addition, 
STAT-dimers translocate to the nucleus, which bind to γ-activated site (GAS) 
enhancers to control gene transcription (Darnell, 1997). High PKC expression can then 
relieve inhibition of RAF and reactivate the MAPK pathway (Corbit et al., 2003). 
Ligand-dependent activation of PLCγ is the acknowledged canonical signalling 
pathway, however recent studies have shown that signalling can also be initiated in 
the absence of FGF ligand by PLCγ1 binding to the C terminus of FGFR2 in an SH3-
dependent manner. As this usually occurs when cellular PLCγ1 concentration levels 
exceed GRB2 levels, it could present an explanation for low GRB2 expression levels, 
heightened PLCγ1 activity and metastatic phenotype in tumour cells (Fearon and 
Grose, 2014; Park et al., 2012; Sala et al., 2008). 
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1.3.5 The JAK/ STAT pathway 
Upon FGFR dimerisation and auto-phosphorylation, JAKs are phosphorylated, 
leading to multimerisation by bringing two JAKS into close proximity resulting in 
trans-phosphorylation. An FGFR/JAK complex is formed that serves as a docking site 
for STATs, which are a family of transcription factors that are latent, residing in the 
cytoplasm until activated. The SH2 domain of STATs is in turn tyrosine 
phosphorylated and STAT dimers translocate to the nucleus, where they bind to GAS 
enhancers to activate or repress gene transcription (Darnell, 1997). In addition to 
influencing cell proliferation and differentiation (Ebong et al., 2004), the JAK-STAT 
pathway is also fundamental for cytokines and growth factors leading to 
haematopoiesis, lactation and development of the immune system and mammary 
glands (Ghoreschi et al., 2009; Liongue et al., 2012; O’Shea et al., 2002). A relatively 
recent study showed that FGFR4 silencing prevents STAT3 phosphorylation and 
subsequently the expression of anti-apoptotic protein c-FLIP (Turkington et al., 2014).  
1.4 Regulation of FGF signalling 
Given its crucial roles, the FGF signalling pathway needs to be tightly regulated. This 
is ensured through both positive and negative feedback loops. These regulatory 
proteins, which are co-expressed with FGFs, inhibit FGF signalling by creating a 
negative feedback loop, but are also themselves controlled by FGF signalling (Figure 
1.4). Key regulators are Sprouty (SPRY) proteins, which are MAPK phosphatases and 
encompass Spry1-Spry4 (Hacohen et al., 1998). Upon RTK stimulation, Spry1 and 2 
but not 4 are phosphorylated, whereas for Spry3, no evidence for growth factor-
induced phosphorylation has been described (Fong et al., 2003; Mason et al., 2004). 
SPRYs have been implicated in several developmental and physiological processes 
and depending on the kinase and pathways activated, different SPRYs selectively 
control growth factor effects and therefore induce varying signal transductions and 
responses (Hanafusa et al., 2002; Sasaki et al., 2003; Yusoff et al., 2002). SPRYs  can 
inhibit receptor tyrosine kinase signalling by directly interacting with RAF and 
prevent its phosphorylation, leading to blockage of MAPK signalling, or it can 
compete for GRB2 binding, interfering with the FRS2α/GRB2 complex and thus 
counteract SOS-induced RAS activation (Sasaki et al., 2003; Thisse and Thisse, 2005). 
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Further regulatory proteins include Sprouty-related Enabled/vasodilator-stimulated 
phosphoprotein Homology 1 Domain-containing proteins (SPRED1 and 2), which 
also inhibit MAPK signalling (Wakioka et al., 2001). SPREDs form complexes between 
RAS and RAF and therefore counteract activation of MEK. 
Other mediators that negatively control FGF signalling are MAPK phosphatase 3 
(MKP3) and Similar Expression to FGF (SEF). MKP3 affects downstream MAPK 
signalling by dephosphorylating ERK1 and ERK2. SEF acts at various points of the 
signalling pathway such as in MEK signalling (Yang et al., 2003), inhibition of RAS 
activation resulting in PI3K pathway inhibition (Kovalenko et al., 2003) or directly by 
interacting with the receptor with its transmembrane form, causing inhibition of 
receptor signalling and phosphorylation of FRS2α and also inhibiting ERK 
phosphorylation (Kovalenko et al., 2003; Thisse and Thisse, 2005; Tsang et al., 2002; 
Xiong et al., 2003). 
Another mechanism of negative regulation involves direct phosphorylation of MAPK 
pathway proteins such as SOS, which hinders its interaction with GRB2, resulting in 
less SOS at the membrane, thus lowering RAS activation (Buday et al., 1995). Also 
RAF can be phosphorylated, which reduces RAF kinase activity and hence diminishes 
MEK and MAPK phosphorylation (Ueki et al., 1994). Furthermore GAB1 can be 
directly phosphorylated by MAPK leading to a decrease in PI3K interacting with 
GAB1 and thus reduced AKT pathway activation (Gual et al., 2001). Ultimately, 
phosphatase and tensin homolog (PTEN) can counteract the PI3K pathway by 
converting PIP3 back to PIP2 (Makker et al., 2014). 
Pleckstrin homology like domain A (PHDLA) family members, have also been 
implicated in negative regulation of the PI3K pathway (Kawase et al., 2009). Three 
known family members exist, PHLDA1, PHLDA2 and PHDLA3 which all contain a 
PH domain and thus are able to bind phosphoinositol lipids. While PHLDA2 is 
assumed to be involved in embryonic development, PHLDA1 and 3 were found to be 
expressed in adult tissue (Frank et al., 1999). PHLDA3 is the most characterised family 
member and defined as a possible tumour suppressor (Kawase et al., 2009). It has 
been shown to be a direct target of p53, creating a negative feedback loop between 
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AKT and PHLDA3 (Liao and Hung, 2010). It also negatively regulates AKT by 
competing with AKT for PIP3 binding sites and thus inhibiting AKT phosphorylation 
leading to apoptosis (Kawase et al., 2009; Ohki et al., 2014). PHLDA1, like PHLDA3, 
has also been found to interact with PIP3 and thus reduce AKT signalling and thereby 
play a role in apoptosis (Hossain et al., 2003; Murata et al., 2014; Neef et al., 2002; 
Toyoshima et al., 2004). Recent work in our group has investigated the role of 
PHLDA1 in drug resistance, where downregulation of PHLDA1 resulted in AKT 
signalling recovery, thus implying that PHLDA1 acts as a negative regulator of AKT 
(Fearon et al., 2018). 
Other regulatory mechanisms are receptor internalisation after receptor activation, 
and subsequent receptor degradation and recycling, which are regulated by CBL-
mediated ubiquitination (Thien and Langdon, 2001). In respect to the receptor, 
signalling can also be regulated by auto-inhibition (Plotnikov et al., 1999; Schlessinger 
et al., 2000; Stauber et al., 2000). FGFRs exist in an equilibrium of an ‘open’ and 
‘closed’ conformation. Alternatively, spliced immunoglobulin domain I (IgI) and the 
acid box of the linker region between IgI and IgII minimise inadvertent FGF signalling 
by forming a ‘closed’ auto-inhibited state (Kalinina et al., 2012). The acid-box 
containing linker region directly suppresses HS-binding affinity of FGFR and thus 
inhibits receptor activation. It therefore only allows ligands with high receptor 
affinity to bind to the receptor by overcoming auto-inhibition. Loss of the linker 
region has been found to be involved in cancer (Kobrin et al., 1993; Mansson et al., 
1989). 
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Figure 1.4. Negative regulation of FGFR signalling. 
There are a number of mechanisms to negatively regulate FGFR signalling. These include recruitment of 
additional proteins (red boxes) (Hacohen et al., 1998; Wakioka et al., 2001; Wang et al., 2002; Yang et al., 
2003), as well as downstream elements such as the MAPK pathway acting upstream to modify activity 
(Buday et al., 1995; Gual et al., 2001; Ueki et al., 1994). 
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1.5 Pathologies resulting from aberrant FGFRs 
1.5.1 Developmental disorders 
FGF signalling plays a crucial role in developmental pathways such as 
embryogenesis, development and organogenesis (De Moerlooze et al., 2000). 
Therefore aberrations in the FGF signalling pathway have been linked to human 
diseases such as congenital syndromes, skeletal dysplasias and deafness (Kan et al., 
2002; Turner and Grose, 2010; Wilkie et al., 2002). These are mostly due to gain or loss 
of function mutations in either the ligands or the receptors and such germline 
mutations are known drivers for a range of developmental disorders (Beenken and 
Mohammadi, 2009). 
In several craniosynostosis syndromes such as Pfeiffer syndrome, Jackson-Weiss 
syndrome, Muenke syndrome, and osteoglophonic dysplasia, gain-of-function 
missense mutations are found (Ibrahimi et al., 2004; Muenke et al., 1994; Roscioli et 
al., 2000; Rutland et al., 1995; White et al., 2005). Craniosynostosis syndromes are 
autosomal dominant diseases affecting cranial suture closure and skeletal and soft 
tissues. In such diseases, FGFR1 and FGFR2 mutations in the linker region between 
IgII and IgIII loops are found, which can alter the specificity of the receptor for ligands 
(Chen et al., 2003; Eswarakumar et al., 2004; Ibrahimi et al., 2001; Yu et al., 2000). For 
example, Pfeiffer syndrome type I is linked to FGFR1 and FGFR2 mutations, whereas 
type II and III with FGFR2 mutations only. In Pfeiffer syndrome type I, 5% of patients 
harbour a gain-of-function P252R mutation of FGFR1, which occurs at the linker 
region between D2 and D3, causing receptor over activation (Robin et al., 1994). As 
Pfeiffer, Jackson-Weiss and Muenke syndrome phenotypes can be caused by different 
FGFRs, this could suggest potentially redundant functions of these receptors in 
skeletal development (Ibrahimi et al., 2004; Schell et al., 1995). Kallmann syndrome 2 
(hypogonadotropic hypogonadism 2) with or without anosmia has been identified to 
be caused by loss of function missense mutations in FGFR1, resulting from a lack of 
production of certain hormones that direct sexual development (Dodé et al., 2003; 
Pitteloud et al., 2005). 
Introduction 
16 
 
Apert syndrome is driven by activating mutations S252W and P253R in FGFR2 and 
these have been modelled in mice (McDowell et al., 2006; Wang et al., 2005). These 
mutations are thought to increase ligand affinity for the receptor and cause 
uncontrolled receptor activation (Ibrahimi et al., 2001). It is suggested that they 
enhance the expression of FGFR2IIIb and its mesenchymal ligand FGF10, resulting in 
premature fusion of cranial plates, which is a key feature of this disease (Yokota et al., 
2014). Apert mutations all remain ligand dependent. The S252W mutation induces a 
modification of the receptor that causes the receptor to remain on the cell surface for 
a prolonged time rather than undergoing rapid recycling, as would a normal receptor. 
This affects downstream signalling pathways resulting in increased ERK 
phosphorylation and hence drives cell proliferation and migration capabilities as well 
as premature differentiation (Ahmed et al., 2008). 
1.5.2 Cancer 
Cancer is one of the leading causes of death (Cancer Statistics, WHO | World Health 
Statistics 2018). In 2012, the worldwide cancer burden was 14.1 million new cases and 
8.2 million cancer-related deaths worldwide. Cancers such as lung, breast, colorectal 
and stomach are the most commonly diagnosed cancers in Europe.  
Hanahan and Weinberg presented six characteristics, so called hallmarks of cancer 
that healthy cells undergo to become cancerous cells. These include uncontrolled and 
sustained proliferation, evasion of cell cycle control, resistance to programmed cell 
death, replicative immortality, ability to induce angiogenesis and ability to invade the 
vasculature and other tissues to metastasise (Hanahan and Weinberg, 2000). In 2011, 
a revised list of cancer hallmarks was postulated, encompassing 10 characteristics 
with two additional enabling hallmarks (Hanahan and Weinberg, 2011) (Figure 1.5). 
Additonal characteristics include development of genomic instability therefore 
generating random mutations and inflammatory state premalignant cells. 
Furthermore, cancer cells are identified to reprogram energy cell metabolism and 
actively evade from elimination by immune cells. Cancer cells acquire these 
characteristics by activation of oncogenes that are the drivers of these processes or 
Introduction 
17 
 
downregulate or inhibit tumour suppressors that would suppress these processes in 
normal cells. 
Deregulated FGF signalling can increase cellular proliferation, confer resistance to cell 
death, increase motility and invasiveness, drive angiogenesis, enhance metastasis, 
and induce resistance to chemotherapy (Turner and Grose, 2010). Perturbations of the 
pathway can occur through a variety of mechanisms; over-expression of FGFs/FGFRs, 
mutations in FGFRs, translocations and loss of regulatory mechanisms (Figure 1.6). 
The majority of such cell signalling aberrations are of an activating nature and thus 
enhance proliferation, migration and angiogenesis resulting in a more malignant 
phenotype (Turner and Grose, 2010). 
Furthermore, negative feedback regulators play a critical role in keeping the FGF 
signalling pathway in control. Loss of feedback control has been related to prostate 
cancer, where a decrease of the signalling antagonists SPRY and Sprouty-related 
(SPRED) has been documented (Assinder et al., 2015). 
 
 
Figure 1.5. FGF signalling in the Hallmarks of Cancer.  
Adapted from Hanahan and Weinberg (2011), with hallmarks affected by FGF signalling highlighted in 
red (Tanner and Grose, 2016).  
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1.5.2.1 Receptor amplification 
FGFRs can be activated through amplification, which is a segmental copy number 
gain resulting in receptor overexpression and correlates with poor survival. 
Amplifications in FGFR3 are less commonly encountered in different types of cancers 
(Nord et al., 2010). In contrast, FGFR1 and FGFR2 amplifications have been described 
in a number of different cancers (Katoh, 2010). In gastric cancer, roughly 10% harbour 
FGFR2 amplifications, which are correlated with poor prognosis and diffuse cancer 
types. Receptor signalling can occur through a ligand-independent manner in gastric 
cancer cell lines with C-terminally truncated FGFR2 (Kunii et al., 2008; Takeda et al., 
2007). Due to the C-terminal FGFR2 truncation, signalling attenuation mechanisms 
are inhibited as the receptor cannot be internalised, resulting in constitutive receptor 
activation (Cha et al., 2009). FGFR1 and FGFR2 amplifications have also been 
implicated in various cancers and associated with poor survival. Amplification of 
chromosomal region 8p11-12 was also commonly found in 10% of oestrogen receptor 
(ER)-positive breast cancers (Adnane et al., 1991; Courjal et al., 1997; Jacquemier et al., 
1994; Reis-Filho et al., 2006). 
Recent studies have also indicated amplifications of FGFR1 in non-small cell lung 
carcinoma (NSCLC) cell lines, with 21-22% of squamous cell carcinoma harbouring 
FGFR1 amplifications. Additionally, 3% of lung adenocarcinoma with FGFR1 
amplifications were shown to be dependent on FGFR1 activity for cell growth 
(Ahmad et al., 2012; Freier et al., 2007). Not all lung cancer cell lines with FGFR1 
amplifications showed sensitivity to FGFR inhibitors. This may be due to different 
phosphorylation status of FRS2. However, in the majority of cell lines tested, the 
FGFR inhibitor PD1703074 potently affected tumour growth and survival. FGFR1 has 
also been found to be amplified in oral squamous carcinoma (Freier et al., 2007) and 
has been found at a low incidence rate in ovarian cancer (Gorringe et al., 2007), 
bladder cancer (Simon et al., 2001) and rhabdomyosarcoma (Missiaglia et al., 2009). 
FGFR1 and FGFR2 were also found to be amplified in 47% of hormone resistant 
prostate cancers and FGFR3 was amplified in 3% bladder cancers. FGFR4 was found 
to be amplified in 30% of adult adrenocortical tumours (Brito et al., 2012). In the 
majority of cancers, amplification of the receptor was associated with worse 
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prognosis and more malignant cancer type. Patients harbouring amplifications have 
been identified as suitable candidates for FGFR-targeted therapy compared to 
individuals with non-amplified tumours (André et al., 2013; Cheng and Alper, 2014; 
Soria et al., 2014). However, treatment of patients with EGFR-targeted monoclonal 
antibody, Cetuximab, yielded good results initially however resistance towards the 
drug was acquired (Zhang et al., 2014). Xenograft experiments determined the cause 
as concomitant FGFR amplification, and FGFR2-targeted therapy led to re-
sensitisation to Cetuximab, highlighting the complexity of receptor tyrosine cell 
signalling. 
1.5.2.2 Autocrine and paracrine stimulation/Isoform switching 
Most of the common FGFR aberrations are ligand-independent and result in 
constitutive receptor activation. However, ligand-dependent signalling is also 
important in driving cancer. This can be through autocrine ligand production of 
cancer cells or paracrine production by stromal cells. This has been confirmed using 
mouse models where FGF was ectopically expressed in either epithelial or stromal 
cells, promoting carcinogenesis (Callahan and Smith, 2000; Memarzadeh et al., 2007). 
The first evidence for autocrine signalling arose from melanoma cancer studies where 
high FGFR1 and FGF2 mRNA levels were observed and, with the use of xenograft 
experiments, an FGFR1-FGF2 autocrine loop was identified as promoting melanoma 
formation (Lefèvre et al., 2009; Wang et al., 2017). Epithelial ovarian cancer shows 
heightened signalling via autocrine stimulation of FGFR2IIIb by its ligand FGF7 
(Steele et al., 2001). An autocrine FGF2-FGFR1IIIc feedback loop has also been 
proposed in non-small lung cancer cell lines resistant towards EGFR-inhibitor 
Gefitinib (Marek et al., 2009). 
Isoform switching is commonly observed in cancers and is associated with a more 
malignant cancer phenotype (Ishiwata et al., 2012; Kawase et al., 2009; Peng et al., 
2014; Turner and Grose, 2010). In epithelial cells, the FGFR2IIIb isoform is commonly 
expressed, whereas in mesenchymal cells FGFR2IIIc is expressed. In breast cancer, 
epithelial expression of FGFR2IIIc resulted in a more invasive cancer phenotype 
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(Shirakihara et al., 2011), and in pancreatic cancer cells, overexpression of FGFR2IIIc 
is associated with enhanced tumour growth and aggressiveness (Ishiwata et al., 2012). 
1.5.2.3 Fusion genes 
Chromosomal translocations resulting in fusion of FGFR1 with other genes have been 
reported frequently in myeloproliferative disorders such as EMS (eosinophilic 
myeloproliferative syndrome) and AML (acute myeloid leukaemia) (Cross and 
Reiter, 2008; Roumiantsev et al., 2004; Xiao et al., 1998). EMS is also called 8p11 
myeloproliferative syndrome, as chromosomal band 8p11 is involved in 
chromosomal translocation process. Chromosomal translocation occurs through the 
rearrangement of two non-homologous parts and a gene fusion can be generated 
when the translocation joins two otherwise separated genes. This can result in an 
amino-terminal peptide fusing with the cytoplasmic kinase domain of FGFR1. 
Commonly, a fusion between 13p12 ZNF198 encoding a zinc-finger protein normally 
localised to the nucleus occurs with FGFR1 (Popovici et al., 1998; Reiter et al., 1998). 
However, as it is missing the nuclear localisation signal the resultant cytoplasmic 
tyrosine kinase is constitutively active due to zinc-finger mediated 
homodimerisation. Oncogenic fusion genes that activate FGFR tyrosine kinase 
domains also occur in glioblastoma, bladder, lung, breast, cervical, thyroid, oral and 
prostate cancers (Carneiro et al., 2015; Costa et al., 2016; Majewski et al., 2013; Parker 
and Zhang, 2013; Singh et al., 2012; Williams et al., 2013; Wu et al., 2013). 
With FGFR1, at least 11 fusion partners have been identified, including ZNF198 and 
BCR (Jackson et al., 2010; Xiao et al., 1998). FGFR1 and FGFR3 fused to transforming 
acidic coiled-coil 1 (TACC1) and TACC3 have been identified frequently in 
glioblastoma (Parker et al., 2013; Singh et al., 2012). FGFR1-TACC1 and FGFR3-TACC3 
gene fusions have also been identified in NSCLC, bladder cancer, multiple myeloma 
and long squamous cell carcinoma (Costa et al., 2016; Wu et al., 2013). These gene 
fusions can result in constitutively active FGFR kinase activity in the mitotic spindle. 
In multiple myeloma, FGFR3-TACC3 fusion also results in 3’ UTR deletions allowing 
the fusion gene to escape microRNA regulation (Parker et al., 2013). 
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In cholangiocarcinoma, translocations involving FGFR2 leading to fusion genes with 
AHCYL1, BICC1, MGEA5, AFF3 and TACC3 have been encountered. Bicaudal C 
homolog 1 (BICC1), which is an RNA-binding molecule that regulates gene 
expression, was found to be fused to full-length FGFR2. The gene fusion again is 
suggested to induce enhanced receptor activity by facilitating oligomerisation. 
Prostate cancer gene fusions involving full-length FGFR2 have been identified with 
FGFR2 under the control of solute carrier family 45, member 3 (SLC45A3), an 
androgen-regulated promoter, resulting in FGFR2 overexpression. It is assumed that 
targeting fusion proteins, where the kinase domain is included, could be a potential 
treatment strategy, as in the case of FGFR2-SLC45A3 it suggested to be both 
susceptible to anti-androgens and FGFR-targeted therapy (Arai et al., 2014; Wu et al., 
2013). 
1.5.2.4 Receptor mutation 
Point mutations in FGFRs can enhance ligand binding or alter ligand specificity if the 
mutation is in the extracellular domain of the receptor. Mutations in the ligand-
binding and transmembrane domain may induce dimerisation of the receptor. 
Commonly, mutations occur in the kinase domain, which also constitutively activate 
the receptor. Mutations in the intracellular domain can impair degradation of the 
receptor, which again results in constitutive signalling (Cho et al., 2004; Haugsten et 
al., 2010). However, also loss of function mutations have been associated with cancer 
(Gartside et al., 2009; Greulich and Pollock, 2011). 
In a number of cancers, somatic mutations have been found that were identical to 
germ line mutations in FGFRs found in developmental syndromes (Kan et al., 2002; 
Pollock et al., 2007). FGFR2 missense mutations have been commonly described in 
endometrial and gastric cancer (Dutt et al., 2008; Jang et al., 2001; Pollock et al., 2007). 
In endometrial cancer (Byron and Pollock 2009), these mutations mirror mutations 
found in chondrodysplasias, such as S252W and N550K mutations in Apert and 
Pfeiffer syndromes, and result in receptor activation (Fearon and Grose, 2014; Pollock 
et al., 2007). They are highly sensitive to FGFR inhibition (Dutt et al., 2008) and, more 
recently, have been well studied in NSCLC (Tchaicha et al., 2014). Such FGFR2 
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mutations are assumed to drive tumourigenesis by changing the ligand affinity or 
inducing ligand-independent dimerisation (Tanizaki et al., 2015). In 57% of gastric 
cancer patients, at least one allele of the common G388R variant of FGFR4 was present 
and expression of this allele was linked with worse prognosis (Ye et al., 2010). 
Mutations in FGFR3 have been observed in 25% cervical and 35% bladder carcinoma, 
that are identical to activating mutations in thanatophoric dysplasia (Cappellen et al. 
1999). In 7.5% of rhabdomyosarcomas, FGFR4 is mutated in the tyrosine kinase 
domain, and associates with advanced stage and poor survival (Taylor et al., 2009). 
Noteworthily, FGFR3 and HRAS mutations are mutually exclusive in bladder cancer 
(Jebar et al., 2005), however that is not the case with PIK3CA mutations (López-
Knowles et al., 2006; Platt et al., 2009). Similarly, in endometrial cancer KRAS and 
FGFR2 mutations are mutually exclusive (Byron et al., 2008). This indicates 
redundancy in the ability of a single activation mechanism to fully induce MAPK 
signalling in these cancers, whereas PI3K signalling can be induced with multiple 
‘hits’ (Byron et al., 2008; Jebar et al., 2005). The importance and functionality of such 
mutations in tumourigenesis, and the potential to target them therapeutically, has 
been validated in mouse models (Tchaicha et al., 2014). 
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Figure 1.6. Mechanisms by which FGF signalling can be altered in cancer.  
The FGF pathway can be corrupted by a number of means, most frequently due to activating mutations 
in receptors, which result in either promiscuous ligand binding or ligand-independent firing (Beenken 
and Mohammadi, 2009). Alternatively, inappropriate expression of ligand or mis-splicing of receptors 
can lead to autocrine signalling; receptor amplification can result in enhanced signalling, or fusion 
proteins resulting from chromosomal translocations can give constitutively active kinase activity (Turner 
and Grose, 2010). Not illustrated above, loss of negative regulators can also lead to dysregulation of 
signalling (Carter et al., 2015; Tanner and Grose, 2016).  
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Table 1.1. FGFR-related malignancies and related cancer types.  
Table of all five FGFRs and their alterations, summarising the different alterations and, for each, the three 
cancer types in which they have been reported to occur most frequently. 
 
Receptor Related Cancer 
FGFR1  
Amplification 
Lung (16.3%) (Cancer Genome Atlas Research Network, 2012) 
Breast (10.8%) (Cancer Genome Atlas Network, 2012) 
Bladder (8.7%) (Cancer Genome Atlas Research Network, 2014a) 
Mutation 
Stomach (4.2%) (Cancer Genome Atlas Research Network, 2014b)  
Melanoma (4.1%) (Hodis et al., 2012) 
Lung (3.4%) (Peifer et al., 2012) 
Deletion 
Prostate (8.2%) (Grasso et al., 2012)  
Lung (3.3%) (Imielinski et al., 2012) 
Bladder (3.1%) (Iyer et al., 2013) 
FGFR2 
Amplification 
Stomach (5.2%) (Cancer Genome Atlas Research Network, 2014b) 
Breast (1.9%) (Cancer Genome Atlas Network, 2012) 
Ovary (1.9%) (Cancer Genome Atlas Research Network, 2011) 
Mutation 
Endometrium (12.5%) (Cancer Genome Atlas Research Network et al., 2013)  
Cholangiocarcinoma (10%) (Jiao et al., 2013) 
Melanoma (4.4%) (Krauthammer et al., 2012) 
Deletion 
Prostate (1.6%) (Grasso et al., 2012) 
Lung (0.9%) (Cancer Genome Atlas Research Network, 2014c) 
Glioblastoma (0.4%) (Brennan et al., 2013) 
FGFR3 
Amplification 
Sarcoma (3.4%) (Barretina et al., 2010) 
Bladder (3.1%) (Cancer Genome Atlas Research Network, 2014a)  
Glioblastoma (2.5%) (Brennan et al., 2013) 
Mutation 
Bladder (19.3%) (Kim et al., 2015) 
Melanoma (3.3%) (Krauthammer et al., 2012) 
Multiple Myeloma (2.4%) (Lohr et al., 2014) 
Deletion 
Lung (1.7%) (Cancer Genome Atlas Research Network, 2012) 
Prostate (1.6%) (Grasso et al., 2012) 
Stomach (1.4%) (Cancer Genome Atlas Research Network, 2014b) 
FGFR4 
Amplification 
Kidney (6.5%) (Cancer Genome Atlas Research Network, 2013) 
Prostate (3.3%) (Grasso et al., 2012) 
Bladder (1.6%) (Cancer Genome Atlas Research Network, 2014a) 
Mutation 
Melanoma (5%) (Hodis et al., 2012) 
Lung (4.3%) (Ding et al., 2008) 
Colorectum (4.2%) (Seshagiri et al., 2012) 
Deletion 
Bladder (1.6%) (Cancer Genome Atlas Research Network, 2014a) 
Stomach (1.4%) (Cancer Genome Atlas Research Network, 2014b) 
Lung (0.6%) (Cancer Genome Atlas Research Network, 2012) 
FGFRL1 
Amplification 
Sarcoma (3.4%) (Barretina et al., 2010) 
Prostate (2.8%) (Barbieri et al., 2012) 
Bladder (2.4%) (Cancer Genome Atlas Research Network, 2014a) 
Mutation 
Bladder (9.1%) (Guo et al., 2013) 
Colorectum (5.6%) (Seshagiri et al., 2012) 
Lung (2.7%) (Imielinski et al., 2012) 
Deletion 
Prostate (1.8%) (Baca et al., 2013) 
Lung (1.7%) (Cancer Genome Atlas Research Network, 2012) 
Stomach (1.7%) (Cancer Genome Atlas Research Network, 2014b) 
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1.6 FGFR-driven cancers 
It is clear that FGFR signalling can drive many different cancers. In this project, the 
focus lies on FGFR-driven gastric, endometrial and lung cancer (Figure 1.7). Lung 
and gastric cancer are two of the major cancer types and mark the number one and 
three cancer-associated deaths respectively (Siegel et al., 2015; Torre et al., 2015). 
Furthermore, endometrial cancer is the main gynaecological cancer type (Plagens-
Rotman et al., 2016).  
 
 
Figure 1.7. Incidence and localisation of lung, gastric and endometrial cancer with FGFR alterations. 
16% of lung cancer patients harbour FGFR1-amplified cancers (Heist et al., 2012), whereas 5-10% are 
FGFR2-amplified in gastric cancers (Kunii et al., 2008) and 12% of endometrial cancers are FGFR2-
mutated (Byron et al., 2008).  
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1.6.1 Gastric cancer 
Stomach, or gastric cancer, is the third most common cause of cancer-associated 
deaths in the word (WHO | World Health Statistics 2018). In 2012, an estimated 
951,600 stomach cancer cases and 723,100 deaths were reported (Ferlay et al., 2015). It 
presents a large obstacle to treat due to its difficult diagnosis and most patients only 
start treatment with advanced disease stage. This is due to the slow development of 
stomach cancer over many years, with pre-cancerous changes occurring in the inner 
lining (mucosa), which rarely causes any symptoms. Approximately 80-96% of 
stomach cancers are gastric adenocarcinomas, arising from the mucosa. Other cancers 
can also be lymphoma, gastrointestinal stromal tumour (GIST) or carcinoid tumours, 
however these are much more infrequent (Abeloff’s Clinical Oncology - 4th Edition). 
Gastric cancer associated risk factors are linked firstly to diet, such as food 
preservation, and low consumption of fresh fruits and vegetables (Karimi et al., 2014) 
and also Helicobacter pylori infection (90% of cases) (Anderson et al., 2010; Plummer et 
al., 2015). Early treatment and eradication of this bacterial infection could prevent the 
development of cancer. Gastric adenocarcinomas are extremely diverse in respect to 
phenotype and genetics and can be mainly distinguished into stages 0-IV based on 
the origin of the cancer and invasion of nearby blood vessels (Figure 1.8). The stomach 
lining is rich in a network of blood vessels and therefore as the cancer becomes more 
advanced, cells can easily spread to lymph nodes or other organs such as liver, lungs 
and also bones. Although such cancers are highly treatable in early stages with 
surgery or chemotherapy, advanced stages (clinical stage IV) result in a median 
survival of only 9-10 months. Since the middle of the 20th century, incidence and 
mortality of gastric cancer have steadily declined in the West due to advances in food 
storage and preservation and also declining Helicobacter pylori infections through 
improved sanitation and antibiotics (Parkin, 2006). Additionally, it was observed that 
in countries with a large smoking population, a reduction in smoking has been 
associated with a reduction in gastric cancer (Bertuccio et al., 2009). Despite a decrease 
in overall gastric adenocarcinoma, gastric cancers of the cardia are on the rise in the 
Western hemisphere. This may be due to increasing obesity or also due to improved 
classification of gastric cancers (Camargo et al., 2011; Corley and Kubo, 2004; de 
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Martel et al., 2013; Devesa et al., 1998; Steevens et al., 2010). Hence, due to the heavy 
burden of gastric cancer and limited treatment options, advancements in treatment 
options are of fundamental importance. 
A number of genetic changes have been observed in gastric cancers such as alterations 
in p53, c-erbl-2, c-MET, adenomatous polyposis coil (APC) and deleted in colorectal cancer 
(DCC) (Correa and Shiao, 1994; Stemmermann et al., 1994; Wright et al., 1992). 
Approximately 5-10% of stomach cancers harbour FGFR2 amplifications (Kunii et al., 
2008) and targeting those is a potential therapeutic approach. However, as with many 
cancers, resistance arises and in some cases this may be from epithelial to 
mesenchymal transition (EMT) following treatment with FGFR inhibitors 
(Grygielewicz et al., 2016). 
 
 
 
Figure 1.8. Schematic representation of gastric cancer and pathological stages. 
Most gastric cancers origin in the inner lining of the mucosa in the stomach and more advanced gastric 
cancers can then evade the gastric lining via the bloodstream to lymph nodes and more distal organs. 
Stage 0: Carcinoma in situ, high grade dysplasia in the stomach lining contained within the mucosa. 
Stage I: Tumour cells have grown into surrounding layers such as the lamina propria, the muscularis 
mucosa and the submucosa. Stage II: The cancer has grown into the surrounding layers and nearby 
lymph nodes. Stage III: The cancerous cells grow into the muscularis propria or subserosa or serosa 
layer and nearby lymph nodes. Stage IV: The cancer cells grow into any layer and infiltrate blood vessels 
and lymph nodes, eventually forming secondary tumour sites at distant organs such as the liver, lungs, 
brain or peritoneum (Hu et al., 2012; Japanese Gastric Cancer Association, 1998).  
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1.6.2 Endometrial Cancer 
In the developed world, endometrial cancer is the most common gynaecological 
disorder and fourth most common cancer in the female population (Byron et al., 2008; 
Pollock et al., 2007). In 2012, 320,000 new cases of endometrial cancer were diagnosed 
worldwide (Ferlay et al., 2015). Patients usually exhibit an early stage tumour 
restricted to the endometrium, which is the lining of the uterus, with little or no 
migration into adjacent tissue (Amant et al., 2005). Endometrial cancer is highly 
treatable with surgery, such as hysterectomy, and more than 80% of patients survive 
for at least 5 years after diagnosis. However, a hysterectomy can have dramatic 
consequences, such as oestrogen deprivation resulting in increased risk of 
cardiovascular syndromes (Atsma et al., 2006) and loss of fertility in patients who are 
pre-menopausal upon diagnosis (Lau et al., 2014; Wright et al., 2009).  
Clinical innovation within endometrial cancer research has advanced compared to 
other cancer treatments, possibly because 75% of women are diagnosed with early 
disease stage (stage I or II) (Figure 1.9) and favourable outcomes with a 5-year 
survival of 75-90% (Creasman et al., 2001; Morice et al., 2016; Rose, 1996). However, 
in patients with later stages and higher grade tumours, the disease commonly 
relapses despite surgery, adjuvant radiotherapy, chemotherapy and clinical 
outcomes are extremely poor (Chaudhry and Asselin, 2009; del Carmen et al., 2012; 
Del Carmen et al., 2011; Ueda et al., 2008). Therefore, overall survival has not 
dramatically improved, and endometrial cancer remains one leading cause of cancer-
associated deaths in women, and a greater understanding of the molecular 
mechanisms is essential. 
There are primarily two divisions of endometrial cancer; endometrioid, which 
accounts for 80% and 20% non-endometrioid, which is further subdivided into serous 
and clear-cell carcinoma. Although non-endometrioid cancers are less common they 
are higher grade by definition. Long-lasting unopposed oestrogen exposure can lead 
to endometrial hyperplasia, which increases possibility of the emergence of atypical 
hyperplasia and eventually results in excessive proliferation of the endometrium 
(Amant et al., 2005). 
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There are various genetic alterations observed in endometrial cancer, such as 
microsatellite instability in 25-30% of cases (Catasús et al., 1998; Duggan et al., 1994) 
and PTEN modifications in 37-61% of cancers, which ultimately results in the 
dysregulation of the PI3K pathway (Yeramian et al., 2013). Furthermore, frequent 
mutations affect genes such as PIK3CA and KRAS (Byron et al., 2008; Yeramian et al., 
2013). 
 
 
 
 
 
Figure 1.9. Schematic representation of endometrial cancer. 
(A) Stage Ia endometrial tumours are limited to the endometrium while stage Ib tumours frequently 
infiltrate into the muscle wall. (B) Stage II tumours are characterised by invasion into the cervix. (C) In 
stage III cancer, tumour cells invade other parts of the pelvis and can be subdivided into tumours 
spreading to the ovaries (IIIa), into the vagina (IIIb) and those which infiltrate lymph nodes (IIIc). (D) 
The highest grade tumours are the ones that have metastasised to the bladder or bowel (IVa) or to more 
distant tissues (IVb). The surgical stage of tumours reflects the five year survival rate of approximately 
85% for stage I, 75% for stage II, 45% for stage III and 25% for stage IV (Amant et al., 2005). 
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FGFR2 mutations have been found in approximately 12% of endometrial cancers 
(Byron et al., 2008). These point mutations act as oncogenic drivers, with S252W and 
N550K being the most common mutations. These mutations were shown to affect FGF 
binding affinity and lead to constitutive receptor activation, respectively (Pollock et 
al., 2007). Knockdown of FGFR2 in endometrial cell lines (MFE-296, AN3CA, MFE-
280) expressing FGFR2 activating mutations, resulted in decreased cellular 
proliferation and survival, compared to FGFR2 wild-type cell lines (Dutt et al., 2008), 
suggesting a dependence of those endometrial cancers on FGFR2 mutations. FGFR 
inhibitors can be used to block growth of such cancers, as observed with the TKI 
inhibitor PD173074 (Byron et al., 2008). Currently, other means to target FGFR-driven 
cancers are in clinical development, such as TKI inhibitors with varying specificity, 
monoclonal antibodies and ligand traps (Figure 1.11, Table 1.2).  
In recent studies within our lab, down-regulation of PHLDA1 was identified as a 
critical factor in the establishment of resistance to FGFR targeting. Upon FGFR2 
inhibition, PI3K signalling is decreased and, as a compensatory mechanism, PHLDA1 
expression is diminished. Since the normal role of PHLDA1 in the cell is to buffer 
AKT signalling by competing for PIP3 binding, although PI3K signalling is decreased, 
AKT signalling can be kept constant, since there is reduced competition with 
PHLDA1 for free PIP3 binding sites (Fearon et al., 2018). The identification and 
dissection of the mechanism of action is of utmost importance in providing greater 
insights into the establishment and circumvention of drug resistance and finding new 
targetable nodes. 
1.6.3 Lung cancer 
Lung cancer is abnormal growth of respiratory epithelial cells and is the major cause 
of cancer-related deaths worldwide, causing an estimated 1.8 million new cases and 
1.59 million deaths in 2012, which accounts for 12.9% of all new cancer diagnoses 
(Ferlay et al., 2015). Even in developed countries, survival is low and lung cancer 
mortality rates are generally similar to incidence rates.  
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The incidence and mortality of lung cancer increases with age and 5-year survival 
rates for lung cancer are very low, with 7.8% for men and 9.3% for women. This is 
due to the fact that 70% of lung cancers are diagnosed at advanced stages when 
treatment is less successful (Siegel et al., 2012). 
The major risk factor for lung cancer development is smoking and lung cancer 
developments have been heavily shaped by tobacco use (Doll et al., 2005; Doll and 
Hill, 1950; Jemal et al., 2008; Thun et al., 2012). More than 50 carcinogens have been 
identified in tobacco smoke, with polynuclear aromatic hydrocarbons (PAHs) and 
tobacco-specific N-nitrosamines (TNSAs) being the most important (Hoffmann and 
Hoffmann, 1997; Shields, 2002). Death rates have dramatically decreased by 45% since 
1990 in men and 19% in women since 2002, due to a decline in smoking. 
Other risk factors for lung cancer development are exposure to carcinogens such as 
radiation of radon (miners), asbestos exposure, or microscopic particles such as silica, 
wood dust and indoor and outdoor air pollution (Alberg et al., 2002; Spyratos et al., 
2013; Turner et al., 2011; Vineis et al., 2004). Furthermore lifestyle, diet and genetics 
have been connected to the development of lung cancer (Alavanja et al., 1996; De 
Stefani et al., 1997; Ruano-Ravina et al., 2003, 2000; Swanson et al., 1997). Gender and 
race were also factors associated with a higher incidence in lung cancer, where 
women are more affected than men, and African Americans exhibit higher risks than 
European men (Gasperino, 2011; Gasperino and Rom, 2004; Harris et al., 1993; Jemal 
et al., 2009; Schabath et al., 2016). Socioeconomic status and geographic location may 
also have implications (Parkin et al., 2005). 
According to the WHO classification, lung cancer is subdivided into small cell lung 
cancer (SCLC), which makes up nearly 18% of tumours and NSCLC such as 
squamous cell carcinoma (SCC), adenocarcinoma (ADC) and large cell carcinoma 
(LCC) accounting for 78-80% of lung cancers (Travis, 2011). Lung cancer can be 
divided into four stages (Stage I-IV) (Figure 1.10). 
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Figure 1.10. Schematic representation of lung cancer. 
Lung cancer can be divided into four stages. Stage I: Cancer cells are present in the underlying lung 
tissues. Stage II: The cancer may have spread to nearby lymph nodes or into the chest wall. Stage III: 
The cancer cells are spreading from the lungs to the lymph nodes or to nearby structures and organs, 
such as the heart, trachea and oesophagus. Stage IV: There is metastasis throughout the body and may 
affect the liver, bones or brain. When NSCLC has spread outside of the lungs, successful treatment can 
be difficult. The 5-year survival rate for stage IV NSCLC is around 1% (Beadsmoore and Screaton, 2003). 
 
 
In recent years with better classification methods, advances in the development of 
targeted therapy towards oncogenes and activated pathways in different lung cancer 
types was achieved (Larsen and Minna, 2011). Such oncogenic modifications are 
mutations in Epidermal Growth Factor Receptor (EGFR) or amplifications in c-MET 
resulting in resistance towards EGFR inhibition (Engelman et al., 2007; Kosaka et al., 
2011). KRAS is commonly mutated in lung cancers and, as RAS is activated 
downstream of EGFR, it is likely that they are EGFR-inhibitor resistant (Petersen, 
2011; Toyooka et al., 2011). FGFR1 amplifications have been reported in up to 16% of 
lung cancers (Heist et al., 2012). It has also been observed that expression of FGFR1 
and its ligand FGF2 was upregulated in NSCLC, providing an escape mechanism for 
cell survival of cancers that are resistant to Afatinib (Azuma et al., 2014).  
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1.7 Targeted therapeutics 
FGF signalling represents an attractive therapeutic target in cancer, due to its function 
in cellular crosstalk, proliferation, anti-apoptosis, angiogenesis, EMT, invasion and 
drug resistance, and the frequency of FGFR alterations in a wide variety of cancers 
(Heinzle et al., 2011; Katoh and Katoh, 2009; Korc and Friesel, 2009; Nilsson et al., 
2010; Ota et al., 2009). Many studies have proven pre-clinical efficacy of FGFR-
targeted therapy in cancer cells, with reductions in proliferation or invasion in cancers 
(André et al., 2013; Byron et al., 2008; Chioni and Grose, 2012; Coleman et al., 2014; 
Grygielewicz et al., 2016; Nogova et al., 2017; Saka et al., 2017; Tabernero et al., 2015; 
Zhang et al., 2012). However, even specific FGFR inhibitors have off-target effects, 
which presents difficulties in successful treatment (Gudernova et al., 2016; 
Mohammadi et al., 1998). Due to the importance of FGFRs in numerous pathologies, 
a range of treatment options, including kinase inhibitors, ligand traps and antibodies 
have been and are currently in development (Figure 1.11). The compounds, which 
are currently in the pipeline for FGFR-targeted treatment, are listed in Table 1.2. 
1.7.1 Kinase inhibitors 
The most clinically advanced FGFR therapeutics to date are multi-kinase inhibitors, 
which target the kinase domain of receptors, thereby preventing downstream 
signalling. There are a number of kinase inhibitors currently in clinical trials (Chen et 
al., 2005; Machida et al., 2005; Matsui et al., 2008; Sarker et al., 2008), each of which 
are small molecule inhibitors, which bind to the ATP-binding pocket of the kinase 
domains with differing affinities. Thus, there are broad range multi-kinase inhibitors 
but also more specific FGFR-directed inhibitors (Zhang et al., 2009). Broad range 
inhibitors are usually weak against FGFR-driven cancers, thus there is a shift on the 
focus to more specific FGFR-targeting inhibitors.  
The Vascular Endothelial Growth Factor (VEGF) receptor and FGFR kinase share 
high structural similarity and several VEGFR kinase inhibitors also inhibit FGFR and 
vice versa. Inhibiting both VEGFR and FGFR has the advantage that two pro-
angiogenic pathways or angiogenesis and proliferation are targeted simultaneously, 
however many tyrosine kinase inhibitors (TKI) that affect multiple targets are less 
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active towards FGFRs and the clinical outcome is unreliable. It can also have 
cumulative effects on the advent of side effects, limiting the deliverability of the drug 
to achieve doses necessary to inhibit FGFR. Ponatinib is a broad-reaching TKI that 
has shown a dismal toxicity profile and was withdrawn for the treatment of chronic 
myeloid leukaemia (CML) due to a high proportion of patients developing arterial 
and venous thromboses (Cortes et al., 2013; Gainor and Chabner, 2015). Thus, 
pharmaceutical companies aim to develop FGFR specific inhibitors, which has been 
complicated by hyperphosphatemia-mediated tissue calcification due to blockade of 
the release of FGF23 from bone and its signal in the kidney (Brown et al., 2005). Kinase 
inhibitors such as Dovitinib and Lucitanib, although also having off-target effects, 
have shown potent effects in clinical trials with patients who harbour FGFR 
amplifications, compared to those that do not (André et al., 2013; Soria et al., 2014). 
PD173074 is an FGFR inhibitor with weak affinity towards other tyrosine kinases, 
however due to poor pharmacokinetics this drug is only used as a tool compound to 
investigate FGFR-inhibitor mediated effects (Knights and Cook, 2010). Treatment 
with PD173074 resulted in cell death and cell cycle arrest in endometrial cancer cell 
lines (Byron et al., 2008) and is connected to the inhibition of both FGFR1 and FGFR2 
transphosphorylation. PD173074 also impaired cell proliferation in a small cell lung 
cancer model, in cell lines and in xenograft tumours (Pardo et al., 2009). 
Other kinase inhibitors, such as AZD4547 and BGJ398, currently in phase II clinical 
trials for solid tumours, are more promising compounds (Clinicaltrials.gov, 2018). 
These small molecules selectively inhibit FGFR1, 2 and 3, resulting in growth 
reduction and apoptosis, especially in cancers with known FGFR alterations. 
Nevertheless, as was observed with other kinase inhibitors, off-target effects such as 
activity towards VEGFR2 follow at high concentrations (Gavine et al., 2012; 
Guagnano et al., 2011).  
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1.7.2 Orthosteric receptor binding 
While small molecule kinase inhibitors remain the most clinically advanced FGFR-
targeted therapeutics, other methods such as antibody-based approaches were 
developed by targeting specific receptor isoforms. Antibodies are supposed to be 
more specific to particular FGFRs and therefore could potentially limit pan-FGFR 
inhibition toxicity. For example, GP369, an anti-FGFR2IIIb antibody, has been 
investigated both in vitro and in vivo and shown to suppress the IIIb isoform in 
FGFR2-amplified breast and gastric cancer cell lines (Nord et al., 2010) and has 
revealed promising results in animal models where the growth of xenograft tumours 
with FGFR2 mutations was reduced in GP369-treated mice (Bai et al., 2010). 
Moreover, an FGFR3 antibody, MGFR1877S, was in phase I clinical trials for multiple 
myeloma and advanced solid tumours (Carter et al., 2015, Clinicaltrials.gov, 2018). 
Beyond cancer therapy, antibody-based approaches have been applied, for example 
with KRN23, which is an anti-FGF23 antibody currently in phase II trials for X-linked 
hypophosphatemia (Carpenter et al., 2014). 
1.7.3 Allosteric receptor binding 
More recently, allosteric receptor inhibitors have been described and the allosteric 
inhibitor SSR128129E has been found to decrease cancer progression and 
inflammation using a mouse model of pancreatic cancer and an arthritis model (Bono 
et al., 2013). Furthermore, it has not shown signs of vascular side effects in the mice. 
SSR128129E does not compete with FGFs for FGFR binding but inhibits FGF-induced 
signalling by allosteric blockade through the formation of an FGF:FGFR complex that 
cannot be internalised and hence limits signalling. The use of this drug could 
therefore present a potent alternative to the use of TKIs (Herbert et al., 2013, 2016). 
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1.7.4 Ligand traps 
In another approach, FGF-ligand trap antibodies such as FP-1039 (GSK3052230), have 
been developed to inhibit ligand binding to the receptor (Harding et al., 2013). It 
consists of an extracellular portion of FGFR1c fused to the Fc domain of IgG1 and 
allows targeting of mitogenic FGF ligands, without affecting hormonal FGFs. This 
approach reduces toxicity while still being active towards tumours observed in lung 
and endometrial cancer models (Harding et al., 2013). This trap acts as an FGF 
‘sponge’ by binding multiple FGFs, resulting in anti-proliferative and anti-angiogenic 
effects. It has demonstrated efficacy in vitro and in vivo in a phase I clinical trial in 
patients with advanced solid tumours (Tolcher et al., 2016). This mode of action may 
be beneficial for the treatment of pathological FGF-stimulated activation of FGFRs; 
however, it is not suitable to treat tumours with kinase aberrations which result in 
constitutive activation of receptor signalling. 
 
Figure 1.11. Therapeutic approaches for targeting FGFR signalling.  
Illustration of the different therapeutic categories. Kinase inhibitors (red circles) represent the most 
numerous drugs. Other approaches include orthosteric antibody-based therapies to block receptor 
binding (green), ligand traps (orange) and allosteric inhibitors (blue) (Tanner and Grose, 2016).  
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Table 1.2. The FGFR-targeting compounds in the development pipeline.  
Current status of therapeutics aiming at the FGF signalling pathway, describing the drug type, 
specificity, developmental status and target cancers. The colour code of the compounds refers to the class 
of therapy, as shown in Figure 1.11. Clinical status and indications are based on information from 
clinicaltrials.org, and information is correct as of July 2015 (Tanner and Grose, 2016).1 
 
Compound Manufacturer Target Status Cancer type 
Multi TKI inhibitors 
Ponatinib 
(AP24534) 
Ariad Pharma FGFR, PDFGR, VEGFR 
Approved 
Phase II 
CML, AML 
Nintedanib 
(BIBF1120) 
Boehringer 
Ingelheim 
FGFR, PDGFR, VEGFR 
Submitted 
Phase III 
HCC 
Lenvatinib 
(E7080) 
Eisai FGFR, PDGFR, VEGFR 
Submitted 
Phase 
II/III 
Thyroid, HCC, 
endometrial, 
melanoma, glioma, 
NSCLC 
Orantinib 
(TSU-68) 
Taiho Pharma FGFR, PDGFR, VEGFR Phase III HCC 
Lucitanib 
(E3810) 
Clovis Oncology/ 
Servier 
FGFR1, VEGFR Phase I/II 
ER+ Breast cancer, 
multiple solid tumours 
Dovitinib 
(TKI258) 
Novartis 
FGFR, PDGFR, 
VEGFR, FLT3, c-KIT 
Phase II 
Multiple cancers 
including endometrial 
and breast 
Brivanib 
(BMS-582664) 
Bristol-Meyers 
Squibb 
FGFR, VEGFR Phase III HCC 
ENMD-2076 CASI Pharma 
FGFR1-2, PDGFR, 
VEGFR, FLT3, c-KIT, 
Aurora Kinase 
Phase I/II Breast, ovarian 
ARQ 087 ArQule FGFR Phase I Multiple solid tumours 
FGFR-specific TKI inhibitors 
AZD4547 Astra Zeneca FGFR1-3 Phase II Multiple solid tumours 
BGJ398 Novartis FGFR1-3 Phase II 
Multiple solid 
tumours, melanoma 
LY2874455 Eli Lilly FGFR1-4 Phase I Multiple solid tumours 
Debio 1347 Debiopharm FGFR1-3 Phase I Solid tumours 
TAS-120 Taiho Pharma FGFR1-4 Phase I/II 
Solid tumours, 
multiple myeloma 
JNJ42756493 
Astex pharma/ 
Janssen 
FGFR1-4 Phase I 
Solid cancers, 
lymphoma, urothelial 
FGFR antibodies 
MGFR1877S 
Genentech/ 
Roche 
FGFR3 Phase I 
Solid tumours, 
multiple myeloma 
SSR128129E 
MedKoo 
Biosciences 
FGFR1 Preclinical 
Only mouse tumour 
models 
FGF traps 
FP-1039 
(GSK3052230) 
Five prime 
therapeutics/ GSK 
FGF1, FGF2, FGF4 Phase I Solid tumours 
                                                     
 
1Abbreviations: AML: acute myeloid leukaemia; CML: chronic myeloid leukaemia; ER+: oestrogen 
receptor positive; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer. Red: Kinase 
inhibitors, Green: Blocking antibodies; Blue: Allosteric inhibitor; Orange: Ligand traps. 
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Within my project, three different FGFR inhibitors, PD173074 (PD), AZD4547 (AZD), 
and NVP-BGJ398 (BGJ) have been used (Figure 1.12), all of which display different 
kinase affinities. PD, which inhibits both VEGFR and FGFR, is classified as a broader 
kinase inhibitor compared to AZD, which is currently in phase II clinical trials for 
lung cancer (Gavine et al., 2012), gastric and oesophagogastric cancers with FGFR2 
amplifications (Smyth et al., 2013). It has been shown to target FGFR1-3, resulting in 
apoptosis and growth inhibition in FGFR-driven cancers. However it has been found 
to have off-target effects against VEGFR2, Insulin-like growth factor (IGF), PI3K and 
AKT, although these are lower than the effect on FGFR (Wheeler and Yarden, 2015). 
BGJ is a selective FGFR1-3 inhibitor in phase II clinical trial and has been shown to 
have an effect in FGFR1-amplified squamous NSCLC, but also FGFR3-amplified 
bladder cancer, FGFR2-fused cholangiocarcinoma, and FGFR1-amplified breast 
cancer (Sequist et al., 2014). 
 
 
 
 
Figure 1.12. Structure of ATP and three FGFR inhibitors PD173074, NVP-BGJ398 and AZD4547. 
The FGFR inhibitors shown are pyrazoloamide derivatives, which compete with ATP for binding to the 
ATP-binding pocket of the FGFR, causing inhibition of FGFR-induced signalling (Gavine et al., 2012; 
Mohammadi et al., 1998). 
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1.8 Resistance to targeted therapy in cancer 
The targeting of specific oncogenic signalling pathways in tumours with specific 
molecular alterations has led to personalised medicine in cancer therapy, where drugs 
target those specific molecular alterations. However due to the heterogeneity of 
cancer cells and the unique genetic landscape, the response to cancer therapies differs 
greatly and resistance to both common cytotoxic chemotherapeutics and also targeted 
therapies has been observed (Holohan et al., 2013). 
The development of drug resistance poses a major obstacle towards successful 
treatment of cancer patients and occurs with all commonly used cancer 
chemotherapeutics. This can be due to cancer cells already being innately resistant or 
due to them acquiring resistance during disease progression following treatment. 
There are a multitude of ways cancer cells can acquire resistance towards 
therapeutics. This is important for different types of cancers and many patients with 
advanced disease relapse due to resistance (Chaudhry and Asselin, 2009; Gnanamony 
and Gondi, 2017; Manzano et al., 2016; Marin et al., 2016; Shanker et al., 2010; Shi and 
Gao, 2016; Zhang and Fan, 2007). To overcome and inhibit the advent of drug 
resistance, a thorough understanding of the mechanisms of the process is required. 
There are physiological factors involved in drug resistance, such as impaired drug 
delivery due to weak vascularisation of large tumours, where there is limited drug 
diffusion (Galmarini et al., 2000). Slow growing tumours have shown to be less 
sensitive towards chemotherapy as common chemotherapeutic agents are designed 
to target cells proliferating at a faster rate (Kondoh et al., 2010; Ramirez et al., 2016). 
Heterogeneity is the natural formation of different variants through genetic, 
epigenetic and transcriptomic properties. Genomic instability can generate a great 
level of intercellular heterogeneity in cancers and, during progression, cancers can 
become even more heterogeneous (Gerlinger et al., 2012; Heppner, 1984). The tumour 
contains a collection of cells with distinct molecular signatures and thus different 
levels of sensitivity towards drugs (Dagogo-Jack and Shaw, 2018). Intrinsic factors 
may arise through primary genotypic variations, different cell cycle stages, stochastic 
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variations and hierarchical organisation according to the stem cell theory (Plaks et al., 
2015). Extrinsic factors encompass pH, hypoxia and paracrine signalling interactions 
with other cancer or stromal cells (Fluegen et al., 2017; Gupta et al., 2011; Kreso et al., 
2013; Nathanson et al., 2014). 
Studies using in vitro resistance models and generating resistant cells, have allowed 
comparison with drug sensitive parental cell lines and have revealed several cellular 
mechanisms by which cancer cells can acquire resistance. Such mechanisms are 
reductions in drug accumulation, availability of the active drug in the cells, efficacy 
of the drug on cellular targets and pro-survival signals which aid cells to evade 
apoptosis (Giaccone and Pinedo, 1996; Longley and Johnston, 2005). 
A common way of acquiring resistance is the upregulation of efflux proteins, so that 
drugs are pumped out of the cell before they can inhibit their target (Gottesman, 2002) 
(Figure 1.13). The drug uptake process is not well understood; however, transporters 
were identified and implicated in drug trafficking. Accelerated drug efflux can be 
mediated by P-glycoprotein (P-gp), which belongs to the family of ATP-binding 
cassette (ABC) transporters. P-gp was first observed in cells resistant to broad 
spectrum drugs such as taxanes, vinca alkaloids, anthracyclines and methotrexate 
(Gottesman, 2002; Polgar and Bates, 2005). In acute myeloid leukaemia (AML), 
approximately 30% of patients express P-gp when they are diagnosed, however when 
patients relapse P-gp upregulation is detected in 50% of patients. Furthermore, P-gp 
expression is associated with a reduced rate of complete remission and a higher risk 
for the emergence of resistance (Gottesman, 2002; Leith et al., 1999). P-gp is also 
expressed in the gastrointestinal tract, where it minimises oral bioavailability of drugs 
(Kagan et al., 2010; Zhou, 2008).  
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Cancer cells can become insensitive to a drug due to cell cycle stage. Thus, a 
chemotherapeutic drug can impact the cell cycle, thereby lessening the effect of other 
chemotherapeutic agents. Cell damage induces cell death and is mediated by three 
fundamental events: necrosis, apoptosis and autophagy. Apoptosis plays an 
important role in animal development and tissue homeostasis (Galluzzi and 
Kroemer, 2008; Jacobson et al., 1997; Oberst et al., 2008). It has been typically divided 
into the intrinsic pathway mediated by mitochondria and the extrinsic pathway 
mediated by death receptors on the cell membrane. Apoptosis by these two pathways 
results in activation of the family of cysteine aspartyl-specific proteases (caspases) 
(Ashkenazi and Dixit, 1998; Hengartner, 2000; Pradelli et al., 2010). The internal 
pathway begins in mitochondria and involves BCL2 and AKT, anti-apoptotic 
proteins, and Bax, Bak and caspase-9, pro-apoptotic proteins. Most anti-cancer drugs 
have been shown to induce classical apoptosis and defects in proteins involved in 
apoptosis are associated with resistance to anti-cancer therapies. For example, 
overexpression of anti-apoptotic genes (e.g Bcl-2, Bcl-Xl), expression of soluble death 
receptors, and inactivation of pro-apoptotic genes through downregulation or 
mutation (Igney and Krammer, 2002). Furthermore, mutations in the tumour 
suppressor p53 can result in drug resistance by inhibiting activation of apoptosis, and 
treatment with DNA damaging alkylating agents has been associated with incidence 
of p53 mutations in patients and could explain resistance to second line 
chemotherapeutics (Sturm et al., 2003). 
Changing drug metabolism plays an important role in drug resistance. It consists of 
phase I reactions such as oxidation, reduction and hydrolysis or phase II reactions, 
such as consumption and conversion. These reactions reduce the activation of pro-
drugs and induce drug inactivation. Cancer cells can use this to their advantage by 
increasing detoxification with the help of cytochrome P450 (phase I) or glutathione 
transferases (phase II) and therefore become drug resistant (Longo-Sorbello and 
Bertino, 2001). 
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Importantly, when therapeutics are dependent on modifications, such as mutations 
or changes in expression levels of targets, this will eventually result in drug 
resistance. Intrinsic or acquired resistance can be caused by mutations in the kinase 
domain that alter the conformation of the receptor and therefore modify drug binding 
(Byron et al., 2013). Gatekeeper mutations are most frequently secondary mutations 
in connection with resistance to TKIs (Antonescu et al., 2005; Branford et al., 2002; 
Chell et al., 2013; Gounder and Maki, 2011; Heinrich et al., 2003, 2008; Mauro, 2006; 
Sleijfer et al., 2007; Van Glabbeke et al., 2005). ATP-competitive small molecule kinase 
inhibitors can no longer bind to the ATP-binding pocket by steric inhibition induced 
by the gatekeeper mutation. Normally TKIs form a hydrogen bond with the residue 
where the gatekeeper mutation occurs allowing the inhibitor to enter the hydrophobic 
pocket and inhibit receptor activation. However, in a gatekeeper mutation the residue 
is substituted with a larger hydrophobic residue and sterically obstructs the 
hydrophobic cleft and the inhibitor can no longer inhibit the receptor (Byron et al., 
2013). It has been found that the V565I gatekeeper mutation in FGFR2 inhibits 
Dovitinib in a similar manner (Byron et al., 2013). 
Resistance towards Gefitinib is often associated with a threonine-to-methionine 
substitution at amino acid position 790 (T790M) of EGFR (Politi et al., 2010). It was 
also frequently encountered in patients already intrinsically resistant towards 
Gefitinib (Girard et al., 2010; Inukai et al., 2006; Mok et al., 2009). The existing 
hypothesis postulates that in patients who respond initially to Gefitinib, a small 
proportion of tumour cells with the resistance mutation already exist and are enriched 
upon Gefitinib treatment (Inukai et al., 2006). 
The emergence of resistance in Vemurafenib-treated patients is one of the clearest 
examples of mutation-induced drug resistance (Davies et al., 2002; Flaherty et al., 
2010). Half of all melanoma patients harbour a mutation in the serine-threonine 
protein kinase BRAF, of which 90% carry the V600E mutation resulting in constitutive 
activation of the target protein, activating the downstream MAPK pathway. 
Vemurafenib is a small molecule inhibitor targeted at V600E mutant BRAF (Tsai et 
al., 2008). Initially, in clinical trials, excellent results were observed, with 80% of 
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patients showing complete or partial regression (Flaherty et al., 2010). Nevertheless, 
the duration of the response only lasted 2 to 18 months, after which resistance to the 
drug was acquired (Flaherty et al., 2010). Several mechanisms have been identified 
by mutation profiling, such as activating mutations in MEK1 (Wagle et al., 2011), 
increased expression of MAP3K8 (Johannessen et al., 2010), activation of CRAF 
(Montagut et al., 2008) and up-regulation of platelet derived growth factor receptor β 
(PDGFRβ) (Nazarian et al., 2010). All of these modifications eventually lead to 
activation of the MAPK pathway, consequently circumventing BRAF inhibition. 
Studies with mouse models suggest that cyclical treatment with the drug could delay 
emergence of resistance and thus possibly extend patient life. With the help of in vivo 
studies, mice were implanted with BRAF mutant tumour cells and sequentially 
treated with the drug for four weeks followed by drug removal for two weeks. The 
control mice that were continuously dosed developed tumours, however sequentially 
treated mice did not (Das Thakur et al., 2013). This again suggests tumour 
heterogeneity to be responsible for a selective advantage giving rise to drug 
resistance, and suggests that acquired drug resistance comes at a cost to cell fitness. 
Other important gatekeeper mutations observed in drug-resistant cancers have been 
identified in BCR-ABL (Young et al., 2006), FLT3 (Smith et al., 2015), FGFR1 (Liang et 
al., 2017) and FGFR2 (Byron et al., 2013; Goyal et al., 2017). Mutations in FGFR 
gatekeeper residues, as seen in FGFR4, were linked to embryonal rhabdomyosarcoma 
and neuroendocrine breast carcinomas (Ang et al., 2015; Shukla et al., 2012). Many 
cancers with aberrations along the FGF signalling axis have shown sensitivity 
towards FGFR inhibitors (Desai and Adjei, 2016; Katoh, 2016), however a number of 
cancer cells display intrinsic resistance (Byron et al., 2013). The FGFR V561M 
mutation was described to cause resistance to PD and FIIN-1. Similarly, the 
gatekeeper mutation, V555M, in FGFR3 in KMS-11 myeloma cells is suggested to 
induce resistance upon treatment with FGFR inhibitor AZ12908010 but also 
crossreacts with other FGFR inhibitors (Zhou et al., 2010).  
Studies in gastric cancer suggest that FGFR-inhibitor resistant cells undergo EMT and 
this could be overcome by potential combination therapies by blocking avian 
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erythroblastosis oncogene B (ErbB)/ human epidermal growth factor receptor 2 
(HER2). Also, in FGFR3-dependent bladder cancer cells, EMT has been observed with 
a change in signalling from FGFR3 to ErbB2/3 (Wang et al., 2015). 
Co-activation of anti-apoptotic pathways causing enhanced survival is often 
observed in cancer cells, with deregulation of the PI3K/AKT pathway, which plays 
an important role in proliferation and apoptosis (Goltsov et al., 2011). This pathway 
has been suggested as a therapeutic target in chemoresistance and administration of 
Doxorubicin in combination with PTEN overexpression induced apoptosis in 
endometrial cancer cells (Wan et al., 2007) . 
 
 
 
 
 
Figure 1.13. Drug resistance mechanisms in cancers. 
Cancers can become resistant to therapeutics by activated efflux pumps, decreased drug uptake, altered 
cell cycle checkpoints, increased drug metabolism, altered apoptotic pathway and altered drug targets 
(Barouch-Bentov and Sauer, 2011; Housman et al., 2014; Kapse-Mistry et al., 2014). 
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Another common resistance mechanism is the activation of downstream signalling 
pathways such as gene aberrations in the MAPK pathway (Phipps et al., 2013). RAS 
mutations have been discovered in a multitude of pathologies and arise in 30% of all 
cancers (Eser et al., 2014; Fernández-Medarde and Santos, 2011; Nandan and Yang, 
2011; Reifenberger et al., 2004). RAS proteins are small GTPases such as HRAS, NRAS 
and KRAS, which regulate a multitude of pathways including the MAPK and 
PI3K/AKT signalling pathways. KRAS G12D mutation is often found in lung and 
pancreatic ductal adenocarcinomas (PDAC) (Jackson et al., 2001; Zorde Khvalevsky 
et al., 2013). KRAS mutations have been associated with EGFR-inhibitor resistance in 
patients with lung adenocarcinoma (Pao et al., 2005) and also resistance to EGFR 
antibodies (Panitumumab and Cetuximab) in colorectal and squamous cell 
carcinomas of the head and neck (SCCHN) (Di Fiore et al., 2007; Lièvre et al., 2006; 
Mehra et al., 2011). 
The PI3K/AKT pathway is an important pathway downstream of tyrosine kinase 
signalling and has been linked to resistance in a number of cancers. Also PIK3CA 
mutations are associated with resistance to EGFR inhibitors such as Erlotinib and 
Gefitinib and also poor survival in patients with NSCLC (Ludovini et al., 2011). There 
is evidence that suggests cross-talk between the MAPK and PI3K/AKT signalling 
pathways and their association with drug resistance to targeted therapeutics (Grant, 
2008). Inhibition of the PI3K/AKT pathway using an mTOR inhibitor activates ERK, 
suggesting a feedback loop between mTORC1 and MAPK signalling (Rozengurt, 
2014). Combination treatment targeting MEK/ERK and mTOR has shown to improve 
anti-tumour effects in a number of preclinical cancer models (Carracedo et al., 2008; 
Grant, 2008). Similarily, in FGFR3-driven cancers, activation of ErbB2/3 induced EMT 
combined with a switch from FGFR3 to ErbB dependency via increased ErbB-2/3 
ligand production. Therefore, dual inhibition of the pathways involved, suggests 
beneficial effects to treat such cancers (Wang et al., 2015). Combination treatment of 
FGFR2 mutant gastric cancer with Mubritinib or AUY922 was also suggested in drug 
resistant cancer (Grygielewicz et al., 2016). Also in Imatinib-resistant GIST with 
elevated FGF2 ligand production through MAPK activation, combination treatment 
with c-KIT and FGFR3 inhibitors blocked tumour growth (Javidi-Sharifi et al., 2015).  
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Tumour heterogeneity is strongly influenced by the tumour microenvironment and 
vice versa. It is suggested that the tumour microenvironment can render cancer cells 
more adaptive (Casciari et al., 1992; Gatenby et al., 2007). There is growing evidence 
of the role the tumour microenvironment plays in cancer progression and physiology 
but also in the emergence of drug resistance (Correia and Bissell, 2012; Fang et al., 
2008; Mumenthaler et al., 2015). The interaction between cancer cells, but also 
between cancer cells and stromal cells or ECM, and several other factors such as 
cytokines and growth factors, are all thought to have implications on the emergence 
of drug resistance. This is possibly induced by providing additional signals for 
tumour proliferation and survival (Dalton, 2003; Hazlehurst et al., 2003; Li and 
Dalton, 2006). The tumour microenvironment can protect cancer stem cells by acting 
as a therapeutic barrier and therefore shields them from being targeted efficiently, 
thus allowing the tumour to reoccur (Klemm and Joyce, 2015). The effect of stromal 
cells has also been found to play a role in drug resistance in oesophageal squamous 
cell carcinoma, where stromal cells could attenuate the effect of Lapatinib inhibiting 
the ErbB pathway by upregulating FGFR and c-MET signalling (Saito et al., 2015). 
In order to study the influence of stromal cells on cancer cell signalling and impact on 
the formation of drug resistance, suitable cell biology models have to be established. 
These models should preferably be as representative as possible of the in vivo 
microenvironment but also comply with the principles for more ethical use of animals 
(in line with the 3Rs). Such 3D cell models, together with high throughput 
technologies such as RNA sequencing, will provide a greater insight into the 
processes employed by drug resistant cells and therefore offer opportunities to 
overcome resistance using rational drug combinations (Holohan et al., 2013). Finally, 
to overcome the obstacle of drug resistance in the therapy of cancer, we require a 
greater understanding of how resistance is acquired by understanding cell signalling 
as an interconnected network, capable of rewiring upon inhibition of the central 
signalling pathways.  
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1.9 Two-dimensional versus three-dimensional cell culture 
Two-dimensional (2D) in vitro cell culture has been used for decades to study 
different cell types and to conduct various drug screening and testing. It has shown 
to be a reliable tool for drug discovery, for example in cancer research for 
identification of small molecules in colorectal cancer treatment or for the 
development of functional cell-based assays (Bialkowska and Yang, 2012; Sadikot et 
al., 2013). This monolayer system allows cells to be grown on a flat glass or polyester 
surface with medium on top, feeding the cell populations (Haycock, 2011). With the 
help of 2D cell culture, myriad biological breakthroughs have been achieved, 
providing a fast, reproducible, cost effective method whilst avoiding in vivo testing 
using animal models. 
Despite 2D cell culture being a useful method to dissect certain molecular events, key 
characteristics in phenotype, function and even protein expression are often lost and 
therefore fail to recapitulate in vivo tissue responses (Bissell et al., 1982; Soares et al., 
2012). 2D cultures do not accurately simulate the rich environment and complex 
processes observed in vivo such as cell signalling, chemistry or geometry (Ravi et al., 
2015). Importantly, with the use of 2D cultures the complexity and heterogeneity of 
tumours cannot be accurately replicated and therefore leads to perturbed signalling 
in addition to morphological changes (Lee et al., 2007). Thus, scientific data from 2D 
experimentation can be misleading (Edmondson et al., 2014). 
Cellular processes such as proliferation, differentiation, metabolism and motility, and 
also response to stimuli, are greatly influenced by the cellular microenvironment. 
These processes can be obstructed or absent in 2D systems (Chen et al., 1997; Itano et 
al., 2003; McBeath et al., 2004; Singhvi et al., 1994). It has been postulated that this is 
due to the flattening of the cells in 2D on the planar surface (von der Mark et al., 1977) 
and therefore loss of their differentiated phenotype (Petersen et al., 1992).  
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Animal models, such as genetically modified mice, provide a platform where the 
tumour microenvironment, vasculature and immune response can all be taken into 
account. However, there is a drive to reduce, replace and refine the use of animals in 
experiments, and furthermore such models are expensive, time consuming and not 
readily available for all biological questions. Thus, there is a demand for novel, 
physiomimetic models more representative of the in vivo environment. When cells are 
grown in three dimensions (3D), cells attachments occur freely around the entire cell 
surface, allowing development of their physiological form and function (Baker and 
Chen, 2012). Table 1.3 presents an overview comparing 2D and 3D cultures. 
There are a number of studies that underline the significance of 3D cell culture and 
reveal the apparent advantages of enabling a more physiological environment and 
recapitulation of the architecture of tissues compared to commonly used 2D 
monolayer systems (Ghajar and Bissell, 2010; Lee et al., 2007; Pampaloni et al., 2007; 
Rizki et al., 2008; Santiago-Walker et al., 2009). Geometry and composition to support 
cellular growth not only influences gene expression but also impacts on cell-cell 
communication. Genes that promote cell proliferation can be suppressed in 3D cell 
culture and therefore normalise the anarchic proliferation found in 2D cell culture 
(Edmondson et al., 2014; Maltman and Przyborski, 2010; Ravi et al., 2015).  
Some cell lines grown in 3D cultures are less sensitive to anti-cancer agents than when 
grown in 2D, however the opposite effect has been observed in different cell lines and 
with other types of 3D culture techniques (Dhiman et al., 2005; Howes et al., 2007). 
Thus, investigating cancer in 3D cultures may reveal key insights in respect to drug 
activity in vivo that might not be observable in 2D alone. Additionally, mechanisms 
responsible for these differences could be discovered e.g. variations in signalling 
pathways or shift in target dependence in cells grown in 3D versus 2D culture 
methods.  
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Finally, it has to be taken into account that 3D cell culture is still a relatively new 
technique and underlying phenomena and implications cannot yet be fully grasped. 
Unfortunately, this method also has some disadvantages, which in time will be 
overcome by technical advances. 
Table 1.3. Advantages and disadvantages of 2D versus 3D cell culture. 
2D 3D 
Advantages Disadvantages Advantages Disadvantages 
 Cost effective 
 Well 
established 
 Easier to 
measure and 
analyse 
 Fast results 
 Not 
representative 
 Lack of 
predictivity 
 No cell-cell 
interaction 
 Reduced 
signalling 
 Physiomimetic 
 Interaction of cell 
types 
 More realistic 
 Reduction of 
animal models 
 Throughput 
 Time 
consuming 
 Oxygen and 
nutrient flow 
 Cost-intensive 
 
1.9.1 3D cell culture models 
2D cell cultures lack the capability to accurately mimic the complexity and 
heterogeneity of tumours as observed in vivo and are not representative of the ECM 
environment found in multicellular organisms. With such simplified models, 
characteristics such as tissue specific architecture, homeostasis, mechanical and 
biochemical cues and cell-cell communication cannot be studied and this information 
is lost (Bissell et al., 2003; Cukierman et al., 2002, 2001; Nelson and Bissell, 2006). 
Growing cells in 3D would enable the study of cellular behaviour in a more 
physiological environment, where interactions between different cell types can be 
taken into account, especially the investigation of the tumour microenvironment in 
cancer cell signalling and tumour progression (Gligorijevic et al., 2014; Langley and 
Fidler, 2011; Onuigbo, 1975; Suh et al., 2014; Witz and Levy-Nissenbaum, 2006). 
In the 1960s, the idea of organotypic models was developed by Wolff and Marin with 
the use of embryonic chick liver, where migration of cells was observed around liver 
explants that were cultivated and therefore tissue culture was induced under organ 
culture (Wolff, 1961; Wolff and Marin, 1960, 1957). In the early 1980s, Mina Bissell, a 
lead researcher at Lawrence Berkeley National Laboratory, first proposed 3D 
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culturing techniques and addressed the importance of tissue microenvironment in 
cancer research (Bissell et al., 1982). Furthermore, keratinocyte models, initially 
developed to study skin differentiation (Fusenig et al., 1983), have evolved from 
single monotypic cell models to multiple cell type models (Schmeichel and Bissell, 
2003) and then further adapted in order to study tumour invasion in organotypic 
cultures using oral squamous cell carcinoma (Nyström et al., 2005).  
3D cell culture models are predominantly important in investigating and visualising 
cancer cell invasion. In order to quantify cell invasion, Transwell® assays have been 
used where cells invade through a porous membrane towards a chemoattractant 
(Nyström et al., 2005). However, this system lacks stromal influence of mesenchymal 
cells and therefore paracrine signalling between two or more cell types is not 
incorporated (De Wever and Mareel, 2003; Liotta and Kohn, 2001; Mueller and 
Fusenig, 2002). Addition of stromal cells allows recapitulation of the physiologically-
important aspects of cancer-stroma interactions and the investigation of the effect of 
stromal cells on proliferation and cellular behaviour of cancer cells. 
This model has been further adapted and the organotypic culture model was created 
(Fusenig et al., 1983). More recently it has been adapted to the 3D culture properties 
of a range of different cancer types (Chioni and Grose, 2012; Coleman et al., 2014; 
Froeling et al., 2009; Mauchamp et al., 1998; Nyström et al., 2005; Sanderson et al., 
1996; Vukicevic et al., 1990). Fibroblasts mixed with collagen and Matrigel™, as the 
ECM, form a stromal equivalent, upon which cancer cells are seeded. The optimal 3D 
cell culture would consist of either primary or immortalised stromal cells from the 
tissue of origin of the cancer under investigation. However, the successful use of these 
cells in such cultures is influenced by the amenability of the primary cells to tissue 
culture, as well as access to adequate amounts of primary tissue. To overcome such 
obstacles, immortalised primary mesenchymal cells from another tissue may be used 
as a substitute (Nyström et al., 2005). 
Establishing 3D culture systems requires precise protocols, adequate cell lines, 
suitable 3D imaging options and quantitative analysis tools. With the invention of 
novel materials and better understanding of the in vivo microenvironment, the gained 
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information can be applied to choose suitable models to address a specific scientific 
question and therefore create more realistic model systems. This is not only limited 
to drug screening and cancer invasion studies but has also shown to be a valuable 
tool in the monitoring of hippocampal neurogenesis (Usui et al., 2017) and also in the 
development and engineering of cardiac tissue (Zimmermann et al., 2006). As all 
tissues types are unique, there are a great variety of techniques using different 
materials and manufacturing processes to choose from, depending on its properties 
and applications. Primarily, 3D cell culture techniques can be divided into scaffold-
based and non-scaffold-based approaches (Table 1.4). Further, cells can be embedded 
within a natural or synthetic matrix, cultured in sterile polystyrene inserts, as 
multicellular aggregates or without any matrix-based substrates. 
1.9.1.1 Scaffold-based 
Scaffolds can be useful in supporting cell growth. Due to the porosity of the material, 
scaffolds enable oxygen, nutrient and waste transport. Cells can proliferate and freely 
migrate within the scaffold structure as well as adhering to it (Breslin and O’Driscoll, 
2013). However, when choosing scaffolds, the structure should, where possible, 
match the tissue of choice and therefore mimic its structure, scale and function. One 
caveat is that the larger and more complex the scaffold, the more laborious cell 
extraction from it may be, leading to artefacts in subsequent analysis. Regardless of 
the scientific question, the scaffold used must be suitable to ensure growth support 
and biocompatibility (Haycock, 2011). Scaffolds have shown promising results with 
in vivo tissue regeneration, as there is the possibility to recreate the natural structure 
and environment of living tissue (Tan et al., 2001). 
Such scaffolds can be hydrogels, membranes and 3D matrices, and have been formed 
from materials that include metals, glasses, ceramics, polystyrene (PS) and 
polycaprolactone (PCL). Cells can be either seeded onto a 3D matrix or mixed within 
a liquid matrix material. Scaffolds can also be coated with biologically derived agents 
such as Matrigel™ or collagen which have been reported to enhance cell growth, 
attachment and mimic the ECM environment (Haycock, 2011; Bao et al., 2015). 
Hydrogel scaffolds are often used, as they exhibit a tissue-like stiffness and mimic the 
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ECM to a certain extent. The tissue-like structure of hydrogels can store nutrients and 
soluble factors secreted by communicating cells such as cytokines and growth factors 
which can freely move through the gel (Haycock, 2011). Furthermore, they contain 
high water properties and natural biomolecules (Huh et al., 2011) such as alginate, 
gelatin, hyaluronic acid, agarose, laminin, collagen or fibrin. However, the process to 
solidify the gel can be complex and therefore makes preparation and manipulation of 
the gels difficult. Synthetic and natural biopolymers can also be used for 3D cell 
culture ranging from inert to biodegradable materials (polyester, polyethylene glycol, 
polyamide, polyglycolic acid, polylactic acid) (Maltman and Przyborski, 2010). 
1.9.1.2 Non-scaffold-based 
Scaffold-free 3D cultures were first described in the 1970s by Robert Sutherland when 
he cultured spheroids using spinner flasks (Sutherland et al., 1970). Later experiments 
involved multicellular spheroids with Chinese hamster v79 lung cells, representing 
nodules as found in several animal and human carcinomas (Sutherland et al., 1971; 
Sutherland and Durand, 1984). Many different cell types have the natural tendency 
to form aggregates and therefore cells can re-establish contact and form a specific 
microenvironment that allows a phenotype similar to tissue. Spheroids are the most 
commonly used form of ex vivo 3D cell culture models. They are self-assembled 
spherical clusters of cells from single cell colonies such as cancer spheroids formed 
with NSCLC A549 (Zanoni et al., 2016) or Colo-699 lung cancer cells (Amann et al., 
2014), or co-culture methods such as hanging drop, rotating culture or concave plate 
methods (Castañeda and Kinne, 2000; Hsiao et al., 2012; Pampaloni et al., 2007). 
Non scaffold-based techniques such as forced-floating method or forced aggregation 
use low adhesion polymer-coated well-plates to form uniform spheroids (Baraniak 
and McDevitt, 2012; Breslin and O’Driscoll, 2013; Yamada and Cukierman, 2007). The 
well-plates are filled with a cell suspension and centrifuged, followed by spheroid 
generation (or formation). The hanging drop method was further adapted, which 
consists of a cell suspension aliquot in medium and incubated under the appropriate 
physiological conditions until spheroids are generated (Foty, 2011; Kelm et al., 2003; 
Ware et al., 2016). Plates are then inverted and the aliquots become droplets of cell 
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aggregates and therefore creating spheroids. Alternatively, the agitation based 
approach uses a bioreactor, where a cell suspension placed into a rotating bioreactor 
gradually transforms into aggregates through cell-cell collisions. Cells cannot adhere 
to the container wall due to the continuous stirring in the bioreactor. Eventually a 
broad range of non-uniform spheroids are formed (Breslin and O’Driscoll, 2013; Serra 
et al., 2012). Multicellular spheroids can be custom made with a range of different cell 
lines and can vary in final spheroid size depending on the cell types used (150-500μm 
in diameter). 
The use of spheroids is especially useful in cancer research, as it enables quick 
evaluations of morphological alterations of transformed cells and ability to mimic 
heterogeneous cell populations incorporating regions of proliferation at the edges 
and also a quiescent core which eventually becomes necrotic (Mehta et al., 2012; Ryan 
et al., 2016; Ware et al., 2016). These alterations happen in both spheroids and 
tumours, due to the restricted inward and outward diffusion of nutrients and oxygen, 
causing hypoxia, accumulation of toxic molecules and changes in pH (Acker et al., 
1987; Carlsson and Acker, 1988; Vinci et al., 2012). 
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Table 1.4. Overview of different 3D cell culture models. 
 Method Material Advantages Disadvantages 
Scaffold-
based 
Polymeric Hard Scaffolds 
Alvetex® 
Polystyrene (PS) and 
Polycaprolactone (PCL) 
 Inert and stable 
 Ready to use and customisable 
 Cell-cell interaction 
 Cells are retrievable 
 Variety of size formats (6, 12, 24, 96-well) 
 Live imaging 
 Additional processing steps 
 Laborious to image/harvest 
 High cell numbers 
 HTS not possible 
 No invasive studies 
 Media renewals 
Polymeric Hard Scaffolds 
Transwell® Inserts 
Polycarbonate 
Polyethylene terephthalate 
(PET) 
 Inert 
 Customisable 
 Live imaging 
 Expensive 
 Media renewals 
 Difficult to retrieve cells 
 Variation through set up process 
Natural hydrogels 
Matrigel™ 
Cultrex® 
Geltrex® 
 pH and temperature sensitive 
 More physiological 
 Injectable 
 Animal factors 
 Batch to batch variations 
 Degrades over time 
Synthetic hydrogels PEG gels  No animal factors 
 No batch to batch variation 
 Bio-inert 
 Toxic substances 
 Difficult to sterilise 
Non-
scaffold-
based 
Hanging drop microplates Microplates  No scaffold needed 
 Low costs 
 Uncontrolled spheroid size 
 Cell proliferation is low 
Spheroids 
Cells native ECM 
Low attachment plates 
 Easy to produce 
 Low costs 
 No additional materials needed 
 Limited spheroid size 
 Lack of matrix interaction 
 Potentially unrealistic 
 Particle uptake 
Microfluidic 3D cell culture Microfluidic system 
 Minimal variations 
 Precise control of environment 
 Real time analysis 
 Very sophisticated model 
 Skill intensive 
 Very expensive materials 
 Difficult to reproduce exact conditions 
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1.9.2 Limitations of 3D cell culture methods 
A major limitation can be that a large number of cells are required for each 
experimental setup, which consequently has implications on the throughput of 
samples, undermining suitability for higher throughput screening (HTS). In addition, 
many 3D techniques are cumbersome and time-consuming, which is another 
limitation to perform large long-term experiments. A cost factor to consider is that 
large volumes of media and/or other cost-intensive reagents such as coating agents 
(collagen, fibronectin or Matrigel™) are required to grow 3D cell cultures. 
Furthermore, assays can last 2-4 weeks on average followed by either histological 
processing or microscopic evaluation, before the experimental outcome can be 
analysed. Due to these reasons there is a need to establish cheaper and faster models. 
1.9.3 Organotypic culture models in cancer 
The word ‘organotypic’ is used as a term to describe the process where tissue is 
harvested from an in vivo organism and placed in vitro in anticipation that it will 
continue its physiological functions and development as within the original organ. 
The cells or tissue are cultured in vitro with growth medium under physiological 
parameters. Organotypics have evolved dramatically and are not only used in 
oncology but also extensively in dermatology and neuroscience (Gähwiler, 1981a, 
1981b, 1988; Hauw et al., 1972; Wolf, 1970). The most important aspect of an 
organotypic cancer model is the simulation of the physiological tumour-stromal 
microenvironment as observed in vivo. Organotypic models should simulate not only 
tumour progression, including cell invasion through basement membranes, but also 
the ECM architecture and spatial organisation and oncogenic signalling involved in 
the generation of drug resistance. 
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1.9.4 Tumour-stromal microenvironment 
The tumour microenvironment, consisting of non-cancerous cells and the ECM is 
found to be one of the main factors influencing cancer growth. The cellular 
components comprise fibroblasts, neuroendocrine cells, endothelial, immune-
inflammatory cells and blood and lymphatic vascular networks, which are required 
for normal tissue homeostasis (H. Li et al., 2007; J. Li et al., 2007). It has been 
implicated in the regulation of cell growth, metastatic potential and the outcome of 
therapy (Goubran et al., 2014; Quail and Joyce, 2013; Whiteside, 2008). The stromal 
cells are not malignant; however their role in supporting cancer cells is essential for 
the survival of the tumour and has therefore become an attractive therapeutic target. 
In a healthy state, the microenvironment can help protect against cancer development 
and invasion, however in a malignant state it may create more stubborn and 
aggressive malignancies (Mroue and Bissell, 2013). Paget’s seed and soil hypothesis 
states that the seed (tumour cells) that metastasise through the blood vessels only 
develop and infiltrate the ECM where a suitable soil or optimal conditions for 
survival are found (Paget, 1989). The ECM is therefore essential for tissue 
organisation and cell survival (Hynes, 2009). To create one 3D model that takes all 
these parameters into account for all different cancer types and stages is a near 
impossible feat. Consequently, custom-made organotypic cancer models addressing 
a specific scientific question have to be designed. 
1.9.5 Fibroblast biology in wound healing and cancer 
Fibroblasts belong to the connective-tissue family, which additionally includes 
cartilage cells, bone cells, fat cells and smooth muscle cells; all of which are involved 
in the secretion of collagenous ECM and are responsible for the architectural 
framework of the body. The cells play an essential role in the support and repair 
functions of tissues and organs. Due to their adaptability of their differentiated state, 
they are important for responses to many different types of damages in all tissues and 
organs. Fibroblasts are the least specialised cells of the connective-tissue family and 
are elongated, spindle-shaped cells which can survive stress-like conditions that 
would be toxic for other cells (Kalluri, 2016). They secrete ECM rich in collagen type 
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I and type II (Li et al., 2007). Following wounding, nearby fibroblasts proliferate and 
migrate towards the wound vicinity, where they secrete collagen to repair the 
damaged tissue, but also act as regulators of inflammation and immunity. 
Myofibroblasts were identified in the wound healing process and contraction of the 
skin (Tarin and Croft, 1969; Tomasek et al., 2002) and are activated by transforming 
growth factor beta (TGF-β) signalling, expressing vimentin and alpha-smooth muscle 
actin (α-SMA) (Micallef et al., 2012; Rønnov-Jessen and Petersen, 1993).  
Activated fibroblasts have been reported to support cancer cell growth, however they 
can function as positive and negative regulators. As fibroblasts release growth factors, 
cancer cells can derive advantageous growth, migration and also survival properties 
and therefore indirectly promote cancer progression, via subversion of pathways 
aimed at controlling tissue damage (Gaggioli et al., 2007). Fibroblasts associated with 
cancer are termed cancer-associated fibroblasts (CAFs) and conventional fibroblasts, 
normal-activated fibroblasts (NAFs) (Albrengues et al., 2015). NAFs may be able to 
suppress neoplastic development by reversing the growth-promoting effect of TGFβ 
and HGF secreted by CAFs (Kuperwasser et al., 2004). NAFs are thought to be 
involved in the suppression of tumour emergence by the deregulation of TGFβ 
signalling and therefore inducing prostatic intraepithelial neoplasia (Bhowmick et al., 
2004). Conversely, normal fibroblasts were found to be transformed to CAF-like 
fibroblasts via secretion of TGF-β1 (Wen et al., 2015) 
CAF-mediated drug resistance is a common phenomenon and CAFs are key players 
in promoting resistance to anti-cancer therapies. Mechanisms of resistance involving 
the stroma comprise the alteration of pathways involving cancer cell–ECM 
interactions, CAF–ECM adhesion and cytokine- or chemokine-induced signalling 
pathways (Meads et al., 2009; Paraiso and Smalley, 2013). The sensitivity of pancreatic 
carcinoma to chemo- or radio-therapy can be affected by CAFs secreting soluble 
factors, thus rendering tumour cells to become less sensitive to Gemcitabine 
treatment (Hwang et al., 2008). It has also been found that in neck squamous 
carcinoma, CAFs secrete MMP7 and therefore protect cancer cells from Cetuximab, 
and upregulate BCL-XL in PC3 cells and hence protect them from Sorafenib-induced 
Introduction 
58 
 
cell death (Kharaziha et al., 2012). CAFs are therefore a potential target in therapeutic 
resistance, underlining the importance of investigating their influence on cancer cells. 
1.9.6 Alvetex® 3D organotypic model 
Alvetex® scaffolds are highly porous polystyrene discs that provide a novel method 
of 3D cell culture. The scaffold is around 200μm thick and consists of a honeycomb of 
voids, each with a pore diameter of 36-40μm. Cells can therefore easily invade the 
substrate, with approximately 75 cells being accommodated in each void (Knight et 
al., 2011). No cell is further than 100μm away from the nutrient source, which ensures 
optimal exchange of nutrients, gases and waste products by passive diffusion similar 
to the typical in vivo environment, where cells are generally no more than 150-200µm 
away from a capillary (Jain et al., 2005; Sarveswaran et al., 2016). Since the scaffold is 
made up from polystyrene, it is completely inert and there is no risk of foreign 
unknown influences from protein or cytokines from animal-derived material. 
Additionally, Alvetex® can be used with conventional cell culture plastic, and 
requires no specialist equipment and is therefore not only suitable for routine use but 
also affordable. The scaffolds are highly stable even during long-term cell culture, 
meaning reduced experimental variability even over long-term studies.  
Alvetex® is suitable for the majority of downstream analytical techniques. Alvetex® 
derived cell cultures can be processed just as normal tissue samples and can be used 
for histology according to standard procedures such as fixation, embedding, thin 
sectioning and counter-staining. These scaffolds are designed to stop cells changing 
their shape and cells maintain their natural 3D shape and structure, which can lead 
to the formation of ‘mini slabs’ of tissue like structures. Cells enter the scaffold where 
they retain their natural 3D architecture and do not flatten out like in conventional 
2D cell culture. Introduction of the z-dimension allows cells within the Alvetex® 
scaffolds to retain their natural 3D form and thus help preserve the natural attributes 
of the cell and bring cells together in a more natural in vivo-like manner. This results 
in the formation of tissue-like structures and cell-to-cell interactions that are more 
representative of normal tissue function found in vivo. Different cells types can be 
grown in co-culture within the scaffolds, either as mixed populations or as distinct 
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layers of different cell types (Knight et al., 2011; I. Smith et al., 2015; Liu et al., 2017; 
Asano et al., 2018). 
The architecture of Alvetex® (Figure 1.14) illustrates the voids which are 
interconnected by pores creating a scaffold with > 90% porosity. Once seeded onto 
Alvetex®, typically cells easily invade the scaffold and start to produce genuine, 
homogeneous 3D cellular structures that resemble micro-slabs of tissue (Knight et al., 
2011). Cells therefore maintain their in vivo morphology and respectively behave and 
respond in a more physiological manner similar to that in vivo (Table 1.5). 
 
 
Figure 1.14. Scanning electron microscopy image of an Alvetex® scaffold.  
High magnification (A) and transverse section (B) of the polystyrene membrane at a thickness of 
approximately 200μm. Alvetex® porosity of >90%. Source: Reprocell Ltd. The scale bar indicates 100μm. 
 
 
 
Table 1.5. Features and benefits of usage of Alvetex® for cell culture work. 
Feature Benefits for 3D cell culture 
Simple polystyrene 
 
 
 
• Easy switch between 2D and 3D cell culture 
• Inert, no new experimental variables 
• Stable, does not degrade 
• Can be precoated with ECM proteins 
Consistent scaffold 
structure 
• Reproducible, consistent results, low batch to 
batch variability 
Scaffold is only 200µm 
thick 
• No cell is ever more than 100µm away from 
each other – mimics in vivo conditions 
• Cells can feed and excrete via passive 
diffusion 
Very high porosity (>90%) 
• Cells can easily and freely move in and 
around the scaffold  
Void dimension is 36-40µm • Up to 75 cells can occupy a single void 
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Alvetex® can be easily coated with ECM proteins such as collagen I, collagen IV, 
fibronectin, laminin or Matrigel™. Primary cells can be directly explanted into 
Alvetex®. The material comes as 200µm discs available as inserts or plates, such as the 
12-well plate format or 24-well plate (useful when restricted cell penetration is 
required, cells are fed from the top of the scaffold only) and scaffold well inserts (6-
well and 12-well inserts where cells are fed from above and below, easy to transfer 
cells into a fresh plate for long-term experiments and enables co-culture experiments). 
With inserts, there are also different media fill options such as feeding only from 
below, media in contact above and below but independent media compartments and 
media in contact above and below with connected compartments. The use of Alvetex® 
is compatible with downstream applications such as sectioning and counterstaining, 
immunohistochemistry, scanning and transmission electron microscopy, but also 
gene and protein expression analysis, isolation of cells for FACS and biochemical 
assays such as MTT and MTS assays. There is also Alvetex® Strata, which can be used 
to support the growth of human pluripotent stem cells on the surface of the 
membrane. This displays a new opportunity to readily access viable cells and enable 
continuous propagation and thus maintaining their 3D structural phenotype. The 
difference between Alvetex® and Alvetex® Strata is in the fine structure and 
architecture. In Alvetex® Strata the voids and pores are significantly smaller (13µm 
and 5µm diameter respectively). The concept of investigating propagating 
pluripotent stem cells on Alvetex® Strata was developed using human embryonal 
carcinoma cells, the malignant counterparts of embryonic stem cells (Przyborski et 
al., 2004). Cells changed their morphology in 3D and expressed high levels of stem 
cell markers Oct4 and SSEA-3 compared to 2D. Therefore growth in Strata promoted 
and maintained their stem cell phenotype. 
There are already a number of studies and publications which have applied Alvetex® 
scaffolds within their research question. The scaffolds have been used with primary 
hepatocytes, where cytochrome p450 expression was found to be radically increased 
in 3D culture and cells showed greater sensitivity to cytotoxins (Schutte et al., 2011). 
Furthermore, co-culture experiments using adipose derived stem cells (ASCs) and 
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endothelial cells have been performed to generate pre-vascularised tissue-engineered 
constructs (Neofytou et al., 2011). Alvetex® scaffolds were used to investigate primary 
cells and long-term 3D culture and drug treatments histologically (Rajan et al., 2011). 
Gene expression studies using HepG2 cells with qPCR (Fox et al., 2010) and enhanced 
bone formation of osteoblast cells cultured in 3D using Alvetex® have been compared 
to 2D systems (Bokhari et al., 2007c). The growth of HepG2 liver cells in Alvetex® 
revealed an enhanced cell structure and function, producing more morphological 
features of mammalian liver tissue. Liver cultures were more heterogeneous and 
developed hepatic structures and showed improved viability and albumin secretion, 
reduced cell damage, enhanced resistance to methotrexate (MTX) induced cellular 
toxicity and increased metabolic activity (Bokhari et al., 2007a, 2007b). Alvetex® has 
also been used to study human stem cell derived neurons using environmental 
scanning electron microscopy. Furthermore cells can be visualised whilst in the 
scaffold membrane and cells can also be retrieved and RNA and protein can be 
extracted from the 3D cultures. Extracted protein was then used to perform 
immunoblotting to monitor expression of neural markers, enhanced neurite 
outgrowth and cellular differentiation (Hayman et al., 2005, 2004). 
There are a range of drug resistance studies performed in conventional 2D cell culture 
(Goltsov et al., 2011; Zhang et al., 2009). However, as studies in 2D do not take into 
account the microenvironment and interactions between cells and their stroma, it 
would be of fundamental interest and value to investigate the formation of resistance 
in a 3D model system, where multiple cell types can be introduced into the scaffold 
and cells can move freely. In previous studies, it has been observed that increased 
cell-cell or cell-matrix interaction in 3D cultures can increase cell differentiation (do 
Amaral et al., 2011), alter cell signalling to ECM proteins (Page et al., 2013), change 
gene expression patterns (Luca et al., 2013) and alter expression of proteins linked to 
cell-matrix and cell-cell adhesions (Santini et al., 2000). 
In this study, Alvetex® scaffolds were used to investigate how fibroblasts affect cancer 
cells in respect to the formation of resistance to FGFR inhibitors. In order to do so, 
FGFR-inhibitor resistant cancer cells were co-cultured with fibroblasts and grown in 
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Alvetex® scaffolds. Since the material is inert, substrates and factors such as collagen 
or Matrigel™ can be administered and modified in the model accordingly and be 
investigated using different methods such as live cell microscopy, immunostaining 
and biochemical assays.  
Organotypic cell culture models such as Alvetex® do not replace animal studies to 
address a specific scientific question; however, in line with the three Rs (replace, 
reduce and refine) this system can deliver greater insights into the cellular and 
biochemical processes and therefore provide predictive information regarding 
cellular responses upon drug treatment. 
 
Introduction 
63 
 
1.10 Functional genomics and data analysis methods 
1.10.1 Microarray and next generation sequencing (NGS) 
The transcriptome encompasses the whole set of transcripts in a cell or tissue. This 
includes RNA molecules from protein coding (mRNA) to noncoding RNA, including 
rRNA, tRNA, lncRNA, miRNA. The key goal of transcriptomics is to catalogue all 
species of transcripts and identify the transcriptional architecture of genes in respect 
to their start sites, 5′ and 3′ ends, splicing patterns and other post-transcriptional 
modifications and to measure the varying expression levels of each transcript during 
development and under different conditions. The transcriptome reflects the genes 
that are being actively expressed at any given time in cells or tissue. Therefore 
deciphering the transcriptome is of central importance to understand molecular 
mechanisms and signalling pathways. Unraveling the transcriptome can also be a 
valuable way to trace phylogenetic relationships between individuals and discover 
biomarkers (Li et al., 2017). 
Several different technologies have been used over the past years to measure gene 
expression. Recently, advances in genome sequencing have enabled high resolution 
gene expression analysis. Microarray technology, based on hybridisation, allows 
RNA samples to be interrogated by binding onto a chip containing single stranded 
DNA molecules, so called probes. RNA is extracted from cells or tissue, reverse 
transcribed and then labelled with a fluorescent dye. Sequences complementary to 
the probe will hybridise, allowing gene expression to be measured optically by the 
amount of fluorescence associated with each probe, using multiple samples in 
tandem (Allison et al., 2006; Tarca et al., 2006). 
Platforms such as Illumina can simultaneously probe for over 47,000 gene transcripts. 
However, despite being a powerful and cheap option, it presents several limitations. 
One of the main flaws is background noise from non-specific binding of cDNA that 
are only partially complementary to the probe, thus resulting in unreliable expression 
measurements. Similarly, comparison between different transcripts in the same 
microarray can be imprecise and use of microarrays is restricted to the detection of 
differential gene expression of the same probe target between different samples 
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(Marioni et al., 2008). There is furthermore a dependence on the existing knowledge 
of the sequences of interest and probe sequences must be pre-specified. 
RNA sequencing (RNA-Seq) is a more recent technology which provides greater 
resolution and also allows mRNA splice variant analysis (Qian et al., 2014). It is 
gradually replacing microarrays to measure gene expression levels, and exon arrays 
in alternative splicing analyses (Wang et al., 2008). Early RNA-Seq approaches 
applied Sanger sequencing technology, which was low throughput, costly and error-
prone and generally not very quantitative. To overcome these limitations, tag-based 
methods were developed, such as serial analysis of gene expression (SAGE) 
(Harbers and Carninci, 2005; Velculescu et al., 1995), cap analysis of gene expression 
(CAGE) (Kodzius et al., 2006; Shiraki et al., 2003) and massively parallel signature 
sequencing (MPSS) (Brenner et al., 2000; Peiffer et al., 2008; Reinartz et al., 2002). 
Although these methods are high throughput and enable precise digital gene 
expression levels, they are still based on Sanger sequencing and short tags are not 
able to be mapped uniquely to the reference genome. 
Only in recent times, with the emergence of next generation sequencing (NGS) 
technology, can we exploit the full potential of RNA-Seq. This method has already 
been used to map and quantify transcriptomes of Saccharomyces cerevisiae, 
Schizosaccharomyces pombe, Arabidopsis thaliana, mouse and human cells (Cloonan et 
al., 2008; Lister et al., 2008; Marioni et al., 2008; Morin et al., 2008; Mortazavi et al., 
2008; Nagalakshmi et al., 2008; Wilhelm et al., 2008).  
One of the main advantages of RNA-Seq is very low if any background signal, as it is 
possible to map DNA sequences distinctly to unique regions of the genome. There is 
no upper quantification limit, which relates with the number of sequences obtained. 
There is a large dynamic range of expression levels by which transcripts can be 
detected (Wang et al., 2009; Westbrook and Lucks, 2017). In contrast, microarrays lack 
the sensitivity for extreme conditions such as low or very high levels of expression 
and therefore have a smaller dynamic range. When compared to quantitative PCR 
(qPCR), RNA-Seq has shown to be highly accurate in quantifying expression levels 
(Nagalakshmi et al., 2008) and spike-in RNA controls of known concentration 
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(Mortazavi et al., 2008). RNA-Seq has also shown high levels of reproducibility for 
both technical and biological replicates (Cloonan et al., 2008). Another advantage is 
that RNA-Seq uses less input RNA as there are no cloning steps, and due to Helicos 
technology there is no amplification step involved. 
The vast number of publications in high profile journals highlights the popularity of 
this new technique (Parkinson et al., 2009). It allows research groups to investigate 
aspects that were not accessible previously with microarrays, such as allele specific 
expression and identification of beforehand unknown transcribed regions 
(Montgomery et al., 2010; Trapnell et al., 2010). It is possible to not only look at gene 
expression but also alternative splicing (Pan et al., 2008), novel transcript expression 
(Guttman et al., 2010), allele specific expression (Degner et al., 2009), gene fusion 
events (Edgren et al., 2011) and genetic variation. As it is still a relatively novel 
technique, there is no common gold standard for analysis or standard pipelines yet 
and experimental and methodological biases exist (Hayden, 2012). Also, for the huge 
amount of data, specialised algorithms and more powerful servers are required to 
analyse the data properly (Pop and Salzberg, 2008). 
The levels of different RNA species in a cell at any given time point are controlled by 
regulatory systems that feed back to each other and therefore allow cells to react to 
environmental changes and also maintain expression patterns specific to the 
particular cell type. These regulatory systems are (1) the regulation of the timing and 
rate of transcription initiation and elongation, (2) the regulation of the processing of 
transcripts, (3) the regulation of the rate of transcript degradation, (4) and the post-
transcriptional modification of transcripts (Heyn et al., 2015). 
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1.10.2 RNA sequencing 
The main steps in an NGS RNA-Seq workflow include; RNA fragmentation into 
random DNA or cDNA fragments, a so-called cDNA library followed by addition of 
adapters to the 5’ and 3’ ends of each fragment. The adapters contain functional 
elements that allow sequencing, including an amplification element and the primary 
sequencing site. Adapter-ligated fragments are then PCR amplified. Next, the cDNA 
library gets analysed by NGS, which results in short sequences which correspond to 
either one or both ends of the fragment. The library sequencing depth depends on the 
techniques with which the output data will be analysed. After that, short sequences 
from one end (single end sequencing) or both ends (paired end sequencing) are 
obtained with a length of typically 30-400bp. Single-read is associated with lower 
costs and a faster technique (1% of Sanger sequencing), where cDNA is only 
sequenced from one end. With paired-end methods, cDNA is sequenced from both 
sides and thus represents a more cost intensive and more laborious approach 
(Sengupta et al., 2011). Double stranded molecules are then denatured into single 
stranded molecules and loaded into a flow cell with surface-bound oligos 
complementary to the library adapters capturing the fragments. Bound fragments get 
amplified by bridge amplification to create clusters of identical molecules which serve 
as the templates for sequencing. Sequencing primers are added and clusters get 
reverse complemented at the same time. During each sequencing step, one 
fluorescently labelled nucleotide is added to each growing complementary strand. 
The dye of the nucleotides is different for each nucleotide type and a laser is then 
used to identify the location and identity of the nucleotide which was incorporated 
into the cluster. The fluorescent dye is removed together with the terminal group and 
the same process is repeated until the desired number of times, usually 30 to 200 
times. At the end, a sequence of images with spots representing a cluster and the 
specific colour represents the base type (Figure 1.15). Nucleotide sequences are 
usually in FASTQ file format. Once the newly identified sequences are obtained, gene 
expression levels can be analysed by aligning to a reference genome. After alignment, 
a number of analysis options are available such as single nucleotide polymorphism 
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(SNP), insertion-deletion (indel), identification, read counting for robust multi-array 
average (RMA) methods, phylogenetic or metagenomics analysis and more. 
 
Figure 1.15. Schematic overview of RNA sequencing.  
RNAs are first transformed into a library of cDNA fragments through either RNA fragmentation or DNA 
fragmentation. Sequencing adaptors (blue and orange) are then added to each cDNA fragment and a 
short sequence is obtained from each cDNA using high-throughput sequencing technology. The 
resulting sequence reads are aligned with the reference genome or transcriptome. This is then used to 
generate a base-resolution expression profile for each gene (Wang et al., 2009). 
 
RNA-Seq is a valuable tool to understand transcriptomic dynamics during 
development and normal physiological changes and analysis and comparison of 
diseased and normal tissues, such as comparing cancerous cells to normal cells. In 
this project RNA-Seq will be used to study drug resistance mechanisms of cancer cells 
by comparing gene expression profiles of drug resistant cancer cell populations to 
their parental lines.  
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1.11 Aims and Objectives 
FGFR2 is amplified in 5-10% of gastric cancer and 12% of endometrial cancer and 
FGFR1 is amplified in 16% lung cancers. FGFR signalling in FGFR1 and 2-amplified 
cancer types has shown to be a suitable target for therapy (Byron et al., 2008; Dutt et 
al., 2008; Konecny et al., 2013; Desai and Adjei, 2016; Yashiro and Matsuoka, 2016). 
However, as resistance is a common side effect towards chemotherapy and hormone 
therapy and also resistance towards other small molecule inhibitors has been 
documented (Goltsov et al., 2012, 2011; Lito et al., 2013; Wagle et al., 2011; Zhang et 
al., 2009), efficacy of prolonged FGFR-targeted therapy is an important area of study. 
As discussed previously, cell signalling and morphology can be altered in 2D culture, 
and therefore 3D cell culture systems enable an in vitro system to be more 
physiologically relevant. Different cell types can be grown together to recreate a 
microenvironment that has shown to be essential for cancer signalling. Addition of a 
third dimension provides spatial organisation in which cellular cues and responses 
are similar to those in vivo (Haycock, 2011; Huh et al., 2011; J. Lee et al., 2008; McBeath 
et al., 2004; Ryan et al., 2016). These responses and gene expression changes can then 
be measured using RNA-Seq (Wang et al., 2009). 
The aims of this study are: 
1. Establish and optimise a 3D model using Alvetex® 3D cell culture technique 
and perform co-culture experiments with fibroblasts and cancer cells. 
2. Generate drug resistant cells in 2D and 3D and investigate resistance of FGFR-
driven cancers using FGFR inhibitors. 
3. Use RNA-Seq, differential gene expression analysis and pathway analysis to 
measure gene expression differences between resistant populations in 3D 
with and without the influence of stromal cells, thereby dissecting differences 
in resistance mechanisms with and without stromal support. 
4. Determine the mechanisms of drug resistance in FGFR2-amplified cancer cell 
lines using a combination of RNA-Seq analysis, biochemical techniques and 
in silico analysis, and use this knowledge to target resistant cell lines by 
synthetic lethality, target modulation or informed small molecule approaches. 
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2.1 Materials 
2.1.1 Cell lines 
The following cell lines have been used (Table 2.1-Table 2.4). 
Table 2.1. Endometrial cancer cell lines. 
Cell line Origin Differentiation state FGFR status Mutated genes Source Cat. No. 
MFE-296 Endometrial cancer 
Intermediately 
differentiated 
FGFR2 mut. 
PTEN 
PIK3CA 
PIK3R1 
HPA 98031101 
AN3CA Endometrial cancer Well differentiated FGFR2 mut. 
PTEN 
PIK3CA 
PIK3R1 
ATCC HTB-111 
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Table 2.2. Gastric cancer cell lines. 
Cell line Origin Tumour source FGFR status Mutated genes Source Cat. No. 
KATOIII Gastric cancer Metastasis FGFR2 amp. TP53 ATCC HTB-103 
NCI-N87 Gastric cancer Metastasis wt 
SMAD4 
TP53 
ATCC CRL-5822 
SNU-16 Gastric cancer Metastasis FGFR2 amp. 
CDKN2A 
TP53 
ATCC CRL-5974 
SNU-5 Gastric cancer Metastasis wt 
CDH1  
CDKN2A 
TP53 
ATCC CRL-5973 
AGS Gastric cancer Primary wt 
CDH1  
CTNNB1  
KRAS 
PIK3CA 
ATCC CRL-1739 
SNU-1 Gastric cancer Primary wt 
KRAS  
MLH1 
ATCC CRL-5971 
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Table 2.3. Lung cancer cell lines. 
Cell line Origin Tumour source FGFR2 status Mutated genes Source Cat. No. 
A549 Lung cancer Primary wt KRAS ATCC CCL-185 
H1299 Lung cancer Primary wt NRAS ATCC CRL-5803 
H520 Lung cancer Metastasis FGFR1 amp. KRAS ATCC HTB-182 
 
Table 2.4. Stromal cell lines. 
Cell line Origin Tissue source Source Cat. No. 
HFF2 Foreskin Primary2 ATCC SCRC-1042 
MRC-5 Lung Primary3 ATCC CCL-171 
                                                     
 
2 Normal human foreskin pooled from four individuals. 
3 Fibroblasts derived from lung tissue of a 14 week old aborted Caucasian male fetus. 
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Figure 2.1. Morphology of endometrial, gastric, lung cancer and fibroblast cell lines. 
(A) Endometrial cancer cell lines (AN3CA, MFE-296). 
(B) Adherent gastric cancer cell lines (AGS, NCI-N87, KATOIII).  
(C) Suspension gastric cancer cell lines (SNU-1, SNU-5 and SNU-16).  
(D) Lung cancer cell lines (A549, H1299 and H520).  
(E) Human foreskin fibroblasts (HFF2) and lung fibroblasts (MRC-5). 
The scale bar indicates 25µm.  
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2.1.2 Chemicals and compounds 
Table 2.5. Chemicals and the manufacturers. 
Reagent Source Cat. No. 
2-Mercaptoethanol Sigma-Aldrich M3148 
10% Ammonium persulphate Sigma-Aldrich A3678  
30% Polyacrylamide solution Fisher Scientific  NC2010  
Absolute Ethanol ≥99.8% Sigma-Aldrich 15727 
Acetic acid glacial Fisher Scientific 10304980 
Agar Sigma-Aldrich A7002 
Agarose (UltraPure™) Invitrogen 16500500 
Bovine Serum Albumin (BSA) Sigma-Aldrich A8022 
Collagen Corning  354236 
Citric acid monohydrate Sigma-Aldrich C7129 
1,4-Diazabicyclo[2.2.2]octane (DABCO) Sigma-Aldrich D2522 
DAKO Pen DAKO S2002 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich D5758 
Dimethyl sulphoxide (DMSO) Fisher Scientific 10080110 
Doxycycline Fisher Scientific BP26531 
DPX mountant Sigma-Aldrich 06522 
Dulbecco’s Modified Eagle’s  
Medium (DMEM) 
Sigma-Aldrich D8437 
Epidermal growth factor (EGF) Sigma-Aldrich E9644  
Ethidium bromide (EtBr) Sigma-Aldrich E1510 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 59418C 
Foetal bovine serum (FBS) Gibco 10500-604 
Formalin (10% v/v neutral buffered)  Cellstor BAF-0010-25A 
Glucose (D+) Fisher Scientific 10141520 
Glycerol AppliChem A1123 
Glycine Fisher Scientific BP381-1 
Heparin sodium salt Sigma-Aldrich H4784 
Isopropanol Acros 389710025 
LB broth Sigma-Aldrich L3147 
Matrigel™ Corning 354234 
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Methanol Sigma-Aldrich 322415 
Mowiol Hoechst 50661910 
MTT Sigma-Aldrich M5655 
MTS Promega G3581 
Nonidet-P40™ (NP40) Invitrogen FNN0021  
Opti-MEM™ Fisher Scientific 31985070 
Paraformaldehyde (PFA) Fisher Scientific 10630813 
Penicillin/ Streptomycin Sigma-Aldrich P4333 
Potassium chloride (KCl) Fisher Scientific 10375810 
Roswell Park Memorial Institute  
(RPMI-1640) Medium 
Sigma-Aldrich R8758  
Skim milk Sigma-Aldrich 70166 
Sodium azide Sigma-Aldrich S2002 
Sodium chloride (NaCl) Fisher Scientific BP3581 
Sodium citrate anhydrous (C6H7NaO7) Fisher Scientific BP327 
Sodium dodecylsulphate (SDS) Fisher Scientific BP1311-1  
Sodium bicarbonate (NaHCO3) Sigma-Aldrich S5761 
Sodium phosphate dibasic (Na2HPO4) Sigma-Aldrich S3264 
TEMED National Diagnostics EC503 
Tween-20 AppliChem A1284 
Xylene Sigma-Aldrich 214736 
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2.1.3 Buffers, solutions and media 
Table 2.6. Buffers and their composition. 
Name Composition 
4% PFA in PBS 
20g Paraformaldehyde 
PBS to a final volume of 500mL 
Acetic ethanol 
5mL Glacial acetic acid 
20mL MilliQ-H2O 
100% Ethanol to a final volume of 
500mL 
Binding buffer (1X) 
10mM Hepes (pH7.4) 
140mM NaCl 
2.5mM CaCl2 
Blocking solution  
(Immunohistochemistry/ 
Immunofluorescence) 
6g BSA  
50µL NP40 
PBS to a final volume of 50mL 
10mM Citrate buffer (pH6.0) 
0.256g Citric acid monohydrate  
2.75g Sodium citrate  
ddH2O to a final volume of 1L 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
500mL DMEM 
5mL Penicillin/Streptomycin (10.000 
units penicillin, 10mg streptomycin/mL) 
50mL FBS (final concentration of 10%) 
DEPC-treated water 
1mL DEPC  
1L ddH2O 
Lysis buffer 
50mL 1M Tris-HCl (pH8.0) 
25mL 2M KCl 
5mL 0.5M EDTA (pH8.0)  
4.5mL NP40  
4.5mL Tween 20  
ddH2O to a final volume of 1L 
Minimum Essential Medium (MEM) 
500mL MEM 
5mL Penicillin/Streptomycin (10.000 
units penicillin, 10mg streptomycin/mL) 
50mL FBS (final concentration of 10%) 
Mounting solution 
200μL DABCO  
1.8mL Mowiol 
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Mowiol 
6g Glycerin 
2.4g Mowiol 
6mL DEPC-treated water 
12mL 0.2MTris-HCl (pH8.5) 
Phosphate buffered saline (PBS) buffer 
(pH7.4) 
137mM NaCl  
2.7mM KCl 
10mM Na2HPO4 
2mM KH2PO4 
PBS-Tween (PBST) buffer 
137mM NaCl  
2.7mM KCl 
10mM Na2HPO4 
2mM KH2PO4 
0.1% Tween-20 
Roswell Park Memorial Institute (RPMI) 
Medium-1640 
500mL RPMI-1640 
5mL Penicillin/Streptomycin 
50mL FBS (final concentration of 10%) 
Resolving gel buffer (pH8.8) 
1.5M Tris Base-HCl 
0.4% SDS 
ddH2O to a final volume of 1L 
SDS-PAGE Running Buffer (pH8.3) 
5mM Tris 
192mM glycine 
0.1% SDS 
SDS sample buffer (5X) 
0.25% Bromophenol blue 
0.5M DTT 
50% Glycerol 
10% SDS 
0.25M Tris-Cl (pH6.8) 
Stacking gel buffer (pH6.8) 
0.5M Tris Base-HCl 
0.4% SDS 
ddH2O to a final volume of 1L 
TAE buffer (1X) 
40mM Tris (pH 7.6)  
20mM acetic acid 
1mM EDTA 
TBE buffer (1X) 
89mM Tris (pH 7.6)  
89mM boric acid 
2mM EDTA 
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TBS 
10mM Tris-HCL (pH 8.0) 
150mM NaCl 
TBS-Tween (TBST) buffer 
10mM Tris-HCL (pH 8.0) 
150mM NaCl 
0.1% Tween-20 
Transfer buffer 
25mM Tris-HCl (pH 7.6) 
192mM glycine 
20% methanol 
Tris-Borate-EDTA (TBE) buffer 
90mM Tris-HCl (pH 8.0) 
80mM Boric acid  
3mM EDTA 
 
2.1.4 Dyes, kits and enzymes 
Table 2.7. Dyes, kits, inhibitors and enzymes. 
Name  Source Cat. No. 
Acarbose Sigma-Aldrich A8980 
Ampicillin Sigma-Aldrich A9518 
Annexin V Alexa Fluor 647 conjugate Thermo Fisher Scientific A23204 
AZD4547 AstraZeneca N/A 
BGJ398 Novartis Pharma N/A 
DAB Vector Laboratories SK-4100 
DAPI Life Technologies P36931 
DNA polymerase Qiagen 203203 
FuGene® HD Promega E2311  
GeneRuler 100bp (100bp – 1000bp) Thermo Fisher Scientific SM0241 
GeneRuler 1kb (250bp – 10000bp) Thermo Fisher Scientific SM0311 
INTERFERin Polyplus  409-10  
Mayer’s Haematoxylin Sigma-Aldrich MHS16 
PD173074 Sigma-Aldrich P2499 
Phosphatase inhibitor  Calbiochem 524625 
Picosirius Red Polysciences Inc. 24901 
Ponceau (0.1% (w/v) in 5% acetic acid)  Sigma-Aldrich P7170  
Propidium iodide Sigma-Aldrich P4864 
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Protease inhibitor  Calbiochem 539131 
Protein assay reagent A Bio-Rad Laboratories 500-0113  
Protein assay reagent B Bio-Rad Laboratories 500-0114  
Protein assay reagent S Bio-Rad Laboratories 500-0115  
Puromycin Santa Cruz Biotechnology sc-205821 
RIPA buffer Millipore 20-188 
RNase-free DNase Qiagen 79254 
Rneasy® Mini Kit Qiagen 74104 
SuperScript II Reverse transcriptase Thermo Fisher Scientific 18080093 
Sybr Green I Master Mix Qiagen 204145 
TDZD-8 
Cayman Chemical 
Company 
16287 
Trypsin Gibco, Paisley, Scotland 59418C 
Vector ABC Vector Laboratories PK-6100 
Weigert’s Haematoxylin Sigma-Aldrich HT1079 
ZymoPURE™ Plasmid Maxiprep Kit Zymo Research D4202 
 
2.1.5 Antibodies 
Table 2.8. Antibodies for IF and WB. 
Primary antibody Host Dilution  Source Cat. No. 
anti-alpha-SMA mouse 1:100 Sigma-Aldrich  A5228  
anti-E-cadherin mouse 1:100 BD Bioscience  610182  
anti-EpCAM rabbit 1:100 Invitrogen MA5-12436 
anti-FGFR1 rabbit 1:1000 
Cell Signaling 
Technology 
9740S 
anti-FGFR2 rabbit 1:1000 
Santa Cruz 
Biotechnology 
sc-122 
anti-GAPDH mouse 1:1000 Millipore MAB374 
anti-HSC70 mouse 1:1000 
Santa Cruz 
Biotechnology 
sc-7298 
anti-IgG goat 1:200 Abcam ab6740-1 
Anti-MDR1 rabbit 1:1000 Abcam ab170904 
anti-Pan-cytokeratin mouse 1:200 DAKO 70622 
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anti-PHLDA1 rabbit 1:1000 Abcam ab133654 
anti-phospho-AKT 473 rabbit Ser473 1:1000 
Cell Signaling 
Technology 
9271S  
anti-phospho-AKT 308 rabbit Thr308 1:1000 
Cell Signaling 
Technology 
4056S 
anti-phospho-ERK 
rabbit 
Thr202/Tyr204 
1:1000 
Cell Signaling 
Technology 
9101S 
anti-REG1A rabbit 1:1000 Abcam ab47099 
anti-total AKT rabbit 1:1000 
Cell Signaling 
Technology 
9272S  
anti-total ERK rabbit 1:1000 Millipore 06-182 
anti-Vimentin mouse 1:200 DAKO M0725 
Secondary antibody Host Dilution  Source Cat. No. 
anti-mouse AF488 donkey 1:200 Life Technologies A21202 
anti-mouse AF546 donkey 1:200 Life Technologies A10036 
anti-rabbit AF488 goat 1:200 Life Technologies A11034 
anti-rabbit AF555 donkey 1:200 Life Technologies A31572 
anti-rabbit IgG-biotin  goat 1:200 DAKO E0432 
anti-mouse-HRP goat 1:1000 Invitrogen A28177 
anti-rabbit-HRP goat 1:1000 Invitrogen 32460 
anti-rat-HRP goat 1:100 Sigma-Aldrich A9037 
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2.1.6 Equipment 
Table 2.9. Equipment. 
Name Source 
ALC International PK121 
BD FACS Aria™ II  BD Bioscience, USA  
BD Fortessa BD Bioscience, USA 
Gel Docx XR Bio-Rad Laboratories Inc. 
IncuCyte™ ZOOM® Essen Bioscience 
Leica EG1150 H+C instrument Leica Microsystems 
Microm STP 120 Spin tissue 
processor 
Microm/ Thermo Fisher Scientific 
Microm HM335 microtome Microm, Walldorf, Germany 
NanoDrop One Thermo Fisher Scientific 
Pannoramic scanner 3D Histech Ltd. 
Phase-contrast light microscope  Olympus, IMT-2, Japan  
peqSTAR thermocycler VWR 
Ultra-Turrax homogenizer Janke & Kunkel, Staufen, Germany 
Zeiss Axiophot 2 light microscope 
with Axiocam Hrc camera 
Carl Zeiss AG, Oberkochen, Germany 
Zeiss LSM 710 Carl Zeiss AG, Oberkochen, Germany 
Amersham Imager 600 GE Healthcare Life Sciences 
StepOnePlus Real Time System Applied Biosystems, Paisley, UK 
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2.1.7 Software 
Table 2.10. Software. 
Software Source 
ApE (A plasmid Editor), v2.047 M. Wayne Davis 
Axiovision 4.2 or 4.6 software Carl Zeiss, Oberkochen, Germany 
BaseSpace Illumina, San Diego, USA 
BD FACSDIVA™ BD Bioscience, USA  
CLC Genomics Workbench 6/7 
CLC bio, a Qiagen Company, Aarhus, 
Denmark 
Cytoscape Institute of Systems Biology in Seattle, USA 
FastQC Brabraham Institute 
FlowJo FlowJo LLC, Ashland, Oregon, USA 
Graph Pad Prism v5.03  Graph Pad Software Inc., La Jolla, USA 
GSEA Broadinstitute 
Illustrator 
Adobe Systems Inc., San José, California, 
USA 
ImageJ 1.429  Wayne Rasband, NIH 
Imaris Bitplane 
IncuCyte™ ZOOM® 
(v20151.2.5599) 
Essen Bioscience 
Ingenuity pathway analysis (IPA) Qiagen Bioinformatics, Hilden, Germany 
Pannoramic viewer 3D Histech Ltd. 
Photoshop CS5/6 
Adobe Systems Inc., San José, California, 
USA 
R Studio R Core Team 
Roche Light Cycler 480 v1.5.0 Roche 
StepOne Plus v2.2 
Applied Biosystems, Carlsbad, California, 
USA 
String Academic consortium 
Zen 2009 Carl Zeiss, Oberkochen, Germany 
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2.1.8 PCR reagents 
Table 2.11. PCR reagents and the manufacturer. 
Name  Source 
dATP, dCTP, dGTP, dTTP 
(dNTPs) 
Invitrogen/ Life Technologies 
10X PCR buffer 
50mM MgCl2 
 
2.1.9 Plasmids 
Table 2.12. Plasmids. 
Name  Source Cat. No. 
pMD2.G Addgene 12259 
pCMVR8.74 Addgene 22036 
pLV-H2B-GFP Addgene 11680 
pLV-H2B-RFP Addgene 26001  
pcDNA3.1 Invitrogen V790-20 
pcDNA3.1 PIWIL1 
Grützner, University of 
Adelaide 
N/A 
pmaxGFP  Lonza VSC-1001 
PL-SIN-PGK-EiP EGFP Addgene 21312 
PHLDA1 GFP Addgene 32699  
PHLDA1 siRNA Dharmacon M-01238901 
pLV-Azurite Addgene 36086 
PHLDA1 shRNA Sigma Mission TRCN0000150307 
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2.1.10 Oligonucleotides 
All Oligonucleotides used in this work were from Eurogenetec.Short hairpin sequences were purchased from Sigma MISSION®. 
Table 2.13. PCR primers for generation of knockdown and overexpression. 
Primers Forward (5 -́3 ́) Reverse (5 ́-3 )́ 
PIWIL1 attB 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACTG
GGAGAGCCCGAGC 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGAGG
TAGTAAAGGCGG 
REG1A shRNA 1 
CCGGCCTGACCTCAAGCACAGGATTCTCGAGAATCCTGT
GCTTGAGGTCAGGTTTTTG 
AATTCAAAAACCTGACCTCAAGCACAGGATTCTCGAG
AATCCTGTGCTTGAGGTCAGG 
REG1A shRNA 2 
CCGGAGTGGCACTGATGACTTCAATCTCGAGATTGAAGT
CATCAGTGCCACTTTTTTG 
AATTCAAAAAAGTGGCACTGATGACTTCAATCTCGAG
ATTGAAGTCATCAGTGCCACT 
REG1A shRNA 3 
CCGGCGCTCCTACTGCTACTACTTTCTCGAGAAAGTAGT
AGCAGTAGGAGCGTTTTTG 
AATTCAAAAACGCTCCTACTGCTACTACTTTCTCGAGA
AAGTAGTAGCAGTAGGAGCG 
 
Table 2.14. Short hairpin sequences for generation of knockdowns. 
Primers Sequence 
shRNA control CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
PHLDA1 shRNA 1 CCGGCCTAATCCGTAGTAATTCCTACTCGAGTAGGAATTACTACGGATTAGGTTTTTG (TRCN0000150307) 
PHLDA1 shRNA 2 CCGGCCTAATCCGTAGTAATTCCTACTCGAGTAGGAATTACTACGGATTAGGTTTTTG (TRCN0000150983) 
PHLDA1 shRNA 3 CCGGCGAGCACATTTCTATTGTCTTCTCGAGAAGACAATAGAAATGTGCTCGTT (TRCN0000152275) 
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To generate a doxycycline inducible PHLDA1 expression construct, the full coding 
sequence of human PHLDA1 (NM_007350.3) was cloned into pDONR™221 
(Invitrogen) and then transferred to pINDUCER21 (ORF-EG) (Addgene #46948) 
using Gateway™ technology (Invitrogen). Lentiviral production and transduction 
was performed as described in section 2.2.16, 2.2.17. 
 
Table 2.15. Mycoplasma testing primers. 
Primers Forward (5 -́3 ́) 
GPO1 F ACT CCT ACG GGA GGC AGC AGT A 
GPO2 F CTT AAA GGA ATT GAC GGG AAC CCG 
MGSO R TGC ACC ATC TGT CAC TCT GTT AAC CTC 
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Table 2.16. FGFR primers. 
Primers Forward (5 -́3 ́) Reverse (5 ́-3 )́ 
FGFR1IIIa AAA GCA CAT CGA GGT GAA CG TTC ATG GAT GCA CTG GAG TC 
FGFR1IIIb TTA ATA GCT CGG ATG CGG AG ACG CAG ACT GGT TAG CTT CA 
FGFR1IIIc TGC TGG AGT TAA TAC CAC CG CCA GAA CGG TCA ACC ATG CA 
FGFR2IIIa AAG GTT TAC AGC GAT GCC CA CTG CTG AAG TCT GGC TTC TT 
FGFR2IIIb AAG GTT TAC AGC GAT GCC CA AGA GCC AGC ACT TCT GCA TT 
FGFR2IIIc GTG TTA ACA CCA CGG ACA AA TGG CAG AAC TGT CAA CAA TG 
FGFR3IIIb GAG TTC CAC TGC AAG GTG TA AAA TTG GTG GCT CGA CAG AG 
FGFR3IIIc AGA ACC TCT AGC TCC TTG TC AGA ACC TCT AGC TCC TTG TC 
FGFR4 TAT CTG GAG TCC CGG AAG TG GTG TGT GTA CAC CCG GTC AA 
 
Table 2.17. Primers used for qRT-PCR analysis. 
Primers Forward (5 -́3 ́) Reverse (5 ́-3 )́ 
B2M AGT TAA GTG GGA TCG AGA C GCA AGC AAG CAG AAT TTG G 
GAPDH CCA TGG AGA AGG CTG GGG CAA AGT TGT CAT GGA TGA CC 
GLUT1 AAC TCT TCA GCC AGG GTC CAC CAC AGT GAA GAT GAT GAA GAC 
HPRT1 GAC CAG TCA ACA GGG GAC AT CCT GAC CAA GGA AAG CAA AG 
PHLDA1 CAG AGG GCA AGG AGA TCG AC GTG GAT TTG ACC GCC AGG AT 
PIWIL1 CAA GTA ATC GGA AGG ACA AA CTA CCA ATG GAT TTT AGA CAA 
REG1A ACA GAG TTG CCC CAG GCC CGG AGA ACT TGT CTT CAC AAG GCA 
SI CAT CCT ACC ATG TCA AGA GCC AG GCT TGT TAA GGT GGT CTG GTT TAA ATT 
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2.2 Methods 
2.2.1 2D Cell culture methods 
2.2.1.1 Basic cell culture applications 
To study gastric cancer, a panel of 6 cell lines was obtained from American Type 
Culture Collection (ATCC). Endometrial MFE-296 and AN3CA cells were obtained in 
house and lung cancer cell lines H1299 and H520 were kindly provided by Prof. John 
Marshall. Cells were cultured in suspension, as semi-adherent or adherent cells in a 
monolayer (Table 2.18) in culture flasks of various sizes (Corning, 25cm2 (430639), 
75cm2 (430641U) and 175cm2 (431080)) in a humidified atmosphere of 37°C and 5% 
CO2.  
2.2.1.2 Passaging cells 
When cells reached approximately 80-90% confluence for adherent cultures and cells 
started clumping for suspension cells, medium was removed and 
trypsin/ethylenediaminetetraacetic acid (EDTA) (GE Healthcare) was added for 5-10 
minutes and incubated to detach cells from the flask surface. Once cells were 
detached, trypsin was inactivated with the relevant medium (Table 2.18). Cell 
suspensions were centrifuged at 250 relative centrifugal force (rcf/ x g, ALC 
International, PK121) for three minutes at room temperature (RT). Following 
centrifugation, supernatant was removed and the cell pellet was re-suspended in 
standard medium. If counting of cells was required, 10μL of the cell suspension was 
mixed with Trypan Blue and from the mixture 10μL was immediately added to a 
FastRead counting haemocytometer (Immune Systems, BVS100) and cells were 
counted manually under a light microscope (Olympus, IMT-2, Japan). Cells were sub-
cultured at a 1:2 to 1:20 ratio, depending on their growth rates. 
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Table 2.18. Summary of cell lines. 
All cell lines and respective cell culture medium used, together with their growth state. MEM = Modified 
Eagle’s Medium, DMEM = Dulbecco’s Modified Eagle’s Medium, FBS = foetal bovine serum, L-Glut = L-
Glutamine, NEAA = Non-essential amino acids, RPMI = Roswell Park Memorial Institute, Ham’s F12 = 
F12 nutrient medium. 
 
Cell line Cell culture medium Growth state 
Endometrial cancer   
MFE-296 MEM, 10% FBS adherent 
AN3CA DMEM, 10% FBS, 2mM L-Glut adherent 
Ishikawa MEM, 5% FBS, 2mM L-Glut, 0.1% NEAA adherent 
Gastric cancer   
KATOIII RPMI-1640, 20% FBS, 2mM L-Glut semi-adherent 
SNU-1 RPMI-1640, 10% FBS suspension 
SNU-16 RPMI-1640, 10% FBS suspension 
SNU-5 RPMI-1640, 20% FBS suspension 
AGS Ham’s F12, 10% FBS, 2mM L-Glut adherent 
NCI-N87 RPMI-1640, 10% FBS adherent 
Lung cancer   
H520 RPMI-1640, 10% FBS adherent 
A549 DMEM, 10% FBS adherent 
H1299 RPMI-1640, 10% FBS adherent 
Fibroblasts   
HFF2 DMEM, 10% FBS adherent 
MRC5 MEM, 10% FBS adherent 
Packaging cells   
HEK293T DMEM, 10% FBS adherent 
 
2.2.1.3 Cryopreservation and thawing of cells 
Stocks of each cell line were kept in liquid nitrogen for long-term storage. To freeze 
cells, cell pellets were taken up in respective freezing medium, consisting of complete 
growth medium and 5% DMSO for all gastric cancer cell lines or 90% FBS and 10% 
DMSO for other cell types, and pipetted into cryovials (Corning, 430489) and slowly 
frozen down at -80°C overnight and later transferred to liquid nitrogen (-196°C).  
To recover cells from liquid nitrogen stocks, cell suspensions were thawed rapidly at 
37°C in a water bath and transferred to a 15mL Falcon™ tube (Corning, CLS430791) 
with complete growth medium. The cell suspension was centrifuged at 250 x g for 
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three minutes to expel residual DMSO. The supernatant was discarded and the cell 
pellet was taken up in pre-warmed fresh complete growth medium (Table 2.18) and 
plated into the appropriate cell culture flasks. Cells were regularly tested for 
Mycoplasma with the primers shown in Table 2.15. 
2.2.1.4 PCR cell line mutation 
To ensure each cell line contained the mutations detailed in the literature, PCR-based 
cell line sequencing was performed. Primers were designed using Primer3Plus 
(Primer3Plus, 2015) to amplify an approximately 200 base pairs (bp) region around 
the mutation site. PCR using HotStarTaq Plus DNA Polymerase (QIAGEN) was then 
performed according to the manufacturer’s instructions and using the PCR conditions 
detailed in Table 2.19. 
The PCR product was subsequently run on a 1.5% agarose gel, containing Gel Red 
(Biotium), and visualised under Ultra Violet (UV) light to ensure a single, strong band 
was produced from the PCR.  
2.2.2 PCR for FGF receptor expression 
To verify the FGFR expression status of the cell lines used, primers for each FGFR 
were used with the PCR cycle settings per Table 2.19. PCR products were then run 
on an agarose gel containing Gel Red and visualised under UV light. All experiments 
were performed in triplicate. 
 
Table 2.19. PCR cycle for the amplification of FGFR sequences. 
Step Temperature (°C) Time (min) Cycles 
Initial denaturation 94 5 1 
Denaturation 94 0.5  
Annealing 58 0.5 35 
Extension 72 0.5  
Final extension 72 7 1 
Hold 16 Indefinitely  
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2.2.3 Serum starvation 
Cells were seeded in 6-well plates in culture medium and incubated at 37°C, 5% CO2. 
After 16 hours for adherent cells, medium was removed and cells were serum starved 
in FBS-free medium for 1, 2, 4, 8, 16 or 24 hours. For suspension cells, cells were serum 
starved immediately after counting. Control cells were treated with complete growth 
medium (Table 2.18) for 24 hours, after which all cells were lysed and protein was 
isolated as described in section 2.2.29. All experiments were performed in triplicate.  
2.2.4 Stimulation assay 
Respective cells were seeded in 6-well plates in culture medium and incubated at 
37°C, 5% CO2. After 16 hours, medium was removed and cells were serum starved in 
FBS-free medium for 4-6 hours. Again, suspension cells were serum starved 
immediately after counting. Media were then exchanged to FBS-free medium 
containing PD (Sigma-Aldrich, P2499) at a final concentration of 2μM, 1μM AZD 
(AstraZeneca, UK), 1.5μM BGJ (courtesy of Valerie Schuele, Novartis Pharma AG) or 
the equivalent volume of DMSO for control wells, for 1 hour. After 15 and 60 minutes 
300ng/mL heparin (Sigma-Aldrich) was added to each well and 100ng/mL FGF2 or 
FGF10 (PeproTech) were used to stimulate cells. After 1 hour, cells were lysed and 
protein was isolated as described in section 2.2.29. All experiments were performed 
in triplicate 
2.2.5 Cell counting 
In order to count cells, cells were washed in PBS, pelleted and re-suspended in 1mL 
complete growth medium (Table 2.18). From the cell suspension 10µL were mixed 
with 10µL Trypan Blue in an Eppendorf and 10µL were pipetted into a 
haemocytometer (FastRead) and viewed using a light microscope. Viable cells from 
three 4x4 squares were counted (Top left, bottom right and middle left) and averaged 
and adjusted for Trypan Blue addition (x2). The same procedure was used for all cell 
counting experiments for consistency. 
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2.2.6 Cell viability assay in 2D 
FGFR inhibitors PD, AZD and BGJ were dissolved to a stock concentration of 10mM 
in DMSO and stored at -20°C, or 4°C for PD. Stock dilutions were then further diluted 
in complete growth medium (Table 2.18) when necessary. 
Gastric, endometrial and lung cancer cells were seeded into 96-well plates and 
incubated at 37°C, 5% CO2. The next day, cells were treated with a range of drug 
concentrations in technical triplicate and, as a control, cells were treated with DMSO 
at the same concentration as in the drug-treated wells. As a positive control for cell 
killing, and background signal, 0.01% Staurosporine was added to three wells. The 
96-well plates were then incubated for 72 hours at 37°C.  
To check viability of treated cells, a (4,5-dimethylthylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay was performed. Medium was removed after 72 
hours incubation with the inhibitor, followed by addition of fresh medium containing 
0.5 mg/mL MTT (Invitrogen). After 3 hours incubation, medium was replaced with 
DMSO to dissolve the formazan crystals. The absorbance was measured at 550nm 
using a spectrophotometer plate reader (Tecan Infinite F50). For some cell lines, such 
as the suspension cells and more recent cell viability assays, a 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium) (MTS) assay 
was used, whereby 10μL of the MTS reagent (Promega G3581) was directly added to 
the wells and absorbance was measured with the spectrophotometer after 1-4 hours, 
depending on the cell line used. The measured values were then normalised to DMSO 
controls after subtracting the background absorbance from the Staurosporine-treated 
wells and displayed graphically using Prism 5 (Graph Pad, USA). Half maximal 
inhibitory concentrations (IC50) of inhibitors tested were calculated with Prism using 
the sigmoid dose–response function. All experiments were performed in biological 
triplicate.  
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2.2.7 Cell viability using IncuCyte™ ZOOM® 
H520 cells were either seeded alone or 2:1 ratio in conjunction with MRC-5 H2B-GFP 
cells into 96-well plates at a density of 1.5 x 103 cells per well. The following day cells 
were treated with BGJ ranging from 0.03nM to 50μM and incubated for 72 hours. The 
plates were then simultaneously placed inside an IncuCyte™ ZOOM® imaging 
system (Essen BioScience), which consists of a microscope gantry that resides within 
a cell incubator and can obtain real time live cell imaging. Channel selection phase 
and fluorescence capturing was selected to distinguish fibroblast cells from cancer 
cells. Four images per well were captured every 30 minutes for two hours and cell 
viability, cell growth area and fluorescence intensity were measured over time. 
2.2.8 Cell cycle analysis 
In order to quantify DNA content, cells were harvested and washed in PBS. Cells 
were then fixed in ice-cold 70% ethanol which was added dropwise to the pellet 
whilst vortexing, thus avoiding the formation of clumps. Cells were fixed for 30 
minutes at 4°C and pelleted. Cells were washed twice in PBS and subsequently 
centrifuged at 250 x g for 5 minutes to avoid cell loss when discarding the supernatant 
especially after spinning out ethanol. Next, cells were treated with 50µL of a 
100µg/mL stock of RNase ensuring only DNA will be stained. DNA was either 
stained using Propidium Iodide (PI, Sigma-Aldrich, P4864) or 4',6-diamidino-2-
phenylindole (DAPI, Life Technologies™, P36931) at a concentration of 50µg/mL 
from a 50X stock solution (2.5mg/mL). Stained cells were then analysed using BD LSR 
Fortessa and FlowJo, v10.7 (BD Biosciences).  
2.2.9 Annexin V cell apoptosis assay  
Cells were seeded at a density of 2.5 x 105 per well in 6-well plate and either treated 
on the same day (suspension cells) or the following day (adherent cells) with the 
respective reagents or DMSO (vehicle control) for 72 hours. Cells were then removed, 
washed with PBS and re-suspended in binding buffer (10mM HEPES, 140mM NaCl, 
2.5mM CaCl2) at a concentration of 106 cells/mL. Of the suspension, 100μL (105 cells 
in 100μL) were transferred to a 5mL round-bottom polypropylene tube. Annexin V-
Alexa Fluor647 (2.5μL) and PI (2.5μL) were added to the cells, gently vortexed and 
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incubated for 15 minutes at RT in the dark. For each experiment control samples were 
prepared and left untreated, or only treated with either PI or Annexin V. Cells were 
analysed by BD LSR Fortessa and FlowJo, v10.7 (BD Biosciences).  
2.2.10 Generation of FGFR inhibitor-resistant cell lines 
Cells were seeded in their respective culture medium, as detailed previously, in 
35mm dishes. After 24 hours, the appropriate concentration of inhibitor or DMSO 
control was added. Medium was changed every 2-3 days. After 7 or 14 days, adherent 
cells were detached from the dish using trypsin/EDTA or just removed and spun in 
the case of suspension cells and counted manually under a light microscope using a 
FastRead haemocytometer. All experiments were performed in triplicate. To generate 
the drug-resistant SNU-16BGJR cell line, cells were exposed to increasing drug dosages 
over a time course of one month, were the drug dosage was doubled at every second 
passage starting with 100nM, reaching a final dosage of 1.5μM BGJ for SNU-16.  
The same approach was used to generate BGJ-resistant H520 cells (H520BGJR) reaching 
a final dosage of 1μM. The resistant cells were cultured until they again had growth 
kinetics in presence of drug similar to that of untreated parental cells. 
For experiments with drug-resistant cells, the cells were kept in inhibitor and then 
medium was exchanged to inhibitor-free medium for 1h prior to cell seeding and 
treatment. 
2.2.11 Immunofluorescence staining of cells on coverslips 
Cells on coverslips were washed, fixed in 4% PFA and permeabilised with 0.1% Triton 
X-100/2% BSA, followed by blocking in 2% BSA/PBS for 1 hour. Coverslips were 
incubated with anti-E-Cadherin (BD Bioscience, 610182) primary antibody diluted 
1:100 in 2% BSA/PBS for 1 hour at RT. After washing the coverslips in 2% BSA/PBS, a 
fluorescent anti-mouse secondary antibody at a dilution of 1:200 in 5% BSA/PBS was 
incubated for 1 hour at RT (followed by mounting using mounting medium 
supplemented with 1μg/mL DAPI). 
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2.2.12 Short interfering RNA (siRNA) knockdown  
Cells were seeded in 6-well plates in complete medium. The following day, at 
approximately 40% confluence, the medium was replaced with 1mL of complete 
medium (Table 2.18). Cells were transfected with a pool of four siRNA 
oligonucleotides targeting the gene of interest at a final concentration of 10nM. 
Control cells were transfected with a pool of non-targeting siGenome siRNA at the 
same concentration. Transfection of the siRNA was facilitated using INTERFERin 
(Polyplus) at 4μL/100μL. INTERFERin and siRNA complexes were prepared in 
Opti-MEM™ (Gibco by Life Technologies™), vortexed and incubated at RT for 20 
minutes before 100μL of the mixture was added to cells in culture medium. Cells were 
incubated for 48 hours or 120 hours before cell lysis or drug treatment and 
confirmation of knockdown was performed by Western blot (section 2.2.29). 
2.2.13 Plasmid preparation and bacterial transformation 
Competent Stbl3 E.coli (Invitrogen) were thawed on ice and 1μg of plasmid DNA was 
added. After 30 minutes of incubation, bacteria were heat shocked at 42°C for 30 
seconds. SOC medium (Invitrogen) was added to the vial on ice before incubation at 
37°C for 1 hour with agitation. After incubation, 150μL of the cell suspension was 
pipetted onto an agar (Fisher Scientific) plate containing 100μg/mL ampicillin (Sigma-
Aldrich, Poole, UK) and incubated overnight at 37°C. Bacterial colonies were picked 
and cultured in 5mL LB broth (Fisher Scientific) containing 100μg/mL ampicillin for 
8 hours. Plasmids were isolated using a Qiagen mini prep kit (Qiagen, Manchester, 
UK) according to manufacturer’s instructions. 
2.2.14 Transfection of genes in cells using Lipofectamine 
Cells were seeded in a T75 culture flask at 40% confluence in standard medium. The 
following day, medium was removed and cells were washed with PBS. Opti-MEM™ 
was warmed to 37°C and 5mL added to each flask. For transfection control wells, 
1μg/μL pmaxGFP (pGFP) (Lonza) was added to 1.25mL Opti-MEM™ in a Falcon™ 
tube. A second Eppendorf tube containing 25μL Lipofectamine 2000 (Invitrogen) 
with 1.25mL Opti-MEM™ was prepared and both solutions were incubated at RT for 
5 minutes. The contents of both tubes were then mixed and incubated at RT for 20 
Materials and Methods 
95 
 
minutes. The total volume was then added to control flasks and incubated at 37°C for 
4 hours. Medium was then removed and replaced with standard culture medium and 
cells incubated at 37°C for 48 hours. For pPHLDA1 transfection, 1μg/μL of plasmid 
was added to 1.25mL Opti-MEM and mixed with the Lipofectamine 2000 
preparation as above and added to the cells. After 16 hours, flasks were inspected 
under UV light for GFP expression. Cells were lysed and PHLDA1 levels analysed 
via Western blot, as outlined in section 2.2.29. 
2.2.15 Transfection of genes using jetPRIME 
In a 6-well plate 1.5 x 105 cells were seeded in 2mL of culture medium. In the case of 
adherent cells, overnight incubation was required. However, suspension cells were 
treated immediately after seeding. Transfection was performed in the presence of 
serum by diluting 2μg DNA in 200μL jetPRIME buffer, followed by vortexing for 10 
seconds. 4μL jetPRIME reagent was added, vortexed 10 seconds and incubated for 
10 minutes at RT. The transfection mix was then added to the cells in serum 
containing medium and incubated at 37°C, 5% CO2. The next day, medium was 
exchanged and cells were incubated for 24 to 48 hours prior to analysis by cell 
counting, PCR or Western blot. 
2.2.16 Lentiviral particle production  
To achieve stable expression of a desired gene in a cell line that shows difficulties with 
being transfected, due to toxicity issues or for experiments that require longer gene 
expression or knockdown of the gene, lentiviral expression systems have been used. 
Lentiviral particles containing fluorescence markers were used to differentiate 
between cells. The system is based on the human immunodeficiency virus, and uses 
four plasmids; pREV, pGAG/Pol, pVSVG, and a final plasmid for the vector to be 
inserted into the host cell. pREV and pGAG/Pol encode for viral proteins required for 
efficient viral packaging. pVSVG encodes a viral protein required for effective 
infection of the viral particles into the host cells (Dull et al., 1998). These plasmids are 
combined and transfected into HEK293T cells, that in turn generate and release viral 
particles into the cell culture medium. The supernatant of the medium can then be 
used to infect target cells (Figure 2.2). To generate a Lentivirus expressing Azurite, 
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EGFP, H2B-RFP or GFP (Figure 2.3), HEK293T cells were grown to approximately 50-
70% confluence. Four hours before transfection, medium was changed to fresh 
DMEM supplemented with 10% FBS. 5μg lentiviral plasmid, 1.75μg of the envelope 
vector pMD2G and 3.2μg of pCMV-dR8.74 were mixed in 470μL Opti-MEM™ 
followed by subsequent addition of 30μL FuGene (Promega). The mixture was added 
dropwise onto the cells and incubated for 30 minutes at 37°C, 5% CO2. The next day, 
the medium was exchanged to normal growth medium and the following day the 
viral supernatant was collected and pelleted. Viral supernatant was then stored at -
80°C until further use. 
 
 
 
Figure 2.2. Schematic overview of lentiviral transfection.  
HEK293 cells serve as packaging cells and are transfected with an envelope plasmid (red), a plasmid 
containing the gene of interest (purple, in this case the fluorescent marker) and packaging plasmid 
(green). The medium containing the virus is collected and target cells are transduced. 
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Figure 2.3. Histone H2B-RFP and H2B-GFP vectors, Azurite and EGFP vector map. 
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2.2.17 Infection of cells with lentiviral supernatant 
To generate cancer cell lines expressing EGFP or Azurite, 1mL viral supernatant was 
added to 2mL of medium containing cells in a 6-well plate and incubated for 24 hours 
at 37°C, 8% CO2. The following day, 1μg/mL Puromycin (Thermo Fisher Scientific) 
was added to the culture medium and cells were incubated at 37°C, 5% CO2. The 
success of the stable transfection and integration of the fluorescent plasmid was then 
tested by fluorescence microscopy and FACS, performed by the Flow Cytometry 
Facility at Barts Cancer Institute.  
2.2.18 Fluorescence activated cell sorting (FACS) of live cells  
To assess EGFP expression or Azurite expression, adherent cells were washed, 
trypsinised and pelleted by centrifugation for 2 minutes at 250 x g. Suspension cells 
were pelleted immediately and cells were re-suspended in 500μL culture medium 
and transferred to round bottom polystyrene FACS tubes (Corning, #352235). 
Cells were sorted using BD FACS Aria™ II (BD Bioscience, USA). Cells were gated 
based on forward scatter (FSC) and side scatter (SCC) to exclude debris and a second 
gate was set to exclude doublets on a dot plot of pulse area (FSC-A) versus height 
(FSC-H). H2B-RFP positive cells were detected with the yellow laser at 610nm 
bandpass filter and H2B-GFP positive cells were detected with the blue laser at 525nm 
bandpass filter. 
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2.2.19 Organotypic cell culture using Alvetex® scaffolds 
Alvetex® scaffolds (Reprocell Ltd.) were used as a novel technique of 3D cell culture. 
The scaffold consists of a polystyrene membrane of 200µm with pore sizes of about 
40µm. In this project mainly 12-well scaffold inserts were used (Figure 2.4). Prior to 
cell seeding, the Alvetex® scaffold was first immersed in 70% EtOH followed by two 
PBS washes and a final culture medium wash. Cells were then seeded dropwise in 
the middle of the scaffold membrane and fed with medium from below (Figure 2.5). 
For co-culture experiments, cells were transfected with lentiviral supernatant as 
described in 2.2.17 and in 2:1 ratio of cancer cells to fibroblasts (Figure 2.6). Cells were 
grown up to 21 days and imaged live using a confocal laser scanning microscope 
(CLSM 710, Carl Zeiss). Additionally, the scaffolds were also fixed and embedded in 
paraffin for immunofluorescence or immunohistochemistry. Different formats of 
Alvetex® were used, 24 well-plates with free floating scaffolds, 12 well insert scaffolds 
and 96-well plates. Scaffolds were either coated with rat tail collagen I (BD 
Biosciences, 354236; 0.8mg/mL), Matrigel™ (BD Biosciences, 354234; 0.8mg/mL) or 
left uncoated. Collagen and Matrigel™-coated scaffolds were incubated at RT for 1-2 
hours. Excess fluid was aspirated and cells were seeded immediately onto the 
scaffolds. The scaffolds containing the cells suspensions were incubated for a 
minimum of 30 minutes at RT to enhance attachment of cells prior to incubation at 
37°C, 5% CO2. 
 
Figure 2.4. Schematic representation of the 3D cell culture model Alvetex. 
The Alvetex® 3D model consist of a polysterene membrane in an insert where cancer cells mixed with 
fibroblasts can be seeded onto. The insert are placed in a 6-well plate. Cultures are fed from underneath. 
This model can be used to assess the effects of pharmacological agents by inclusion of such drugs in the 
medium (Chioni and Grose, 2012, Coleman et al., 2014, Froeling et al., 2009). In this model, cells are fed 
every 2-3 days for the duration of the experiment, after which they are formalin fixed, sectioned and 
stained for a range of cellular markers. 
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Figure 2.5. Alvetex® workflow for 12-well insert scaffolds. 
Scaffolds were submerged in 70% EtOH followed by two PBS washes. Cells were then seeded on top of 
the scaffold and incubated at RT for 30 min. Medium was then fed from below to create a chemotactic 
gradient. 
 
 
 
 
 
 
 
Figure 2.6. Alvetex® cell seeding.  
Cells were seeded 2:1 cancer cells to fibroblasts onto uncoated, collagen or Matrigel™-coated Alvetex® 
scaffolds. 
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2.2.20 3D Cell viability assays 
96-well Alvetex® plates consist of a black plate with a clear plastic base, with an 
Alvetex® scaffold at the bottom of each well. The Alvetex® scaffold has been heat 
welded to the base of the wells in a process which does not alter its physical structure. 
Cells growing in Alvetex® scaffolds are exposed to culture medium from above only 
and predominantly reside in the top portion of the scaffold. As with 2D culture, 
coating reagents to enhance cell attachment can be considered (e.g. ECM proteins). 
As with the Alvetex® insert, prior to use, sample wells were rehydrated with 70% 
ethanol (~100μL). Ethanol was removed by aspiration and wells were washed once 
with 200μL PBS and then immediately with 200μL appropriate cell culture medium 
to avoid drying of the scaffold. Next, 200μL of medium containing 5 x 103 to 105 cells 
were seeded into the wells and incubated for 1 hour at RT before treatment to increase 
attachment and uniformity. The MTT or MTS assay was performed as described in 
section 2.2.6 with the exception, that before measuring absorbance, 100μL of medium 
in the wells was transferred to a clear 96-well plate and measured at 550nm with a 
spectrophotometer. All experiments were performed in technical triplicate. 
2.2.21 3D drug resistance 
In order to generate drug resistant cancer cells in 3D, 106 cells were seeded into 12-
well insert Alvetex® scaffolds according to section 2.2.19. In terms of cell culture 
conditions, SNU-16 H2B-RFP cells were seeded alone or in co-culture with HFF2-
EGFP cells (2:1). The following day medium was removed and medium containing 
100nM BGJ or an appropriate concentration of the vehicle control was fed from below 
(Figure 2.7). Medium was changed every second day and the concentration of the 
FGFR inhibitor was doubled at every second medium change. Control samples of the 
conditions were live imaged once a week using a confocal microscope. Monoculture 
and co-culture control wells were harvested after 2 weeks, BGJ-treated co-culture 
samples were harvested (section 2.2.26.1) after 4 weeks together and monoculture 
BGJ-treated cells were harvested after 8 weeks when resistant cell populations were 
observed. 
 
Materials and Methods 
102 
 
 
 
Figure 2.7. Generation of resistant cells in 3D experimental layout.  
SNU16 H2B-RFP and HFF2-EGFP fluorescently tagged cells were seeded 2:1 or SNU-16 H2B-RFP cells 
alone into Alvetex® 12 well-insert scaffolds and treated either with the vehicle control DMSO or BGJ 
until resistant cell populations were observed. 
 
2.2.22 Live image acquisition 
Alvetex® scaffolds were removed from the 6-well plate using tweezers and placed 
onto a 35mm glass coverslip-bottomed dish (Greiner bio-one, 627 861). The confocal 
microscope was equipped with a heated chamber set to 37°C, 5% CO2 to simulate the 
incubator conditions. The dish with the Alvetex® scaffold was then positioned into a 
heated 35mm dish-holder on an automated x-y scanning stage in the chamber. In situ 
overlapping sections of H2B-RFP positive cells in the z-axis were detected using a 
568nm excitation line and 602nm emission and H2B-GFP or EGFP and H2B-GFP-
positive cells were detected using a 488nm excitation line and 517nm emission. Along 
the z-axis, series of images of 700μm square (x-y plane) were acquired at constant 
4μm intervals with a 1μm overlap to approximately 200μm depths through the 
scaffold, using a long working distance 20x air objective (Carl Zeiss, Objective LD 
Plan-Neofluar 20x/0.4 Corr M27). Per sample, three images were acquired to calculate 
statistical significance. 
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2.2.23 Image rendering using Imaris  
The raw laser scanning microscope (.lsm) Z-stack data files acquired using the LSM 
710 were imported to the image analysis software Imaris (Bitplane AG, Switzerland). 
With the base software, 3D images of the Z-stacks were rendered and background 
noise was removed, generating smooth surfaces, a higher resolution and sharper 3D 
images. Within a 700μm x 700μm x 200μm image, cellular volumes of H2B-RFP 
positive and EGFP or H2B-GFP positive cells were measured, which were 
represented in comma-separated value (.csv) files (in addition further parameters 
such as area, intensity, position, sphericity, and volume were also generated), 
allowing high content data analysis. 
2.2.24 Cell retrieval from Alvetex® for RNA and protein extraction 
As opposed to other common organotypic methods, cells in Alvetex® scaffolds can be 
retrieved from the scaffolds for RNA extraction or protein extraction. Scaffolds were 
removed from the wells and, with a sterile scalpel or sterile dissecting scissors, cut 
into small pieces to increase the surface of the detaching agent. The pieces were 
transferred to a sterile 15mL Falcon™ containing 5mL of 0.25% Trypsin-EDTA and 
incubated at 37°C, 5 % CO2 and secured with autoclave tape on a shaking platform 
set to 100rpm for 10 minutes, thus ensuring the maximize the range of agitation. To 
increase detachment the tube was shaken by hand for 10 seconds followed by 
transferring the resulting cell suspension to a 50mL centrifuge tube and 5mL FBS-
containing medium was added to neutralise the trypsin solution. Detached cells were 
kept at 37°C, 5% CO2. Trypsinisation of the quarters was repeated with another 5mL 
0.25% Trypsin-EDTA and transferred into the same 50mL tube. Cells were pelleted at 
250 x g for 5 minutes and re-suspended in appropriate volume of medium for the 
downstream process. 
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2.2.25 Histology methods 
2.2.25.1 Fixation, harvesting and processing organotypic samples 
Alvetex® scaffolds were removed from the 6-well plate and fixed in 10% v/v neutral 
buffered formalin (Cellstor, BAF-0010-25A) for 12 hours at 4°C followed by washing 
with PBS twice. The membrane was removed from the scaffold using a scalpel, placed 
into histology embedding cassettes held in between two sponges and transferred to 
70% v/v ethanol for at least three hours until embedded in paraffin. Samples were 
dehydrated, then processed through xylene and in 60°C paraffin, using a Leica 
ASP300 processor. Samples were embedded in paraffin using a Leica EG1160 H+C 
instrument and stored at 4°C. 4μm paraffin sections were cut using the Microm 
RM2255 microtome and placed on Superfrost slides, which were then incubated at 
37°C overnight to dry the samples. The sections were then stored at RT or 
Haematoxylin-Eosin (H&E) stained using the Leica autostainer XL CV5030. Sample 
embedding and H&E staining was performed by the Histopathology Department, 
Barts Cancer Institute. 
2.2.25.2 Deparaffinisation of paraffin-embedded tissue sections  
Histological analysis of paraffin embedded samples required the sections to be 
completely free from paraffin and then rehydrated via increasing concentration 
gradients of ethanol. The sections were then stored in PBS until further use. 
 
Table 2.20. Deparaffinisation and rehydration of paraffin-embedded samples. 
Procedure Duration 
Xylene  2 x 10 min 
100% EtOH 10 min 
100% EtOH 2 min 
90% EtOH 2 min 
80% EtOH 2 min 
50% EtOH 2 min 
Distilled water 1 min 
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2.2.25.3 Immunofluorescence staining of paraffin-embedded scaffolds 
Slides of 4μm thick paraffin sections of Alvetex® scaffolds were dewaxed in xylene 
and rehydrated through a series of graded ethanol and transferred to PBS. To retrieve 
antigens, slides were placed in 10mM sodium citrate buffer (pH 6.0) and boiled in the 
microwave for 11 to 20 minutes on maximum power. The slides were subsequently 
cooled using cold water for three minutes and then washed three times for 5 minutes 
with PBST, rinsed twice in PBS and then sections were encircled using a DakoPen. 
Samples were permeabilised with 0.2% Triton/PBS for 5 minutes at RT. Unspecific 
binding sites were blocked by incubating the slides in PBSABC buffer (containing 2% 
BSA, 10% FBS) for 1 hour at RT, followed by incubation in primary antibody at a 
dilution of 1:100 in PBSABC buffer overnight at 4°C in a humidified box. The 
following day, slides were washed three times with PBS and incubated with a 
fluorescence-conjugated secondary antibody at a dilution of 1:200 in PBSABC buffer 
for 1 hour at RT. The slides were washed again three times in PBST for 5 minutes and 
incubated with DAPI in PBS for 10 minutes. The slides were washed in PBS, dipped 
in distilled water and mounted with Mowiol before being stored at 4°C.  
2.2.25.4 Microscope image acquisition 
Confocal images were acquired at RT using a confocal microscope (LSM710; Carl 
Zeiss). Images were taken using a 20x air objective (Carl Zeiss, Objective LD Plan-
Neofluar 20x/0.4 Corr M27). The acquisition software used was ZEN 2009 (Carl Zeiss). 
Thresholds were set per slice and remained constant for all images analysed. 
Bright-field images were acquired at RT using a light microscope (Axiophot; Carl 
Zeiss) fitted with a camera (AxioCam HRz; Carl Zeiss). The objective used was a Plan 
Neofluar with 10x magnification and 0.3 aperture. The acquisition software used was 
AxioVision Release 4.8 (Carl Zeiss). The Pannoramic 250 high throughput scanner 
(3D Histech Ltd.) was used for whole and enlarged image acquisitions of the Alvetex® 
slides stained with H&E and IHC stainings. 
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2.2.25.5 Statistical data analysis  
In all experiments, quantitative statistics were calculated with Prism 5, unless 
otherwise stated. Descriptive statistics are presented as a means ± standard errors. 
Comparisons between two sample groups used Student’s T-tests, whereas 
comparison of more than two sample groups used one-way analysis of variance 
(ANOVA). 
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2.2.26 RNA methods 
2.2.26.1 RNA isolation and purification from cells 
Cells were seeded in 6-well plates and harvested at 80% confluency for RNA isolation 
using an RNeasy® Mini kit (QIAGEN, Manchester, UK). Cells were washed twice 
with PBS followed by the addition of 350μL RLT buffer per well. Cells were scraped, 
collected and placed into an Eppendorf and 250μL 100% EtOH was added and mixed 
thoroughly. RNA was then purified according to the manufacturer’s instructions. To 
elute RNA, 20μL RNAse-free water was added and centrifuged as previously 
described. This step was repeated with 10μL RNAse-free water, yielding a total 
volume of 30μL. The concentration of the purified RNA was measured using a 
Nanodrop 1000 spectrophotometer and then stored at -80°C until further use. 
2.2.26.2 cDNA synthesis 
To synthesise cDNA, 1μL 50μM random hexamer primers (Thermo Fisher Scientific), 
1μg of purified total RNA and 1μL dNTPs (10mM each) were diluted in RNAse-free 
water to a volume of 12μL. The mix was heated to 65°C for 5 minutes and then placed 
immediately into ice. To this mixture 4μL 0.1M Dithiothreitol (DTT) and 1μL 5X first 
strand buffer were added, mixed and incubated at RT for 2 minutes. Then 1μL (200 
units) SuperScript™ II RT (Invitrogen) was added, mixed and reverse transcription 
was then achieved using a Flexigene thermal cycler (Techne, Stone, UK) according 
the settings of 25°C for 10 minutes, 42°C for 50 minutes, 70°C for 15 minutes. The 
resulting cDNA was then stored at -20°C. 
2.2.26.3 Quantitative real time PCR (q-RT PCR) 
For q-RT PCR, a master mix was prepared consisting of 1μL of cDNA mixed with 
RNAse-free water to a volume of 5μL per well. As for the respective primers (10mM 
forward and reverse primer in ddH2O) (Custom Oligo, Invitrogen), 0.15μL were 
mixed with 4.85μL SYBR ROX (Qiagen) and pipetted into the cDNA. As a control, the 
same master mix was also prepared but instead probed with primers for the 
housekeeping genes Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) (Custom Oligo, Invitrogen). 
Three replicates were performed per condition and gene. q-RT PCR was performed 
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in the StepOnePlus Real Time System (Applied Biosystems, Paisley, UK) as described 
in Table 2.21. The q-RT PCR reaction was evaluated by analysing the melt curves to 
assess qRT PCR amplicon length using the StepOne software v2.2. 
 
Table 2.21. qRT-PCR steps in the StepOnePlus Real Time System. 
 Cycles Target (°C) Duration 
Preincubation 1 95 15 min 
Amplification 40 
95 
60 
72 
30 s 
30 s 
30 s 
Melting curves 40 
56 
95 
60 s 
15 s 
Cooling 1 4 30 s 
The relative expression levels were calculated using the 2-ΔΔCT method (Livak and 
Schmittgen 2001). The mean values of each condition were related to the expression 
levels of the reference housekeeping genes GAPDH and HPRT for normalisation. 
Statistical analysis was then performed using Prism 5. In order to compare two 
groups of data, a Mann-Whitney test was used. Error bars indicate the mean standard 
deviation and asterisks show significance between compared groups. 
2.2.27 RNA sequencing 
Cells were grown in Alvetex® until resistant populations were found by live cell 
imaging, or until control wells were fully confluent. Cells were retrieved from 
scaffolds as described in section 2.2.24 and total RNA was extracted using the 
RNeasy® Plus RNA extraction kit (QIAGEN), according to the manufacturer’s 
instructions. Additionally, working utensils were UV and RNAseZap-treated. Cell 
pellets were resuspended in RLT buffer supplemented with 1% ß-mercaptoethanol, 
which irreversibly denatures RNAses by reducing disulphide bonds and destroying 
the native conformation for the enzyme functionality together with guanidinium 
isothiocyanate (GITC) contained in the lysis buffer any RNAse present will be 
inactivated. In addition, a DNAse digestion step of the purified RNA with RNAse-
free DNAse was included. RNA concentration and purity was checked with a 
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Nanodrop spectrophotometer. Total RNA was then run on agarose gels (0.2μg/mL) 
containing ethidium bromide and visualised in a UV chamber. To further check the 
quality of RNA, the RNA Integrity Number (RIN) of 100ng RNA was measured on a 
pico chip using the Agilent Bioanalyzer 2100, which is a microfluidics-based platform 
that separates and quantifies RNA molecules according to their sizes. Results were 
analysed using the 2100 Expert software (Syngene, Cambridge, UK). The resulting 
RIN number reflects the degree of degradation of the sample and a value above 7 is 
expected. From total RNA, mRNA was isolated, fragmented and primed with the 
help of AMPure XP beads. Then the first-strand cDNA was synthesised followed by 
second strand synthesis. The double-stranded cDNA was purified using 1.8X 
Agencourt AMPure XP beads followed by performing the end prep of the cDNA 
library. Next, adaptor ligation was performed and the ligation reaction was purified 
again using AMPure XP beads. The ligated DNA was then PCR enriched and purified 
again using the AMPure XP beads. The library quality was then evaluated on a 
Bioanalyser (Agilent High Sensitivity Chip). For the final amplification 12 cycles were 
used. Each sample was run in duplicate. The raw sequencing data were delivered in 
FASTQ format. 
RNA sequencing was performed using the Illumina platform at Barts Genome 
Centre. The resulting data were analysed using Genome Studio, R, Microsoft Excel 
and Prism 5 software. 
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2.2.28 Pathway analysis 
From the differential gene expression analysis data, different tools were used to 
analyse the up and downregulated pathways. 
2.2.28.1  Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) 
The DAVID database v6.8 (beta) (http://david.niaid.nih.gov) is a free online 
bioinformatics resource developed by the Laboratory of Immunopathogenesis (LIB) 
and was used for an initial comparison of regulated genes. The database encompasses 
a full knowledgebase and provides a comprehensive set of functional annotation 
tools for investigators to understand biological meaning behind large list of genes. A 
list of the regulated genes is fed into the database and according to the Ensembl code 
annotated to a specific gene. This then allows identification of enriched biological 
themes in gene ontology (GO) terms and cluster genes into functional-related gene 
groups. Furthermore, it lists gene-disease associations, protein interactions and 
enables investigation of protein functional domains and motifs. Genes were then 
visualised on KEGG pathway maps. With DAVID however only gene IDs were used 
and fold changes were not taken into account.  
2.2.28.2 Gene Set Enrichment Analysis (GSEA) 
Gene set enrichment analysis can be used to study gene sets that have been grouped 
together due to their implications in the same biological pathway or location on a 
chromosome. Software enrichment scores (ES) were calculated, which represents the 
amount to which the genes in the set are over-represented at either the top or bottom 
of the list according to Kolmogorov-Smirnov statistics. Statistical significance of ES 
by phenotypic-based permutation test produced a null distribution for the ES. It was 
adjusted for multiple hypothesis testing for a large number of gene sets that were 
analysed one at a time. The enrichment scores for each set were normalised and false 
discovery rate was calculated. 
Files with pre-ranked (.rnk file) and .chip file names of genes were uploaded and 
analysed using the ‘GSEAPreranked’ tool. As a gene set database, 
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c2.cp.kegg.v5.1.symbols.gmt was used. Perturabtions were set to 1000 and ‘Ranked 
list’ to rnk file and ‘Chip platform’ was used. The name of the analysis was set and as 
an enrichment statistics ‘classical’ was used. DEall files were used and p2 weighted 
with DEall genes or classical with DEall genes was set. Gene sets were set to 200 
(http://software.broadinstitute.org/gsea/downloads.jsp. Subramanian 2015). 
2.2.28.3 Ingenuity pathway analysis 
IPA is an associative tool that is used to predict the effect on the organism and the 
mechanism of this effect from the data provided by the user. It allows drawing 
inferences between genes that can be tested to check their legitimacy. From the tool 
bar, the dataset was uploaded and saved as a .txt file. As a file format the flexible 
format was used. Contains column header was selected as yes. As an identifier, 
flexible was chosen. For analysis ID, observation 1 Log ration observation 2 p value 
was chosen and saved. In the next section analyse/filter dataset core analysis and run 
analysis was started. To analyse the outcome first canonical pathways were 
investigated, which displays the molecules of interest within well-established 
signalling or metabolic pathways. Next, upstream regulators were analysed to see 
which upstream molecules were predicted to have been activated or inhibited to have 
led to the expression patterns found in the dataset. Furthermore, downstream effects 
can be evaluated to explore the diseases and biological processes in the dataset. 
Regulator effects help to create hypotheses for how upstream regulators might drive 
downstream biology. 
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2.2.29 Western blotting 
2.2.29.1 Isolation of proteins 
Cells were washed twice with PBS followed by lysis in a suitable volume of 
Radioimmunoprecipitation assay (RIPA) buffer (Millipore, 20-188), supplemented 
with 1:100 protease (Millipore, 539131) and phosphatase inhibitors (Millipore, 
524625). The cells were left on ice for 5 minutes before scraping with a rubber 
policeman and subsequently placed into Eppendorf tubes. After briefly vortexing the 
samples, cell debris were centrifuged at 15,000 x g for 15 minutes at 4°C. The 
supernatant containing the proteins was then transferred into fresh Eppendorf tubes 
and stored at -20°C or directly assayed for protein concentration. 
2.2.29.2 Measuring protein concentration 
Protein concentration of samples was determined with a BioRad DC protein assay 
(BIORAD, Reagent A, 500-0113; Reagent B, 500-0114; Reagent S, 500-0115) according 
to the manufacturer’s protocol. Values were measured using a spectrophotometer at 
650nm. Following protein concentration measurement and calculation of the 
standard curve consisting of different BSA concentrations in PBS, Laemmli sample 
buffer (5X) was added and samples were boiled at 100°C for 5 minutes. Samples were 
then stored at -20°C until further use. 
2.2.29.3 Western blot analysis 
Equal concentrations of denatured protein (15-40μg) were loaded onto 10% SDS-
PAGE gels. After protein separation by electrophoresis, proteins were transferred to 
a nitrocellulose membrane (GE Healthcare Life Sciences, Whatman, 10 401 196). 
Ponceau S (Sigma-Aldrich®, P7170) was used to confirm adequate transfer. 
Membranes were then incubated in 5% milk in PBS at RT for 30 minutes, washed in 
PBS and incubated with primary antibody in 5% BSA/PBS overnight at 4°C. 
Membranes were subsequently washed with 0.1% Tween20-TBS (TBST) (Applichem, 
A13890500) and incubated with HRP-conjugated secondary antibody in 5% milk for 
1 hour at RT. Specific protein bands were visualised using Amersham ECL Western 
Blotting Detection Kit (GE Healthcare, RPN2106) and photographic film (Super RX, 
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47410 19230). More recently, blots were imaged digitally (Amersham Imager 600), 
according to the manufacturer’s instructions. 
 
Table 2.22. Formulation of polyacrylamide gels for SDS-PAGE gels. 
 Resolving Gel Stacking Gel 
 5% 7.5% 10% 12% 14% 15%  
dH2O 11.5mL 9.8mL 8.2mL 6.8mL 5.5mL 4.8mL  6.9mL 
Resolving 
Gel 
Buffer 
(pH 8.8) 
5mL 5mL 5mL 5mL 5mL 5mL 
Stacking 
Gel Buffer 
(pH 6.8) 
3mL 
Bis-Acryl 
(30%) 
3.3mL 5mL 6.7mL 8mL 9.3mL 10mL  2mL 
10% APS 150µL 150µL 150µL 150µL 150µL 150µL  150µL 
TEMED 15µL 15µL 15µL 15µL 15µL 15µL  15µL 
 
When the membranes were probed with antibodies where cross-reaction was 
possible, membranes were stripped using Re-blot Plus Mild (Millipore, 2502) for 10 
minutes, washed with PBS, blocked with 5% milk in PBS for 15 minutes and washed 
again in PBS. Membranes were then re-probed with primary antibody as described 
above. 
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3.1 Introduction 
Previous research has revealed that therapies targeting specific aberrations that drive 
carcinogenesis have led to promising responses in patients in the clinics. As FGFs and 
their receptors are potent cell proliferation and survival inducers, FGF signalling is 
often hijacked in cancer and many different types of cancers have acquired 
aberrations in FGFs but more importantly also in FGFRs. 7.1% of all tumour types 
have genetic alterations along the FGF-FGFR axis and specific FGFR alterations have 
been associated with certain types of tumours and therefore revealing FGFR 
aberrations as a suitable biomarker. Preclinical studies have further shown that 
FGFR2 is a promising therapeutic target in cancer and several FGFR inhibitors are in 
clinical trials for cancer treatment (Dienstmann et al., 2014). 
In 2012, 320,000 new endometrial cancer cases have been diagnosed worldwide and 
even though approximately 12% of endometrial cancers harbour FGFR2 mutations, 
little is known about their importance in driving tumourigenesis of this cancer type 
(Byron et al., 2008). Multiple endometrial cancer cell lines with FGFR2 mutations are 
highly sensitive to FGFR inhibitors including PD (Dutt et al., 2008, Byron et al., 2008), 
Ponatinib (Gozgit et al., 2013, Kim et al., 2015), AZD (Kwak et al., 2015), BGJ and 
Dovitinib (Konecny et al., 2013).  
In gastric cancer, 5-10% harbour FGFR2 amplifications and/or mutations (Carter et 
al., 2017; Chon et al., 2017; Jung et al., 2012). It is considered the third leading cause 
of death from malignant disease worldwide with 989,000 new cases of gastric cancer 
and 738,000 deaths worldwide (Ferlay et al., 2010). Furthermore, the 5-year survival 
rate is only 30-35% and the presence of FGFR2 amplifications in patients is associated 
with poorer overall survival, poor prognosis and more wide spread disease (Jung et 
al., 2012; Shoji et al., 2015). Gastric cancer cell lines with FGFR2 amplifications show 
evidence of ligand-independent signalling and are highly sensitive to FGFR inhibitors 
(Takeda et al., 2007). It has further been shown that TKIs such as AZD show activity 
in several colorectal and gastric cancer cell lines (Xie et al., 2013) and those patients 
harbouring cancers with FGFR2 amplifications could benefit from FGFR-targeted 
drug therapy. 
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Lung cancer FGFR aberrations are of particular importance and FGFR1 is amplified 
in as many as 16-19% of squamous non-small cell lung cancers (SqCLC) (Preusser et 
al., 2014). Lung cancer is the most common cancer in the world and in 2012 1.6 million 
lung cancer associated deaths were estimated (Didkowska et al., 2016). In preclinical 
studies, it was shown that a subset of FGFR1-amplified small cell lung cancer is highly 
sensitive to FGFR-inhibitor treatment with PD and studies involving xenograft 
models transplanted with transformed cells derived from FGFR1-amplified NSCLC 
cancer patients have shown that AZD halts tumour growth and promotes regression 
(Pardo et al., 2009; Zhang et al., 2012). 
Given the abundance of FGFR-specific therapies that are currently in clinical trials for 
several cancer types, coupled with the high occurrence of FGFR aberrations in 
endometrial, gastric and lung cancer worldwide, it is of utmost importance to 
investigate the effects of these alterations and of targeted drug therapy. Especially 
long-term drug treatment has to be investigated as chemoresistance is a major issue 
in targeted therapies as was observed previously in several cancers (Flaherty et al., 
2010; Holohan et al., 2013; Wagle et al., 2011).  
Previous work in the group focussed on the role of FGFR2 mutations in endometrial 
cancer and its role in drug resistance to delineate cellular mechanisms on how drug-
resistant endometrial cancer cells emerge. From this work, a promising protein was 
identified that is involved in drug resistance and its targeting could circumvent drug 
resistance in these cancers (Fearon et al., 2018). However, cancers from different 
tissues can show different reliance on downstream signalling pathways and therefore 
it is essential to investigate FGFR inhibitor treatment of cancer from different tissue 
origin. Furthermore, alternative FGFR aberrations such as receptor amplifications 
could result in a different outcome compared to cancers harbouring FGFR mutations.  
This study mainly focusses on gastric cancers harbouring FGFR2 amplifications and 
to study FGFR inhibitor treatment, we used Infigratinib (BGJ), an orally bioavailable 
pan-FGFR inhibitor with potent anti-angiogenic and anti-proliferative properties in 
FGFR-mutant or FGFR-amplified cancers (Guagnano et al., 2011). In a global phase I 
clinical trial of BGJ in patients with advanced solid tumours with FGFR gene 
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alterations (Nogova et al., 2017), out of a cohort of 132 patients with FGFR1-amplified 
squamous cell NSCLC and FGFR3-mutant bladder/urothelial cancer treated with BGJ 
≥ 100 mg/d, 7 patients achieved partial response. BGJ is currently being evaluated in 
phase II trials as a single agent in several FGFR-dependent malignancies 
(NCT02160041, NCT02150967). As small molecule inhibitors are the most advanced 
compounds in clinical trials, it is essential and of particular interest to investigate the 
effects of such drugs on cancers harbouring FGFR aberrations. 
In this chapter, gastric cancer cells were characterised in respect to cell proliferation, 
cell death and cell signalling by treating them with FGFR inhibitors and also 
compared to endometrial and lung cancer cell lines harbouring FGFR aberrations to 
delineate similarities in treatment outcomes. Additionally, a novel 3D model was 
developed and optimised, due to the every growing need for more physiological 
experimental setups. Furthermore, in a 3D model multiple cell types can be grown 
together therefore creating a tumour microenvironment that has been found to 
greatly influence tumourigenesis (Wang et al., 2017). 
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3.2 Cancer cell line characterisation 
The main focus of this work lies on gastric cancer cell lines harbouring FGFR-
amplifications and therefore a gastric cancer panel from ATCC (TCP-1008TM) was 
purchased. From the six gastric cancer cell lines, two harboured FGFR2 amplifications 
and the rest were wild-type for FGFR2. SNU-16 and KATOIII are FGFR2-amplified 
and both have a TP53 mutation and SNU-16 additionally has a CDKN2A mutation 
(for mutation profiles of all gastric cancer cell lines see Table 2.1-Table 2.4 in the 
methods section). Initial experiments and optimisations were undertaken with MFE-
296 and AN3CA cell lines and compared to cells of the gastric cancer panel and 
furthermore lung cancer cell lines, H520 and H1299 that were kindly provided by 
Prof. Marshall and Prof. Sharp (BCI). 
After extensive literature search, SNU-16 cells were chosen for the main study as they 
exhibited particularily high levels of FGFR2 amplifications, while SNU-1 were chosen 
as their wild-type counterpart, which are like SNU-16 also suspension cells (Kunii et 
al., 2008; Xie et al., 2013). To establish the role of FGFR mutations, MFE-296 and 
AN3CA that harbour the N550K FGFR2 mutation (COSMIC), were chosen, which 
results in constitutive activation of kinase activity (Byron et al., 2008). Table 3.1 
summarises the cell lines, which have been used. 
 
Table 3.1. Cancer cell lines that were predominately used in the project. 
Name Cancer type Receptor alteration Mutations 
SNU-16 gastric FGFR2 amplification p53, CDKN2A 
SNU-1 gastric FGFR2 wt KRAS, MLH1 
AGS gastric FGFR2 wt 
CDH1, CTNNB1, 
KRAS PIK3CA 
MFE-296 endometrial FGFR2 mutation (N550K) PI3Ka, PTEN 
AN3CA endometrial FGFR2 mutation (N550K, K310R) PTEN 
H520 lung FGFR1 amplification p53 
H1299 lung FGFR1 wt p53 
  
Results Part I 
119 
 
3.3 Cell survival of endometrial, gastric and lung cancer cells treated 
with RTK inhibitors  
As FGFR inhibitors are being investigated in clinical trials for different types of 
cancers (Clinicaltrials.gov, 2018), the effects of FGFR inhibition in endometrial, gastric 
and lung cancers were assessed. Three different FGFR kinase inhibitors were used: 
PD, which is a common small molecule tool compound (Knights and Cook, 2010), 
AZD and BGJ (see section 1.7), which are currently in trials for FGFR1 and 2-amplified 
solid tumours and are potent, selective and orally bioavailable inhibitors of FGFR 
tyrosine kinases 1-4 (Clinicaltrials.gov, 2018). To assess their potential to block RTK 
signalling in cancer cells, survival assays were performed. Cells were treated with a 
range of different concentrations of AZD and BGJ and cell survival was analysed 72 
hours post drug treatment. Cells were analysed using either MTT for adherent or 
MTS for suspension cells. Gastric SNU-1 cells from the gastric cancer panel, which 
are FGFR2-wildtype, were not sensitive to lower concentrations of BGJ as shown by 
a shift to the right, while FGFR2-amplified gastric SNU-16 cancer cells were highly 
sensitive to FGFR2 inhibition (Figure 3.1), which is also reflected in the difference of 
IC50 values comparing FGFR2-amplified and wildtype cell survival. SNU-16 cells also 
showed similar survival curves upon treatment with AZD, which resulted again in 
sensitivity and reduction of cell numbers with increasing drug concentration 
(Appendix Figure 8.1). AGS cells, which also express wild-type FGFR2, served as an 
adherent control cell line. The AGS cell line, similarly to SNU-1 cells, was less 
sensitive to low FGFR inhibitor concentrations and was eventually killed after using 
the maximum dose of 1μM of BGJ (Figure 3.2). 
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Figure 3.1. SNU-16 cells are sensitive towards BGJ. 
SNU-1 and SNU-16 gastric cancer cells were plated in triplicate into 96-well plates and exposed to BGJ 
concentrations ranging from 1.5nM to 50µM for SNU-1 cells and ranging from 0.006nM to 50µM for 
SNU-16 cells. Cell viability was measured after 72h incubation. Control cells were treated with DMSO 
and as a background control 1% Staurosporine was added to wells containing cells. The cell viability 
index was then measured subtracting the background signal and adjusting to the controls. An average 
of three biological MTS experiments in technical triplicate is shown with error bars indicating standard 
error of the mean (SEM). The green curve represents SNU-1 cells and the blue curve represents SNU-16 
cells. LogIC50 and IC50 values were calculated in GraphPad Prism 5. 
 
For other gastric cell lines, the optimal treatment dose for AZD and BGJ, was also 
determined (Appendix Figure 8.2). Lung cancer cell line A549, which is FGFR1 
wildtype and FGFR1-amplified H520 cells were also exposed to BGJ and AZD to 
show that drugs are not universally toxic (Appendix Figure 8.3).  
 
 
Figure 3.2. FGFR2 wildtype gastric cancer cells are less sensitive to FGFR inhibition. 
AGS cells were treated with drug concentrations ranging from 0.5 to 1000nM of PD, AZD or BGJ. Cell 
viability was measured after 72h incubation. Control cells were treated with DMSO and as a background 
control 1% Staurosporine was added to wells containing cells. The cell viability index was then measured 
subtracting the background signal and adjusting to the controls. An average of three biological MTS 
experiments in technical triplicate is shown with error bars indicating SEM. LogIC50 and IC50 values were 
calculated in GraphPad Prism 5. 
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3.4 FGFR2 gene amplification confers sensitivity in gastric cancer to 
selective FGFR inhibition in 2D 
To compare and assess sensitivity towards FGFR inhibition of SNU-16 and SNU-1 cell 
lines, cells were grown in presence of FGFR inhibitor BGJ, followed by cell counting 
(Figure 3.3A). SNU-16 cells generally grew at a lesser pace than SNU-1 cells and cell 
numbers were significantly reduced upon FGFR inhibition. In SNU-1 cells on the 
other hand, cell numbers remained unchanged between vehicle and drug-treated 
conditions. The reduction in cell numbers in SNU-16 cells, was also shown to be a 
dose-dependent effect, as an increase in inhibitor concentration resulted in a 
significantly increased reduction in cell counts compared to vehicle-treated cells 
(Figure 3.3B). 
 
 
Figure 3.3. FGFR inhibition in FGFR2-amplified gastric cancer cells results in a dose-dependent 
reduction in cell numbers. 
FGFR2-amplified SNU-16 and wildtype SNU-1 cells were seeded into 6-well plates and treated with 
1.5µM BGJ for 72h (A). In another experiment, SNU-16 cells were exposed to 500nM, 1.5µM or 5µM BGJ 
or vehicle and incubated for 72h (B). The medium containing the cells was collected and resuspended in 
1mL complete growth medium and SNU-16 cell numbers were assessed using Trypan blue and cell 
counting with a haemocytometer using a light microscope. Experiments were performed in biological 
triplicate with error bars indicating SEM. Statistical analysis was performed using Student’s T-test, 
*p<0.05, **p<0.01. 
 
To assess the potential of ATP-competitive inhibitors to block RTK signalling in 
cancer cells, they were treated with FGFR inhibitors PD, AZD and BGJ. Previous data 
have shown endometrial cancer cells to be sensitive to FGFR inhibition in 2D culture 
using PD (Byron et al., 2008). To confirm this in the cell lines used in my project, cells 
were treated with 1μM PD, AZD or BGJ, or DMSO at the same concentration as a 
vehicle control. Cell signalling was then analysed using Western blot after three days 
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incubation of the cells with the different drugs. Again, blots were probed for 
signalling antibodies of the ERK and AKT pathway and the housekeeping protein 
HSC70 was used as a loading control (Figure 3.4, Figure 3.5). SNU-16 cell protein 
lysates were analysed, showing a significant decrease in phosphorylation of 
signalling proteins AKT and ERK in drug-treated cells (Figure 3.4A). Levels of p-AKT 
were more reduced with FGFR inhibitor treatment compared to p-ERK protein 
expression levels. Total AKT and ERK signalling remained unchanged upon FGFR 
inhibition. To compare signalling of FGFR2-amplified gastric cancer cells to FGFR2 
wildtype gastric cancer cells, the same was also done for SNU-1 and AGS cell lines. 
Again, cells were treated with the three FGFR inhibitors and with vehicle at the same 
concentration in control wells. AGS and SNU-1 cancer cells were not affected by the 
drug in the same manner as SNU-16 cells. AKT phosphorylation in SNU-1 and AGS 
cells could have been inhibited at different, potentially shorter, time points compared 
to SNU-16 cells. Therefore no distinct change in AKT phosphorylation levels was 
observable in drug-treated cells as compared to vehicle-treated cells on the protein 
level at the chosen timepoint. SNU-16 cells were also subjected to increasing dosages 
of BGJ and Western blot analysis was performed (Figure 3.4B). With increasing BGJ 
concentration, p-ERK was gradually decreased and with 5µM BGJ, t-AKT showed a 
slight reduction in protein expression levels compared to the vehicle control. 
To investigate if amplifications of the kinase domain also affect sensitivity in respect 
to FGFR1, cell signalling of lung cancer cell lines harbouring FGFR1 amplifications 
was measured and it was confirmed that H520 cells are highly FGFR1-amplified 
compared to other lung cancer cells (Appendix Figure 8.4). Signalling upon drug 
treatments with PD, AZD and BGJ was then compared to lung cancer cell lines that 
are wildtype for FGFR1 and also to lung fibroblasts (Figure 3.5). AKT and ERK 
phosphorylation was significantly reduced in FGFR1-amplified H520 cells, whereas 
it remained unchanged in H1229 FGFR1 wildtype lung cancer cells. MRC-5 lung 
fibroblasts did not express p-AKT and exhibited unchanged p-ERK signalling. 
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Figure 3.4. AKT and ERK signalling in FGFR2-amplified gastric cancer cells are reduced with FGFR inhibitor treatment compared to FGFR2 wildtype cells and p-ERK 
signalling is reduced in a dose-dependent manner.  
SNU-16, SNU-1 and AGS cancer cells were seeded into 6-well plates and treated with 1μM PD, AZD or BGJ for 72h, followed by measuring AKT and ERK signalling to assess 
the effects of the drugs on FGF signalling (A). SNU-16 harbour FGFR2 amplifications and show a significant decrease in p-AKT (Ser743) and p-ERK signalling in drug-treated 
samples. AGS and SNU-1 cancer cells are FGFR2-wild-type and showed less sensitivity towards the different drugs used. The blots are representative of three individual 
experiments. Increasing the inhibitor concentration (500nM, 1.5 and 5µM BGJ) in SNU-16 cells resulted in a dose-dependent reduction in p-ERK expression levels (B). The blots 
are representative of three individual experiments (Appendix Figure 8.5). 
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Figure 3.5. FGFR1-amplifed lung cancer cell lines exhibit reduced phosphorylation of AKT and ERK signalling compared to FGFR1 wildtype lung cancer cells.  
H520, H1299 lung cancer cells and MRC-5 lung fibroblast cells were treated with 1μM PD, AZD or BGJ for 3 days and AKT and ERK signalling was assessed to see if there is an 
effect of the drug on FGF signalling. H520 cells harbour FGFR1 amplifications and show a significant decrease in p-ERK signalling in drug-treated samples. p-AKT only seems 
slightly reduced. H1299 cancer cells are FGFR1-wildtype and showed no sensitivity towards the different drugs used. The same was true for MRC5 cells, however, no p-AKT 
could be detected. HSC70 served as loading control. The experiment was performed three times with the same result (Appendix Figure 8.6-Appendix Figure 8.8).  
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3.5 Fibroblast growth factor stimulation promotes AKT and ERK 
signalling in FGFR1/2-amplified and FGFR2-mutated cells 
To assess the effect of cancer cell stimulation and inhibition, MFE-296, SNU-16 and 
H520 cells were serum starved and treated with 100ng/mL FGF2 or FGF10 for 15 and 
60 minutes. MFE-296 cells were only treated with FGF2 but with all three FGFR 
inhibitors PD, AZD or BGJ or vehicle control. In the case of SNU-16 and H520 cells, 
only BGJ was used but both FGF2 and FGF10. FGF2 was chosen for MFE-296 cells as 
it activates the IIIC variants of FGFR1 and FGFR2 efficiently, which are expressed by 
MFE-296 cancer cells. 
FGF2 stimulation in MFE-296 cells activated the MAPK pathway, as shown by 
increased ERK phosphorylation on threonine and tyrosine residues 202 and 204 
(thr202 and tyr204). Upon treatment of the cells with FGFR inhibitors, p-ERK 
signalling was inhibited (Figure 3.6). The effect varied between inhibitors used and 
was completely abolished in BGJ-treated MFE-296 cells whereas with PD and AZD, 
still slight levels were expressed at 15 minutes. 
FGF2 stimulation also increased AKT signalling in MFE-296 cells and with all three 
FGFR inhibitors phosphorylation of AKT was decreased. Upon inhibition, p-AKT 
levels were decreased but returned back to normal at the 60 minutes FGF2 stimulation 
time point. Overall comparable data were observed in MFE-296 cells with the 
different FGFR inhibitors. 
FGF stimulation of FGFR2-amplified SNU-16 gastric cancer and FGFR1-amplified 
H520 lung cancer cells and subsequent inhibitor treatment resulted in decreased p-
ERK signalling. In SNU-16 cells both FGF2 and FGF10 stimulation increased ERK 
phosphorylation (Figure 3.7). In H520 cells, FGF2 stimulation lead to increased p-ERK 
levels at 15 and 60 min and was efficiently blocked upon FGFR inhibitor treatment 
with BGJ. Similar results were achieved with FGF10, however less intense than with 
FGF2 (Figure 3.8). 
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Figure 3.6. Effect of FGF2 stimulation and FGFR2 inhibition on cell signalling in MFE-296 cells. 
MFE-296 cells were grown in 6-well plates and were serum-starved for 6 hours and stimulated with 
100ng/mL FGF2 in the presence of 300ng/mL heparin in serum-free medium for 15 and 60 minutes. 
Where indicated cells were treated with 1µM PD, AZD or BGJ for 1 hour. Cells were then harvested and 
protein lysates were analysed on a 10% PAGE gel and immunoblotted with antibodies directed against 
p-ERK, t-ERK, p-AKT and t-AKT. Stimulation of MFE-296 cells activated the MAPK pathway, which 
was inhibited by 1µM PD, AZD or BGJ. FGF2 stimulation also increased p-AKT signalling which was 
again inhibited by the FGFR inhibitors. 20µg protein was loaded in each lane. 
 
 
 
Figure 3.7. Effect of FGF2 and FGF10 stimulation and FGFR2 inhibition on cell signalling in SNU-16 
cells. 
SNU-16 cells were grown in 6-well plates and were serum-starved for four hours and stimulated with 
100ng/mL FGF2 or FGF10 in the presence of 300ng/mL heparin in serum-free medium for 15 and 60 
minutes. Where indicated cells were treated with 1µM BGJ for 1 hour. Cells were then harvested and 
protein lysates were analysed on a 10% PAGE gel and immunoblotted with antibodies directed against 
p-ERK, t-ERK, p-AKT and t-AKT. Stimulation of SNU-16 cells with both FGF2 and FGF10 activated the 
MAPK pathway, which was inhibited by 1µM BGJ. FGF2 stimulation also increased p-AKT signalling 
which was again inhibited by the FGFR inhibitors. 20µg protein was loaded in each lane. 
Results Part I 
 127 
 
 
Figure 3.8. Effect of FGF2 and FGF10 stimulation and FGFR2 inhibition on cell signalling in H520 
cells. 
H520 cells were grown in 6-well plates and were serum-starved for four hours and stimulated with 
100ng/mL FGF2 or FGF10 in the presence of 300ng/mL heparin in serum-free medium for 15 and 60 
minutes. Where indicated cells were treated with 1µM BGJ for 1 hour. Cells were then harvested and 
protein lysates were analysed on a 10% PAGE gel and immunoblotted with antibodies directed against 
p-ERK, t-ERK, p-AKT and t-AKT. Stimulation of H520 cells with both FGF2 and FGF10 activated the 
MAPK pathway, which was inhibited by 1µM BGJ. FGF2 stimulation also increased p-AKT signalling 
which was again inhibited by the FGFR inhibitors. 20µg protein was loaded in each lane. 
 
3.6 Alvetex® organotypic 3D cell culture model development 
Thus far, investigations have focussed on cancer cells alone in 2D culture. However, 
my aim was to determine the effect of stromal support on drug resistance in 3D. In 
order to investigate the effect of FGFR2 inhibition in a more physiologically relevant 
form, a 3D organotypic model was developed. It is based on a 3D scaffold method, 
Alvetex®, which consists only of a polystyrene scaffold membrane. First of all, 
different seeding concentrations were tested with 2.5 x 105, 5.0 x 105 and 1.0 x 106 cells 
per scaffold (Figure 3.9). Using the highest cell density did not overfill the scaffold 
and therefore going forward this cell seeding density was used for all experiments. 
 
 
Figure 3.9. Cell seeding concentrations. 
SNU-16 cells were resuspended at a concentration of 1 x 107 cells/mL and 25 (2.5 x 105), 50 (5.0 x 105) or 
100µL (1.0 x 106) of the cell suspension were seeded into Alvetex® scaffolds. After one week incubation, 
the scaffolds were fixed, paraffin-embedded and H&E stained. The images are representatives of three 
individual experiments. The scale bar indicates 100µm. 
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The 3D model was also developed to investigate the tumour environment and 
investigate the effect of fibroblast signalling upon cells, as the tumour 
microenvironment is recognised to play an essential role in cancer malignancy (Wang 
et al., 2017). To investigate stromal support, human foreskin fibroblasts (HFF2) were 
used. Ideally, HFF2 cells should not be sensitive towards the drug and therefore cell 
viability of HFF2 cells was assessed and showed no sensitivity towards BGJ (Figure 
3.10) or AZD (Appendix Figure 8.9). 
 
 
Figure 3.10. Human foreskin fibroblasts are less sensitive towards BGJ. 
HFF2 cells were plated in triplicate into 96-well plates and exposed to BGJ concentrations ranging from 
0.5 to 1000nM. Cell viability was measured after 72h incubation. Control cells were treated with DMSO 
and as a background control 1% Staurosporine was added to wells containing cells. The cell viability 
index was then measured subtracting the background signal and adjusting to the controls. An average 
of three biological MTS experiments in technical triplicate is shown. LogIC50 and IC50 values were 
calculated in GraphPad Prism 5. 
 
The effect of drug inhibition on HFF2 cells was also assessed on the protein level, and 
expression levels of AKT and ERK signalling were unaffected in HFF2 cells upon 
drug treatment with AZD (Appendix Figure 8.10). Fluorescently transfected HFF2 
cells behaved in the same manner as untransfected cells in respect to sensitivity 
towards FGFR inhibition.  
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3.7 Visualisation of cancer cells and fibroblasts in Alvetex® scaffolds 
To visualise and distinguish co-culture cells in the scaffolds, cells were fluorescently 
tagged (according to section 2.2.17). MFE-296 cells were initially transfected with viral 
supernatant with an Azurite construct (viral supernatant was provided by Dr. E. 
Carter) and HFF2 cells with EGFP, which was available in the laboratory. 
Transfection of MFE-296 cells with a lentiviral plasmid expressing the Azurite blue 
resulted in MFE-296-Azurite cells (Figure 3.11A). The same was also performed for 
HFF2 cells with a construct expressing EGFP, giving rise to HFF2-EGFP cells (Figure 
3.11B). Cells were grown for 8 passages and then sorted using flow cytometry to 
assess efficiency of the transduction and selected for MFE-296 Azurite and HFF2-
EGFP positive cells. 
 
Figure 3.11. Cell sorting of MFE-296-Azurite and HFF2-EGFP cells. 
Azurite and EGFP-transduced MFE-296 and HFF2 cells were grown for 8 passages followed by cell 
sorting using FACS. P1 displays the selection of live cells and P2 and P3 were used to discriminate cell 
doublets. P4 the selects for EGFP-positive cells using channel B530/30-A to detect EGFP signal. P5 selects 
for Azurite-positive MFE-296 cells using channel B525/50-A. 
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EGFP transfection efficiency in HFF2 cells was high, with over 98% of cells being 
EGFP positive (Figure 3.12,).  
 
 
 
Figure 3.12. EGFP expression level of untransfected HFF2 fibroblasts and EGFP plasmid transfected 
HFF2 cells. 
HFF2 cells were transfected with a lentiviral plasmid expressing EGFP and grown for 8 passages 
followed by FACS cell sorting. 
 
As a preliminary experiment, HFF2 cells were grown for 7 days, either mixed with 
cancer cells, or only HFF2-EGFP alone on coverslips, and visualised by fluorescence 
microscopy (Figure 3.13). EGFP labels the cytoplasm, allowing to visualise the 
morphology of cells. MFE-296 cells stained positive for E-cadherin. 
 
 
 
Figure 3.13. Co-culture Immunofluorescence of HFF2-EGFP cells and resistant MFE-296 and parental 
cells. 
MFE-296 and HFF2-EGFP cells were either seeded alone or in co-culture on coverslips. The following 
day coverslips were PFA-fixed and imaged with a fluorescence confocal microscope. MFE-296 cells stain 
for E-Cadherin while EGFP-transduced cells were visualised using the GFP channel. The cell nuclei were 
stained using DAPI. 
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The role of the tumour stroma has shown to have an effect on the formation of 
resistance in different cancers (Donner, 2012; Olson and Joyce, 2013; Wang et al., 
2009). Therefore, studying the interaction between fibroblasts and cancer cells could 
give a greater insight into mechanisms underpinning resistance. 3D organotypic 
models provide a more physiomimetic system to study this. In my project, I have 
used Alvetex® scaffolds, where endometrial MFE-296 and gastric SNU-16 cancer cells 
were seeded together with HFF2. MFE-296 cancer cells and HFF2 fibroblasts were 
labelled previously with fluorescent markers using lentiviral constructs, creating 
MFE-296-Azurite and HFF2-EGFP. The cells were then seeded in a 2 (cancer): 1 
(fibroblast) ratio into scaffolds and incubated for 30 min at RT. The scaffolds were 
then fed from below with complete growth medium to create a chemotactic gradient 
stimulating the cells to migrate towards the medium. Cells were grown in scaffolds 
for 7-14 days, with medium changes every two days. After seven days, the scaffolds 
were imaged via confocal laser scanning microscopy (Zeiss LSM 710) to produce high 
resolution detailed images. Scaffolds were placed into a 30mm dish in a humidified 
and heated (37°C) chamber. Since the cells were transduced with fluorescent markers, 
lasers were adjusted to 488nm emission for fibroblasts (green) and 450nm emission 
for cancer cells (blue). Z-stacks were acquired at 4μm intervals with a 1μm overlap to 
circa 200μm depth using a long working distance 20x objective (LWD 20x). 
Cell survival of gastric, endometrial and lung cancer cells was also compared to cells 
grown with or without stromal cells or cells grown in 2D versus 3D in 96-well Alvetex® 
plates (Appendix Figure 8.11). Cells grown together with fibroblasts and cells grown 
in 3D were both less sensitive to FGFR inhibition using BGJ, highlighting the 
importance to study cancer in presence of fibroblasts and also in 3D. Growth of lung 
cancer cells upon FGFR inhibition with and without stromal support was also 
analysed with IncuCyte™ ZOOM®, allowing to measure cell confluence and average 
area. Again, cells grown with lung fibroblasts resulted in higher cell confluence and 
average area and therefore decreased sensitivity to FGFR inhibition (Appendix 
Figure 8.12).  
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3.8 Optimising coating methods and scaffold formats  
3.8.1 Scaffold coating 
Since Alvetex® scaffolds consist of polystyrene scaffold webs, it could be coated with 
collagen and Matrigel™. However, compared to collagen and Matrigel™-coated 
scaffolds, the uncoated scaffolds showed the best attachment and proliferation of 
MFE-296-Azurite and HFF2-EGFP cells (Figure 3.14). The fluorescence image 
displays live cell image acquisition through the scaffold with both HFF2-EGFP and 
MFE-296-Azurite cells, with highest cell numbers in uncoated scaffolds compared to 
collagen and Matrigel™-coated scaffolds in 24-well plates. 
 
Figure 3.14. Different coating methods of 24 well-plate Alvetex® scaffolds.  
(A) Confocal microscopy of 24 well-plate Alvetex® scaffolds either coated with collagen or Matrigel™ or 
left uncoated with MFE-296 and HFF2 cells. Comparison of coatings such as with collagen and 
Matrigel™ of the 24 well plate Alvetex® scaffolds. (B) H&E staining of 24 well-plate Alvetex® scaffolds 
either coated with collagen or Matrigel™ or left uncoated. Comparison of coatings such as with collagen 
and Matrigel™ of the 24 well plate Alvetex® scaffolds. Scale bars indicate 100μm. 
 
After 7-14 days, Alvetex® scaffolds were fixed with 10% formalin, embedded in 
paraffin and subsequently stained for H&E (Figure 3.14). In the H&E staining, it is 
clear that the uncoated scaffold remained more intact as compared to the collagen 
and Matrigel™-coated scaffolds, and there were more cells present in uncoated 
scaffolds.  
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3.8.2 Scaffold formats 
There are different Alvetex® formats available, not only in size of the scaffolds but 
also the pore size of the polystyrene material. In the Alvetex® scaffolds, the pore size 
is 42μm and in Alvetex® Strata the pore size is 15μm. Therefore, it is more difficult for 
the cells to distribute in the Strata scaffold. As the scaffold was more rigid because of 
the denser pores, the scaffold did not disrupt when embedded scaffolds were 
sectioned. It was not possible to see cells using live cell imaging using confocal 
microscopy (Zeiss LSM 710), therefore scaffolds were embedded in paraffin and 
sections were stained for H&E. Although SNU-16 cells were used, which are 
generally smaller cells, only very few cells invaded the scaffold. For these reasons, 
this format was not further used in this project. (Appendix Figure 8.13).  
To check if there is a difference between growing cells in a 24-well plate Alvetex® or 
in 12-well inserts, scaffold coating and cell growth was analysed in 12-well inserts. 
12-well inserts were coated with Matrigel™ or left uncoated. Again, uncoated 
scaffolds displayed a better cell attachment and cells grew better than in Matrigel™-
coated scaffolds (Figure 3.15). Compared to 24-well plates, more cells were observed 
in 12-well inserts as medium can be fed from below only if desired. 
 
 
 
Figure 3.15. HFF2 cells exhibit increased attachment to uncoated scaffolds than Matrigel™-coated 
scaffolds. 
EGFP-positive HFF2 cells were seeded into 12-well Alvetex® inserts left uncoated or coated with 
Matrigel™. After one week incubation, cells were imaged live with a fluorescence microscope. The scale 
bar indicates 100µm. 
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Similarly, in collagen-coated scaffolds using 12-well inserts, fewer cells grew 
compared to uncoated scaffold inserts (Figure 3.16). Therefore, for all future 
experiments 12-well inserts were used, as using this format delivered the best cell 
attachment and growth results. 
 
 
Figure 3.16. Growing cells in uncoated Alvetex® scaffolds delivers the best results. 
Comparison of H&E staining of an uncoated 12-well insert Alvetex® scaffold and H&E staining of a 
collagen-coated 12-well insert Alvetex® scaffold containing MFE-296 cells. Scaffolds were coated or left 
uncoated and incubated for 1h followed by cell seeding. The cells in the scaffolds were incubated for one 
week followed by fixation, paraffin-embedding and H&E staining. The whole scaffold scale bar indicates 
2000μm and magnification scale bar indicates 100μm. 
 
3.8.3 Drug treatment of co-cultures in Alvetex® scaffolds 
To test the effect of FGFR inhibitors on co-culture cells in 3D, fluorescently labelled 
MFE-296-Azurite and HFF2-EGFP fibroblasts were seeded at a 2:1 ratio into 12-well 
insert scaffolds. Per well, 107 cells in 100μL were seeded, incubated for 30 min at room 
temperature and fed from below with complete growth medium and incubated at 
37°C. The next day, cells were treated with two different dosages of the drug and 
investigated using fluorescent confocal microscopy 7 days after drug treatment. 
Simultaneously, scaffolds were also stained for H&E (Figure 3.17). From the 
fluorescence images and also H&E staining, where also the whole scaffold could be 
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imaged, it could be shown that MFE-296 cells co-cultured with HFF2 cells were 
indeed sensitive towards AZD and more cells could be killed with a higher drug 
concentration or cells stopped growing and therefore resulted in lower cell numbers 
compared to vehicle-treated cells in 3D. In this experiment it could also be observed 
that the fuller the scaffold the more intact it remained as, due to the low cell number 
in the drug-treated sample, the scaffold was disrupted upon fixation and sectioning. 
 
 
Figure 3.17. AZD treatment of FGFR2-mutated endometrial cells kills cells with increasing dosage. 
Endometrial MFE-296 cells were seeded 2:1 with fibroblasts into 12-well insert Alvetex® scaffolds and 
grown for one week and imaged with confocal fluorescence microscopy, followed by fixation, paraffin-
embedding and H&E staining and imaging with the Pannoramic scanner. Cells were treated with 1μM 
(B) or 2.5μM AZD (C) or as a control cells were treated with DMSO (A). Blue cells indicate MFE-296-
Azurite cells and green HFF2-EGFP cells. Whole scaffold scale bar (left panel) indicates 2000μm and 
magnification and fluorescence scale bars indicate 100μm.  
 
The same was also performed for the FGFR inhibitor BGJ, to check if there was a 
similar effect by treating MFE-296-Azurite and HFF2-EGFP fibroblasts with another 
FGFR inhibitor. With this drug a higher concentration was used and with the highest 
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drug concentration, cells were almost entirely killed compared to the vehicle control 
(Figure 3.18). 
 
 
Figure 3.18. BGJ treatment of FGFR2-mutated endometrial cells kills cells with increasing dosage. 
Endometrial MFE-296 cells were seeded 2:1 with fibroblasts into 12-well insert Alvetex® scaffolds and 
grown for one week and imaged with confocal fluorescence microscopy, followed by fixation, paraffin-
embedding and H&E staining and imaging with the Pannoramic scanner. Cells were treated with 1μM 
(B) or 5μM BGJ (C) or as a control cells were treated with DMSO (A). Blue cells indicate MFE-296-Azurite 
cells and green HFF2-EGFP cells. Whole scaffold scale bar (left panel) indicates 2000μm and 
magnification and fluorescence scale bars indicate 100μm.  
 
Similarly, SNU-16 suspension cells were seeded into 12-well Alvetex® scaffolds and 
treated with BGJ. Again, cells treated with BGJ were highly sensitive to the drug and 
cell numbers were dramatically reduced (Figure 3.19). Also, this shows that 
suspension cells can be grown in Alvetex® scaffolds. To see how BGJ drug treatment 
affected SNU-16 in co-culture with stromal cells, cells were again treated with BGJ, 
leading to a significant decrease in cell number. HFF2 cells gathered at the bottom of 
the scaffolds whereas SNU-16 remained mostly near the top (Figure 3.20). 
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Figure 3.19. SNU-16 cells grown in Alvetex® are highly sensitive to BGJ inhibition. 
FGFR2-amplified SNU-16 cells were seeded into 12-well Alvetex® inserts, treated with vehicle or 1.5µM 
BGJ and grown for one week with medium exchanges every second day, followed by fixation, paraffin-
embedding and H&E staining. The whole scaffold scale bar indicates 2000μm and magnification scale 
bar indicates 100μm. 
 
 
 
Figure 3.20. FGFR2-amplified cancer cells with stromal cells are sensitive to FGFR inhibition. 
FGFR2-amplified SNU-16 cells together with HFF2 cells were seeded 2:1 into 12-well Alvetex® inserts, 
treated with vehicle or 1.5µM BGJ and grown for one week with medium exchanges every second day, 
followed by fixation, paraffin, embedding and H&E staining. Whole scaffold scale bar indicates 2000μm 
and magnification scale bar indicates 100μm. The experiment was performed twice (Appendix Figure 
8.14).  
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FGFR2 wildtype SNU-1 suspension cells were also exposed to BGJ in Alvetex® 12-
well inserts and did not show sensitivity to the drug in 3D (Figure 3.21) and also in 
co-culture with stromal cells (Figure 3.22). 
 
 
Figure 3.21. FGFR2 wildtype gastric cells are not killed through FGFR inhibition. 
FGFR2-wt SNU-1 cells were seeded into 12-well Alvetex® inserts, treated with vehicle (A) or 1.5µM BGJ 
(B) and grown for one week with medium exchanges every second day, followed by fixation, paraffin, 
embedding and H&E staining. Whole scaffold scale bar indicates 2000μm and magnification scale bar 
indicates 100μm. 
 
 
 
Figure 3.22. FGFR2 wildtype gastric cells co-cultured with stromal cells are drug-insensitive. 
FGFR2-wt SNU-1 cells together with HFF2 cells were seeded 2:1 into 12-well Alvetex® inserts, treated 
with vehicle (A) or 1.5µM BGJ (B) and grown for one week with medium exchanges every second day, 
followed by fixation, paraffin, embedding and H&E staining. Whole scaffold scale bar indicates 2000μm 
and magnification scale bar indicates 100μm. 
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Drug sensitivity of fibroblasts was also investigated. HFF2 cells seeded into Alvetex® 
scaffolds and treated with BGJ did not show sensitivity towards the drug (Figure 
3.23) and are therefore ideal to use for the co-culture model, where fibroblasts cells 
should not be killed by FGFR inhibition.  
 
Figure 3.23. Fibroblast cells are not sensitive towards FGFR inhibitors. 
HFF2 cells were seeded into 12-well Alvetex® inserts, treated with vehicle or 1.5µM BGJ and grown for 
one week with medium exchanges every second day, followed by fixation, paraffin, embedding and 
H&E staining. Scale bar in the whole scaffold image indicates 2000µm and in the magnified image 
100µm. The experiment was performed twice (Appendix Figure 8.15). 
 
Also, cells with FGFR1 amplifications, such as H520 lung cancer cells, showed to be 
highly sensitive towards BGJ drug inhibition (Figure 3.24). 
 
Figure 3.24. FGFR1-amplified lung cancer cells are sensitive to FGFR inhibition. 
FGFR1-amplified H520 were seeded into 12-well Alvetex® inserts, treated with vehicle or 1.5µM BGJ and 
grown for one week with medium exchanges every second day, followed by fixation, paraffin, 
embedding and H&E staining. Whole scaffold scale bar indicates 2000μm and magnification scale bar 
indicates 100μm.  
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3.9 Visualisation and analysis of data in 3D using Imaris 
To measure cell growth in 3D, Z-stacks were acquired at intervals of 4µm so that the 
whole scaffold thickness could be imaged via confocal microscopy. The individual Z-
stacks can then be merged together using Imaris software, which compiles each Z-
stack section to create a 3D image, thus allowing the interpretation of 3D microscopy 
datasets with segmentation options. Imaris rendered Z-stacks of MFE-296-Azurite 
and HFF2-EGFP cells grown cells in 3D in Alvetex® allowing the visualisation of cell 
interactions and cell morphology. Since MFE-296 do not tend to clump together, 
individual cells could be identified with Imaris (Figure 3.25). 
 
Figure 3.25. MFE-296 cells treated with AZD in Alvetex® scaffolds rendered in Imaris. 
MFE-296-Azurite and HFF2-EGFP cells were grown in co-culture 2:1 in Alvetex® scaffolds and treated 
with 1µM AZD followed by fluorescence confocal microscopy after 72h. Z-stacks were then rendered 
into a 3D image with Imaris. The scale bar indicates 100µm. 
 
SNU-16 cells however, were clumping together and single cells could not be clearly 
identified using Imaris despite adjusting settings in Imaris to segregate cells (Figure 
3.26). Therefore, to be able to compare cell growth more precisely between conditions, 
cell volume was compared for SNU-16 cells. 
 
 
Figure 3.26. SNU-16 cells treated with BGJ in Alvetex® scaffolds and rendered with Imaris. 
Untagged SNU-16 cells were seeded into Alvetex® scaffolds and treated with vehicle of 1.5µM BGJ and 
grown for 72h. DAPI was added to the medium to stain the cell nuclei of SNU-16 cells and Z-stacks were 
acquired with fluorescence confocal microscopy. Z-stacks were then rendered in Imaris. The scale bar 
indicates 100µm.  
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To visualise SNU-16 cells, initially cells were also transfected with Azurite, however 
the signal was very low and cells could not be properly identified in scaffolds with 
fluorescence live cell imaging. Instead of using Azurite, an H2B-RFP construct was 
used that only stains the nucleus of the cells and did not affect the morphology of 
cells (Appendix Figure 8.16). Cells were then sorted for H2B-RFP expression, as done 
previously for Azurite and EGFP-positive cells (Appendix Figure 8.17). Fluorescent 
cells were also generated for H520 lung cancer and MRC-5 lung fibroblasts 
(Appendix Figure 8.18). Combining visualisation of cells with a fluorescent marker 
and Imaris, cell concentration was assessed. For SNU-16 cells, the highest cell 
concentration was used to generate drug resistant cells in 3D (Figure 3.27). 
 
 
 
Figure 3.27. Cell seeding densities for SNU-16 cells in Alvetex® 12-well inserts. 
H2B-RFP-positive SNU-16 cells were seeded into Alvetex® scaffolds at different concentrations and 
grown for one week followed by Z-stack acquisition with fluorescence confocal microscopy and 
rendering with Imaris. The scale bar indicates 100µm. 
 
Since MFE-296 and SNU-16 cells exhibit different proliferation rates, the optimal cell 
seeding ratio was also assessed in Alvetex® scaffolds for SNU-16 cells. Since SNU-16 
cells appear to grow slower than HFF2 cells, again a ratio of 2:1 was ideal for SNU-16 
and HFF2 cells to assess drug resistance in co-culture cells in 3D (Figure 3.28). 
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Figure 3.28. Co-culture of SNU-16 H2B-RFP and HFF2-EGFP cells. 
SNU-16-H2B-RFP and HFF2-EGFP cells were seeded 1:1, 1:2 or 2:1 in Alvetex® scaffolds and grown for 
one week. Z-stacks were acquired and rendered in Imaris. Simultaneously, scaffolds were fixed, 
paraffin-embedded and H&E stained (H&E stainings and additional replicates in Appendix Figure 
8.19). 
 
3.9.1 Cell retrieval from Alvetex® scaffolds 
To extract RNA from cells grown in 3D, cells had to be retrieved from the Alvetex® 
scaffolds. Co-cultures of MFE-296-Azurite and HFF2-EGFP were grown in uncoated 
scaffolds for 14 days. Scaffolds were washed twice in PBS and cut into smaller pieces 
and incubated in trypsin/EDTA in a shaker for 15 min at 37 °C at 100rpm. Then 
medium was added to trypsin/EDTA and collected in another 15mL Falcon tube. This 
step was repeated twice with fresh trypsin/EDTA and cells were then together with 
the previous suspension pelleted, resuspended in 300μL complete growth medium 
and taken to flow cytometry for cell sorting (ARIA II). 
As a control, MFE-296 and HFF2 cells without fluorescent markers were grown in 
parallel in Alvetex® scaffolds for 14 days on uncoated scaffolds. Cells were harvested 
as described above and no cells positive for Azurite (P4) or EGFP (P6) could be 
measured (Figure 3.29). 
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Figure 3.29. FACS after cell retrieval from Alvetex® scaffolds. 
(A) FACS of MFE-296 cells and HFF2 fibroblasts without a fluorescent marker retrieved from uncoated 
Alvetex® scaffolds. (B) FACS of MFE-296 cells and HFF2 fibroblasts with fluorescent markers retrieved 
from uncoated Alvetex® scaffolds. In the first panels of the FACS data the gating was adjusted to select 
for healthy cells excluding dead cells and debris (P1). In the second and third panels gates were created 
to exclude duplicates. In the fourth and fifth panels Azurite and EGFP positive cells were gated (P4 and 
P5). (C) Overview of the events of the ungated and gated FACS measurements. 
 
With this method, it was shown that it was possible to retrieve cells from the scaffolds, 
and this will be applied for future experiments. SNU-16-H2B-RFP and HFF2-EGFP 
cells were then grown in Alvetex® 12-well inserts, treated with BGJ and rendered with 
Imaris as a trial experiment (Figure 3.30). 
 
Figure 3.30. SNU-16-H2B-RFP cells alone and together with HFF2 cells in Alvetex®. 
SNU-16 cells were either seeded alone or together with HFF2 cells into Alvetex scaffolds. After 24h the 
medium was exchanged to medium containing 1.5µM BGJ and depending on the density of the cells, 
exchanged every 1-2 days. Scaffolds were imaged after one week. Z-stacks were acquired, rendered with 
Imaris.  
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3.10 Discussion 
3.10.1 FGFR aberrations are predictors for drug sensitivity 
The primary aim of this study was to investigate the effect of FGFR2 amplifications 
in gastric cancer cells on drug sensitivity to FGFR inhibitors in a 3D setting, with the 
help of stromal cells. Initial investigations provided new insights into the significance 
of FGFR amplifications in gastric and lung cancer and FGFR2 mutations in 
endometrial cancer. Three different FGFR kinase inhibitors PD, AZD and BGJ were 
tested, with similar effects on the cancer cells studied. FGFR-amplified and mutated 
cells were sensitive to drug and cell death was induced. FGFR wildtype cell lines were 
less sensitive to FGFR inhibition and this has been shown by the difference in IC50 
values between FGFR2-amplified and FGFR2 wildtype gastric cancer cells, with a 
higher IC50 value in FGFR2 wildtype cells. This was also confirmed from findings 
from tumour tissue of gastric cancer patients where FGFR2 was genetically amplified. 
Furthermore, this is consistent with data where an array of gastric cancer cell lines 
with FGFR2 amplifications were tested in response to AZD (Xie et al., 2013). FGFR2-
mutated endometrial MFE-296 cancer cells were previously used in the group and 
showed sensitivity to FGFR inhibition due to a mutation in the kinase domain of the 
receptor. Also FGFR1-amplified H520 lung cancer cells were tested and showed 
sensitivity to FGFR inhibitors. FGFR wildtype cells were eventually killed due to off 
target effects of increasing drug concentrations.  
Previous studies have used PD treatment to investigate the effect of FGFR inhibition 
on gastric cancer cells and, where protein expression levels were investigated, the 
findings were consistent with data that showed that SNU-16 cells were more sensitive 
to FGFR inhibition than SNU-1 or AGS cells (Kunii et al., 2008). 
Upon stimulation of FGFR-amplified cell lines with FGF2 and FGF10, cell signalling 
was elevated. Both SNU-16 and H520 cells showed to be activated more by FGF2 than 
FGF10 as FGF2 signals through all FGFRs while FGF10 is more specific to FGFR2b 
(Jaskoll et al., 2005; Ornitz and Itoh, 2015).   
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3.10.2 3D Alvetex® model optimisation 
The use of 3D organotypic cultures is increasing and has been used to investigate cell-
cell interactions and phenotypic effects upon drug treatments, as they are more 
closely mimicking the in vivo properties of tumours (Chioni and Grose, 2012; Coleman 
et al., 2014; Froeling et al., 2009; Gaggioli et al., 2007). An ideal 3D organotypic model 
should display a tissue-specific physiological microenvironment that enables cells to 
proliferate, form aggregations and differentiate. Such a model should allow cell-cell 
and cell-ECM interactions and address tissue-specific stiffness, oxygen and nutrients 
diffusion and metabolic waste (Griffith and Swartz, 2006). To this day, there are no 
3D models that include all necessary parameters in providing a scaffold to support 
cell growth for long term applications without any interference. Therefore 3D models 
have to be chosen for specific applications. More traditional cell culture models 
include spinner flasks (Sutherland et al., 1971) or gyratory rotation devices (Breslin 
and O’Driscoll, 2013), which allow the generation of 3D spheres, however this is not 
compatible for HTS applications. Scaffold-based 3D models mimic cell-cell and cell-
ECM interactions the closest and therefore for this project a relatively recent scaffold 
model, Alvetex®, was established to study drug resistance. The 3D model should 
allow an increased surface area for cells to interact with each other and investigate 
the effect of stromal cells on cancer signalling. The advantages of this model over 
conventional 3D models is the ability to assess drug treatment over prolonged time 
periods, making it suitable to generate resistant cells in 3D where other models tend 
to either spontaneously disintegrate in the case of spheroids, or shrink in the case of 
gel based 3D models (Khaitan et al., 2009; Nath and Devi, 2016). 
Another advantage is the ability to grow cells without influence from animal proteins 
that could render the model less physiomimetic. The scaffolds could be coated with 
surfactants if desired. However, the reconstituted ECM from Matrigel™ was derived 
from a mouse sarcoma line and, although it has shown to increase engraftment and 
attachment of cells, it has also been shown to activate signalling pathways and 
stimulate cells to transform into a more primitive state. Therefore it may be unsuitable 
to use to study cell signalling in human cancers (Henson et al., 2007). Fortunately, cell 
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attachment of MFE-296 cells to scaffolds was observed to be the highest in uncoated 
scaffolds. Rather than helping cells attach to the scaffold, it seemed as if the surfactant 
was blocking the pores therefore hindering cell invasion into the scaffold. The 
surfactant concentration could have been diluted, however as attachment in uncoated 
scaffolds was already high and leaving scaffolds uncoated was desired, all 
experiments were conducted with uncoated scaffolds. 
Adherent MFE-296 and HFF2 cells attached readily to the scaffold as these cells 
regained their morphology in the 3D structure and are rather large cells. However, 
SNU-16 cells were suspension cells and also smaller. Therefore due to cell loss, a 
larger number of cells had to be seeded compared to other cell types. There are 
different formats available, such as 6-well and 12-well inserts and 12, 24-well and 96-
well plates. The well-plate formats would be simpler in utilisation and useful for HTS 
applications, as scaffold membranes reside in the plate and are not required to be 
transferred, and medium is added from the top. However, due to the fact that the 
scaffolds sit at the bottom of the well-plate no chemical gradient can be established 
as can be done with scaffold inserts, where medium can be either only fed from the 
top or below only or both. This was especially important for SNU-16 cells as it was 
observed that the highest cell attachment was achieved using 12-well inserts and 
feeding medium only from below, therefore enabling the cells to migrate into the 
scaffold. Furthermore, better results were observed with SNU-16 cells when the cell 
suspension volume was kept low and incubating scaffolds with the cells at room 
temperature for 30min to 1h prior to submerging the scaffolds in medium, which 
further aided attachment of suspension cells. 
Stromal cells are recognised to play an important role in malignancy of cancer cells, 
creating a niche for tumour cells protected from the influences of drug inhibition 
(Olson and Joyce, 2013; Wang et al., 2017; Whiteside, 2008). To investigate the effect 
of stromal cells on FGFR2-amplified gastric cancer cells in 3D, the effect of drug 
inhibition was also assessed in fibroblasts. Both HFF2 and MRC-5 lung fibroblasts 
were not sensitive to drug inhibition and, interestingly, initial experiments showed 
that when cancer cells were treated with FGFR inhibitors in presence of fibroblasts, 
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cell viability was increased, with higher IC50 values compared to cancer cells alone. 
Even more so, growing co-culture cells in 3D compared to 2D using MFE-296 and 
HFF2 cells in a cell viability assay resulted in higher IC50 values in 3D 96-well plates, 
highlighting the importance to study cancer drug response in 3D in the presence of 
fibroblasts. Cancer cells normally grow at a lower pace than fibroblasts and therefore, 
for co-culture experiments, the optimal ratio of cancer cells and fibroblast had to be 
determined, revealing the best results with double the cancer cells compared to 
fibroblasts. Fibroblasts could have been also treated with mitotic inhibitors such as 
Mitomycin C that would stop proliferation of fibroblasts (Ponchio et al., 2000). Cells 
also regained their natural cell shape in Alvetex® scaffolds, which was especially 
observed with fibroblasts as they regained their spindle-like morphology. 
Interestingly fibroblasts, when seeded together with cancer cells, migrated through 
the scaffold and resided more in the bottom half of the scaffold, whereas cancer cells 
remained in the top half of the scaffold, which could be due to the migratory 
properties of fibroblast cells (Kole et al., 2005). 
The effects of drug treatment in 3D were consistent with previous data acquired in 
2D, and FGFR inhibitor treatment of cells in 3D resulted in cell death. Insensitivity to 
the drug was recapitulated with SNU-1 cells in the 3D model, which suggests that the 
growth inhibition in SNU-16 and H520 cells upon FGFR inhibition resulted through 
blockade of aberrant FGFR signalling rather than off-target effects of the drug. 
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3.10.3 Visualisation, analysis and cell retrieval of cells for 3D experiments 
Most groups use histology to assess growth of cancer cells in 3D at a predetermined 
time point (Fang et al., 2016; Xu et al., 2016). In this project however, it was attempted 
to monitor the emergence of drug resistant populations in 3D. To achieve this, cancer 
cells and fibroblasts were transduced with fluorescent markers and, since the scaffold 
is thin and made of transparent polystyrene, it was possible to image through the 
whole scaffold. However, attempts to image through the medium in the well-plate 
were unsatisfactory and therefore inserts were transferred to a glass-bottom dish 
prior to imaging. Rendered Z-stacks allowed quantification of cells and showed 
changes in cell morphology. Over time, less MFE-296 cells expressed Azurite, 
whereas the proportion of HFF2 expressing EGFP was high, similar to post cell 
sorting. Thus, I suspected that the cells lose the fluorescent marker over time. SNU-
16 cells did not express Azurite efficiently and therefore a nuclear marker was used 
for SNU-16 cells instead of a cytoplasmic marker. 
As the scaffold consists of inert polystyrene, the cells could be trypsinised and 
retrieved from the scaffold. This was improved by cutting the scaffold into small 
pieces and increasing trypsin volume and trypsinisation repeats on a shaker, allowing 
gentler cell retrieval for further analysis. 
With the optimisation of the 3D model and the generation of fluorescent cancer and 
stromal cells, the tools were established to investigate the formation of drug-resistant 
cancer cells in 3D with and without stromal support. 
 
   
 
 
 
 
 
 
 
 
 
 
 Chapter IV: Results Part II 
Generation of resistant cells in 2D and 3D 
cultures and RNA sequencing 
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4.1 Introduction 
Knowledge about molecular modifications that drive cancer progression and their 
effect on the response to therapies has encouraged the development of novel target 
treatments. The fibroblast growth factor-receptor interaction (FGF-FGFR) is a 
common target for different types of cancer (Ornitz and Itoh, 2015). Furthermore, 
specific alterations of FGFR are more prevalent in certain types of cancer and 
therefore could represent potential biomarkers.  
In the previous chapter, such cancers were characterised and it was shown that 
cancers with FGFR alterations are sensitive towards FGFR inhibition, both in 2D and 
3D. Small molecule inhibition is the most widely used means of therapy and FGFR 
signalling has been postulated as a viable therapeutic target, especially in FGFR 
altered cancers (Byron et al., 2008; Konecny et al., 2013; Schmidt et al., 2015). However, 
resistance to both chemo- and hormone therapy is common in recurrent endometrial, 
gastric and lung cancer, and acquired or intrinsic resistance to small molecule 
inhibitors have been described in other carcinomas (Goltsov et al., 2012; Lito et al., 
2013; Wagle et al., 2011; Zhang et al., 2009). The outcome and efficacy of long-term 
FGFR-targeted therapy however, is an important aspect to study. 
Intrinsic or acquired drug resistance to kinase inhibitors is one of the major difficulties 
in successful cancer therapy, which is not only the case for conventional 
chemotherapy but also targeted drug therapies (Holohan et al., 2013). The survival of 
cancer patients largely relies on early cancer detection and effective treatment. We 
require a greater understanding of how resistance is acquired and need to view cell 
signalling as an interconnected network, capable of rewiring upon inhibition of 
dominant signalling pathways. Drug resistance is a multifaceted problem and can 
occur in different stages e.g.; (1) reduced drug accumulation in cells due to decreased 
uptake or efflux through pumps; (2) decreased activity of the drug; (3) diminished 
efficacy due to increased target or; (4) increased ability of cancer cell to repair the 
damage caused by the drug. Other mechanisms are evasion of apoptosis or 
deregulation of apoptotic pathways and upregulation of proliferation and survival 
signalling pathways. Furthermore, the tumour microenvironment and in particular 
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the involvement of stromal cells, has been suggested to be linked to the emergence of 
resistance in supporting cancer cell growth through the release of growth factors and 
proteases to move through the ECM and therefore act as tumour-promoting cells 
(Bissell et al., 2005; Sung et al., 2007; Whiteside, 2008). 
This results chapter focusses on drug resistance in FGFR-driven cells and the 
generation of drug resistance both in 2D conventional cell biology, and in 3D. In the 
3D model, additionally, the effect of stromal support in drug resistance will be 
investigated and compared to cancer cells alone. During the development of drug 
resistance, cancer cells rewire their signalling networks and gene expression and 
signalling pathways in drug-resistant cancer cells and normal cancer cells, with and 
without stromal support, will be compared using RNA-Seq. 
4.2 Drug resistance in 2D 
In order to generate FGFR-inhibitor resistant gastric cancer cell lines, SNU-16 cells 
were treated with FGFR inhibitor BGJ. As shown previously in section 3.3, SNU-16 
cells are highly sensitive towards FGFR inhibitors. To generate BGJ-resistant SNU-16 
cells, cells were exposed to increasing doses of BGJ over a time-course of two months 
leading to a final dosage of 1.5µM BGJ. Every second medium exchange the dosage 
of the drug was doubled and cells were left to grow. Once resistant cells, with similar 
growth rates as uninhibited cancer cells, were generated, cells were then maintained 
with complete growth medium supplemented with 1.5µM BGJ. 
As opposed to publications from other groups (Grygielewicz et al., 2016), the 
morphology of the cells did not appear to change (Appendix Figure 8.20). However, 
the cells seemed to proliferate much faster and medium had to be exchanged much 
more frequently compared to the parental cells as indicated by a colour change of the 
medium from red to orange through a metabolic effect and through cell counting of 
parental and drug-resistant SNU-16 cells. 
To investigate whether the cells were resistant towards the FGFR inhibitor, parental 
SNU-16 and BGJ-resistant SNU-16 (SNU-16BGJR) were exposed to a wide range of 
concentrations of the BGJ inhibitor over 72 hours and cell viability was measured via 
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MTS assay (Figure 4.1). As a vehicle control, DMSO was used and drug 
concentrations were adjusted so that all samples contained the same amount of 
DMSO. Staurosporine was used as a positive control as it is a potent, non-selective 
inhibitor of protein kinases to induce cell death. 
 
 
 
 
Figure 4.1. Cell viability index curve of SNU-1, SNU-16 and SNU-16BGJR in 2D. 
Parental and BGJ-resistant SNU-16 gastric cancer cells were plated in triplicate into 96-well plates and 
exposed to BGJ concentrations ranging from 1.5nM to 50µM for SNU-1 and SNU-16BGJR cells and ranging 
from 0.006nM to 50µM for SNU-16 cells. Cell viability was measured after 72h incubation. Control cells 
were treated with DMSO and as a background control 1% Staurosporine was added to wells containing 
cells. The cell viability index was then measured subtracting the background signal and adjusting to the 
controls. An average of three biological MTS experiments in technical triplicate is shown with curves 
indicating the average of the mean with the corresponding error bars showing SEM. LogIC50 and IC50 
values were calculated in GraphPad Prism 5. 
 
In the resistant cell line, a clear shift to the right and therefore higher BGJ 
concentration tolerance was observed with the curve being a plateau compared to the 
parental cell line curve. This confirms that resistant cells are less sensitive toward the 
drug. Additionally, the effect of other FGFR inhibitors such as AZD and PD were 
tested on SNU-16BGJR cells indicating a cross resistance to other FGFR inhibitors 
(Appendix Figure 8.21). 
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To further confirm drug resistance, drug sensitivity was compared to SNU-16 
parental cells and also SNU-1 cells, which harbour no FGFR2 amplifications or 
mutations. Cells were grown in 6-well plates and either treated with DMSO control 
or BGJ and grown for 72 hours. Cells were then harvested and resuspended in 
complete growth medium before being counted using Trypan blue with a 
haemocytometer and a light microscope. BGJ drug-sensitive ‘parental’ SNU-16 cells 
exhibited reduced growth in the presence of BGJ (Figure 4.2), whereas SNU-16BGJR 
and SNU-1 showed no sensitivity towards BGJ and exhibited similar growth as 
compared to controls. 
 
 
 
 
Figure 4.2. SNU-16 cells are highly sensitive towards BGJ. 
FGFR2-amplified SNU-16 and BGJ-resistant SNU-16 (SNU-16BGJR) and FGFR2 wildtype SNU-1 cells were 
plated in triplicate into 6-well plates and treated with 1.5µM BGJ for 72h. Cells were harvested and 
resuspended in 1mL complete growth medium and counted using Trypan blue with a haemocytometer. 
DMSO control treated cell numbers are represented by black filled columns and drug-treated samples 
with red columns. The graphs show the average of the mean with the corresponding error bars showing 
SEM. The experiment was performed in biological triplicate. Student’s T-test, **p<0.01. 
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Another method to observe drug sensitivity was to measure cell signalling upon drug 
treatment of SNU-16BGJR cells. As performed previously, for SNU-16 cells, the resistant 
counterpart was subjected to 1µM PD, 1µM AZD or 1.5µM BGJ and Western blot 
analysis was performed. As opposed to SNU-16 cells, resistant cells did not show 
lower p-ERK levels and no p-AKT signalling was measurable in drug resistant SNU-
16 cells (Figure 4.3).  
 
 
 
 
Figure 4.3. SNU-16BGJR cells treated with FGFR inhibitors are not sensitive towards FGFR inhibition. 
Cells were plated into 6-well plates and treated with vehicle (DMSO) or 1µM PD, 1µM AZD or 1.5µM 
BGJ for 72h. 20μg lysate was loaded per lane and specific proteins detected using antibodies against p-
AKT, p-ERK, t-AKT, t-ERK. HSC70 served as a loading control. The blots shown are representatives of 
two independent experiments.   
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To determine the effect of drug resistance in the resistant cells, cells were plated into 
6-well plates and medium was exchanged with complete growth medium without 
BGJ. Cells were harvested over a time range of 24 hours with time-points after 1h, 2h, 
4h, 8h, 16h and 24h. Control wells were kept with medium containing BGJ. p-AKT 
initially increased after 1h but then gradually decreased towards the 24 hour time-
point. However, p-ERK reappeared, following initial downregulation, being back to 
baseline levels after 24 hours (Figure 4.4).  
 
 
 
 
Figure 4.4. Removing BGJ from SNU-16BGJR cells suggests cross-talk between p-ERK and p-AKT 
signalling. 
BGJ resistant SNU-16 cells were plated into 6-well plates and incubated overnight in medium containing 
BGJ (1.5µM). The next day, the medium was exchanged to complete growth medium without BGJ and 
cells were harvested after 1h, 2h, 4h, 8h, 16h and 24h. As a control, cells were kept in complete growth 
medium containing 1.5µM BGJ. 20μg protein was used for Western blot analysis and probed for p-AKT 
and p-ERK and as controls, t-AKT and t-ERK. The blots shown are a representative of two independent 
experiments (Appendix Figure 8.22). 
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4.3 Drug resistance in 3D culture 
The standard method to study drug resistance in cancers is to study biochemical, 
physiological and morphological cues in 2D monolayer cultures. There are only a few 
in vivo alternatives to study the effects and there is a need for a more physiological 
model representing signalling within cancer cells. 
There have been a vast number of advancements in 3D cell culture to mimic the in 
vivo microenvironment and signalling processes, not only between cancer cells but 
also other cell types playing a role in cancer progression such as stromal cells (De 
Wever and Mareel, 2003; Hanchen et al., 2007). Many cells in the stroma contain 
tumour-suppressing abilities and are responsible for the integrity of epithelial cells 
(De Wever and Mareel, 2003). However, these properties can change during 
malignancy and eventually lead to tumour growth and migration through the 
expression of ECM molecules and growth factors such as TGF-β, VEGF and FGFs 
(Hughes, 2008). The diversity of cells and amount of ECM proteins in the tumour 
microenvironment plays a major role in the emergence of drug resistance, as it can 
create a barrier that the drugs must cross in order to reach cancer cells and promote 
metastasis (Affo et al., 2017; Kopanska et al., 2016; Romero-López et al., 2017; Shin 
and Mooney, 2016). Furthermore, fibroblasts have been found to be involved in the 
activation of signalling pathways, such as the Wnt/β-catenin signalling pathway, in 
many types of cancers including ovarian cancer, NSCLC and glioblastoma 
(Aprelikova et al., 2013; Johnson et al., 2013; Kaur et al., 2016). It is therefore of 
fundamental importance to additionally investigate the influence of stromal cells on 
drug resistance in cancer cells using a suitable cell culture model. 
Due to these reasons, and to study drug resistance mechanisms in cancers such as 
FGFR2-driven gastric cancer cells, I developed a novel 3D cell culture model and 
optimised it to address specific scientific questions (See Chapter III). This approach is 
ideal for long-term experiments such as to investigate the emergence of drug 
resistance in 3D in cancer cells over time. 
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4.3.1 Drug-resistant SNU-16 cells in Alvetex scaffolds 
BGJ-resistant SNU-16 cells that were generated in 2D were seeded into Alvetex 
scaffolds to investigate growth properties of the resistant cells. As was observed with 
SNU-16 cells, the SNU-16BGJR cells attached to the scaffold grew within it and formed 
cell aggregates. After growing the cells for 1 week, the scaffolds were PFA-fixed and 
paraffin-embedded, followed by H&E staining (Figure 4.5).  
 
 
Figure 4.5. BGJ-resistant SNU-16 cells were insensitive to BGJ treatment in Alvetex®. 
SNU-16BGJR cells were seeded into 12-well insert Alvetex® scaffolds and incubated overnight. The cells 
were grown in the scaffolds for 1 week. Medium containing 1.5µM BGJ was fed from below and 
exchanged every 2 days. The experiment was performed in triplicate (Appendix Figure 8.23, Appendix 
Figure 8.24). Scale bar indicates 1000µm in the left panel and 100µm in the enlarged panel. 
 
Next, SNU-16BGJR cells were mixed in a 2:1 ratio with HFF2 cells, as determined in 
Chapter III, and seeded into scaffolds. After 7 days culture, they were PFA-fixed, 
paraffin-embedded and stained with H&E for analysis. As primary gastric stromal 
cells are difficult to obtain, HFF2 cells were used, representing the stromal 
component. The co-cultured cells grew uniformly in the scaffold, and as with the 
SNU-16BGJR cells alone, did not exhibit sensitivity towards the inhibitor. Growth 
within the scaffold was also compared between resistant cells alone and in 
conjunction with fibroblasts (Figure 4.6). BGJ-sensitive SNU-16 cells were compared 
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to SNU-16BGJR cells and SNU-1 cells, which are not sensitive towards the inhibitor as 
they do not harbour FGFR amplifications (Figure 4.7). SNU-16 cells were sensitive as 
seen by decreased cell growth and SNU-1 and SNU-16BGJR cells showed no sensitivity, 
and within 1 week proliferated until the scaffolds were fully occupied by cells. 
 
Figure 4.6. SNU-16BGJR grown alone and with HFF2 cells in Alvetex® displayed no sensitivity to FGFR 
inhibition. 
SNU-16BGJR cells were grown alone or mixed with HFF2 cells 2:1 and were seeded into 12-well insert 
Alvetex® scaffolds and incubated overnight. The cells were grown in the scaffolds for 1 week. Medium 
containing 1.5µM BGJ was fed from below and exchanged every 2 days. The experiment was performed 
twice (Appendix Figure 8.25). Scale bar indicates 1000µm in the left panel and 100µm in the enlarged 
panel. 
 
 
Figure 4.7. FGFR2-amplified gastric cancer suspension cells are killed by FGFR inhibition compared 
to drug-resistant and FGFR2 wildtype gastric cancer cells. 
Cells were seeded into 12-well insert Alvetex® scaffolds and incubated overnight. Medium containing 
1.5µM BGJ was fed from below and exchanged every 2 days. Scaffolds were grown for 1 week followed 
by PFA-fixation, paraffin-embedding and H&E staining. The experiment was performed in triplicate. 
Scale bar indicates 100µm.  
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4.3.2 Generation of drug-resistant gastric cancer cells in 3D using Alvetex 
As previously described, the 12-well insert format of Alvetex and feeding medium 
solely from below produced the best results in respect to cell attachment and growth. 
Therefore, to generate and monitor BGJ drug resistant cells in 3D, 12-well inserts were 
used and medium was only fed from below to avoid cell loss. To investigate the effect 
of fibroblast signalling on cancer cells, and its involvement in drug resistance, another 
condition where SNU-16 cells were mixed with HFF2 cells in a 2:1 ratio, as previously 
determined, was incorporated in the experimental setup. SNU-16 H2B-RFP (red) cells 
and SNU-16 H2B-RFP admixed with HFF2-EGFP (green) were seeded into 12-well 
insert scaffolds. After 24h the medium was exchanged to medium containing BGJ and 
subsequently exchanged every 1-2 days. Cells were exposed to increasing dosages of 
BGJ. During every other medium exchange the drug concentration was doubled, until 
reaching 500nM final concentration of BGJ and until resistant populations were 
observed using confocal microscopy (Figure 4.8). Z-stack in situ 3D images were 
acquired using live cell imaging confocal microscopy once a week and, after 4 weeks, 
DMSO-treated SNU-16 cells and DMSO and BGJ-treated co-culture cells were 
harvested. BGJ-treated SNU-16 cells without stromal support were harvested after 8 
weeks, when similar cell volume populations to DMSO-treated were observed 
(Figure 4.9). BGJ-treated SNU-16 cells were initially highly sensitive even to lower 
BGJ concentrations. However, over prolonged exposure, cells grew exponentially and 
caught up with vehicle-treated SNU-16 cells. Interestingly, co-culture cells formed 
drug resistant populations much faster than cancer cells alone. In vehicle-treated co-
culture, SNU-16 cells initially grew as expected however cell numbers decreased, 
which could be due to cell overgrowth and cells not receving enough nutrients 
although towards later stages, medium was exchanged daily. Also, fewer HFF2-EGFP 
cells were found in DMSO-treated co-cultures compared to BGJ-treated cells. 
Prolonged BGJ treatment of co-culture cells seemed to accelerate HFF2 cell growth. 
Additionally, a better cell attachment to the scaffold was observed in co-cultured cells 
(Figure 4.10). Z-stacks were rendered using Imaris and from the information that can 
be acquired with Imaris analysis, differences in cell volume was measured and 
compared. 
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Figure 4.8. Gastric cancer cells with and without stromal support were rendered resistant in 3D using Alvetex scaffolds. 
(A) Imaris rendered live cell images of SNU-16 cells alone and SNU-16 cells co-cultured with HFF2 cells. Cells were grown in Alvetex scaffolds and treated with increasing 
dosages of BGJ until resistant populations of the fluorescently-labelled cells were observed via confocal microscopy. Images were taken once weekly (Appendix Figure 8.26-
Appendix Figure 8.31); here only start and end time point images are shown. Red cells (H2B-RFP) indicate SNU-16 cells and green cells (EGFP) indicate HFF2 cells. The experiment 
was performed in biological and technical triplicate. Scale bar indicates 100µm. (B) Change in cell volume of DMSO-treated (blue) and BGJ-treated (orange) SNU-16 3D cultures. 
(i) Cell volumes of DMSO treated and BGJ-treated SNU-16 cells grown in Alvetex alone for four and 8 weeks respectively. (ii) Cell volumes of DMSO and BGJ-treated SNU-16 
cells grown in co-culture in Alvetex over a time period of four weeks. (iii) Cell volumes of HFF2 cells grown in co-culture and treated with DMSO or BGJ over four weeks in 
Alvetex. 
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Figure 4.9. Drug-resistant gastric cancer cells were generated after 8 weeks in 3D using Alvetex for cancer cells alone and after four weeks for cancer cells with stromal 
support.  
Comparison of SNU-16 cells treated with vehicle or BGJ with different dosages over a time span of 4 weeks. (B) Analysis of SNU-16 treated with vehicle or BGJ over four weeks. 
Student’s T-test, *p<0.05, **p<0.01. (C) Imaris images of SNU-16 treated with BGJ of week 5, 6, 7 and 8. The experiment was performed in biological and technical triplicate. Per 
condition three images were taken using a confocal microscope. Scale bar indicates 100µm.  
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Figure 4.10. Drug-resistant gastric cancer cells with stromal support were generated after four weeks in 3D using Alvetex. 
(A) Comparison of co-culture cells treated with vehicle or BGJ with different dosages over a time span of four weeks. (B) Histogram analysis of the change of the volume of co-
culture cells treated with vehicle or BGJ over a time span of four weeks. Student’s T-test, ***p<0.005. The experiment was performed in biological and technical triplicate. Per 
condition three images were taken using a confocal microscope. Scale bar indicates 100µm.  
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In parallel, replicates of the experiment were fixed, paraffin-embedded and sectioned, 
followed by H&E staining (Figure 4.11). H&E staining of the fixed scaffolds from each 
condition showed the effect of BGJ on cell numbers of SNU-16 cancer cells alone and 
SNU-16 cancer cells in combination with HFF2 cells. RNA was harvested from the 
scaffolds according to the description in section 2.2.26.1 for RNA sequencing. 
 
Figure 4.11. H&E images of parental SNU-16 cells and co-culture cells grown in Alvetex. 
(A) H&E staining of SNU-16 cells in Alvetex treated with DMSO or BGJ. Once cell density was reached 
(four weeks for DMSO-treated and 8 weeks for BGJ-treated cells), scaffolds were fixed in formalin, 
processed to paraffin and stained with H&E. (B) H&E staining of SNU-16 cells co-cultured with HFF2 
cells in Alvetex. Once cell density was reached (four weeks for both DMSO-treated and BGJ-treated 
cells), scaffolds were fixed in formalin, processed to paraffin and stained with H&E. The right panel 
shows the magnification of the scaffold. The scale bar in the left panel represents 1000m. The scale bar 
in the right panel indicates 100m.   
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4.4 Cluster profiles of gastric cancer cells are formed in respect to 
treatment and cell conditions 
Thousands of genetic variants have been associated with cancer and disease-
associated SNPs affect gene expression levels (Ciriello et al., 2013; Stranger et al., 
2007). Changes in gene expression might be important in mechanisms for genetic 
variants to have an effect on the resulting phenotype. As RNA sequencing produces 
short cDNA sequences, rather than hybridisation intensities as with microarrays, it 
can also elucidate aspects of gene structures, including position of introns, exons, 
transcription start sites, and polyadenylation sites. Using RNA-Seq, it is possible to 
determine not only whether a treatment or condition affects overall RNA abundance 
but also whether it affects splicing patterns, transcription start site use, and many 
other aspects of RNA transcription and post-transcriptional processing. The RNA-
Seq technique was first reported in 2008 (Lister et al., 2008; Mortazavi et al., 2008; 
Nagalakshmi et al., 2008). Of these, the best cited is Mortazavi et al. from the 
laboratory of Barbara Wold at Caltech. This article introduced the concept of Reads 
Per Kilobase of transcript per Million mapped reads (RPKM) as a measure of gene 
expression. 
In order to compare FGFR inhibitor resistance in 3D, 12 samples were used for RNA-
Seq; vehicle-treated SNU-16 cells, BGJ-resistant SNU-16 cells and the same for 
conditions with HFF2 cells in combination each in biological triplicate. After 
harvesting and purification of RNA from the scaffolds, the RNA integrity number 
(RIN) value was measured, where a value over 8 was achieved for all samples and 
therefore suitable to perform RNA-Seq. RNA-Seq was performed by the Barts and 
The London Genome Centre using the Illumina platform with NextSeq™ 500 High 
Output Run (150 cycles) with a read length of 75 base pairs (bp) and required 20M 
reads per sample with paired end sequencing, which increases the mapping 
efficiency. As an input, 100ng RNA was used and paired fastq files were generated 
using the CASAVA software (Illumina), followed by quality control. RNA-Seq reads 
in the FASTA output were mapped to the human genome (hg38) HTSeq and 60-70% 
of reads aligned uniquely to the hg38 feature (Appendix Table 8.1). Differential 
expression analysis was then performed using Limma. The p values were further 
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adjusted using the Benjamini and Hochberg procedure (Glueck et al., 2008), which 
was performed with R studio using Bioconductor, with the bioinformatics 
department performing the initial analysis. In order to identify significantly regulated 
genes, a fold change criteria of |LogFC|>2 with an adjusted p-value <0.05 was 
applied. 
 
Table 4.1. Conditions used for differential gene expression analysis. 
Name Description 
SNU-16d DMSO-treated SNU-16 cells 
SNU-16b BGJ-treated SNU-16 cells 
FIBROd DMSO-treated co-culture cells 
FIBROb BGJ-treated co-culture cells 
 
The aim was then to compare differentially expressed genes in SNU-16b, resistant to 
BGJ (SNU-16BGJR) with SNU-16d (SNU16 parental cell line) treated with DMSO and 
FIBROb, co-culture cells consisting of SNU-16 cells and HFF2 cells resistant to BGJ 
(Co-cultureBGJR) versus FIBROd, which are co-culture cells treated with vehicle. 
After transcriptome analysis was performed as an initial sanity check, principal 
component analysis (PCA) was performed to evaluate variation and reveal strong 
patterns between datasets but also to check if sample classes cluster separately. It was 
developed for large data to tease out differences and relationships between samples 
and it extracts the fundamental structure of data without the need to build a model 
to represent it. Reduction of the number of variables into a smaller set of variables 
(principal components) eases interpretation of original data and allows detection of 
relationships. Therefore, PCA is essentially summarising variance (Black and 
Watanabe, 2011; David and Jacobs, 2014; Ma and Dai, 2011; Zhang and Castelló, 2017).   
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The PCA plot for the datasets described above encompasses all 12 samples (Figure 
4.12). All triplicates cluster closely, indicating the replicates have a highly similar 
signature. Since co-culture cells also contain HFF2 cells, PC1 is lower and the 
triplicates go in the same direction. The same is true for SNU-16 cells alone which 
have a higher PC1 value. Also in respect to treatment the replicates cluster closer to 
each other and BGJ-treated replicates have a lower PC2 value. Therefore, the 
replicates cluster according to their cell components and treatment. These results 
indicate that DMSO-treated SNU-16 cells and SNU-16 cells exposed to HFF2 cells are 
transcriptionally different from SNU-16 cells and SNU-16 cells exposed to HFF2 
treated with BGJ. Importantly, adding a stromal component also separates 
transcription profiles both in DMSO and BGJ-treated cells. 
 
 
Figure 4.12. Gene expression profiles of SNU-16 and co-culture cells grown in Alvetex cluster closely 
according to treatment and cell type. 
Principal component analysis plot of SNU-16 cells (diamond) and SNU-16 cells with HFF2 (circle) treated 
with vehicle (DMSO) and BGJ-resistant SNU-16 cells alone (triangle) and co-cultured with HFF2 (square) 
in 3D Alvetex model, showing the variation in the RNA sequencing data. Each shape of the same colour 
represents a biological triplicate and shows the degree of variance per conditions and replicate. 
Triplicates cluster together and different conditions cluster separately.  
Results Part II 
 167 
 
To help with further interpretation, a dendrogram was built showing the 
relationships between the different samples (Figure 4.13). This plot shows a clustering 
dendrogram where samples that are most similar occupy closer positions in the tree 
(measured by height), while samples that are less similar are separated by larger 
numbers of branch points. 
 
Figure 4.13. Gene expressions of cells cluster more closely according to their cell type than 
treatment. 
The figure shows a cluster dendrogram showing the number of branches separating samples 
indicating the similarities between conditions. Treatment samples are named BGJR, control samples 
are named parental. It resulted in the clustering of two discrete clusters representing the distinct 
transcriptome signatures of the two cell type conditions. Within the two clusters, another two distinct 
clusters according to the treatments were generated. 
 
A dendrogram merges the closest pair of classes and then further merges the next 
closest pair followed by the succeeding pair until all classes are merged. The distances 
between all pairs of classes are then updated after every merger and the distances at 
which the signatures of classes are merged are then used to construct a dendrogram. 
The distances at which each pair of classes is merged can then be interpolated using 
the scale bars of the dendrogram graph.  
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There are a vast number of tools available to analyse RNA-Seq data. Networks of 
genes can be generated and up and downstream effects investigated, together with 
diseases associated with the gene signatures in the datasets. Importantly, pathway 
analysis can give an idea which pathways are significantly up and downregulated 
and therefore represent a key pathway for the cancer cell. 
Networks of the significantly regulated genes were generated using STRING and 
Cytoscape (with the ClueGo plugin) to generate gene interaction networks. Next, 
pathway analysis tools including Ingenuity pathway analysis (IPA), DAVID, KEGG 
pathways and GSEA were used and different approaches were applied to identify 
targetable regulated pathways and genes. 
4.4.1 Expression analysis of SNU-16 cells alone 
In total, 1588 genes were analysed. Of these, 603 genes were significantly regulated, 
from which 235 genes were upregulated in DMSO-treated SNU-16 cells and 368 genes 
were upregulated in SNU-16BGJR. 
First of all, gene interaction networks were generated using STRING (Appendix 
Figure 8.32, Appendix Figure 8.33) and cytoscape. Cytoscape is an open source 
software platform to help visualise complex molecular interaction networks with the 
incorporation of expression profiles and other data. To generate the interaction 
networks of all regulated genes in a dataset, the ClueGo plugin was used. The ClueGo 
plug-in visualises the non-redundant biological terms for large clusters of genes into 
a functionally grouped network (Figure 4.14). With this the interconnected nature of 
this dataset was shown as a static image. However, the tool is interactive and was 
used to identify overlapping pathways and gene interactions that can be analysed 
using the software. 
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Figure 4.14. Regulated genes of gastric cancer cells form a network interaction diagram. 
Interaction networks of gene expressions of gastric cancer cells made resistant to BGJ in Alvetex® were 
built using only genes that were significantly regulated (>2, <-2). Genes that did not form interaction 
networks with other significantly regulated genes were excluded. 
 
The volcano scatter plot enables quick visual identification of those data points that 
display large magnitude changes that are also statistically significant (Figure 4.15). 
 
Figure 4.15. Volcano plot of SNU-16 vs SNU-16BGJR cells. 
The volcano scatter plot indicates significance versus fold-change on the y and x-axes. 
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The effect of the clustering is further supported by the depiction of gene expression 
patterns in a heat map of significantly regulated genes, which is a 2D representation 
of data, where values are represented by colours indicating genes that drive the 
observed clustering pattern (Figure 4.16). Gene expression changes between 
biological replicates were similar, however distinct patterns were observed between 
drug-treated and vehicle-treated SNU-16 cells in 3D. 
From the significantly regulated genes, the top 20 targets that were found to be up- 
and downregulated in SNU-16 cells, treated with DMSO over 8 weeks, were 
investigated in more detail (Figure 4.17). An overview of the full names and functions 
of the top 5 candidates that are up and downregulated in BGJ-treated SNU-16 cells 
are listed in the Appendix (Appendix Table 8.2, Appendix Table 8.3). Numerous 
significantly upregulated genes belong to sugar metabolism pathways with sucrase-
isomaltase (SI) being upregulated the most, by over 8-fold. Other upregulated genes 
are commonly involved in cytotoxic metabolism. In the downregulated genes, Piwi-
like protein 1 (PIWIL1) was downregulated by over 7-fold. 
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Figure 4.16. Heat map of SNU-16 cells versus SNU-16BGJR cells in 3D. 
The heat map shows all the significantly regulated genes between DMSO-treated (SNU-16d, blue) and 
BGJ-treated (SNU-16b, yellow) SNU-16 cells, explaining the variation seen in the PCA plot. Red genes 
indicate upregulation, while green indicates downregulation of genes. Each condition was sequenced in 
biological triplicate. 
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Figure 4.17. Top 20 up and downregulated genes in SNU-16BGJR compared to parental SNU-16 cells. 
RNA was extracted from parental SNU-16 cells and SNU-16BGJR grown in Alvetex scaffolds. RNA 
sequencing showed in total 603 genes that were significantly altered. (A) 368 genes were significantly 
upregulated in SNU-16BGJR cells compared to parental SNU-16 cell line (top panel). The 20 transcripts 
with the highest fold change relative to the parental cells are shown. (B) 235 genes were significantly 
downregulated compared to parental SNU-16 cell line (bottom panel). The 20 transcripts with the 
highest negative fold change relative to the parental cells are shown. Three technical and three 
biological replicates of each condition were run on the Illumina platform, followed by differential 
gene expression analysis by calculating the fold change between the resistant populations compared 
to the parental cells. 
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4.1.1 Expression analysis of co-culture cells 
The same approach was also used with SNU-16 cells exposed to the influence of 
fibroblasts, and gene interaction networks were generated. In total, 1385 genes were 
analysed in co-culture cells. Among the 662 genes that were significantly regulated, 
359 genes were upregulated in DMSO-treated co-culture cells (FIBROd) and 303 
genes were upregulated in BGJ-treated co-culture cells (FIBROb). The interaction 
network shows the connections and interactions of all significant genes in this dataset, 
excluding genes that did not form any interactions (Figure 4.18). The volcano plot 
indicates scattering of genes, which is much narrower compared to the cancer cells 
alone (Figure 4.19). 
 
Figure 4.18. Regulated genes of gastric cancer cells co-cultured with stromal cells form a network 
interaction diagram. 
Interaction networks of gene expressions of co-culture cells made resistant to BGJ in Alvetex® were 
built using only genes that were significantly regulated (>2, <-2). Genes that did not form interaction 
networks with other significantly regulated genes were excluded. 
Results Part II 
 174 
 
 
Figure 4.19. Volcano plot of co-culture cells. 
The volcano scatter plot indicates significance versus fold-change on the y and x axes. 
 
Again, the effect of the clustering is further supported by the depiction of gene 
expression patterns in a heat map of co-culture cells of significantly regulated genes 
(Figure 4.20). Similarly, as in the cancer cells alone, expression profiles of biological 
replicates move in the same direction and also treatments cluster together and exhibit 
similar expression profiles. As for SNU-16 cells before, from the significantly 
regulated genes, the top 20 up- and downregulated genes were plotted in a graph 
with regenerating islet-derived 1 (REG1A) and REG1B being the most upregulated 
genes by 12-fold and 10-fold respectively and Alpha-fetoprotein (AFP) was 
downregulated the most by 12-fold (Figure 4.21). In the appendix, descriptions of the 
top 5 up- and downregulated genes and functions can be found in more detail 
(Appendix Table 8.4, Appendix Table 8.5). 
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Figure 4.20. Heat map co-culture cells. 
The heat map shows all the significantly regulated genes between DMSO-treated (FIBROd, blue) and 
BGJ-treated (FIBROb, yellow) co-culture cells, explaining the variation seen in the PCA plot. Red 
genes indicate upregulation, while green indicates downregulation of genes. Each condition was 
sequenced in biological triplicate. 
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Figure 4.21. Top 20 up and downregulated genes in co-culture cells. 
RNA was extracted from parental co-culture (SNU-16 and HFF2) cells and co-cultureBGJR grown in 
Alvetex scaffolds. RNA sequencing showed in total, 662 genes that were significantly altered. (A) 
303 genes were significantly upregulated in co-cultureBGJR cells compared to parental co-culture cells 
(top panel). The 20 transcripts with the highest fold change relative to the parental cells are shown. 
(B) 359 genes were significantly downregulated compared to parental co-culture cells. The 20 
transcripts with the highest negative fold change relative to the parental cells are shown. Three 
technical and three biological replicates of each condition were run on the Illumina platform, followed 
by differential gene expression analysis by calculating the fold change between the resistant 
populations compared to the parental cells. 
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To compare up and downregulated genes between monoculture and co-culture 
conditions, Venn diagrams were generated, comparing common genes between 
SNU-16 cells and SNU-16 cells with HFF2 cells in the upregulated (A) and 
downregulated datasets (B). 100 genes were found to be upregulated in both SNU-16 
cells alone and co-culture cells, whereas 80 genes were downregulated in the two 
datasets (Figure 4.22). 
 
Figure 4.22. Monoculture and co-culture conditions show similarities in gene regulation.  
Significantly regulated genes of SNU-16 and co-culture cells were compared to each other and Venn 
diagrams of shared and distinct genes were generated. (A) Common upregulated genes comparing 
SNU-16 and co-culture cells. (B) Common downregulated genes comparing SNU-16 and co-culture cells. 
 
In addition to comparing co-culture cells and monoculture to their vehicle controls, 
conditions were also compared to each other so that, when comparing DMSO treated 
SNU-16 cells to DMSO-treated co-culture cells 2480 were regulated in total, 1591 
genes were upregulated in DMSO-treated SNU-16 cells and 1385 genes were 
upregulated in DMSO-treated co-culture cells. In FGFR inhibitor treated cells, 3413 
genes were regulated, among which 2028 genes were upregulated in SNU-16BGJR cells.  
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Additonally, heat maps of up and downregulated genes of comparisons between 
DMSO-treated SNU-16 and co-culture and also BGJ-treated SNU-16 and co-culture 
cells were generated (Appendix Figure 8.34, Appendix Figure 8.35). Furthermore, all 
four datasets were compared to each other, identifying common genes that were 
shared between all datasets generated from differential gene expression analysis 
(Appendix Figure 8.36). 
4.5 Drug-resistance in gastric cancer is potentially driven by 
metabolic processes 
Gene products do not work alone, but rather in an intricate network of interactions, 
making it essential to study gene networks. When analysing RNA-Seq data, a 
fundamental aspect of the analysis is to investigate groups of genes that are 
functionally meaningful. A response is shown by the enrichment of association of 
genes within the gene set to experimental condition or sample. 
First of all, the node is identified, which represents a list of genes and therefore a one-
dimensional representation of the data. A pathway is then a linked list of 
interconnected nodes and as such a two-dimensional representation of the data. As a 
next step a network can be built which then represents interconnected pathways and 
gives information about cellular function and regulatory processes and therefore 
reveals a multi-dimensional representation. This is useful to determine if the 
differentially expressed genes are associated with a certain biological process or 
molecular function. 
Network analysis shows key components of different pathways and how they 
interact with one another. This can be useful for identifying regulatory events that 
influence multiple biological processes and pathways (Curtis et al., 2005; Werner, 
2008). Therefore, pathway analysis forms the bridge to the future and will help to 
fully understand the molecular basis of diseases such as cancer and the emergence of 
drug resistance. To date, there is limited software available to analyse RNA-Seq data. 
However, there are a vast number of methods to analyse microarray data which can 
be well applied to analyse RNA-Seq data. 
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Initially, datasets were analysed using the DAVID tool, which condenses a list of 
genes or associated biological terms into organised classes of related genes or biology, 
called biological modules. This organization is accomplished by mining the complex 
biological co-occurrences found in multiple sources of functional annotation. It is a 
powerful method to group functionally related genes and terms into a manageable 
number of biological modules for efficient interpretation of gene lists in a network 
context (Dennis et al., 2003; Huang et al., 2009a, 2009b). 
DAVID bioinformatics resources consist of an integrated biological knowledge base 
and analytics tools aimed at systematically extracting biological meaning from large 
gene/protein lists. The procedure first requires uploading a gene list containing any 
number of common gene identifiers followed by analysis using one or more text and 
pathway-mining tools such as gene functional classification, functional annotation 
chart or clustering and functional annotation table. With this, it is possible to gain an 
in-depth understanding of the biological themes in lists of genes that are enriched in 
genome-scale studies. 
 
Table 4.2 Significantly regulated pathways using KEGG in DAVID. 
Only significantly regulated genes (threshold=2, -2) were included of SNU-16 (A) and co-culture (B) cells. 
Significant pathways are indicated by p<0.05. Pathways of particular interest are highlighted in red. 
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Retinol pathway 
 
Figure 4.23. The retinol pathway is significantly upregulated in drug-resistant gastric cancer cells. 
Upregulated genes are highlighted in red and downregulated genes are indicated in green. 
 
4.5.1 BGJ-resistant SNU-16 cells undergo metabolic changes and switch energy 
metabolism  
Expression profiles were analysed using GSEA to detect altered pathways and results 
were cross-referenced with genes in the KEGG database to determine the signalling 
pathways responsible for the differential clustering observed in PCA. Using the 
normalised enrichment scores (NES), significantly regulated pathways were grouped 
into functional classes. In total, 14 pathways were upregulated (FDR<0.05) in SNU-
16BGJR cells, with 57% of the significantly upregulated pathways belonging to the 
metabolic category, 22% categorising to genetic information processing and each 7% 
into organismal systems, environmental information processing and human diseases 
(Figure 4.24A). In contrast, among the downregulated pathways, 12 pathways were 
significantly downregulated of which 33% categorise to human diseases, 25% to 
metabolic pathways, 17% to both genetic and environmental information processing 
and 8% to cellular processes (Figure 4.24B). 
The most upregulated pathways in the metabolic processes were drug (NES=3.042, 
FDR<0.001) and xenobiotic (NES=2.786, FDR<0.001) metabolism by cytochrome P450. 
Furthermore, amongst the metabolic pathways, retinol (NES=2.425, FDR<0.006), 
steroid hormone (NES=2.122, FDR<0.028), starch and sucrose (NES=2.092, 
Results Part II 
181 
 
FDR<0.029), drug metabolism by other enzymes (NES=2.060, FDR<0.033), glutathione 
(NES=2.053, FDR<0.032) and fatty acid metabolism (NES=1.977, FDR<0.045) were 
upregulated significantly. 22% of upregulated pathways fall into the category of 
information processing, with the ribosome pathway as the most upregulated 
(NES=2.954, FDR<0.001), followed by graft versus host disease (NES=2.324, 
FDR<0.011) and maturity onset diabetes of the young (NES=2.263, FDR<0.015). Other 
pathways that were upregulated included the Renin angiotensin system (NES=2.577, 
FDR<0.001) of the organismal systems, which has been implicated in the development 
or invasion of several kinds of cancer tissue (Wegman-Ostrosky et al., 2015). In 
environmental information processes, cell adhesion molecules (CAMs) (NES=2.193, 
FDR<0.019), and autoimmune thyroid disease in human diseases (NES=2.100, 
FDR<0.030) were significantly upregulated (Table 4.3A). 
Among the human diseases in the downregulated pathways, the arrhythmogenic 
right ventricular cardiomyopathy (ARVC) pathway was downregulated the most 
(NES=-2.614, FDR<0.006), followed by hypertrophic cardiomyopathy (NES=-2.459, 
FDR<0.004), dilated cardiomyopathy (NES=-2.301, FDR<0.009) and Huntington’s 
disease (NES=-2.037, FDR<0.033). In the metabolic pathways, steroid biosynthesis 
(NES=-2.369, FDR<0.009), biosynthesis of unsaturated fatty acids (NES=-2.368, 
FDR<0.007) and oxidative phosphorylation (NES=-2.331, FDR<0.009) were 
downregulated significantly. Oxidative phosphorylation is involved in the 
generation of energy in the form of adenosine triphosphate (ATP), which takes place 
in the mitochondria. This pathway is used by all aerobic organisms and is highly 
efficient, however mitochondria consume cellular oxygen, releasing reactive oxygen 
species as a by-product (Solaini and Harris, 2005), which have been implicated in 
cancers by inducing oxidative damage. ROS are needed by cancer cells to grow due 
to their accelerated growth, however this can also induce death in cancer cells (Denko, 
2008; Nogueira et al., 2008) and therefore cancer cells have been found to switch to 
other energy sources such as glycolysis. Cancer cells take up glucose for aerobic 
glycolysis, which is an inefficient method for energy production and is referred to as 
the Warburg effect (Warburg, 1956). However, cancer cells use the catabolism of 
glucose to produce pyruvate or lactate in the cytoplasm and use this as fuel. Cancer 
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cells can therefore adapt to environmental changes and have a selective advantage 
under unfavourable conditions (Chen et al., 2008; Marusyk and Polyak, 2010). In 
genetic information processing, the proteasome pathway (NES=-1.984, FDR<0.039) 
was further downregulated and in environmental information processing, cytokine-
cytokine receptor interaction (NES=-2.087, FDR<0.031) and the calcium signalling 
pathway (NES=-1.934, FDR<0.050) were significantly decreased (Table 4.3B). 
Based on extensive literature research and the outcomes of the GSEA analysis, the top 
up and downregulated pathways were investigated more closely and enrichment 
profiles were generated and upregulated genes responsible for the enrichment of 
these pathways were crosschecked with the genes in the dataset (Figure 4.25, Figure 
4.26). 
 
 
 
Figure 4.24. Categorisation of enriched pathways according to KEGG in SNU-16BGJR cells compared 
to parental cells.  
Pie charts indicate the percentages of all upregulated (A) and downregulated (B) pathways of SNU-16 
cellsBGJR cells compared to parental SNU-16 cells in 3D. Expression profiles were analysed using NES 
from GSEA linked to the KEGG pathway database. NES: normalised enrichment score. 
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Table 4.3. Significantly regulated pathways according to KEGG.  
GSEA identified multiple enriched pathways based on the KEGG gene set. (A) Significantly most 
upregulated and (B) downregulated pathways. FDR-value<0.05. Pathways of particular interest are 
highlighted in red. 
 
 
 
Figure 4.25. GSEA expression profiles of significantly upregulated pathways in SNU-16BGJR cells. 
Enrichment plots of upregulated pathways from the comparison between SNU-16 and SNU-16BGJR cells 
using KEGG. SNU-16BGJR cells were positively enriched for the retinol pathway (A) and starch and 
sucrose metabolism (B). Vertical lines indicate the positions of the genes along the comparison for each 
gene set. Cut-off FDR value<0.05. Genes involved in enrichment of retinol pathway and starch and 
sucrose pathway are shown below the graphs with respective fold changes (Table 4.4). 
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Table 4.4. Significant genes driving upregulated pathways in SNU-16BGJR cells. 
 
 
As glucose and sucrose metabolism seems to play an important role in drug 
resistance, the starch and sucrose metabolism raised interest, which has been among 
the significantly regulated pathways in the dataset. When crosschecking back to the 
individual gene expression levels, SI and UGT2A3 were the top two genes involved 
in the pathway. 
 
Figure 4.26. GSEA expression profiles of significantly downregulated pathways in SNU-16BGJR cells.  
Enrichment plots of downregulated pathways from the comparison between SNU-16 and SNU-16BGJR 
cells using KEGG. SNU-16BGJR cells were negatively enriched for the steroid biosynthesis (A) and 
oxidative phosphorylation (B). Vertical lines indicate the positions of the genes along the comparison for 
each gene set. Cut-off FDR value<0.05. Genes involved in enrichment of retinol pathway and starch and 
sucrose pathway are shown below the graphs. 
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In the oxidative phosphorylation pathway, the only significantly downregulated 
genes was NADH dehydrogenase (ubiquinone) 1 alpha sub-complex, 4-like 2 (NDUFA4L2) 
with a fold change of -4.192. 
4.5.2 BGJ-resistant co-culture cells produce increased levels of ECM proteins 
As for SNU-16 cells, regulated pathways comparing DMSO-treated and BGJ-treated 
co-culture cells were grouped into functional classes using the KEGG database. In co-
culture cells the majority of the upregulated pathways categorise into human diseases 
with 44%, followed by 19% organismal systems, 15% environmental processes, each 
11% metabolic and cellular processes (Figure 4.27A). Among the downregulated 
genes 67% categorise into metabolic pathways, 18% in genetic information processing 
and 11% and 4% in human diseases and organismal systems respectively (Figure 
4.27B).  
Among the upregulated pathways the ECM receptor interaction pathway 
(NES=3.644, FDR<0.001) was upregulated the most (Table 4.5A, Figure 4.28A), which 
represents the interaction with the stromal component. As observed before with 
cancer cells alone, CAMs were upregulated significantly (NES=1.922, FDR<0.033). In 
contrast to cancer cells alone, among the downregulated pathways, the ribosome 
pathway was downregulated the most (NES=-4.031, FDR<0.001) (Table 4.5B). 
However, similarly to SNU-16 cells alone, oxidative phosphorylation (NES=-3.424, 
FDR<0.001) and steroid biosynthesis (NES=-2.407, FDR<0.003) were downregulated. 
The ribosomal pathway was downregulated by the downregulation of ribosomal 
proteins (RPs) (Figure 4.28B). Many RPs also fill several roles that are independent of 
protein biosynthesis, called extra-ribosomal functions (Vaarala et al., 1998). For 
example RPS29, which was one of the genes contributing to the enrichment of the 
ribosome pathway in the BGJ-resistant co-culture cells, has been found to be 
implicated with tumour suppressor activity (Coppock et al., 2000). In the case of 
oxidative phosphorylation, again as with cancer cells alone, a switch to other energy 
metabolisms such as glycolytic energy production could have occurred. 
Results Part II 
186 
 
 
 
Figure 4.27. Categorisation of enriched pathways according to KEGG in co-cultureBGJR cells compared 
to parental cells.  
Pie charts indicate the percentages of all upregulated (A) and downregulated (B) pathways of co-
cultureBGJR cells compared to parental co-culture cells in 3D. Expression profiles were analysed using 
GSEA linked to the KEGG pathway database. 
 
Table 4.5. Significant regulated pathways according to KEGG in co-culture cells.  
Upregulated (A) and downregulated (B) pathways according to NES. Biologically interesting pathways 
based on literature search are highlighted in red. 
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Figure 4.28. Up and downregulated pathways in co-culture cells. 
Enrichment plots of downregulated pathways from the comparison between vehicle-treated and BGJ-
treated co-culture cells using KEGG. Co-cultureBGJR cells were positively enriched for the ECM 
interaction pathway (A) and negatively enriched for the ribosome pathway (B). Vertical lines indicate 
the positions of the genes along the comparison for each gene set. Cut-off FDR value<0.05. Genes 
involved in enrichment of the ECM interaction pathway are shown below the graphs (Table 4.6). No 
significant genes were encountered in the ribosome pathway. 
 
Table 4.6. ECM pathway upregulated genes in RNA sequencing data. 
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Pathways of cancer cells alone and co-culture cells were compared and overlapping 
pathways were investigated. In the upregulated pathways, drug-resistant SNU-16 
and co-culture cells shared 57 pathways and 46 in the downregulated pathways. In 
the common pathways sucrose and starch was upregulated indicating that sugar 
plays an important role in energy metabolism in both conditions. Among the 
downregulated pathways as described above, oxidative phosphorylation is 
downregulated in both conditions. 
 
 
 
Figure 4.29. Upregulated and downregulated pathways of gastric cancer alone and in co-culture reveal 
a singifcant overlap.  
Venn diagrams of common upregulated genes comparing SNU-16 and co-culture cells (A) and common 
downregulated genes comparing SNU-16 and Co-culture cells (B). 
 
Further analysis using ingenuity pathway analysis (IPA), allowed more specific 
analysis of interactions and regulation of the genes, spatial organisation (Appendix 
Figure 8.37), pathways alterations and also comparisons of analysed datasets. 
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Pathways were also analysed with SPIA (Appendix Figure 8.38), which is a 
Bioconductor package in R, however the main focus will be on IPA. 
Initially, the FGF signalling pathway sparked interest, which revealed that pathways 
downstream of FGFR were upregulated in SNU-16BGJR cells (Figure 4.30). What 
particularly drives the pathway according to the IPA database is AKT signalling, 
resulting in cell survival and cAMP response element-binding protein (CREB) 
upregulation, which are transcription factors increasing transcription of genes that 
ultimately lead to cell differentiation, growth, morphogenesis and angiogenesis 
(Gubbay et al., 2006; Li et al., 2011). This could be induced by other RTKs such as MET 
activation through hepatocyte growth factor (HGF), which was upregulated in the 
SNU-16BGJR dataset.  
 
 
Figure 4.30. FGF signalling pathway in SNU-16BGJR cells. 
FGF signalling is downregulated in drug-resistant SNU-16 cells, whereas HGF is upregulated, which 
leads to activation of pathways downstream of FGF signalling and specifically upregulation of AKT and 
upregulation of CREB, ultimately activating transcription of genes involved in cell differentiation, 
growth, morphogenesis and angiogenesis.  
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CREB can be activated through phosphorylation of kinases, such as AKT, p90Rsk, 
protein kinase A, and calcium/calmodulin-dependent kinases (Sun et al., 1994). It is 
involved in the regulation of genes including cyclins, Bcl-2 and Egr-1, which through 
aberrant expression induce oncogenesis. In a number of human cancers including 
acute myeloid leukaemia (AML) and non–small cell lung cancer, CREB was 
upregulated resulting in constitutive phosphorylation and malignant transformation 
of cells (Seo et al., 2008; Shankar et al., 2005).  
The retinol pathway was particularly interesting in cancer cells alone as it was 
significantly upregulated in DAVID and GSEA using KEGG and was investigated 
using IPA (Figure 4.31). In SNU-16BGJR cells, cellular triacylglycerol lipase, retinol-
binding protein, carboxylesterase and retinal dehydrogenase were upregulated, 
which are involved in retinol regulation and all-trans retinol and retinoate production. 
The main factor driving the pathway, however is the cellular retinol-binding protein 
(CRBP). It is an intracellular cytosolic protein, which transport and mediate 
metabolism and function of retinol, retinal and retinoic acid and belong to the fatty 
acid binding-protein gene family (Glatz and van der Vusse, 1996). CRBP are 
potentially involved in the transformation of retinol to retinoic acid by oxidation in 
target tissues and therefore regulation of retinoic acid in cells (Ghyselinck et al., 1999; 
Napoli, 1999). Two CRBPs are known, CRBP-1 and 2, with CRBP-1 playing and vital 
role in the uptake of retinol followed by esterification and therefore enhancing 
bioavailability and transcriptional activity. Furthermore, CRBP-1 has been associated 
with embryonic development, growth, vision and survival of vertebrates (Dirami et 
al., 2004; Doldo et al., 2015). Further, a correlation between loss of CRBP-1 and breast 
cancer development was found, and CRBP was identified as a suppressor of 
anchorage-independent growth (Kuppumbatti et al., 2001). Additionally to loss of 
CRBP-1 in breast cancer, CRBP-1 downregulation has been encountered in 
endometrial, ovarian and prostate cancer and was associated with increased 
malignancy (Jerónimo et al., 2004; Kuppumbatti et al., 2000; Orlandi et al., 2006; 
Roberts et al., 2002). Whereas in in lung adenocarcinoma and laryngeal cancer, CRBP-
1 was upregulated and was associated with poor prognosis (Chen et al., 2018; Doldo 
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et al., 2015; Peralta et al., 2010). Similarly, upregulation of CRBP in drug-resistant 
gastric cancer cells could signify a more aggressive cancer type. 
 
 
 
 
Figure 4.31. Retinol and retinoate biosynthesis. 
The retinol pathway was upregulated in drug-resistant SNU-16 cells through the upregulation of 
CRBP and tricylglycerol lipase, carboxylesterase and retinol dehydrogenase. 
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From previous analysis, the sucrose metabolism has been found to be enriched in 
drug-resistant SNU-16 cells and was also found upregulated using IPA (Figure 4.32). 
SI and ALDOB, which are significantly upregulated in this pathway, are both 
involved in sugar degradation. 
 
 
 
Figure 4.32. Sucrose degradation in SNU-16BGJR cells compared to parental SNU-16 cells. 
Sucrose alpha-glucosidase (SI) and fructose-bisphosphate aldolase (ALDOB) are both significantly 
upregulated in the sucrose degradation pathway, which ultimately results in increased glucose and ATP 
production.  
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Comparing significantly upregulated pathways in IPA, the serotonin degradation 
pathway seemed to play a role in drug resistance both in SNU-16 and also co-culture 
cells (Appendix Figure 8.39). Serotonin has been found to stimulate tumour growth 
in aggressive cancers and elicits mitogenic activity both in normal and cancer cells 
(Sarrouilhe et al., 2015). This could indicate that SNU-16 cells upregulate serotonin 
production to accelerate growth and angiogenesis in the cells. 
With IPA, also interaction networks with genes of interest that were significantly up- 
and downregulated can be generated. From these networks, direct influences on the 
genes of interest were found and direct interactions investigated (Appendix Figure 
8.40-Appendix Figure 8.42). For example, from the REG1A interaction map 
(Appendix Figure 8.42), a direct interaction between REG1A and BCL2L1, can be 
found. BCL2L1, which belongs to a protein family, sharing Bcl-2 homology domains, 
encodes a pro-survival signal and therefore upregulation of REG1A in co-culture cells 
could indicate enhanced resistance to apoptosis. 
In drug-resistant co-culture cells, together with the sucrose degradation metabolism 
also the glycolysis I pathway has been found to be upregulated (Figure 4.33). This is 
an oxygen-independent metabolic pathway, which could support downregulation of 
oxidative phosphorylation in drug-treated cells. It mainly utilises fructose to generate 
energy, which is cleaved by sucrose-isomaltase in the sucrose metabolism. Most of 
the energy of cancer cells is derived from glycolysis, which means glucose is 
converted to lactase although oxygen is available. This method, which is termed 
Warburg effect generates less energy than oxidative phosphorylation (Warburg, 
1956), however cancer cells potentially benefit from this pathway as it provides them 
with precursors for biosynthetic pathways such as amino acids, NADPH and ribose 
sugars needed for DNA and RNA synthesis. Factors that mainly drove the pathway 
in drug-resistant SNU-16 cells were ALDOB, as before resulting in increased glucose 
generation, and hepatocyte nuclear factor 1 homeobox B (HNF1β), which was 
involved in transformation of intracellular metabolism to enhance aerobic glycolysis 
and therefore also contributing to the Warburg effect. In ovarian carcinoma cells, 
HNF1β expression resulted in a reduction of intracellular ROS and thus resistance to 
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ROS ,which may be a consequence of the Warburg effect and therefore helps cells 
survive in hypoxic conditons under oxidative stress (Amano et al., 2015). Neurogenic 
differentiation 1 (NeuroD1) regulated the expression of insulin genes and mutations 
in this gene can lead to maturity-onset diabetes of the young 6 (MODY6) (Horikawa 
et al., 2018). NeuroD1 upregulated β cell development in drug-resistant cells and as 
β cells are involved in insulin storage and release increased levels of insulin could be 
produced in drug-resistant cells. There have been links between gastric cancer and 
diabetes and there could be shared risk factors such as, hyperglycemia, H. pylori 
infection, high salt intake, medications and comorbidities (Malecki et al., 1999; Tseng 
and Tseng, 2014). Insulin showed to affect proliferation of gastric cancer cells, 
inducing chemoresistance of gastric cancer cells to 5-fluorouracil, which is possibly 
involving upregulation of P-glycoprotein (Wei et al., 2015). 
 
 
Figure 4.33. Glycolysis I pathway upregulation in co-culture cells. 
Hepatocyte nuclear factor 1 homeobox B (HNF1β) activates or inhibits transcription of target genes and 
was upregulated in SNU-16BGJR cells affecting foetal endocrine pancreas development and volume. Also 
ALDOB, which results in increased glucose production, was upregulated. Furthermore, Neurogenic 
differentiation 1 (NeuroD1) was upregulated, which in turn upregulates β cell development.   
Results Part II 
195 
 
 
 
Figure 4.34. Comparison of pathways in cancer cells alone and with stromal cells. 
Red boxes indicate upregulated pathways with increasing intensity, while blue indicates downregulated 
pathways. 
 
Expression of pathways in both datasets including SNU-16 cells versus co-culture cells 
can be visualised (Figure 4.34), with thyroid hormone metabolism being most 
upregulated in both datasets. Thyroid hormones play important roles in regulating 
normal metabolism, development, and growth, however they can also stimulate 
cancer cell proliferation (Lin et al., 2016) and therefore play a role in cancer growth in 
SNU-16 and co-culture cells. 
Taken together, these data have shown that FGFR2-amplified gastric cancer cells 
could be rendered resistant to FGFR inhibition in 2D, but also in 3D with and without 
stromal support. Alvetex scaffolds have been proven to be a suitable model to study 
drug resistance over longer time periods. Differential gene expression analysis from 
RNA-Seq data with different tools and databases have revealed interesting genes and 
pathways including pathways involved in cytoprotective mechanisms but also 
energy metabolism and, in the case of co-cultured cells, also ECM structure, which 
could be further analysed using different approaches such as substrate modifications, 
drug treatments in addition to overexpression and knockdown of genes.   
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4.6 Discussion 
4.6.1 Drug resistance in 2D 
Due to the high level of FGFR2 amplifications of SNU-16 cells, drug resistance was 
studied with these cells. Over prolonged exposure to FGFR inhibition, SNU-16 cells 
acquired resistance. This was confirmed by regaining proliferation rates similar to 
untreated cells and exhibiting similar cell viability and growth properties to FGFR2 
wildtype SNU-1 cells. This was further confirmed through protein expression levels 
of drug-resistant cells similar to FGFR2 wildtype cancer cells. Often with drug-
resistant SNU-16 cells, no p-AKT signalling was detected, which could be due to 
several reasons, such as high-speed centrifugation, where proteins of larger sizes can 
be captured in the pellet, antibody quality or the cells simply not expressing it 
anymore (due to the age of the cells). No morphological changes were encountered 
and cells were still in suspension rather than undergoing EMT as described 
(Grygielewicz et al., 2016). This could be due to different incubation conditions or 
other environmental properties or differences in media composition. However, 
resistant SNU-16BGJR cells proliferated at a faster rate compared to the parental cell 
line as observed in several experiments when the same cell number was seeded and 
compared. SNU-16BGJR, conversely to the parental cell line, exhibited similar protein 
expression levels as SNU-1 cells and showed no sensitivity to FGFR inhibitor 
treatment. Resistant cell lines were also generated with the H520 lung cancer cell line, 
giving rise to H520BGJR cells (Appendix Figure 8.43). H520 cells initially grew evenly 
and dispersedly, however upon drug resistance observations showed the formation 
of clumps and cell aggregates. With the generation of drug-resistant lung cancer cells, 
cell signalling and drug sensitivity could be further assessed in the future.  
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4.6.2 Drug resistance in 3D and RNA sequencing 
A healthy tissue stroma acts as a barrier against tumourigenesis but, in the presence 
of tumour cells, crucial changes are initiated that transform the environment into one 
that supports tumourigenesis (Junttila and de Sauvage, 2013). The stroma constitutes 
a large proportion of solid tumours and in some carcinomas, makes up more than 
80% of the overall tumour mass. Stromal cells constitute to a heterogeneous 
population of different cell types; the tumour stroma is composed of neoplastic cells, 
but also non-malignant cells, such as normal stromal cells, infiltrating immune cells, 
cytokines and chemokines, and specialised fibroblasts, such as CAFs, all embedded 
in a network of extracellular matrix proteins (collagen, laminin, elastin and 
fibronectin) (Rupp et al., 2015). In colorectal cancer for example, the stroma is in direct 
contact with the adenoma and once it becomes activated, an altered phenotype is 
displayed that produces growth-promoting factors, as well as enhancing tumour cell 
proliferation and migration, thus speeding up tumourigenesis and depicting 
important drivers of tumourigenesis (Mo et al., 2016). 
Fibroblasts, a major cell type also in the colonic stroma, are responsible for tissue-
remodelling and homeostasis by providing a structural scaffold and regulating 
growth factors (Chen et al., 2014). Myofibroblasts, found surrounding the colonic 
crypt, are mainly involved in the synthesis of various collagens and other 
extracellular matrix proteins, thus producing the scaffold (Kalluri, 2016). In tumour 
tissues, activated fibroblasts can be identified by their expression of α-SMA. Stromal 
cells possibly co-evolve with cancer cells to become CAFs, which have been 
implicated to promote tumour development and progression (Gaggioli et al., 2007), 
as they have the ability to nourish cancer cells with an abundance of growth factors. 
CAFS have genetic and epigenetic changes which lead to alterations in expression 
and metabolic mechanisms (Kiaris et al., 2004). Thus, cancer cells are capable of 
reprogramming normal fibroblasts into CAFs with pro-tumourigenic activity and 
enhanced cell proliferation, a process that is mediated by cancer cell-derived factors 
(Mukaida and Sasaki, 2016). Little is known regarding the epithelial-stromal 
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interactions during the very early stages of development of resistance and therefore 
it is of utmost importance to study the influence of stromal cells on cancer cells. 
The 3D Alvetex structure is highly versatile and has proven useful to study 
resistance experiments and for co-culture cells, as SNU-16 cells could be grown 
together with HFF2 cells in the structure over longer time periods up to 8 weeks 
where other 3D models often fail (Mewes et al., 2012). To study stromal interaction, 
HFF2 cells were used in co-culture with SNU-16 cells due to the difficulties involved 
with obtaining tissue specific primary gastric fibroblasts. To generate resistant cells 
in 3D, the drug dose to generate resistant cells in 2D had to be lowered as cells in 3D 
were more sensitive to the drug as shown by reduced cell numbers compared to 
vehicle-treated cells. Potentially, this experiment could be repeated and the cultures 
could be kept longer so that the same drug concentration as in 2D could be reached. 
Interestingly, SNU-16 cells with stromal support were observed to become resistant 
faster than cancer cells alone, which almost took double the amount of time (4 versus 
8 weeks). When comparing DMSO-treated to BGJ-treated co-culture cells, a larger 
number of fibroblasts were retained within the scaffolds in the BGJ-treated condition. 
In the DMSO-treated condition, fibroblasts migrated through the scaffold and 
attached to the bottom of the 6-well plate. It is possible that the drug-induced stress 
helps the HFF2 cells to attach to the scaffold or stops the fibroblasts from migrating 
through. Additionally, the influence of the drug could alter their morphology and 
slow or stop them from migrating through the scaffold. It is known that fibroblasts 
express various matrix metalloproteinases (MMPs), which are responsible for 
remodelling of the ECM. These are necessary for many physiological events such as 
wound repair however are often also dysregulated in a variety of diseases including 
cancers. MMPs can influence the tumour environment through the induction of 
angiogenesis, tumour growth, and metastasis (Bhowmick et al., 2004; Kalluri, 2016). 
The use of MMP small molecule inhibitors such as Marimastat induced 
morphological changes in fibroblasts in a breast cancer study (Sparano et al., 2004; 
Zucker et al., 2006). Another study has also discussed cytoskeletal transformations in 
fibroblasts upon various drug treatments using elasticity measurements with an 
Results Part II 
199 
 
atomic force microscope (AFM) (Rotsch and Radmacher, 2000). Stress fibers are 
cytoskeletal structures, which are composed of cross-linked actin filament bundles in 
fibroblasts which are the contractile structure in these cells and these undergo 
continuous assembly and disassembly, which allows cells to maintain cellular tension 
and adapt to various forces (Hirata et al., 2007; Kaunas et al., 2005). Drug treatments 
could therefore affect stress fibers in fibroblasts that impact elasticity of cells. 
External factors may have led to fluctuations and variations between samples and 
data collection time points. This could be due to the fact that live cell 3D culture 
samples had to be transported from the ground floor laboratory to the microscopy 
suite on the third floor in a Styrofoam box. During transportation cells could have 
dislodged from the scaffold. Additionally, acquisition of one Z-stack sample took 
approximately 15 minutes, although the scaffolds were kept in a temperature 
controlled and humidified gas chamber during imaging, fluctuations in temperature 
and CO2 concentration could have affected cell growth and attachment. Medium 
exchanges were performed very carefully and medium was only fed from below, to 
avoid cells from being forcefully removed, however it could still be that some cells 
were flushed out. Also during optimisation, it has been observed that fibroblasts 
migrate through the scaffold, especially in the vehicle-treated conditions, and 
attached to the well-plate bottom. Therefore to avoid toxic waste accumulation from 
cells and to ensure sufficient nutrient supply, in addition to exchanging the medium 
regularly, scaffolds were transferred to fresh well-plates once a week post-imaging. 
The scaffolds were imaged over time to observe changes in cell growth, the effect of 
drug treatment and the formation of resistant cells. Scaffolds had to be removed from 
the 6-well plate and transferred to a sterile glass-bottom dish. In some of the Imaris 
images, cell layers appeared to be tilted, this may be due to the ability of some cells 
to invade deeper into the scaffold and also simply that the scaffold was not perfectly 
straight. This may be due to a drop of liquid or not sitting perfectly flat in the glass 
bottomed dish. As SNU-16 cells prefer to form clumps of cells in aggregates, it is 
difficult to distinguish single cells from each other even when adjusting the 
parameters in Imaris. Therefore, rather than comparing cell numbers, cell volumes 
Results Part II 
200 
 
were calculated and compared between conditions. Vehicle-treated SNU-16 cells 
rapidly proliferated in the scaffold and were harvested after four weeks, whereas the 
BGJ-treated cells grew very slowly and only after a time span of four weeks started 
recover and form resistant populations until harvesting at 8 weeks. Once drug-
resistant populations were formed, as observed by 3D live cell imaging, cells were 
extracted from the scaffold. Although this process was performed carefully and 
rapidly, the dissociation and lysis could have effects on the cellular signalling of these 
cells (Day et al., 2016; Fulda et al., 2010). RNA concentration and purity checks were 
performed with a Nanodrop spectrophotometer and all samples possessed a high 
enough RNA concentration and purity with A260/A230 between 2.07-2.16. However, 
to perform successful RNA sequencing the integrity of RNA (RIN) (Gallego Romero 
et al., 2014) is crucial to generate RNA-Seq libraries and should have a RIN value of 
at least 6.5., which all of the samples exceeded. Triplicates of DMSO and BGJ-treated 
SNU-16 cells alone and co-culture grown in 3D were run for RNA sequencing. 
However, ideally an additional condition, where mixed co-culture cell populations 
could have been separated using FACS, would have been useful to investigate the 
influence of HFF2 cells on the cancer cells in a more isolated manner. Due to the cost 
limitations of this method, only the essential samples were run for RNA sequencing. 
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4.6.3 Differential gene expression analysis 
Commonly, for interpretation of gene expression datasets, gene set enrichment 
analysis based on functional annotation of the differently expressed genes is 
performed to associate genes with a certain biological process or molecular function. 
With GSEA, regulated pathways could be clustered into functional classes. In BGJ-
resistant SNU-16 cells the majority of pathways have been found to harbour a 
metabolic or xenobiotic function, which could be due to increased proliferation of 
cancer cells and also to metabolise the drug. MET overexpression has been associated 
with several epithelial and mesenchymal cancers and represents a prognostic factor 
associated with malignancy and has been found in a large number of gastric cancer 
patients (Zhang et al., 2016). MET overexpression for example, has been implicated 
with resistance to EGFR inhibitors in lung cancer (Hammerman et al., 2009) and high 
HGF expression levels were found to induce resistance to c-MET RTK inhibitors in 
gastric cancer (Ahn et al., 2017). 
In respect to downregulated pathways, one pathway particularly stood out both in 
cancer cells alone and in co-culture cells, such as oxidative phosphorylation. Cancer 
cells adapt their metabolism to ensure enough molecules to promote tumour growth 
and hence also modify their environment. Cancer cells often have a higher glucose 
consumption than normal cells and often require other means of ATP generation and 
therefore activate glycolysis (Shanmugam et al., 2009). A downregulation in oxidative 
phosphorylation could therefore indicate that such a switch has occurred and 
although oxidative phosphorylation is more efficient in ATP formation, the release of 
ROS could damage cancer cells. This could tie in well with drug-resistant cancer cells 
increasing glucose generation through increased sucrose and starch pathway activity 
and consequently switching to glycolysis from oxidative phosphorylation.  
The ECM is the most abundant component in tumour microenvironment and can 
regulate tumour cell behaviours and tissue tension homeostasis (Paszek et al., 2005). 
The upregulation of the ECM in drug-resistant co-culture cells, might possibly be due 
to co-culture cells forming their own matrix with increased ECM proteins to create a 
stiffer ECM architecture and therefore obstructing the drug reaching their target or 
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slowing this process down and therefore cancer cells can acquire resistance towards 
the drug (Nguyen et al., 2014; Schrader et al., 2011; Shin and Mooney, 2016). Cancer 
cells have also been found to use the remodelled stiff matrix as invasion highways, as 
seen with glioma cells exploiting a matrix rich in blood vessels and rigid myelin 
sheath bundles (Giese et al., 1996). Collagen serves as a major scaffold of the tumour 
microenvironment and its remodelling can promote tumour infiltration, 
angiogenesis, invasion and migration (Page-McCaw et al., 2007). Collagen was seen 
as a passive barrier to resist tumour cells; it is now understood that collagen plays an 
active role in promoting tumour progression (Fang et al., 2014). A change in collagen 
levels in the tumour microenvironment releases biomechanical signals, which signal 
to both tumour and stromal cells, triggering a cascade of biological events and 
increased or decreased deposition of collagen can be associated with augmented 
malignancy (Arnold et al., 2010; Levental et al., 2009). Interestingly, many collagen-
encoding genes and other matrix building blocks were found to be upregulated in 
inhibitor-resistant co-culture cells, which could indicate that drug-resistant co-culture 
cells upregulated the ECM pathway producing more ECM molecules and therefore 
possibly creating a stiffer ECM architecture, thus blocking drug activity on the cells. 
When cross-checking with the genes that are responsible for the enrichment of the 
pathway, many of the COL genes are significantly upregulated, which is a further 
indication for a potential role of collagens in drug resistance, as overexpression could 
protect cancer cells against chemotherapeutic agents by lengthening the time needed 
for the penetration of the collagen network, which can result in drug resistance 
(Januchowski et al., 2016; Netti et al., 2000). This could therefore influence the 
malignancy of cancer cells and make them resistant to the drug by ECM remodelling. 
Therefore, not only cancer cells have to be taken into account when treating cancer 
also targeting stromal cells could be a viable method (Gaggioli et al., 2007). 
In drug-resistant SNU-16 cells, the ribosome pathway, which is essential for protein 
synthesis, was significantly upregulated, indicating altered mRNA translation, which 
is important in cancer initiation (Chu et al., 2016). The pathway could be potentially 
upregulated to support accelerated proliferation and growth of drug-resistant cells. 
In drug-resistant co-culture cells however, the ribosome pathway was significantly 
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downregulated. While it was proven that ribosome biogenesis is required for active 
proliferation, it is not the only function of RPs and they have also been implicated in 
cellular transformation and the perturbation of RPs may reduce the levels of 
survival/protective factors and therefore could favour cancer development and 
progression (Steller, 1995). 
4.6.3.1 The retinol pathway is a double-edged sword in SNU-16 and co-culture 
cells 
Using both DAVID and GSEA, the retinol pathway raised particular interest, as it was 
significantly regulated both in SNU-16 cells alone and in co-culture cells. Retinol, or 
vitamin A, has received great medical interest in the past and has been used for 
thousands of years for treatment. It cannot be synthesised and is ingested through 
diet in the form of retinol, retinyl ester, or β-carotene. It is stored as retinyl esters in 
hepatic tissue in stellate cells and gets reversibly oxidised to retinal through retinol 
dehydrogenases (O’Byrne and Blaner, 2013). Retinal dehydrogenases further oxidise 
retinal irreversibly to all-trans retinoic acid (all-trans RA) and is then further oxidised 
by mainly CYP26. Retinoic acid is the active metabolite and was found to regulate 
various biological processes such as development, differentiation, proliferation, and 
apoptosis (Lai et al., 2003; Noy, 2010; Ross et al., 2000; Wang and Kirsch, 2002). Retinol 
has six biologically active isoforms and different isomers activate different receptors, 
thus leading to different biological effects. There are two distinct classes of receptors 
for retinoids: retinoic acid receptors (RAR) and rexinoid receptors (RXR), which 
belong to the peroxisome proliferator-activated receptor (PPAR) family. RARs are 
also known to interact with the oestrogen signalling pathway (Ross-Innes et al., 2010). 
Rexinoids are retinoids that specifically bind to RXR and have been used effectively 
in cancer therapy (Bushue and Wan, 2010). Retinoids are comprised of three units: a 
bulky hydrophobic region, a linker unit, and a polar terminus, which is usually a 
carboxylic acid (Das et al., 2014). There are different types of retinoid-binding 
proteins, which are isomer specific and located in either intracellular or extracellular 
compartments (Noy, 2000). They stabilise retinoids and make them soluble, but also 
have a role in transportation and metabolism of retinoids. Therefore, retinoids 
together with binding proteins and nuclear receptors elicit cellular actions. Vitamin 
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A, which circulates in the blood, is bound to serum by retinol binding protein (RBP) 
and then once in the cell together with all-trans retinal is associated with different 
isoforms of cellular retinol-binding proteins (CRBP), while all-trans retinoic acid binds 
to cellular retinoic acid-binding protein isoforms (CRABP). Therefore, the retinol 
binding protein and receptor work together, to exert the specific effects of RAs. RAs 
can also bind both PPARβ and δ, which are the receptors for fatty acids (Berry and 
Noy, 2009; Schug et al., 2007; Shaw et al., 2003). 
Secretion of RBP is regulated by the availability of retinol and the intracellular 
concentrations of retinoids are controlled by a number of metabolic enzymes, which 
react in response to external signals (Wolf, 2007). However, RBP secretion is inhibited 
by Vitamin A deficiency, resulting in protein accumulation in the endoplasmic 
reticulum of hepatic parenchymal cells. In the presence of retinol, RBP binds retinol 
and moves along the Golgi apparatus and is then secreted into blood. Retinol 
dehydrogenases (ADHs) oxidize retinol to all-trans retinal, which is further 
metabolised to RA by retinaldehyde dehydrogenases (ALDHs). In particular, RDH10 
which metabolises retinol to retinaldehyde is an essential enzyme in this metabolic 
pathway. The synthesis and metabolism of the bioactive metabolites of retinol are 
sometimes impaired in cancer cells in contrast to normal cells. A number of studies 
indicate that retinoids halt cell cycle progression in cancer via signalling pathways, 
either directly or indirectly through altering cyclins, cyclin-dependent kinases 
(CDKs) and cell-cycle inhibitors (Mongan and Gudas, 2007). Thus, RA can cause a 
block in the G1 phase of the cell cycle inducing an increase in the proportion of cells 
in the G0/G1 phase and a decrease in cells in S phase. Among the RARs, RARβ2 can 
be activated by RA resulting in its inhibitory effect on cell proliferation (Altucci et al., 
2007; Faria et al., 1999; Seewaldt et al., 1995). Cyclin D1, one of the regulators of cell-
cycle progression is often overexpressed in a number of cancers such as head and 
neck, lung, stomach, and breast (Kim and Diehl, 2009). Furthermore, treatment with 
retinoids has been associated with an increase in ubiquitination and proteolysis of 
cyclin D1 in human bronchial cells (Ma et al., 2005) and in a decrease in cyclin D1 
messenger RNA (mRNA) and protein levels in HepG2 human hepatoma cells (Suzui 
et al., 2002), which results in decreased CDK activity hindering cells to transition from 
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S phase to G1 phase (Malumbres and Barbacid, 2009). Retinoids can also induce 
apoptosis in cancers and post-maturation apoptosis in acute promyelocytic 
leukaemia (APL) by inducing tumour-selective death ligand (TRAIL) (Altucci et al., 
2007). Consequently, since retinoids can both promote cell-cycle arrest but also induce 
apoptosis, they could be useful drugs for the treatment of cancers. However, many 
cancers become resistant to retinoids. Upon retinol deprivation a different type of 
programmed cell death occurs independent of receptor activation, which is 
accompanied by an increase in reactive oxygen species, reductions in ATP and NAD+, 
and PARP-1 activation (Chiu et al., 2008). Inhibition of PARP-1 prevents this form of 
programmed cell death, indicating that retinol levels are needed to prevent depletion 
of NAD+ and cell death. Therefore, retinoids have gained great attention as a 
chemotherapeutic due to their influences on differentiation, anti-proliferative, pro-
apoptotic, and effects as an anti-oxidant. The most abundant retinoid is all-trans 
retinoic acid (ATRA), which is in clinical trials for lymphoma, leukaemia, melanoma, 
lung cancer, cervical cancer, kidney cancer, neuroblastoma, and glioblastoma 
(Bushue and Wan, 2010). In 1995, the FDA approved ATRA for treating 
promyelocytic leukaemia (APL) and promotes the degradation of mutant 
promyelocytic leukaemia protein (PML)-RARα and release of co-repressors 
(Grignani et al., 1998; Yoshida et al., 1996). In addition to cell cycle arrest, ATRA also 
induce post-maturation apoptosis through the activation of TRAIL (Jiménez-Lara et 
al., 2004). Similarly to other therapeutics, resistance towards retinoids arises and 
displays a major obstacle in successful treatment. Deregulation of retinoid signalling 
is quite common in carcinogenesis, for example epigenetic silencing of RARβ or 
translocation of RARα to generate oncogenic fusion proteins (Freemantle et al., 2003). 
Due to the importance of retinol metabolism in cell-cycle and apoptosis and the fact 
that it was significantly upregulated in SNU-16BGJR cells, it raised tremendous interest. 
In the retinol pathway, a shift to the right can be observed (Figure 4.24), potentially 
driving the formation of 4-oxo-retinoic acid, which is a biologically active geometric 
isomer of RA and enhances gap junctional communication in cells (Hanusch et al., 
1995; Pijnappel et al., 1993). Metabolic transformation of ATRA to 4-hydroxylated RA 
appears to be primarily catalysed by cytochrome P450 (CYP26) in human skin cells, 
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which was also upregulated in the dataset. Stromal CYP26 can metabolise 
pharmacological concentrations of ATRA and neutralise the drug’s activity to induce 
differentiation (Su et al., 2015). Additionally, ATRA was found to induce stromal 
CYP26, which creates a protective environment and, with the use of CYP26 inhibitors, 
microenvironment-induced ATRA-resistance could be overcome (Norsworthy et al., 
2015; Su et al., 2015). Furthermore, the generation of retinoyl-glucuronide was 
enhanced and when investigating the retinol pathway with GSEA and crosschecking 
what might drive the pathway, UDP glucuronosyltransferase (UGT2A3), which is a 
microsomal enzyme, was significantly upregulated. Such enzymes are responsible for 
the glucuronidation of exogenous and endogenous compounds, such as drugs, and 
high expression levels have been implicated in tissues involved in drug clearance, 
which is mostly the liver followed by the gastrointestinal tract and the kidneys. Drug-
resistant SNU-16 cells could therefore use UGT enzymes for drug elimination. Other 
genes that lead to enrichment of the pathway were Cyp genes and ADH1C, which 
metabolise a wide selection of substrates including ethanol and retinol. 
Previous studies have shown retinoyl-glucuronide to be present in several tissues in 
vitamin A deficient rats given retinoic acid and has been found to be involved in 
detoxification (Silva and DeLuca, 1982). However, another possibility would involve 
CRBP-1, which is controlling the availability of retinol in cells and was associated 
with inhibition of early steps in transformation. Downregulation of CRBP-1 was 
observed in several cancers (Kuppumbatti et al., 2000; Orlandi et al., 2006), including 
gastrointestinal cancers (Esteller et al., 2002) resulting in loss of cellular differentiation 
and tumour progression. When comparing to IPA data however, it becomes clear that 
CRBP genes are upregulated and contribute to the upregulation of the pathway in 
SNU-16BGJR cells, which could indicate, that together with retinoids, activation of 
other pathways occur, resulting in a more malignant phenotype of SNU-16 cells. 
Recently, CRBP-1 has been associated with wound healing and arterial tissue 
remodelling processes, which cancer cells potentially can use to their advantage 
(Cvetković et al., 2003; Neuville et al., 1997). 
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In co-culture cells however, the retinol pathway is downregulated. According to IPA, 
this is driven by downregulation of NADP-retinol dehydrogenase and triacylglycerol 
lipase, which enable the oxidation of retinol to retinol and from retinyl ester to retinol. 
This could indicate that less retinol is generated and retinal is favoured. It could 
therefore be that co-culture cells decrease ATRA production in cells to avoid cell 
proliferation arrest and induction of apoptosis in cells. Therefore, the implication of 
retinol in SNU-16 cells is an interesting pathway to study and understand the double 
edged activity of the metabolic pathway. 
4.6.4 Significantly regulated genes of interest 
4.6.4.1 Sucrase-Isomaltase upregulation and the role of glucose 
Interestingly, when comparing cancer cells alone, many upregulated genes in SNU-
16BGJR cells were involved in sugar metabolism and cytoprotective mechanisms. 
Sucrase-Isomaltase (SI), which was the top hit among the upregulated genes in drug-
resistant gastric SNU-16 cells and was also upregulated in co-culture cells, is a 
disaccharide glycoprotein hydrolase, which is normally restricted to the brush border 
membrane of the enterocytes of the small intestine (Zweibaum et al., 1983). Its 
purpose is the digestion of carbohydrates, such as starch, sucrose and isomaltase to 
ultimately produce energy in the form of ATP (Berg et al., 2002). It was found to be 
significantly enhanced during neoplastic transformation of the colonic epithelium, 
and 55% of primary colorectal cancers expressed SI and resulted in a 1.83-fold 
increased risk of death from colorectal carcinoma (Jessup et al., 1995). Due to its high 
expression in colon cancers and also Barrett’s mucosa, it could serve as a biomarker 
of early neoplastic dysplasia (Zweibaum et al., 1983; Iannettoni et al., 1996). Increased 
sucrase expression was also found with enhanced invasion by human gastric 
carcinomas with progression (Nakamura et al., 1998). These publications could 
indicate that higher SI levels in BGJ-resistant SNU-16 cells could give them an 
advantage over parental SNU-16 gastric cancer cells by generating more ATP and 
therefore more energy as tumours require ATP and NADH, not only for metastasis 
and proliferation, but also for survival (Oronsky et al., 2014). ATP is also elevated in 
the tumour microenvironment and affects Ca2+ signalling and has effects on anti-
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apoptotic (Bcl-2) and pro-apoptotic (Bax) proteins, promoting cancer transformation 
and progression (Song et al., 2016). 
4.6.4.2 Upregulation of ALDOB as an alternative way for ATP generation 
Aldolase B (ALDOB) was the second most upregulated gene in SNU-16BGJR cells 
compared to parental cells and was also upregulated in drug-resistant co-culture 
cells. ALDOB plays an essential role in glycolysis and gluconeogenesis (Vella, 1995). 
ALDOB is one of three isoenzymes of human aldolases, normally expressed in liver, 
kidney and intestine (Tolan et al., 1987). It catalyses the reversible cleavage of fructose 
1,6-bisphosphate (FBP) into glyceraldehyde 3-phosphate (G3P) and 
dihydroxyacetone phosphate (DHAP) as well as the reversible cleavage of fructose 1-
phosphate (F-1-P) into glyceraldehyde and DHAP. It is therefore involved in the 
breakdown of glucose and is particularly important in the metabolism of fructose. 
When fructose is absorbed it is phosphorylated by fructokinase into F-1-P, which is 
broken down into glyceraldehyde and DHAP and further phosphorylated by triose 
kinase to form G3P. These products can then be used in the glycolytic-gluconeogenic 
pathway and can be turned into either glucose or pyruvate (Ye et al., 2018). Aberrant 
expression of ALDOB has been studied in hepatocellular carcinoma and gastric 
cancer (Asaka et al., 1988; Peng et al., 2008; Song et al., 2004; Tao et al., 2015). High 
expression of ALDOB is associated with poor prognosis for rectal cancer patients 
receiving neoadjuvant concurrent chemoradiotherapy (CCRT) and is associated with 
poor tumour advancement, lymphovascular and perineural invasion before and after 
CCRT but also poor response to CCRT, and therefore is an interesting target for 
patients with rectal cancer (Tian et al., 2017). It is also associated with hepatocellular 
carcinoma (HCC), which often exhibits an aberrant expression of glycolytic enzymes, 
such as type II hexokinase (HKII) and ALDOB and cancer cells with a high glycolytic 
rate have shown to have an advantage in tumour growth (Peng et al., 2008). 
Most malignant cells generate ATP mainly via glycolysis and lactic acid fermentation 
but not via the tricarboxylic acid (TCA) cycle (Warburg, 1956). This phenomenon is 
termed ‘the Warburg effect’, and has proven to be useful to detect malignancy (Devic, 
2016). Therefore, by upregulating SI and ALDOB, BGJ-resistant cancer cells could 
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have a growth and survival advantage by upregulating glucose metabolism and 
therefore alternative ATP generation in contrast to oxidative phosphorylation, which 
was found to be downregulated in both datasets. 
4.6.4.3 PIWIL1 induces self-renewal capacity in cancer stem cells 
Cancer is driven by genetic abnormalities as described previously, however it can 
also additionally be induced by aberrant epigenetic alterations. Such changes are for 
example alterations in DNA methylation, histone modifications and small noncoding 
RNA deregulation (Kanwal and Gupta, 2012). There are three major classes of small 
regulatory RNAs; microRNAs, small interfering RNAs (siRNAs) and PIWI-
interacting RNA (piRNA). Being only identified in 2006, piRNAs are a relatively 
recent discovery and were found to interact with P-element-induced wimpy testis 
(PIWI) proteins, which are a subclass of the conserved Argonaute family of proteins 
and play a role in germline cells (Girard et al., 2006; Grivna et al., 2006; Watanabe et 
al., 2006). Argonaute proteins contain PIWI-Argonaute-Zwille (PAZ) and PIWI motifs 
that are involved in stem cell self-renewal, RNA silencing and translational regulation 
in various organisms and are suggested to play a role as an intrinsic regulator of the 
self-renewal capacity of germline and haematopoietic stem cells. PIWI proteins bind 
piRNAs, which are thereby amplified in a Dicer-independent manner resembling a 
ping pong cycle (Brennecke et al., 2007; Vagin et al., 2006). This then leads to 
transposon repression through base-pairing and degradation (Gunawardane et al., 
2007). Reactivation of PIWI expression, primarily PIWI-like protein 1 (PIWIL1) and 2 
(PIWIL2), through aberrant DNA methylation resulting in genomic silencing has 
been documented in numerous types of tumours (Qiao et al., 2002; Tan et al., 2015; 
Litwin et al., 2018). Small non-coding RNA (ncRNA) deregulation has been 
investigated in several types of cancer in recent years (Kanwal and Gupta, 2012) and 
these aberrations have been found to be connected to the hallmarks of cancer 
including deregulated cell proliferation, altered apoptosis, genomic instability, 
invasion, and metastasis (Tan et al., 2015), which drive the transformation of wild-
type cells into malignant cells with metastatic potential and infinite proliferation 
capacities (Kanwal and Gupta, 2012; Kristensen et al., 2009). PIWIL expression varies 
based on the tissue of origin, such as in urological tumours (RCC and bladder cancer), 
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the expression of PIWIL genes is more likely to be downregulated and loss of 
expression is associated with a more aggressive phenotype and reduced survival 
(Iliev et al., 2016). Several mechanisms of how PIWIL1 promotes tumour progression 
have been suggested, such as cell cycle arrest at the G2/M stage in gastric cancer cells 
(Liu et al., 2006), CDK1 silencing through methylation in osteosarcoma (Siddiqi et al., 
2012) and PIWIL1 as a target of RAS-associated domain family protein 1 C (RASSF1C) 
in lung cancer (Reeves et al., 2014). RASSF1C possibly phosphorylates ERK members 
and hence activates MEK-ERKl/2 signalling, which results in infinite self-renewal of 
tumour stem cells. It has been suggested that the PIWI-piRNA complex contributes 
to cancer development and progression by promoting a stem-like state of cancer cells, 
or cancer stem cells (CSCs) (Ng et al., 2016; Siddiqi et al., 2012; Siddiqi and 
Matushansky, 2012) and plays a driving role in degradation or inhibition of tumour 
suppressor genes or oncogenes (Moyano and Stefani, 2015). Thus PIWI-piRNA 
complexes contribute to carcinogenesis by aberrantly methylating DNA, which 
results in genomic silencing and induction of a stem-like state of cancer cells (Moyano 
and Stefani, 2015; Ng et al., 2016; Siddiqi et al., 2012; Siddiqi and Matushansky, 2012). 
PIWIL1 is therefore an interesting target and was the most downregulated candidate 
in the mono cell BGJ-resistant SNU-16 dataset, and was also found to be 
downregulated in co-culture cells. It could therefore be that PIWIL1, together with 
piRNA, supports SNU-16 cancer cells by induction of self-renewal capacity in these 
cells or in the activation or repression of oncogenes and tumour suppressor genes 
respectively. This however has to be further elucidated with experiments addressing 
these questions, potentially by overexpressing PIWIL1 in cells, where PIWIL1 is 
downregulated, by plasmid transfection. Also, PIWIL1 could be knocked down with 
shRNAs in parental cells to observe if this would render cells less sensitive to FGFR 
inhibition.  
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4.6.4.4 REG genes induce glucose repression to survive 
Top candidates in co-cultured cells were members of the regenerating family also 
known as islet cells regeneration factor (ICRF) or islet of Langerhans regenerating 
protein (REG), with REG1A and REG1B, the most upregulated genes. They belong to 
the calcium-dependent lectin (C-type lectin) gene superfamily (Hartupee et al., 2001) 
and encode five small proteins, secreted by the exocrine pancreas, including REG1A 
and B. These proteins are primarily involved in liver, pancreatic, gastric and intestinal 
cell proliferation or differentiation (Miyaoka et al., 2004; Unno et al., 1992). They were 
first regarded as endogenous growth factors isolated from pancreatic islet β cells 
(Terazono et al., 1988; Watanabe et al., 1990) and are acute phase reactants, lectins, 
anti-apoptotic factors, or growth factors for pancreatic islet cells, neural cells, and 
epithelial cells in the digestive system (Broekaert et al., 2002; Dusetti et al., 1994). REG 
genes were found to be sensitive to tissue injury and served as a prognostic indicator 
of tumour survival. They could serve as early biomarkers of carcinogenesis and have 
been found in gastric cancer previously (Watanabe et al., 1990; Zenilman et al., 1997). 
High REG1A mRNA expression was also associated with a susceptibility to 
Dacarbazine and Cisplatin in melanoma (Sato et al., 2013). Thus, it could therefore be 
an interesting novel therapeutic target. 
Additionally, there has been extensive evidence for the involvement of aberrant 
REG1A expression in cancer development in oesophagus, stomach, colon, pancreas, 
liver, lung, breast, and bladder cancer (Astrosini et al., 2008; Cavard et al., 2006; Geng 
et al., 2009; Hayashi et al., 2008; Kimura et al., 1992; Lee et al., 2008; Minamiya et al., 
2008; Motoyama et al., 2006; Sasaki et al., 2008; Sekikawa et al., 2008; Yoshino et al., 
2005). Promoter methylation could be one of the regulatory mechanisms for REG1A 
expression in melanomas and could therefore be an interesting biomarker (Sato et al., 
2013). Furthermore, in ErbB2-positive breast cancer patients, REG1A expression was 
higher than those with ErbB2-negative disease and the 10-year survival rate amongst 
patients with lower levels of REG1A was significantly higher than those with 
increased levels (Sasaki et al., 2008). REG1A has also been implicated as a regulatory 
subunit in glucose repression and associates with serine/threonine-protein 
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phosphatase PP1-2 (GLC7) to regulate the glucose repression regulatory pathway (Tu 
and Carlson, 1995). In co-culture cells, upregulation of REG1A and B could therefore 
be an indication for the cells trying to lower gluconeogenesis to avoid hyperglycemia, 
which is associated with high ROS levels. By upregulation of REG genes, cancer cells 
potentially protect themselves from ROS-induced damage or cell death. It is therefore 
interesting to investigate altered REG1A expression in co-culture cells to see if 
altering expression of REGs could induce apoptosis or necrosis and resensitise cancer 
cells. 
4.6.5 Conclusion 
Pathway analysis depends on existing databases and the data used are not always 
completely annotated, with many gene interactions therefore relatively speculative. 
Additionally, most canonical pathways are built from knowledge acquired from a 
small number of experiments with narrow cell models. Therefore, interpretation of 
such data from different tissue has to be done with caution. Still it is of importance to 
find targetable pathways to treat cancer drug resistance and gene expression analysis 
and pathway analysis is an appropriate method to search for essential pathways and 
targetable nodes. 
In the next Results chapter, the most promising targets from the RNA sequencing 
results have been validated using different approaches such as drug combinations, 
shRNA knockdown and overexpression and alteration of medium components. 
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5.1 Introduction 
In the previous chapter, it has been demonstrated that using Alvetex® is an ideal 
model to generate BGJ-resistant SNU-16 cells in 3D to study drug resistance. Alvetex® 
scaffolds have been applied to a vast number of scientific purposes, however no 
resistance studies have been performed to date (Gomez-Roman et al., 2017; Knight et 
al., 2011; Ugbode et al., 2016). There are a number of publications supporting the 
importance of the tumour microenvironment, and particularly the influence of 
stromal cells, on drug resistance (Donner, 2012; Paraiso and Smalley, 2013; Sebens 
and Schafer, 2012; Zhang and Huang, 2011). Using RNA-Seq to compare drug 
resistance in the presence or absence of fibroblasts, a number of highly interesting 
genes and associated pathways have been revealed (Chapter IV). Interestingly, in the 
cancer cell monoculture condition, many genes were significantly regulated that were 
specific to the gastric or intestinal milieu. Also, interestingly, but perhaps predictable, 
was that many genes are involved in cytoprotective or xenobiotic mechanisms. The 
most interesting aspect however was the upregulation of genes involved in metabolic 
processes such as glucose metabolism (SI, ALDOB, UGT2A) with SI and ALDOB being 
the top hits (Figure 5.1). In the co-culture studies, many regulated genes were 
involved in collagen synthesis or members of the regenerating family. Myriad 
analysis tools are available, using different algorithms and databases. In respect to 
pathway analysis, of particular interest was the retinol pathway, as it was altered both 
in cancer cells alone and co-culture cells. Furthermore, the sucrose and starch 
pathway was strongly upregulated, which is mainly driven by SI and ALDOB, which 
are enzymes involved in sucrose and fructose degeneration and glucose production. 
This aligns well with a downregulation in oxidative phosphorylation, indicating a 
switch to glycolytic metabolism. PIWIL1 was downregulated the most in drug-
resistant SNU-16 cells and was also among the top downregulated genes in co-culture 
cells and could therefore be an essential gene involved in drug resistance. REG1A was 
upregulated the most in drug-resistant co-culture cells and is specific to co-culture 
cells and could explain the difference with stromal support. 
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Different approaches have been used to analyse and compare the different datasets 
to identify targetable nodes involved in drug resistance in FGFR-driven cancers in 
3D, which will be discussed in this chapter. 
 
 
 
Figure 5.1. Genes of interest in drug-resistant SNU-16 and co-culture cells used for target validation.  
Upregulated genes in BGJ-resistant SNU-16 cells alone (A) and BGJ-resistant co-culture cells (B) that 
were interesting targets included SI, ALDOB and UGT2A3 which were found in both cancer cells alone 
and co-culture cells. Drug-resistant co-culture cells furthermore highly expressed REG1A, which was 
validated as well. PIWIL1 was both significantly downregulated in drug-resistant cancer cells alone (C) 
and co-culture cells (D). 
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5.2 Retinol pathway 
The retinol pathway was identified as being significantly regulated using DAVID and 
GSEA, and was upregulated in SNU-16BGJR cells (Figure 4.23, Figure 4.31). To 
investigate the importance of the retinol pathway on the emergence of drug resistance 
in SNU-16 cells, cells were treated with all-trans retinoic acid (ATRA). We 
hypothesised that addition of ATRA to resistant cells would resensitise the drug 
resistant cancer cells given the effects on differentiation. Retinoic acid treatment has 
been connected to reduced motility of pancreatic stellate cells, resulting in reduced 
proliferation and increased apoptosis in pancreatic cancer cells (Froeling et al., 2011). 
The effect of ATRA was analysed using cell cycle analysis with FACS, in MFE-296 
cells (Figure 5.2, Appendix Figure 8.44), SNU-16 parental cells (Appendix Figure 
8.45, Appendix Figure 8.46) and BGJ-resistant SNU-16 cells (Figure 5.3). Distinct 
subpopulations could be identified in MFE-296 cells and treatment of MFE-296 cells 
with BGJ led to an increase in cells in G1 phase and also increased sub G1 fraction, 
indicating cell cycle arrest and increased cell death. This was supported by a reduced 
number of cells in S and G2 phase, indicating fewer proliferating cells. However, 
ATRA treatment did not have a dramatic effect in MFE-296 cells, except a potential 
tendency to increase the fraction of cells in G2. In contrast, SNU-16 cells were highly 
sensitive to BGJ treatment, and also did not form homogenous populations as was 
observed with MFE-296 cells, hence posing a difficulty in data analysis. However, in 
respect to the G1 subpopulation, it could be concluded, that upon BGJ treatment, the 
G1 subpopulation slightly increases whereas the G2 subpopulation shows a tendency 
to decrease (Appendix Figure 8.45). In response to ATRA, there was a tendency for a 
decrease in the G1 subpopulation (Appendix Figure 8.46). Treatment of BGJ-resistant 
SNU-16 cells with ATRA did not show a clear indication on the effect of ATRA on 
cell cycle behaviour, with merely a tendency of a reduction of cells in S phase (Figure 
5.3). 
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Figure 5.2. ATRA treatment in MFE-296 cells results in a shift to G1 and reduction in G2 and S phase. 
Endometrial MFE-296 cancer cells were plated into 6-well plates and treated with 1µM ATRA and 1.5µM 
BGJ and corresponding vehicle controls. After 72h cells were fixed in 70% Ethanol, followed by 
propidium iodide (PI) staining and cell cycle analysis using flow cytometry. Typical cell cycle profiles 
are shown for one of three individual biological replicates (Appendix Figure 8.44). The histogram shows 
the values indicating the average proportion of cells in the different phases (G1=blue, S=yellow, 
G2=green, sub G1=red). The error bars indicate SEM. Statistical analysis was performed using one-way 
ANOVA analysis, p<0.05=*, p<0.01=**, p<0.005=***. 
 
Figure 5.3. ATRA treatment of SNU-16BGJR potentially reduces proliferation. 
BGJ-resistant SNU-16 cancer cells were plated into 6-well plates and treated with 1µM ATRA and 1.5µM 
BGJ and corresponding vehicle controls. After 72h cells were fixed in 70% Ethanol, followed by DAPI 
staining and cell cycle analysis using flow cytometry. Typical cell cycle profiles are shown for one of 
three individual biological replicates (Appendix Figure 8.47). The histogram shows the values indicating 
the average proportion of cells in the different phases (G1=blue, S=yellow, G2=green, sub G1=red). The 
error bars indicate SEM. Statistical analysis was performed using one-way ANOVA, p<0.05=*, p<0.01=**, 
p<0.005=***.  
Results Part III 
218 
 
Another means to investigate the effect of compounds such as ATRA on cell 
behaviour is to measure the percentage apoptotic cells with Annexin V. This was 
done for SNU-16 and BGJ-resistant SNU-16 cells upon FGFR inhibition, where 
increased apoptotic and necrotic cells could be measured with BGJ treatment 
(Appendix Figure 8.48). As retinoic acid is involved in the regulation of apoptosis, I 
was interested to investigate the effect of growing cells in the presence of ATRA and 
BGJ and measure apoptosis and necrosis in cells. MFE-296 cells in presence of ATRA, 
displayed less necrosis and cells showed less sensitivity to combination treatment, as 
indicated by increased live cell counts and decreased numbers of necrotic cells 
(Figure 5.4).  
 
 
Figure 5.4. ATRA protects from cell death in absence of BGJ in endometrial cancer cells. 
Endometrial MFE-296 cancer cells were cultured for 72h in 6-well plates in the presence of either 1µM 
ATRA, 1.5µM BGJ or a combination of the two, with respective vehicle controls, DMSO and EtOH. 
Apoptosis and necrosis were detected by staining cells with Annexin V and PI. Percentages of apoptotic, 
live and necrotic cells in the different conditions are shown. The experiment was performed once.  
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SNU-16 cells were sensitive to ATRA and BGJ treatment, with ATRA treatment 
resulting in higher numbers of apoptotic and necrotic cells (Figure 5.5). Combination 
treatment potentiated this effect even further, as shown by even higher cell numbers 
undergoing apoptosis and necrosis compared to ATRA treatment alone and 
increased apoptosis compared to BGJ treatment alone. 
 
 
 
Figure 5.5. Combination treatment may potentiate apoptosis and necrosis in gastric cancer cells. 
Gastric parental SNU-16 cancer cells were grown in 6-well plates in the presence of either 1µM ATRA 
or 1.5µM BGJ with respective vehicle controls, DMSO and EtOH and in combination for 72h. Apoptosis 
and necrosis was detected by staining cells with Annexin V and PI. Percentages of apoptotic, live and 
necrotic cells in the different conditions are shown. The experiment was performed once. 
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BGJ-resistant SNU-16 cells did not respond to retinoic acid treatment and apoptotic 
and necrotic cell numbers were unchanged in BGJ and combination treated cells 
(Figure 5.6). This could indicate that SNU-16BGJR cells are not only resistant to BGJ but 
also ATRA. 
 
 
 
 
Figure 5.6. BGJ-resistant gastric cancer cells are insensitive to retinoic acid. 
Gastric BGJ-resistant SNU-16 cancer cells were grown in 6-well plates in the presence of either 1µM 
ATRA or 1.5µM BGJ with respective vehicle controls, DMSO and EtOH and in combination for 72h. 
Apoptosis and necrosis was detected by staining cells with Annexin V and PI. Percentages of apoptotic, 
live and necrotic cells in the different conditions are shown. The experiment was performed once. 
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5.3 Sucrose and starch metabolism pathway 
The sucrose metabolism pathway plays an important role in proliferation and growth 
and was one of the pathways significantly upregulated in the BGJ-resistant SNU-16 
dataset generated in 3D. The main genes appearing to drive this pathway in cancer 
cells were SI and ALDOB (Figure 5.7). SI was the top upregulated gene and encodes 
a glucosidase enzyme specific to the intestinal brush border, which functions in 
enzymatic cleavage of sucrose or maltose into glucose that is further used to generate 
energy in the form of ATP (Sim et al., 2010). After extensive literature search and 
discussion, one hypothesis was that the end product of the enzymatic reaction 
glucose could drive drug resistance in SNU-16 cells. 
 
 
Figure 5.7. SI and ALDOB are significantly upregulated in the sucrose degradation pathway.  
Sucrose alpha-glucosidase (SI) and fructose-bisphosphate aldolase (ALDOB) are upregulated in SNU-
16BGJR cells generated in 3D causing an upregulation of the sucrose and starch degradation pathway.  
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If resistant cells upregulate glucose production, this would also mean that glucose 
transportation is increased. Therefore, expression of glucose transporter 1 (GLUT1) 
was measured with qPCR analysis in parental gastric cancer cells, SNU-16 treated 
with BGJ, and BGJ-resistant cancer cells. GLUT1 is encoded by SLC2A1 and facilitates 
the transport of glucose across the plasma membrane. It is increased upon lower BGJ 
concentrations and dramatically increased in resistant cells (Figure 5.8). 
 
  
Figure 5.8. Glucose transport is elevated in drug-resistant gastric cancer cells. 
RNA was harvested from SNU-16 treated with 500nM, 1µM and 1.5µM BGJ or treated with vehicle 
DMSO and SNU-16BGJR kept in 1.5µM BGJ and reverse transcribed into cDNA, followed by qPCR 
analysis according to manufacturer’s instructions. 
 
In order to investigate a potential effect of glucose on the generation of resistant cells, 
medium without glucose supplements was purchased. First of all, cells were grown 
in normal medium and medium without glucose and cell numbers were counted 
using a light microscope (Figure 5.9). SNU-16BGJR cells generally proliferate faster than 
parental SNU-16 cells and growing the cells in medium without glucose had a more 
dramatic effect in parental SNU-16 cells compared to drug-resistant cells. 
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Figure 5.9. SNU-16BGJR cells have a growth advantage in medium without glucose relative to parental 
cells. 
Parental SNU-16 and SNU-16BGJR cells were grown in medium with and without glucose. Cells were 
harvested after 3 days and counted with a haemocytometer. The experiment was run in biological 
triplicate. The error bars indicate SEM. Red bars indicate parental SNU-16 cell and green bars SNU-16BGJR 
cells. Statistical analysis was performed using one-way ANOVA, p<0.05=*, p<0.01=**, p<0.005=***, 
p<0.001=****. 
 
Cells were then exposed to different glucose concentrations by controlled addition of 
glucose to the medium, based on literature search for a low concentration (1g/L) and 
a high concentration (4g/L) (Huang and Xiong, 2015; Weil et al., 2009). The normal 
glucose concentration in complete growth medium (CM) is 2g/L and as a control also 
a condition without any glucose addition was included (0g/L). Cell growth was 
measured by cell counting. MFE-296 cells and SNU-16 cells were furthermore treated 
with different concentrations of BGJ (500nM, 1µM and 1.5µM). After growing the 
cells in medium with different glucose levels, cells were harvested and stained with 
DAPI or PI and cell cycle analysis was performed.  
MFE-296 cells showed clearly distinct and uniform subpopulations (Figure 5.10). In 
absence of glucose, the G2 subpopulation was generally smaller and increased upon 
increasing glucose concentration. Also, a shift towards the right on the horizontal axis 
with a larger S phase population in 1g/L and 2g/L glucose was observed. When BGJ 
was added to the cells, a decrease in cell counts of cells in G2 phase was observed. 
Upon glucose addition to the medium, cells proliferated more in drug compared to 
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without drug. Additionally, increased numbers of cells in G2 phase were counted, 
however the proportion did not increase significantly when adding a higher glucose 
concentration. SNU-16 cells tend to be more heterogeneous and subpopulations are 
not clearly defined, especially upon adding BGJ (Appendix Figure 8.49). The same 
was also done with SNU-16BGJR cells, however BGJ was kept at the final concentration 
used to generate drug-resistant cells (1.5µM). In drug-resistant cells, altering glucose 
concentration did not have an influence on cells in G1, S or G2 phase, however cell 
death was reduced in medium containing glucose compared to medium without 
glucose (Figure 5.11). Therefore, it can be concluded that addition of glucose increases 
the number of proliferating cells, as seen in MFE-296 cells, and potentially reduces 
cell death in BGJ resistant cells. SNU-16 cells seem to perform better under higher 
glucose concentrations, however no clear conclusions can be drawn as different 
populations cannot be separated due to their heterogeneity upon glucose and 
inhibitor treatment. 
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Figure 5.10. MFE-296 cells proliferate best under normal glucose concentrations. 
MFE-296 cells were seeded into 6 well-plates and grown in medium with either no glucose, 1, 2 or 4g/L glucose and either 500nM, 1µM and 1.5µM BGJ or vehicle control DMSO. 
After 72h cells were fixed in 70% Ethanol, followed by PI staining and cell cycle analysis using flow cytometry. The histograms show the cell counts as peaks demonstrating the 
distinct subpopulations (A). 
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Average proportion of cells in the different phases were calculated with GraphPad Prism 5 (G1=blue, S=yellow, G2=green, sub G1=red) (B). This experiment was performed once. 
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Figure 5.11. Glucose supplementation reduces SNU-16BGJR cell death. 
BGJ-resistant cells were seeded in medium without glucose and supplemented with 0, 1, 2 and 4g/L glucose and 1.5µM BGJ. As a control a condition was included 
were cells were grown in normal complete growth medium (CM). After 72h cells were fixed in 70% Ethanol, followed by PI staining and cell cycle analysis using flow 
cytometry. This figure is a representation of three individual experiments (Appendix Figure 8.50) with error bars indicating SEM. The histogram shows the values 
indicating the average proportion of cells in the different phases (G1=blue, S=yellow, G2=green, sub G1=red). Statistical analysis was performed using one-way 
ANOVA, p<0.05=*, p<0.01=**, p<0.005=***.  
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SNU-16 cells grown in different glucose concentrations were analysed by Western 
blot (Figure 5.12). No bands were observed for p-AKT, which was however observed 
previously with this cell type. Interestingly, p-ERK signalling was dramatically 
reduced at 2g/L and 4g/L glucose concentrations compared to low glucose 
concentrations.  
 
 
 
Figure 5.12. MAPK signalling is increased in low glucose concentrations compared to higher glucose 
levels. 
SNU-16 cells were grown in medium with different glucose concentrations and without glucose and 
grown for 72h followed by Western blot analysis. p-AKT signalling could not be measured however p-
ERK signalling was reduced in SNU-16 cells grown in medium supplemented with 2 and 4g/L glucose. 
 
Increasing glucose concentration did increase proliferation significantly, and was not 
strongly indicative for an involvement in drug resistance. Therefore, instead of 
adding glucose, which is the final product of the enzymatic cleavage through SI, to 
the cells, it was hypothesised that addition of the substrate of SI (sucrose) might affect 
resistance. As before, different concentrations were used; adding no sucrose, 1g/L, 
2g/L and 4g/L sucrose to the medium and counting cells and also FACS analysis for 
Annexin V, to measure apoptosis and necrosis in cells. 
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In normal medium containing glucose, resistant cells appeared to proliferate more 
with higher sucrose concentration (Figure 5.13). Adding 1g/L sucrose to the medium 
doubled cell numbers, whereas further addition of sucrose increased cell numbers 
only slightly more. Compared to resistant cells, parental cells seem to show no 
indicative trait in respect to sucrose concentration (Figure 5.14). When parental cells 
were treated with an FGFR inhibitor however, cells performed better with higher 
sucrose concentrations in the medium, as shown by a steady increase in cell number 
(Figure 5.14). 
 
 
 
Figure 5.13. BGJ-resistant cells perform better in medium with glucose and sucrose. 
Drug-resistant SNU-16 cells were grown in 6-well plates in medium with and without glucose and 
exposed to 0, 1, 2 or 4g/L sucrose in absence of glucose in the medium. After 72h cells were harvested 
and counted with Trypan blue and a haemocytometer with a light microscope. The graph represents 
three biological replicates. The error bars indicate SEM. CM=complete growth medium. 
 
 
 
 
Figure 5.14. SNU-16 cells and SNU-16BGJR cells proliferate more in high Sucrose levels. 
Parental and drug-resistant SNU-16 cells were grown in 6-well plates and exposed to 0, 1, 2 or 4g/L 
sucrose. Additionally parental cells were exposed to 1.5µM BGJ and drug-resistant SNU-16 cells were 
kept in 1.5µM BGJ. After 72h cells were harvested and counted with Trypan blue and a haemocytometer 
with a light microscope. The graph represents three biological replicates with error bars indicating SEM.  
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Parental cells were then treated with different concentrations of BGJ in the presence 
of sucrose and cell growth was compared (Figure 5.15). Treating cells with BGJ 
decreased cells numbers in all three drug concentrations (500nM, 1µM and 1.5µM) 
and increasing sucrose concentration in BGJ-treated cells resulted in higher cell 
counts. In the vehicle-treated condition, cell growth increased with higher sucrose 
concentration, except for the highest concentration, possibly due to overcrowding of 
cells and insufficient nutrient supply. 
 
 
 
 
Figure 5.15. SNU-16 cells treated with BGJ survive better with higher sucrose levels. 
SNU-16 cells were grown in 6-well plates and treated with 500nM, 1µM or 1.5µM BGJ or vehicle control 
DMSO. After 72h cells were harvested and cell numbers were counted with trypan blue and a 
haemocytometer with a light microscope. The graph represents biological triplicate and error bars 
indicate SEM. 
 
 
SNU-16 cells were grown in the presence of different sucrose concentrations and 
protein expression was measured by Western blot (Appendix Figure 8.51). p-ERK 
levels were unchanged with different sucrose concentrations, however p-AKT levels 
dropped at higher sucrose levels. Simultaneously, SNU-16 parental and BGJ-resistant 
cells were run on the same gel to compare protein expression (Figure 5.16). Compared 
to parental cells, p-AKT signalling was increased in resistant cells and did not 
decrease with increased sucrose levels, in contrast to the parental cells. However, p-
ERK signalling in SNU-16BGJR cells was reduced compared to parental cells. 
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Figure 5.16. Signalling in SNU-16 and SNU-16BGJR cells grown in medium containing different levels 
of sucrose. 
Parental and BGJ-resistant SNU-16 cells were exposed to medium containing 0, 1, 2 and 4g/L sucrose 
and grown for 72h followed by Western blot analysis. Protein expression of p-AKT, t-AKT, p-ERK, t-
ERK and HSC70 was analysed. 
 
The effects on cell numbers in SNU-16 and SNU-16BGJR cells raised the question if it is 
caused by upregulation of SI and if upregulation actually results in increased activity. 
As SI is involved in sucrose degradation, and hence generation of glucose, the effects 
of SI inhibition were investigated. There are no specific SI inhibitors available, 
however acarbose has been previously described to inhibit the sucrase subunit of the 
enzyme with reduced activity towards the isomaltase subunit. Acarbose is a pseudo-
tetrasaccharide with an amine group instead of a hydroxyl group and competitively 
interacts with SI and therefore inhibits the generation of glucose by inhibition of the 
enzymatic cleavage of sucrose (Figure 5.17). It was therefore anticipated that acarbose 
treatment of cells would have an effect on sensitivity of cancer cells when treating 
with kinase inhibitors such as BGJ. Cells were exposed to 14µM acarbose, based on 
the literature (Lee et al., 2012; Mohan et al., 2014). Combination of sucrose and 
acarbose treatment of SNU-16 cells resulted in lower cell numbers in high sucrose 
concentrations compared to growing cancer cells in sucrose alone (Figure 5.18). 
Simultaneously, cell viability of parental SNU-16 and drug-resistant SNU-16 cells to 
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acarbose was assessed, exhibiting a minor reduction in cell viability with increasing 
acarbose concentration (Appendix Figure 8.52). The same was also observed in H520 
lung cancer cells (Appendix Figure 8.53). 
When treating parental SNU-16 cells with different acarbose concentrations, a 
reduction in cell number was observed in cells grown in medium without glucose but 
different sucrose concentrations (Figure 5.19). 
 
 
 
Figure 5.17. Acarbose competitively inhibits α-glucosidase SI. 
Acarbose is a pseudotetrasaccharide and is structurally similar to oligosaccharides. Acarbose however 
harbours an amine group whereas oligosaccharides have an extra ether group. It competitively inhibits 
α-glucosidases such as SI that are located in the brush border of the small intestine and therefore 
delaying glucose absorption by decreasing the breakdown of complex carbohydrates (Rosak and Mertes, 
2012). 
 
 
 
 
 
Figure 5.18. Acarbose decreases cell number of parental and drug-resistant cells in high sucrose levels. 
Parental (A) and drug-resistant SNU-16 (B) cells were grown in 6-well plates and exposed to 0, 1, 2 or 
4g/L sucrose with and without 14µM Acarbose supplemented in the medium. After 72h cells were 
harvested and counted with Trypan blue and a haemocytometer with a light microscope. The graph 
represents three biological replicates. The error bars indicate SEM. 
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Figure 5.19. Acarbose treatment of SNU-16 cells reduces cell numbers in medium without glucose 
with increasing sucrose levels. 
Parental SNU-16 cells were grown in 6-well plates and exposed to 0, 1, 2 or 4g/L sucrose with either 
50nM, 200nM, 800nM or 3.2µM Acarbose in medium without glucose (A) or complete growth medium 
(B). After 72h cells were harvested and counted with Trypan blue and a haemocytoemter with a light 
microscope. The graphs represent three biological replicates with error bars indicating SEM. 
 
 
To investigate if acarbose can inhibit SI and therefore inhibit drug-resistant SNU-16 
cells, live, apoptotic and necrotic cells were counted by FACS (Figure 5.20). The same 
drug concentrations as with the parental SNU-16 cells were used. Treatment of cells 
with different acarbose concentrations however did not result in a higher number of 
apoptotic and necrotic cells. As acarbose inhibits SI by competitive inhibition of the 
intestinal enzymatic hydrolysis of oligosaccharides, it was hypothesised that sucrose 
needs to be present to see an effect in SI inhibition. Thus, cells were also grown in 
sucrose and acarbose together to see if they influence each other and again apoptosis 
and necrosis were measured (Figure 5.22). In parental SNU-16 cells, combining 
sucrose and acarbose resulted in a slight decrease in apoptotic and necrotic cells with 
high sucrose levels. However, this effect was also observed in vehicle-treated cells 
(Figure 5.21). In drug-resistant cells, acarbose treatment resulted in higher apoptotic 
and necrotic cells in low sucrose levels and also slightly more in high sucrose levels 
(Figure 5.22). Low acarbose levels increased apoptotic cells, whereas high acarbose 
concentration lowered apoptotic cells counts but increased necrosis. 
Analysis of SI protein expression was performed with the research group of Dr. 
Hassan Naim (University of Veterinary Medicine Hannover), who developed an 
antibody against SI, as other SI antibodies are not highly specific, however no clear 
bands could be observed (Appendix Figure 8.54). 
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Figure 5.20. Acarbose treatment of SNU-16BGJR cells does not induce apoptosis. 
BGJ-resistant cells were seeded into 6-well plates in medium containing different sucrose concentrations and treated with 50nM, 200nM, 800nMm or 32µM acarbose or vehicle 
and grown for 72h followed by fixation and Annexin V staining. The graphs show representative images of the scatter plots of three individual experiments (Appendix Figure 
8.55). Live, apoptotic and necrotic cells are shown as a histogram with error bars indicating SEM. 
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Figure 5.21. High sucrose levels reduce cell death in parental gastric cancer cells. 
Parental cells were seeded into 6-well plates in medium containing different sucrose concentrations and treated with 50nM, 200nM, 800nMm or 32µM acarbose or vehicle and 
grown for 72h followed by fixation and Annexin V staining. The graphs show representative images of the scatter plots of three individual experiments of the condition without 
sucrose (the rest of the sucrose concentrations are in the appendix) (Appendix Figure 8.56-Appendix Figure 8.58). Live, apoptotic and necrotic cells are shown as a histogram 
with error bars indicating SEM. 
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Figure 5.22. Drug-resistant SNU-16 cells are more sensitive at low sucrose levels. 
BGJ-resistant cells were seeded into 6-well plates in medium containing different sucrose concentrations and treated with 50nM, 200nM, 800nMm or 32µM acarbose or vehicle 
and grown for 72h followed by fixation and Annexin V staining. The graphs show representative images of the scatter plots of two individual experiments of the scatter plots of 
the condition without sucrose (the rest of the sucrose concentrations are in the appendix) (Appendix Figure 8.59). Live, apoptotic and necrotic cells are shown as a histogram 
with error bars indicating SEM. 
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In addition to upregulation of SI, ALDOB was also upregulated significantly and the 
second most upregulated gene in drug-resistant gastric cancer cells without stromal 
support. As SI is upregulated it could be that ALDOB has to be upregulated 
subsequently to break down fructose at a similar pace as SI breaks down sucrose, so 
that it does not have toxic effects on cells. Therefore, I hypothesised that ALDOB 
blockade would lead to accumulation of fructose-1-phosphate (F-1-P), which is toxic 
for cells (Ali et al., 1998; Tran, 2017). TDZD-8, a selective non-ATP competitive 
inhibitor of glycogen synthase kinase 3 (GSK 3β), was used to treat cancer cells to 
inhibit ALDOB activity (Grandjean et al., 2016). Inhibition of ALDOB would therefore 
lead to a block in the transformation of fructose into glyceraldehyde and 
dihydroxyacetone phosphate (DHAP), resulting in the accumulation of F-1-P, which 
is highly toxic for cells resulting in cell death (Figure 5.23). 
 
 
 
Figure 5.23. F-1-P accumulation in the fructose metabolism results in cell death. 
Fructose is phosphorylated to fructose-1-phosphate (F-1-P) by fructokinase. F-1-P then undergoes 
hydrolysis by aldolase B (ALDOB) to form dihydroxyacetone phosphate (DHAP) and glyceraldehyde. 
These trioses then either enter the gluconeogenic pathway for glycogen replenishment or the complete 
metabolism in the fructolytic pathway to pyruvate, which enters the Krebs cycle, and is converted to 
citrate and subsequently directed toward de novo synthesis of fatty acids. The absence of ALDOB results 
in the accumulation of F-1-P, which following fructose ingestion inhibits glycogenolysis and 
gluconeogenesis resulting in fatal liver failure. Inhibition of ALDOB therefore results in less available 
glucose (adpated from Charrez et al., 2015). 
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When treating cells with TDZD-8, BGJ-resistant cells appeared to be more sensitive 
towards the drug compared to parental SNU-16 cells (Figure 5.24). Cell viability 
decreased more in drug-resistant gastric cancer cells as TDZD-8 concentration 
increased. 
 
 
 
Figure 5.24. Drug-resistant SNU-16 cells are more sensitive to TDZD-8 than parental cells. 
Parental and BGJ-resistant SNU-16 gastric cancer cells were plated in triplicate into 96-well plates and 
exposed to TDZD-8 concentrations ranging from 0.38nM to 50µM. Control cells were treated with DMSO 
and as a background control 1% Staurosporine was added to wells containing cells. After 72h the cell 
viability index was measured and values plotted on a graph. The curves represent an average of 6 
biological replicates per cell line with error bars indicating SEM. LogIC50 and IC50 values were calculated 
in GraphPad Prism 5. 
 
To determine whether TDZD-8 induces cancer cell death, cells were subjected to 
Annexin V staining followed by flow cytometry analysis. Proportions of cells 
undergoing apoptosis and necrosis were similar between parental and drug-resistant 
cells (Appendix Figure 8.60, Appendix Figure 8.61). At the highest TDZD-8 
concentration, in SNU-16BGJR, a slight increase in apoptotic cells was observed, 
whereas in parental cells no change was observed. 
 
To investigate if there is a synergistic effect of inhibition of SI and ALDOB, acarbose 
and TDZD-8 were combined and BGJ-resistant cells were treated with a range of 
concentrations followed by cell viability analysis (Figure 5.25). The curves however 
look quite similar and there is no evident shift, although it could be hinted at the 
combination treatment rendering cells slightly more sensitive.  
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As before also apoptosis and necrosis was investigated in drug-resistant cells treated 
with either sucrose or acarbose in conjunction with TDZD-8. However as with cell 
viability, no clear effect can be seen in combination treated cells. 
 
 
 
Figure 5.25. Drug-resistant SNU-16 cells cannot be efficiently killed using combination treatment. 
SNU-16BGJR cells were seeded into 6-well plates in medium containing either 2g/L sucrose (A) or 14 µM 
acarbose (B) and treated with 1.6µM, 3µM, 6,3µM or vehicle. Apoptosis and necrosis was investigated 
by staining cells with Annexin V and PI and analysed using flow cytometry. The graphs represent three 
individual experiments. Apoptotic, live and necrotic cells are displayed as histograms with error bars 
indicating SEM (C). Drug-resistant SNU-16 cells were either treated with sucrose (2g/L) or acarbose 
(14µM) and a range of TDZD-8 concentrations. The experiments were performed in biological triplicate 
(Appendix Figure 8.62). 
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5.4 PIWIL1 overexpression potentially resensitises drug-resistant 
gastric cancer cells 
PIWIL1 was the gene that was downregulated the most in the SNU-16 dataset and is 
also among the most downregulated genes in drug-resistant co-culture cells. Reduced 
PIWIL1 expression has been associated with worse prognosis and PIWIL1 proteins 
have been linked to hallmarks of cancer such as deregulated cell proliferation, altered 
apoptosis, genomic instability, invasion, and metastasis (Tan et al., 2015). PIWIL1 was 
extensively studied and through literature search a research group was identified 
who generously provided an overexpression plasmid containing PIWIL1 (Lim et al., 
2014). PIWIL1 was inserted into the KOZAK cassette of a pcDNA3.1 plasmid 
(Appendix Figure 8.63). Cells were transfected with the plasmid containing PIWIL1 
and SNU-16BGJR transfected with PIWIL1 exhibited a tendency to reduce cell numbers 
compared to SNU-16BGJR cells transfected with the control empty vector (Figure 5.26). 
 
 
 
 
Figure 5.26. PIWIL1 overexpression shows a tendency to reduce cell numbers. 
Drug-resistant cells were seeded into 6-well plates and transfected with either pcDNA3.1 with an empty 
vector or pcDNA3.1 containing PIWIL1. Cells were then counted using a light microscope. Error bars 
indicate SEM and the experiment was performed in biological triplicate. 
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Therefore it was investigated if PIWIL1 overexpression would induce apoptosis in 
cells and the proportion of cells undergoing apoptosis and necrosis was investigated 
(Figure 5.27). PIWIL1 transfection did not alter apoptotic and necrotic cell counts. 
 
 
Figure 5.27. PIWIL1 overexpression does not induce apoptosis in drug-resistant cells. 
Parental SNU-16 (A) and SNU-16BGJR (B) cells were seeded into 6-well plates and transfected with 
plasmids containing an empty vector or PIWIL1 and as a control for transfection with a plasmid 
containing GFP and with the transfection reagent only. Apoptosis and necrosis was investigated by 
staining cells with Annexin V and PI and analysed using flow cytometry. The graphs represent three 
individual experiments. Apoptotic, live and necrotic cells are displayed as histograms (C) with error bars 
indicating SEM. PIWIL1 was also transfected with Lipofectamine® in another experiment (Appendix 
Figure 8.64). 
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5.5 REG1A and collagen genes potentially influence drug resistance 
in co-culture cells 
REG1A was the most upregulated gene in drug-resistant co-culture cells. REG1A is a 
growth factor involved in tissue regeneration and proliferation in the mucosa of the 
gastrointestinal tract. It is known to affect pancreatic β cells and has been observed in 
various malignant tumours (Geng et al., 2017; Hayashi et al., 2008; Kimura et al., 1992; 
W.-S. Lee et al., 2008; Minamiya et al., 2008; Motoyama et al., 2006; Sasaki et al., 2008; 
Sekikawa et al., 2008; Yoshino et al., 2005). 
Sections from the 3D resistance RNA-Seq experiment were stained with REG1A 
antibody (Appendix Figure 8.65). Sections with the drug-resistant co-culture possibly 
reveal a stronger REG1A staining compared to vehicle-treated co-culture cells. To 
investigate the importance of REG1A in drug-resistant cells, REG1A was knocked-
down lentivirally using shRNAs both in drug-resistant SNU-16 and HFF2 cells. 
Knockdown of REG1A was analysed with Western blot (Appendix Figure 8.66, 
Appendix Figure 8.67) and FACS (Appendix Figure 8.68). With the REG1A antibody 
however, no bands appeared at the expected size and no significant differences in cell 
counts were measured. 
REG1A knocked down BGJ-resistant SNU-16 and HFF2 cells were then also seeded 
into Alvetex® scaffolds and grown for one week in presence of BGJ, followed by 
fixation, H&E staining (Appendix Figure 8.69) and REG1A antibody staining 
(Appendix Figure 8.70). The cells in the scaffolds were also imaged with a 
fluorescence confocal microscopy and Z-Stacks were rendered with imaris and cell 
volumes of SNU-16BGJR cells with REG1A knockdown and HFF2 cells with REG1A 
knockdown were compared (Appendix Figure 8.71). With this, a basis for further 
experiments involving investigation of the role of REG1A in drug resistance in co-
culture was set. 
Interestingly, a great number of collagen-associated genes were upregulated in co-
culture cells. An initial experiment was to stain Alvetex® scaffolds with Oil Red O to 
stain triglycerides and lipids (Appendix Figure 8.72).  
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5.6 Findings in 2D are not representative in 3D 
Comparing gene expression in 2D versus 3D, it was found that in 2D, gene expression 
could behave very differently, with several genes regulated in the opposite direction 
than in 3D cultures (Figure 5.28). REG1A however, is also upregulated in drug-
resistant cells in 2D. To compare, gene expression was also analysed in MFE-296 cells, 
where it is known that PHLDA1 is downregulated in FGFRi-resistant MFE-296 cells 
(Figure 5.29). In SNU-16BGJR cells however, PHLDA1 was upregulated, in contrast to 
the downregulation in the RNA-Seq data in 3D (Figure 5.30). 
 
 
Figure 5.28. Relative gene expression levels of targets.  
Gene expression levels of SNU-16 versus SNU-16BGJR cells in 2D and 3D and co-culture cells in 3D. 
Comparison of SI gene expression (A), PIWIL1 expression (B) and REG1A expression (C). The 
experiments were performed in biological triplicate. **p<0.01, ****p<0.001.   
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Figure 5.29. Expression of targets in MFE-296 cells and AZD-resistant MFE-296 cells. 
Parental MFE-296 and AZD-resistant MFE-296 cells were harvested and RNA extracted, which was 
reverse transcribed into cDNA. Gene expression was then assessed using qPCR for PHLDA1, PIWIL1 
and GLUT1. *p<0.05, ****p<0.001. 
 
 
Figure 5.30. PHLDA1 expression in SNU-16 and SNU-16BGJR cells. 
Parental SNU-16 and BGJ-resistant SNU-16 cells were harvested and RNA extracted, which was reverse 
transcribed into cDNA. Gene expression was then assessed using qPCR for PHLDA1. *p<0.05. 
 
PHLDA1 upregulation in BGJ-resistant SNU-16 cells was also confirmed by Western 
blot (Figure 5.31). 
 
 
Figure 5.31. PHLDA1 expression in SNU-16 and BGJ-resistant SNU-16 cells. 
Protein was extracted from parental SNU-16 and SNU-16BGJR cells and 10µg was loaded into each lane 
and Western blot analysis was performed probing for PHLDA1 and HSC70. The experiment was 
performed in biological triplicate.  
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5.7 Comparison of common gene expression between datasets 
5.7.1 MFE-296 microarray 
The differential gene expression levels of parental SNU-16 and BGJ-resistant SNU-16 
and co-culture cells were also compared to gene expression of AZD-resistant 
endometrial cancer line MFE-296, which was performed previously in the group 
(Fearon et al., 2018). 
 
 
 
 
Figure 5.32. Comparing expression of genes between MFE-296 resistant to PD and SNU-16 cells 
resistant to BGJ.  
The top right corner indicates genes that are downregulated in drug-resistant MFE-296 and SNU-16 cells. 
The MFE-296 data was generated in 2D, while SNU-16 drug-resistant cells were generated in 3D. 
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Table 5.1. Comparison of the SNU-16 dataset to the MFE-296 dataset.  
Cut off at correlation >2. Endometrial cancer cell line MFE-296 was made resistant to AZD and 
microarray analysis was performed. 
 
Gene name Description Correlation 
Regulation in 
drug resistant 
cells 
DUSP6 dual specificity phosphatase 6  15.809 Down 
PHLDA1 
Pleckstrin homology-like domain family A 
member 1 
14.532 Down 
ETV5 ets variant 5  13.638 Down 
ETV4 ets variant 4  8.554 Down 
SPRY4 sprouty RTK signalling antagonist 4  8.404 Down 
MSX2 msh homeobox 2  6.193 Down 
TRIB2 tribbles pseudokinase 2  6.151 Down 
EMP1 epithelial membrane protein 1 4.035 Down 
SLC40A1 solute carrier family 40, member 1  3.760 Up 
SH3BGRL 
SH3 domain binding glutamate-rich protein 
like 
3.378 Up 
CPE carboxypeptidase E  3.271 Up 
LYPD6B LY6/PLAUR domain containing 6B  3.267 Down 
SRPK2 SRSF protein kinase 2  3.087 Up 
MCOLN3 mucolipin 3 2.805 Up 
CTGF connective tissue growth factor  2.666 Down 
FABP3 fatty acid binding protein 3, muscle and heart  2.629 Up 
HLA-DRA 
major histocompatibility complex, class II, DR 
alpha  
2.599 Up 
MAT1A methionine adenosyltransferase I, alpha 2.405 Up 
 
From previous work in our group, PHLDA1 has been identified to play a role in drug 
resistance in endometrial cancer cells and PHDLA1 is downregulated in AZD-
resistant MFE-296 cells (Appendix Figure 8.73). PHLDA1 was also significantly 
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downregulated in BGJ-resistant SNU-16 cells in 3D using Alvetex®, however not in 
co-culture cells (Figure 5.33). 
 
 
Figure 5.33. PHLDA1 expression in 3D resistance gene expression comparison. 
PHLDA1 gene expression was compared between all samples and was significantly down in BGJ-
resistant SNU-16 cells. SNU-16d = DMSO-treated SNU-16 cells, SNU-16b = BGJ-treated SNU-16 cells, 
FIBROd = DMSO-treated co-culture cells, FIBROb = BGJ-treated co-culture cells, r=repeat. 
 
When comparing genes regulated in the same direction, in addition to PHLDA1 also 
DUSP6 was shown and expression was also analysed in SNU-16 cells using Western 
blot (Figure 5.34). Again, in contrast to the RNA-Seq data, DUSP6 was also 
upregulated in SNU-16BGJR cells. 
 
 
Figure 5.34. DUSP6 and PHLDA1 expression in SNU-16 and SNU-16BGJR cells. 
Protein of parental and drug-resistant SNU-16 was extracted and subjected to Western blot analysis 
probing for DUSP6, PHLDA1 and HSC70 as a loading control. The blots represent three individual 
experiments. Further blots are in the appendix (Appendix Figure 8.74). 
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5.7.2 Effect of PI3K and MEK inhibitors on MFE-296 cells 
PHLDA1 expression was further investigated by inhibition of FGFR2 downstream 
pathways. MFE-296 cells were treated with MEK inhibitor U0126 (1μM) and PI3K 
ZSTK (1μM) and PHLDA1, p-AKT and p-ERK levels were compared to total AKT 
and ERK, as well as HSC70 levels (Figure 5.35). Phosphorylated AKT and PHLDA1 
were both reduced upon PI3K inhibitor treatment. While p-ERK was dowregulated 
in cells treated with the MEK inhibitor.  
 
 
 
 
Figure 5.35. Treatment of MFE-296 cells with PI3K inhibitor ZSTK inhibits both p-AKT and PHLDA1.  
MFE-296 cells were exposed to 1µM ZSTK and 1µM U0126 and cells were harvested after 72h and 
analysed by Western blot probing for p-AKT, PHDLA1, p-ERK and HSC70 as a loading control. The 
blots are representative of three individual experiments (Appendix Figure 8.75). 
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PHLDA1 expression levels were also investigated in AN3CA cells over a time span 
of 24 hours with exposure to AZD for 1, 4, 8 and 24 hours, revealing loss of PHLDA1 
expression after 24 hours. Upon addition of the FGFR inhibitor also p-ERK levels were 
slightly reduced (Figure 5.36). The same was also done for MFE-296 cells with PD and 
AZD. PHLDA1 levels were initially reduced in PD and AZD-treated MFE-296 cells, 
which returned to basal levels after 24 hours for PD-treated cells and already after 
four hours for AZD-treated cells. Phosphorylation of ERK was dramatically reduced 
in FGFR inhibitor treated MFE-296 cells (Figure 5.37). 
 
 
Figure 5.36. After 24h AZD treatment PHLDA1 levels are down in AN3CA cells. 
AN3CA cells were exposed to 1µM AZD and cells were harvested after 1, 4, 8, and 24 and analysed by 
Western blot probing for p-AKT, PHDLA1, p-ERK and HSC70 as a loading control. The blots are 
representative of two individual experiments (Appendix Figure 8.76). 
 
 
 
Figure 5.37. PHLDA1 expression returns to basal levels after 24h in FGFR2-mutated endometrial 
cancer cells. 
MFE-296 cells were exposed to 5µM PD and 1µM AZD and cells were harvested after 1, 4, 8, and 24 and 
analysed by Western blot probing for p-AKT, PHDLA1, p-ERK and HSC70 as a loading control. The 
blots are representative of three individual experiments (Appendix Figure 8.77, Appendix Figure 8.78).  
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5.7.2.1 Long-term FGFR inhibitor treatment of AN3CA cells 
After short-term treatment of AN3CA cells with FGFR inhibitors such as PD or AZD, 
PHLDA1 levels were decreased (Figure 5.36). Next, we also wanted to probe 
PHLDA1 and AKT and ERK signalling after long-term drug treatment. Cells were 
treated with PD at a concentration of 1μM for 7 days. Medium with the drug was 
exchanged every two days. There was no effect observable in PHLDA1 or p-AKT. 
However p-ERK levels were decreased in drug-treated cells after 7 days. 
 
 
Figure 5.38. After 7 days PD treatment PHLDA1 levels are back to normal in AN3CA cells. 
PHLDA1 and p-AKT levels are reversed to basal levels of AN3CA cells after 7 days PD treatment. 
PHLDA1 levels and p-AKT levels are unchanged after treatment of cells for 7 days with FGFR inhibitor 
PD. However p-ERK levels are decreased in 7 days treated cells. This image is representative of three 
individual experiments (Appendix Figure 8.79). 
 
PHLDA1 was knocked down in MFE-296 cells with three different shRNAs, which 
was confirmed with Western blot (Appendix Figure 8.80). MFE-296 cells with 
PHLDA1 knockdowns were then grown in Alvetex® and treated with PD and AZD, 
which did not reduce cell numbers in MFE-296 cells. This confirmed findings that 
PHLDA1 knockdown confers resistance to FGFR inhibition (Appendix Figure 8.81). 
Gene expression levels were also compared to other datasets found on the Gene 
Expression Omnibus (GEO) database. The gene with the highest correlation between 
the SNU-16 and MFE-296 dataset (Fearon et al., 2018) was dual specificity phosphatase 
6 (DUSP6). Also PHLDA1, which was discussed previously, was the second common 
downregulated gene. Gene expression signature of drug-resistant SNU-16 cells was 
further compared to to FGFR1-amplifed DMS114 small cell lung cancer cell line made 
resistant to BGJ (3µM) (Accession: GSE92651) and FGFR3-mutated urothelial 
Results Part III 
251 
 
carcinoma cell line RT112 also made resistant to BGJ (5µM) (Accession: GSE92651) 
(Table 5.2, Table 5.3). In the comparison between MFE-296 and SNU-16 and RT112 
and SNU-16 two genes were shared such as epithelial membrane protein (EMP1) and 
DUSP6. Whereas BGJ-resistant DMS114 compared to drug-resistant SNU-16 cells did 
not share genes with the MFE-296 and RT112 datasets. 
Table 5.2. DMS114 dataset compared to SNU-16 dataset.  
Small cell lung cancer cell line DMS114 was made resistant to BGJ at a concentration of 3µM. 
 
Gene name Description Correlation 
Regulation in 
drug resistant 
cells 
FLRT3 fibronectin leucine rich transmembrane protein 3 8.605 Down 
IFITM3 interferon induced transmembrane protein 3 6.077 Down 
NRIP1 nuclear receptor interacting protein 1 5.550 Up 
EYA1 EYA transcriptional coactivator and phosphatase 1 5.005 Up 
ETV1 ets variant 1  4.712 Down 
SOX4 SRY-box 4 3.536 Up 
DCN decorin 3.286 Up 
TBX2 T-box 2 2.760 Up 
HMOX1 heme oxygenase 1 2.144 Up 
FSTL1 follistatin like 1 2.009 Up 
MAP1B microtubule associated protein 1B 1.889 Up 
TXNIP thioredoxin interacting protein 1.824 Down 
CNKSR2 connector enhancer of kinase suppressor of RAS 2 1.488 Up 
ID2 
inhibitor of DNA binding 2, dominant negative 
helix-loop-helix protein 
1.354 Up 
COTL1 coactosin-like F-actin binding protein 1 1.230 Up 
CYR61 cysteine-rich, angiogenic inducer, 61 1.028 Up 
EDIL3 EGF-like repeats and discoidin I-like domains 3 0.918 Down 
MAGI1 
membrane associated guanylate kinase, WW and 
PDZ domain containing 1 
0.847 Up 
TMEM170B transmembrane protein 170B 0.825 Up 
RCN1 reticulocalbin 1 0.645 Up 
TCF12 transcription factor 12 0.306 Up 
ASNA1 
arsA arsenite transporter, ATP-binding, homolog 1 
(bacterial) 
0.214 Down 
TPD52 tumour protein D52 0.186 Up 
RSU1 RAS suppressor protein 1 0.172 Up 
S1PR1 sphingosine-1-phosphate receptor 1 0.165 Up 
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Table 5.3. RT112 dataset compared to SNU-16 dataset. 
Urothelial cancer cell line RT112 was made resistant to BGJ at a concentration of 5µM. 
 
Gene name Description Correlation 
Regulation in 
drug resistant 
cells 
LGALS1 lectin, galactoside-binding, soluble, 1 20.730 Down 
DUSP6 dual specificity phosphatase 6 18.230 Down 
PLAT plasminogen activator, tissue 15.322 Down 
NRCAM neuronal cell adhesion molecule 10.927 Up 
AGR2 
anterior gradient 2, protein disulphide 
isomerase family member 
6.774 Down 
EMP1 epithelial membrane protein 1 5.373 Down 
CEACAM1 
carcinoembryonic antigen-related cell 
adhesion molecule 1 (biliary glycoprotein) 
4.060 Down 
LRP1 LDL receptor related protein 1 3.604 Down 
PODXL podocalyxin-like  2.333 Up 
SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) 1.970 Up 
ASNS 
asparagine synthetase (glutamine-
hydrolyzing) 
1.437 Up 
GSTM4 glutathione S-transferase mu 4 1.394 Up 
SLC1A3 
solute carrier family 1 (glial high affinity 
glutamate transporter), member 3  
0.594 Down 
GSTM3 glutathione S-transferase mu 3 (brain) 0.502 Up 
PSAT1 phosphoserine aminotransferase 1 0.340 Up 
 
Taken together, these data have shown that, most importantly, conclusions from 2D 
data can not be drawn and applied to in vivo data or 3D models. Gene expression 
varied greatly between drug-resistant cells generated in 2D and 3D. It has been shown 
that retinol and glucose may play a role in drug-resistance, which will be adressed in 
the discussion. Furthermore, the SNU-16 dataset was compared to other datasets 
from endometrial, lung and urothelial cancer cells and two FGFR inhibitors such as 
AZD and BGJ to identify differences and similarities in gene signatures. 
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5.8 Discussion 
5.8.1 Retinol pathway 
Vitamin A and its natural derivatives and metabolites such as β-carotene, retinol, 
retinal, isotetrinoin, ATRA, 9-cis retinoic acid, and 13-cis retinoic acid have important 
functions in critical biological processes including cell differentiation, growth, and 
apoptosis (Theodosiou et al., 2010). Therefore, it was hypothesised that by treating 
cancer cells with ATRA, cells might be resensitised towards BGJ treatment. As 
expected, treatment of cells with BGJ induced cell cycle arrest, as shown by an 
increase of cells in G1 phase and decrease of cells in S and G2 phase. Furthermore, the 
sub G1 population was increased in drug-treated cells, indicating increased cell death 
in FGFR2-mutated endometrial cells. This however, was not observed in BGJ-resistant 
gastric cancer cells. In parental SNU-16 cells, the influence of ATRA treatment was 
not significant and only showed a tendency of a decrease in cells undergoing 
apoptosis and a slight increase in G1 populations. This effect could be explained by 
the dual function of retinoic acid and its receptors, as they are not only involved in 
the classical pathway but play also a role in other essential pathways. Thus, retinoic 
acids have been shown to regulate NF-κB, IFN-γ, TGF-β, VEGF and MAPK and also 
chromatin remodelling (Cras et al., 2012; Dilworth and Chambon, 2001; Papi et al., 
2012; Piskunov and Rochette-Egly, 2012; Tang and Gudas, 2011; Ying et al., 2011). 
RARs and RXRs can form heterodimeric interactions with other receptors, including 
oestrogen receptor-α, AP-1, peroxisome proliferator-activated receptor (PPAR), liver 
X receptor (LXR) and vitamin D receptor and therefore influence and regulate these 
pathways (Hua et al., 2009; Lefebvre et al., 2005; Schug et al., 2007; Wang et al., 2001; 
Willy et al., 1995). Notably, these pathways often have opposite functions compared 
to the classical pathway. For example, RA activation of the PPARβ/δ pathway 
resulted in the induction of pro-survival genes as opposed to the anticipated activity 
of RARs and RXRs in differentiation (Schug et al., 2007). This could be a potential 
mechanism how cancer cells not only develop resistance to RA but also overcome 
drug inhibition.  
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Another possibility is that the cancer cells have lost receptors necessary for RA to 
exert its function, by epigenetic regulation of RAR genes. RARβ has been found to be 
lost in a number of solid tumours, such as breast cancer (Mehrotra et al., 2004; Sirchia 
et al., 2000; Widschwendter et al., 1997). Therefore, treatment with ATRA would 
result in no activation of the classical or non-classical pathway. This could be the case 
for the cancer cells studied in this work and potentially RARs could be reexpressed 
by using DNA methyltransferase (DNMT) and histone deacetylase (HDAC) 
inhibitors (Sirchia et al., 2002). Cancer cell proliferation could then possibly be 
reduced by combination of DNMT or HDAC inhibitors with ATRA and FGFR 
inhibitors. 
However, there may be other mechanisms by which cancer cells affect RARs. It has 
been reported, that loss of co-activators resulted in upregulated RA metabolism, 
decreased numbers in RA or reduced RARα signalling (McPherson et al., 2007; 
Moghal and Neel, 1995; Ren et al., 2005; White et al., 1997). Loss of co-activator AF-2 
in lung cancer, for example, resulted in lower RARβ expression. Reduced RARα 
signalling could negatively influence RARβ activation by lowered activity in 
chromatin remodelling, which is necessary for RARβ expression. It could also be that 
cross-talk between RARs and ER, as observed in breast cancer, could allow cancer 
cells to bypass therapeutic targeted pathways (Ross-Innes et al., 2010).  
Most interestingly, upregulated RA metabolism could lead to RA elimination through 
4-hydroxylation, 18-hydroxylation and glucuronidation and therefore diminish the 
biological activity of ATRA. Cytochrome P450, which belongs to the CYP26 family, 
has been described as an RA metabolising factor, resulting in hydroxylated forms of 
RA, including 4-OH-RA, 4-oxo-RA, and 18-OH-RA (White et al., 1997). It was also 
observed that P450 mRNA expression was induced by RA and therefore could 
demonstrate an auto-regulatory mechanism of RA levels. This could align well with 
the results from RNA-Seq pathway analysis and associated upregulation of the 
retinol pathway. When cross-checking in which direction the pathway is driven it can 
be concluded that the pathway shifted towards hydroxylated metabolites such as 4-
OH-RA and, 18-OH-RA and also glucuronidated RA metabolites (Figure 4.23). 
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Therefore, upregulation of the retinol pathway in the SNU-16 dataset could indicate 
RA elimination by upregulated retinol metabolism. This finding is also reinforced by 
the fact that ATRA treatment did not affect apoptosis and necrosis in SNU-16BGJR cells 
and showed to be insensitive towards the metabolite, whereas parental SNU-16 cells 
exhibited increased apoptotic and necrotic cells numbers and FGFR inhibitor 
treatment coupled with retinoic acid treatment could potentiate its effects. 
Additionally, there could also be a mechanism independent of RARs, such as aberrant 
c-MYC or p53 expression, which has been implicated in RA resistance in patients with 
neuroblastoma and oral premalignancies (Lippman et al., 1995; Reynolds et al., 2000). 
p53 is mutated in SNU-16 cells, however with wildtype expression levels of p53 
(Chang et al., 1997; Ku and Park, 2005). C-MYC on the other hand has been found to 
be overexpressed in SNU-16 cells (Park et al., 1998), which could potentiate the effect 
of ATRA resistance and insensitivity coupled with ATRA elimination through 
increased retinol metabolism. 
5.8.2 Sucrose and starch pathway and associated genes 
Metabolism differs dramatically in cancer cells compared to normal cells, especially 
energy production, which is dependent on aerobic glycolysis in cancer cells. Other 
metabolic changes include enhanced fatty acid synthesis and glutamine metabolism. 
It has been shown previously, that these abnormal metabolic properties in the 
Warburg effect have been associated with therapeutic resistance in cancer therapy. 
Inclusion of metabolic targeting in cancer therapy could therefore offer a promising 
and selective approach to overcome drug resistance in cancer cells. It was already 
observed in 1959 by Warburg that glycolysis rates were abnormally high in cancer 
cells and a Warburg effect would indicate that cancer cells prefer a glycolytic 
breakdown of glucose for energy instead of mitochondrial oxidative phosphorylation 
(Gatenby and Gillies, 2007; Gillies et al., 2008; Hsu and Sabatini, 2008; Kroemer and 
Pouyssegur, 2008; Vander Heiden et al., 2009; Warburg, 1956).  
Therefore, the Warburg effect describes increased glucose consumption through 
glycolysis and cancer cells dysregulate metabolism to use the abundant resource 
available in the body. This mechanism enables cancer cells to be released from the 
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restraints on growth observed in healthy cells. The starch and sucrose degradation 
pathway is involved in the degradation of sucrose into glucose and therefore it was 
hypothesised that upregulation of the starch and sucrose degradation pathway, 
coupled with upregulation of SI, results in increased glucose concentration in cells. A 
number of studies have confirmed the connection between obesity and gastric cancer 
(Abnet et al., 2008; Chow et al., 1998; Ji et al., 1997; Kubo et al., 2005; Yang et al., 2009). 
Higher serum glucose levels significantly increased gastric cancer incidence and 
aggressiveness. Altered glucose metabolism could therefore be an important 
indicator to distinguish gastric cancer cells from normal cells as abnormal glucose 
metabolism was observed in a number of studies involving gastric cancer (Cai et al., 
2010; Hirayama et al., 2009; Hur et al., 2014; Wu et al., 2010). A common explanation 
for increased glycolysis in cancer is hypoxia resulting from the rapid growth of cancer 
cells (Daşu et al., 2003) with hypoxia-inducible factor (HIF)-1 being the transcription 
factor involved in responding to changes in cellular oxygen to help cells in survival 
in hypoxic microenvironment (Lum et al., 2007; Wang et al., 1995). Positive HIF-1α 
expression was observed in patients and associated with poor prognosis for patients 
with gastric cancer. Activation of the RAS-MAPK signal transduction pathway and 
PI3K-AKT-mTOR signalling, and loss of tumour suppressor proteins, such as PTEN 
and p53, increased HIF-1α expression (Fukuda et al., 2002; Laughner et al., 2001). HIF-
1α directly stimulates glycolysis by activating the expression of glucose transporters 
and several key glycolytic enzymes, such as hexokinases (HK), Pyruvate kinase 
isozymes M2 (PKM2) and Lactate dehydrogenase A (LDH-A). The HIF-1α-dependent 
pathway increases glycolysis and inhibits mitochondrial O2 consumption, therefore 
promoting tumour cell survival (Kim et al., 2006). Myc is another important proto-
oncogene, which plays an important role in glucose metabolism and enhances 
expression of glycolytic genes including glucose transporter 1 (GLUT1) (Buller et al., 
2008). In many cancers also loss of p53 initiates the glycolytic pathway and reduces 
oxidative phosphorylation (Wu et al., 2014). p53 increases oxidative phosphorylation 
and decreases glycolysis via downregulation of genes such as GLUT1 (Watanabe et 
al., 2010). GLUT1 was found to be upregulated in BGJ-resistant SNU-16 cells, and to 
a lesser extent GLUT4, upregulation has been associated with endometrial, gastric, 
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squamous cell carcinoma and ovarian cancers (Abdou et al., 2015; Liu et al., 2015; Ma 
et al., 2015; van de Nes et al., 2015). Upregulation of GLUT1 in BGJ-resistant cells 
could indicate that resistant cancer cells transport more glucose and therefore have 
increased glucose uptake to meet the metabolic demands of drug-resistant cancer 
cells. Upregulation of GLUT1 in parental cells treated with BGJ could indicate that 
cancer cells, upon stress, upregulate GLUT1, which has been associated in the 
regulation of ROS (Andrisse et al., 2014). 
Several glycolytic enzymes have been associated with the progression of gastric 
cancer (Qiu et al., 2011; Rho et al., 2007; Wang et al., 2012). Overexpression of glucose-
6-phosphate dehydrogenase (G6PD), which is responsible for the conversion of 
glucose into ribose-5-phosphate, the first key step in glycolysis, has been associated 
with progression of gastric cancer. G6PD levels have also been suggested to play a 
role in NADPH production, which protects cells from DNA damage induced by ROS 
(Wang et al., 2012).  
Similarly, SI could be involved in carcinogenesis and resistance and SI overexpression 
has been involved as a predictor for Barrett's adenocarcinoma of the gastric cardia 
(Iannettoni et al., 1996). Due to the importance of SI in cancer and its involvement in 
the generation of glucose, it was hypothesised that glucose addition could be the 
driver for drug resistance in gastric cancer cells. Addition of glucose to the cells 
however mainly resulted in increased proliferation and toxic effects in high 
concentrations in parental cells. It could be suggested that supplementing the 
medium with higher glucose concentrations could impact drug sensitivity in parental 
SNU-16 cells and render them less sensitive to the drug. Further aspects that support 
this hypothesis are the downregulation of oxidative phosphorylation, as cells use 
glycolysis instead, and increased fatty acid metabolism, which provides cancer cells 
with lipids for membrane biogenesis of fast proliferating cells conferring an growth 
and survival advantage (Pandey et al., 2012). Fatty acid biosynthesis was upregulated 
in the SNU-16 monoculture dataset, which could further support the hypothesis. 
Upregulation of both GLUT1 and SI could also explain better tolerance to lack of 
glucose in drug-resistant cells (Figure 5.9). Parental SNU-16 cells react more 
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sensitively to glucose absence in the medium than do SNU-16BGJR cells. This indicates 
that, with the upregulation of GLUT1 and SI, the cells can cope with lack of glucose 
and use sucrose to generate glucose via SI. MFE-296 cells also showed higher 
proliferation in medium containing glucose. At high glucose levels however, cells 
started to proliferate less. SNU-16 cells generally also seemed to perform better with 
addition of glucose. This suggests that glucose transport is elevated in drug-resistant 
cells to meet the metabolic needs of cancer cells for growth and signalling. 
Interestingly, Western blot analysis of SNU-16 cells exposed to different glucose 
concentrations revealed a lower p-ERK expression in cells exposed to 2 and 4g/L 
glucose. This could indicate that cells require glucose, however at higher 
concentrations it will not further increase proliferation of these cells. In initial studies 
in Drosophila, ERK signalling was found to regulate glucose metabolism to maintan 
glucose levels in cells. Downregulation of p-ERK could therefore suggest an 
adaptation to maintain circulating glucose at appropriate levels (Becker et al., 1996; 
Zhang et al., 2011). Since it is hypothesised that in resistant cells glucose levels are 
heightened through increased enzymatic activity of SI, it could be explained that there 
is no effect of glucose addition in BGJ-resistant cells and the effect of sucrose on 
resistant cells would be more interesting to investigate. Sucrose levels did induce 
proliferation in SNU-16BGJR cells. In parental cells however, toxic effects were observed 
at high concentrations, which could be due heightened proliferation and therefore 
cells overcrowding and not receiving enough nutrients. Interestingly, treating 
parental cells with BGJ resulted in lower cell numbers as expected, however with 
increasing sucrose concentration cells performed better and cell numbers increased. 
Whether SI upregulation leads to increased activity needs to be established. This 
should be further investigated as there is a long way between activation and maturity 
including post-translational modification and trafficking/localisation. 
AKT signalling does not only play a role in apoptosis, cell proliferation, transcription, 
and cell migration but also in glucose metabolism. AKT includes three highly similar 
isoforms, AKT1, AKT2, and AKT3 (Calera et al., 1998), of which AKT2 is involved in 
the translocation of the glucose transporter GLUT4 to the cell surface, resulting in 
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insulin-induced glucose uptake into cells (Garofalo et al., 2003). The insulin receptor 
tyrosine kinase is implicated in the activation of AKT through a pathway involving 
insulin receptor substrate (IRS), phosphatidylinositol 3 kinase (PI3K), 3-
phosphoinositide-dependent protein kinase 1 (PDK1) and AKT (Maarbjerg et al., 
2011). Insulin activates this pathway, leading to increased glucose uptake, and insulin 
generation increases with higher carbohydrate ingestion, including sucrose (Tsuchiya 
et al., 2014). Dephosphorylation of AKT could therefore indicate that cells are trying 
to regulate glucose metabolism by inhibiting AKT signalling. Interestingly, 
comparing p-AKT expression in parental and BGJ-resistant cells, p-AKT expression 
remains the same in high sucrose concentrations, supporting the hypothesis that cells 
keep AKT signalling, induced by insulin, at constant level to metabolise more glucose, 
as opposed to parental cells which regulate glucose metabolism by reducing AKT 
signalling. Drug-resistant SNU-16 cells therefore rely on glucose metabolism, which 
gives them an advantage over parental cells. It is therefore crucial to identify the 
involvement of SI in this process and, if sucrose degradation is inhibited, also insulin-
dependent activation of AKT could be reduced together with glucose uptake in cells. 
Interestingly, p-ERK signalling was reduced in SNU-16BGJR cells, compared to parental 
cells. ERK signalling has been associated with pyruvate kinase isoenzyme PKM2, 
which mediates the rate-limiting step of glycolysis through catalysis of 
phosphoenolpyruvate (PEP) dephosphorylation to produce one molecule of ATP. 
PKM2 is often upregulated in cancers (Eigenbrodt et al., 1997) and PKM2 knockdown 
decreased E-Cadherin activity and enhanced EGF/EGFR signalling (Wang et al., 
2013), therefore promoting cell migration and invasion. Drug-resistant SNU-16 cells 
could therefore have lower p-ERK signalling and obtain a more aggressive and 
migratory phenotype. 
Acarbose is used as an anti-diabetic drug and used in the treatment of type-2 diabetes 
and serves as a blood sugar control method. It works by slowing down glucose 
digestion and absorption in the small intestine (Gomez-Zubeldia et al., 1993; Krause 
et al., 1982). Therefore, acarbose was used to inhibit SI activity, as it binds to the 
enzyme and inhibits it from cleaving further oligosaccharides such as sucrose or 
maltose to glucose. The concentration of acarbose depends on the concentration of 
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the SI enzyme, however that is difficult to assess, therefore a range of different 
concentrations was used to block the SI enzyme. N- (nt) and C-terminus (ct) of SI have 
different affinities, whereby ctSI can be inhibited with 200nM and ntSI is inhibited 
using 14µM. In cell counts, addition of acarbose resulted in a decreased number of 
drug-resistant cells, however no change was observed in apoptosis and necrosis. This 
indicates that acarbose does influence cell growth in resistant cells, however does not 
induce apoptosis or necrosis. A similar effect was observed with ALDOB inhibitor 
TDZD-8, which did not induce changes in apoptosis and necrosis, however did 
reduce cell counts in gastric cancer cells and more so in drug-resistant cells. This could 
be connected to TDZD-8 having toxic effects through blockade of ALDOB and 
therefore an accumulation of F-1-P in cells resulting in lower cell proliferation. 
Combining acarbose and TDZD-8 however did not induce a dramatic effect in cells, 
which could be due to the cells opting for other ways to sustain proliferation and 
survival in cells. 
5.8.3 Significantly regulated genes in 3D and comparison to 2D 
Initial experiments were conducted with other significantly regulated genes from the 
RNA-Seq data. PIWIL1 was downregulated the most in drug-resistant monoculture 
and also among the most significantly downregulated genes in co-culture cells. It is 
an important member of the Argonaute protein family, and contains evolutionarily 
conserved PAZ and Piwi motifs that play crucial roles in stem cell proliferation, 
embryogenesis, growth and development, as well as differentiation an maturation 
and RNA silencing in multiple organisms (Cox et al., 1998; Liu et al., 2010). 
Importantly, it may play a role as an intrinsic regulator of the self-renewal capacity of 
germline and haematopoietic stem cells. It is not clear if PIWIL1 overexpression was 
efficient in drug-resistant SNU-16 cells as no antibody against PIWIL1 was available, 
however transfection of SNU-16BGJR cells with the plasmid containing PIWIL1 and 
therefore bringing PIWIL1 back into cells, reduced cell numbers and therefore growth 
in resistant cells. This however needs to be further investigated by possibly also 
knocking PIWIL1 down in parental cells. 
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First experiments were also performed with REG1A, which was together with REG1B 
the most upregulated genes in the co-culture condition and was specific for resistant 
cells with stromal support. REG1A belongs to the calcium-dependent lectin 
superfamily and encodes five small proteins, secreted by the exocrine pancreas, 
including REG1A and B. They play important roles in tissue regeneration and in cell 
proliferation in tumours originating from epithelium and in the mucous of the 
gastrointestinal tract (Miyaoka et al., 2004; Unno et al., 1992). REG1A downregulation 
in SNU-16BGJR and HFF2 cells did seem to reduce cell numbers, with some of the 
shRNAs used. However with others, an increase in cell numbers was observed. 
Furthermore, knock-down of REG1A in cells could not be confirmed by Western 
blotting, as the bands and the expected size were not found but at a different size. 
This could be due to the antibody not being specific enough and therefore 
downregulation could be tested rather with PCR than Western blotting.  
Interestingly, PHLDA1 expression in 2D differed greatly from PHLDA1 expression 
in 3D. PHLDA1 was identified in drug-resistant endometrial cancer in a microarray, 
which was however performed in 2D. These experiments, together with the qPCR 
data highlight the importance to differentiate between 2D versus 3D cell culture. 
Furthermore, this could indicate that PHLDA1 has another function in gastric cancer 
cells than in endometrial cells. Originally, PHLDA1 was identified as a pro-apoptotic 
protein associated with T-cell receptor activation-induced apoptosis (Frank et al., 
1999; Park et al., 1996). In endometrial cancer cells, PHLDA1 downregulation resulted 
in resistance by AKT recruitment to free PIP3 sites to maintain cell proliferation and 
survival upon kinase inhibitor treatment (Fearon et al., 2018). In addition to its 
function to induce apoptosis, PHLDA1 has also shown to harbour anti-apoptotic 
properties through insulin-like growth factor 1 (IGF-1) signalling, together with the 
p38 MAPK pathway in NIH-3T3 cells, and via the PI3K pathway in normal skin 
fibroblasts (Toyoshima et al., 2004; S. Wu et al., 2010). It was shown that PHLDA1 
downregulation through shRNA increases apoptosis. PHLDA1 was also found to be 
upregulated in colon cancer and in human intestinal adenoma and carcinoma and 
PHLDA1 knockdown inhibited cell migration (Sakthianandeswaren et al., 2011). Also 
high PHLDA1 expression has been associated with high metastatic potential (Ren et 
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al., 2015). This suggests that PHLDA1 is tissue-specific and possibly has different 
roles in different cancers and also in 2D and 3D. 
Furthermore, expression levels of other regulated genes were compared and it was 
shown that a number of genes such as SI and PIWIL1 were in fact downregulated or 
upregulated in drug-resistant SNU-16 cells generated in 2D as opposed to drug-
resistant cancer cells generated in 3D. SI was significantly downregulated in drug-
resistant SNU-16 cells, whereas PIWIL1 was upregulated, however not significantly. 
REG1A gene expression was upregulated in monoculture in 2D and 3D and also co-
culture in 3D. This suggests that the effects of glucose and sucrose on drug-resistant 
and parental SNU-16 cells were rather through an SI-independent manner. These 
findings further highlight the difference in cell signalling between 2D and 3D cell 
culture and underline the importance to study cancer signalling in 3D.  
5.8.4 Comparison to other datasets 
The discovery of novel gene/protein targets, but also targetable pathways, is of 
utmost importance and finding similarities between different cancers can be highly 
interesting and useful in helping to understand cancer mechanisms such as drug 
resistance. To compare gene signature to FGFR2-amplified drug-resistant SNU-16 
cells, three different datasets were used including drug-resistant FGFR2-mutant MFE-
296, RT112 with FGFR3 fusion genes and FGFR1-amplified DMS114 cells. PD and 
AZD-resistant MFE-296 cells were generated previously in the group and a 
microarray was conducted (Fearon et al., 2018). RT112 and DMS114 were both 
rendered resistant to BGJ and RNA-Seq was performed (Datta et al., 2017) as was 
done for SNU-16 cells. In BGJ-resistant RT112 and DMS114, drug resistance is 
induced in an AKT-dependent manner. When comparing the different gene 
signatures, no genes were shared between all four datasets, however DUSP6 was 
found downregulated in drug-resistant MFE-296, SNU-16 and RT112 cells and 
epithelial membrane protein 1 (EMP1) in MFE-296, SNU-16 and DMS114 cells. DUSP6 
is a negative regulator of the ERK signalling cascade (Li et al., 2007). Generally, DUSPs 
are stress-induced negative feedback regulators of MAPK and have been found to be 
important for the maintenance of cellular homeostasis in response to growth factors. 
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Loss of DUSP6 through hypermethylation of its promoter in pancreatic cancer leads 
to a more aggressive and invasive phenotype (Furukawa, 2007; Furukawa et al., 2005, 
2003). In lung cancer, DUSP6 could be a growth suppressor whose down-regulation 
is involved in the progression process of lung cancers (Okudela et al., 2009). EMP1 is 
associated to tumour metastasis and low EMP1 expression has been associated with 
increased disease severity (Sun et al., 2014). From this it can be concluded, that gene 
signatures are relatively distinct and potentially tissue-specific. Comparison of 
different datasets however, can draw attention to further interesting targets that 
could play a role in cancer tissues treated with similar drugs or similar origin. 
5.8.5 Conclusion 
In this chapter, the importance of 3D assays was highlighted and drawing conclusions 
from 2D data to the in vivo state should be done with caution. The importance of 
glucose for resistance in gastric cancer cells has been validated, however it appeared 
to be SI-independent in cells from 2D experiments. This could however be different 
in cells grown in 3D. ALDOB blockade affected cell numbers in drug-resistant cells 
and potentially slows proliferation of cells, however if ALDOB upregulation induces 
resistance or if it is through a combination of several pathways needs to be further 
elucidated. 
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6.1 Overview 
Cancer is becoming increasingly prevalent in the world despite attempts in 
decreasing mortality rates and it is estimated that cancer cases per year will rise to 
over 20 million by 2025 (Bray and Soerjomataram, 2015). Both lung and gastric cancer 
are considered two of the major causes for all cancer-related deaths worldwide (Siegel 
et al., 2012; Torre et al., 2015), whilst endometrial cancer is the main gynaecological 
cancer type affecting women (Plagens-Rotman et al., 2016). Due to the incidence and 
importance of these cancers, it is essential to study the different forms of the disease 
in order to identify them sooner and find successful treatment options for patients 
suffering from these types of cancers. Cancers can be driven by genetic alterations 
such as aberrations along the FGF signalling pathway and most commonly affecting 
the FGF receptor. In gastric cancer, up to 10% and in lung cancer up to 16% of patients 
were found to harbour FGFR2 amplifications, while 12% of endometrial cancer 
patients showed FGFR2 mutations. FGFs together with their receptors mediate a 
myriad of cellular processes ranging from embryonic development to differentiation 
and proliferation (Böttcher and Niehrs, 2005; Feldman et al., 1995; Ghabrial et al., 
2003; Polanska et al., 2009; Yamanaka et al., 2010). It is evident, that this pathway with 
its receptors is often hijacked by cancer cells in order to drive their own proliferation 
and tumour progression (Tanner and Grose, 2016). Major advances in cancer therapy 
have led to the invention of small molecule inhibitors that are more effective targeted 
drug treatments of cancers with specific alterations, which have been applied in a 
number of different RTK-driven cancers (Byron et al., 2008; Carter et al., 2015). 
Numerous small molecule inhibitors have shown success in clinical trials (Gavine et 
al., 2012; Kelly et al., 2018, Pal et al., 2018). One of the main pitfalls however, is the 
emergence of resistance towards such RTK inhibitors, which presents a major obstacle 
in successful therapy (Holohan et al., 2013). Signalling alterations induced by the 
treatment of cancers with small molecule inhibitors often results in compensatory 
signalling (Holohan et al., 2013). Hence, the effect of such treatments has to be closely 
studied and monitored and novel approaches have to be applied, which takes into 
account the alterations acquired upon RTK inhibitor treatment.  
  
 
6.2 FGFR inhibition and generation of drug-resistant cancer cells in 
2D 
In this work, one of the main focuses was investigating FGFR-driven gastric cancers. 
From a panel of gastric cancer cell lines, SNU-16 was chosen as it harbours high levels 
of FGFR2 amplifications and exhibited sensitivity towards FGFR inhibitors. By 
gradually increasing FGFR inhibitor concentration over time, SNU-16 cells could be 
rendered resistant to the FGFR inhibitor BGJ. Parental SNU-16 cells were highly 
sensitive to PD, AZD and BGJ compared to SNU-1 cells, which do not harbour any 
FGFR2 amplifications. SNU-1 and BGJ-resistant SNU-16 cells showed similar cell 
viability profiles and protein expression. BGJ-resistant cells also showed cross-
resistance towards other FGFR kinase inhibitors such as PD and AZD, as shown with 
p-ERK expression levels at similar levels as vehicle-treated cells. 
Receptor aberrations are associated with sensitivity towards kinase inhibitors, 
presenting a viable therapeutic target, which could reveal cancers that could be 
treated with small kinase inhibitors (Brooks et al., 2012; Dieci et al., 2013), however 
over prolonged treatment such cancers can acquire resistance. 
6.3 3D cell modelling and differential gene expression analysis 
6.3.1 3D Alvetex® model 
Success rates in clinical trials are relatively low, with more than half of all drug trials 
failing in phase II and III due to a lack of efficacy. A third of all studies then further 
fail due to safety concerns (Arrowsmith and Miller, 2013). Therefore, it is essential to 
investigate drug resistance in vitro prior to entering clinical trials. Although 2D 
studies can give valuable initial insights in cancer drug resistance, studying drug 
resistance in cancers using a 3D setting will present more physiomimetic results and 
insights (Pampaloni et al., 2007; Ravi et al., 2015). 3D modelling is an accepted tool to 
perform more in vivo-like experiments to address all different kinds of scientific 
questions, including drug resistance in cancers. Cells grown in 3D structures not only 
recapitulate their in vivo morphology, but also show more representative function, 
invasion and protein and gene expression as compared to growing cells in traditional 
2D models (Baker and Chen, 2012; Chen et al., 1997; Haycock, 2011). Thus, it is of 
  
 
utmost importance to establish an in vitro 3D assay that provides a physiomimetic 
microenvironment to monitor and recapitulate the tumour-stromal interactions. In 
order to investigate drug resistance, including cancer signalling in a 3D model, it is 
important to choose a model where there is no foreign influence that could induce 
signalling artefact. Organotypic cultures, such as those used in the study of breast and 
pancreatic cancers (Chioni and Grose, 2012, Coleman et al., 2014), provide a tool 
capable of assessing the effects of small molecule inhibition in the context of a 3D 
environment, comprising an ECM-like stromal cell-containing component, however 
as these cultures comprise of collagen and Matrigel™, this could alter signalling due 
to animal protein influences and batch to batch variations. In order to study drug 
resistance in gastric cancer, I developed a novel 3D model using Alvetex® scaffold 
inserts. One of the great advantages this model has over the organotypic cultures, is 
the absence of foreign material, and however as it is a scaffold structure many cells 
fall through the pores, which could be optimised with different pore sizes or other 
coating methods which enhance attachment. In this project, Alvetex® scaffolds have 
proven to be valuable tools in order to study cancer resistance in 3D and different 
cancer cell types were grown successfully in the scaffolds also in conjunction with 
other cell types such as fibroblasts. I showed that drug-sensitive gastric cancer cells 
could be rendered resistant in 3D and cancer cells cultured in tandem with fibroblast 
cells acquired resistance faster than cancer cells alone. This could indicate that 
fibroblast cells support and promote cancer cells by providing essential growth 
factors. In a similar study involving lung cancer, it has been found that CAFs aid 
resistance in lung cancer by secreting proteins that allow the cancer cells to evade 
apoptosis and therefore become resistant to EGFR inhibitors (Choe et al., 2015). 
Several studies also discuss the microenvironment as a protective niche for cancers 
that enables cells to escape the effects of chemotherapy or radiation (Olson and Joyce, 
2013; Sung et al., 2007). 
Fibroblasts play a major role in tissue repair and the similarity between wound 
healing and tumour development have been long recognised (Dvorak, 1986). The 
function of fibroblasts can however change dramatically upon oncogenic 
transformation and are associated with hallmarks of cancer discussed by Hanahan 
  
 
and Weinberg (Hanahan and Weinberg, 2000). In prostate and pancreatic cancers, 
high abundance of fibroblasts in tumours has been associated with an increase in 
ECM or remodelling of the ECM architecture such as rendering the matrix more rigid 
and therefore creating a barrier preventing drug dissemination (Feig et al., 2012; 
Neesse et al., 2011). Potentially, HFF2 cells protected SNU-16 cells from cytotoxic 
effects of BGJ, by secreting ECM proteins therefore creating a niche for cancer cells to 
reside and proliferate (Olive et al., 2009). 
The Alvetex® 3D model proved highly suitable to study drug resistance in 3D with 
co-cultures as cells could be grown in scaffolds without influence from other material 
that could overshadow cell signalling. In addition to this, growing cells over longer 
periods is one of the great advantages of this model. Ideally, the effects of 
tumourigenic mutations would be compared to non-malignant cells arising from the 
same tissue of origin. However, it is extremely difficult to obtain such gastric stromal 
cells commercially and cells would have to be immortalised in order to use in a 3D 
model. The use of these cells would further improve the model and provide an even 
more physiomimetic assay to study drug resistance and paracrine signalling between 
cancer cells and fibroblasts in gastric cancer. 
To visualise the cells in the scaffold and distinguish between the different cell types, 
cultures were transduced with lentiviral constructs containing fluorescent markers. 
For RNA-sequencing, RNA from co-culture cells was run combined. Ideally, cancer 
cells could have been separated from stromal cells by cell sorting with the help of 
fluorescent markers. Therefore, the influence of stromal cells on cancer cells could be 
analysed without the gene signature of HFF2 cells in the dataset that complicates the 
distinction between effects of cancer or stromal cells. Also, a condition with 
fibroblasts only could have given greater insights and could have allowed 
distinguishing which gene regulations were driven by fibroblasts. Nevertheless, cell 
sorting imposes a great amount of cellular stress onto cells, which could alter cell 
signalling and therefore was decided against. In the future, a variety of different cell 
types could be included such as immune cells and thus more complex 3D cell culture 
models could be built to attempt to move even closer to the in vivo state. 
  
 
6.3.2 Dissection of drug resistance mechanisms in 3D using RNA-Seq 
After establishing that SNU-16 cells acquire resistance to FGFR inhibitors also in 3D, 
RNA-Seq was used to gain insight into the differences in the transcriptomes of 
parental and resistant cells in a global, unbiased manner across all different 
conditions and changes in cell signalling. Transcriptomic analysis of drug-resistant 
SNU-16 cells and SNU-16 together with HFF2, showed a distinct gene expression 
signature common to drug resistant cells, compared to their parental counterparts. 
The assessment of these differences led to investigations of the potential mechanism 
underlying the resistance to FGFR inhibition. The main focus was on investigating 
the difference in cell signalling between gastric cancer cells with and without stromal 
support, which resulted in interesting observations including upregulation of 
metabolic pathways. The majority of targets that were found to positively drive drug 
resistance in cancer cells alone were involved in metabolic processes and pathway 
analysis revealed that most upregulated pathways have a metabolic function. 
Metabolomics analysis in addition to RNA-Seq would allow further valuable insights 
in measuring enriched metabolites stimulated by drug resistance. Serum metabolic 
profiling has been used previously to identify metabolic mechanisms in gastric cancer 
(Song et al., 2012). With the identified metabolites, alterations in glycolysis, amino 
and fatty acid, cholesterol, and nucleotide metabolism in gastric cancer patients could 
be determined. Thus, this method in conjunction with RNA-Seq could allow insights 
into metabolic drug resistance mechanisms. 
Another interesting aspect from the dataset was the upregulation of a number of 
genes involved in collagen formation in co-culture cells, which reflects the influence 
of fibroblasts. The resulting effect of the upregulation could be increased ECM 
proteins and therefore a more rigid and stiffer matrix, preventing diffusion of 
inhibitors to reach cells, especially cancer stem cells (Erler et al., 2009; Schrader et al., 
2011; Tilghman et al., 2010; Weigelt et al., 2014).  
  
  
 
When measuring gene expression levels and protein expression using drug-resistant 
cells generated in 2D, gene expression often conflicted with data from 3D. This 
suggests that assumptions cannot be drawn from 2D to 3D or in vivo conditions as 
this can result in highly distinct outcomes. Ideally gene expression analysis would 
also be performed in human gastric cancer tissue treated with kinase inhibitors. 
The datasets were also compared to other datasets that were generated previously in 
our group or found in published datasets. Comparison of available datasets in respect 
to similarities and differences will give valuable insights in the cancer type or drug 
investigated and the emergence of resistance.  
6.4 Target validation 
What was immediately evident was the involvement of metabolic mechanisms in 
drug-resistant cancer cells. A number of metabolic pathways were found to be 
upregulated, most notably the retinol and sucrose degradation pathways. Retinoic 
acid has already been widely used in the clinic due to its importance in a vast number 
of biological processes such as development, differentiation, proliferation, and 
apoptosis (Fanjul et al., 1994; Voigt and Zintl, 2003). Retinoids have been found to 
suppress carcinogenesis and cells were found to reduce retinol signalling in order to 
advance carcinogenesis together with a loss of RARβ expression (Widschwendter et 
al., 1997). On the other hand RA signalling was involved in malignant transformation 
(Bukhari et al., 2007; Pisano et al., 2007; Shah et al., 2001; Wang et al., 2009). Also, in 
an ErbB2-induced mammary tumourigenesis model, RARβ expressed by stromal 
cells was essential for tumourigenesis (Liu et al., 2011). As ATRA did not influence 
cell death in drug-resistant cells, it was hypothesised that upregulation of the retinol 
pathway is connected to RA elimination. The effect of retinol addition to SNU-16 and 
SNU-16BGJR cells therefore needs to be further elucidated and, especially, also the 
expression of retinoic acid receptors such as RARβ, which could give more insights 
in the role of retinol signalling in drug resistance. Additionally, RA receptors could 
be inhibited with shRNAs to investigate the effect on cancer cells and treatment with 
a FGFR inhibitor could potentiate the effect. 
  
 
The sucrose degradation pathway belongs to metabolic pathways as well and glucose 
has been found to fuel carcinogenesis by providing increased energy in the form of 
ATP (Hsu and Sabatini, 2008). Altering sucrose concentrations has shown initial 
interesting data and could display a potential mechanism to influence cancer 
proliferation and survival. It has to be further elucidated what role SI plays, or if the 
effects are independent of SI and ALDOB. Acarbose is used to treat diabetic patients 
by blocking alpha glucosidase, which is an enzyme needed to digest carbohydrates 
(Campbell et al., 1996). Treatment of cells with acarbose, did not show dramatic 
effects and therefore it is hypothesised that the effect is SI-independent. Notably, 
upregulation of the sucrose degradation pathway and upregulation of SI could not 
only be associated with glucose generation, it could also allow cells to generate 
intermediates in glycolysis such as NADPH, or making ribose, serine or glycine 
(Israelsen et al., 2013). However, treatment of cells with TDZD-8, which arrests the 
pathway in the F-1-P state, was associated with a reduction in drug-resistant cell 
number, without increasing cell death, indicating that TDZD-8 slows down cell 
proliferation. TDZD-8 together with an FGFR inhibitor could therefore block cell 
proliferation effectively. It would also be valuable to study further regulated 
pathways from the dataset such as the fatty acid pathway. However, when 
investigating the different regulated pathways, it is clear that they are interconnected 
and this could therefore indicate that multiple pathways should be targeted, to 
overcome redundancy. 
Initial experiments with REG1A and PIWIL1 were promising and need further 
investigation. PIWIL1 overexpression did show a reduction in cell numbers in drug-
resistant cells. In addition, PIWIL1 knockdown in parental SNU-16 cells could 
potentially render cells resistant to FGFR inhibitors. The implications of REG1A 
knockdown in co-culture are less evident. It can be assumed that REG1A knockdown 
reduces cell numbers but further experiments are needed to identify if REG1A is 
important in stromal or cancer cells.  
Analysis of RNA-Seq data of gastric FGFRi-resistant cells grown in 3D and target 
validation has led in different directions. Few of the traditional FGFR targets have 
  
 
been identified and potentially there are indirect mechanisms driving drug resistance 
in these cancers rather than directly through reactivation of FGF signalling. A number 
of genes, such as upregulation of CYP and UGT, and thus upregulation of cytochrome 
P450 and upregulation of the retinol pathway and downregulation of oxidative 
phosphorylation, were identified that are connected to drug resistance in cancers in 
general to protect them from cellular damage and to promote drug detoxification. The 
switch in metabolic activity by upregulation of SI and ALDOB and pathways 
associated with glucose generation, such as sucrose and starch degeneration, 
glycolysis I and fatty acid biosynthesis pathways, might be an indirect resistance 
mechanism, independent from FGF signalling and merely a way to cope with limited 
nutrition or building block availability and protection of cells from oxidative stress. 
From Ingenuity pathway analysis, signalling through FGFs was downregulated in 
drug-resistant cells grown in 3D. Cells potentially bypassed dependency on FGF 
signalling by co-opting other kinases such as Met, through upregulation of HGF. 
Downstream of FGF signalling, PI3K/AKT signalling was upregulated, as observed 
with other FGFR-driven cancer types following use of FGFR inhibitors previously 
(Baselga et al., 2012; Hu et al., 2014; Datta et al., 2017). The PI3K/AKT pathway is an 
essential pathway in regulating cell behaviour. In FGFR2-amplified gastric cancer 
cells glucose metabolism was elevated, possibly increasing production of insulin and 
IGF, which in turn activate the PI3K/AKT pathway (Manning and Toker, 2017). This 
effect could also be separate from glucose concentration in cells through amplification 
induced, ligand-independent, activation of FGF signalling and thus activation of 
downstream PI3K/AKT signalling. Further downstream, this could result activation 
of CREB or mTOR signalling, thus stimulating cell growth and proliferation. 
Targeting a combination of the pathways discussed, such as those associated with 
glucose generation and the PI3K pathway, to inhibit glycolysis, gluconeogenesis and 
proliferation, could therefore potentially resensitise FGFRi-drug-resistant cells. Thus, 
through improved understanding of the diversity of resistance pathways in cells, 
independent of the initial oncogenic driver, we can try to exploit novel therapies to 
target drug resistant cancers.  
  
 
6.5 Concluding remarks 
Using a novel defined 3D model system and RNA-Seq in combination with 
biochemical methods and microscopy, differential signalling in FGFR2-driven gastric 
cancer cells has been elucidated, in a more physiological manner. RNA-Seq proved 
to be a powerful tool to assess differential gene expression. Potential pathways and 
genes have been analysed and several possible mechanisms postulated how gastric 
cancer cells acquire drug resistance in 3D. 
From differential genes expression and pathway analysis, it can be concluded that a 
multitude of mechanisms play a role in drug resistance. Metabolic pathways play a 
substantial role, such as energy production and cytoprotective mechanisms. Whether 
this phenomenon is specific to gastric cancer or could be applied to other cancer types 
needs to be further elucidated and was partially studied using FGFR-altered 
endometrial and lung cancer cell lines. Differential gene expression comparisons 
across datasets from the GEO database and from data generated in the group have 
been performed. This needs to be extended to further data that are available, to 
identify patterns and reveal similarities and differences.  
Further investigations using Alvetex® and comparing to expression in 2D and also in 
vivo would provide essential information, allowing comparison between them to 
delineate similarities and differences to generate a more predictable 3D model. 
Furthermore, additional cell types could be included such as immune cells to generate 
a model that resembles the in vivo state even more closely. Manipulation of altered 
pathways in drug-resistant cells should be also performed in Alvetex®, as differential 
gene expression analysis was performed with cells grown in 3D. Combination 
treatments could be the way forward and in recent years a number of combination 
trials are underway (Bayat Mokhtari et al., 2017; Chao et al., 2018; Kelly et al., 2018; Li 
et al., 2012; Mahipal et al., 2018; Sun et al., 2016). 
A substantial proportion of patients do not respond to the targeted therapies that are 
currently available, which requires better patient selection and personalised targeted 
therapy. However, no clinically validated and robust biomarkers exist as of now to 
  
 
select suitable patients for targeted therapy. Therefore the use of combination 
therapies could aid enhancing the effect of targeted therapies by not only targeting 
FGF signalling but also other aspects of tumourigenesis such as inhibiting 
angiogenesis, blocking immune evasion and enhancing anti-tumour immunity 
(Katoh, 2016). About 40% of combination trials involve programmed death (PD)-1 
and Pembrolizumab (Keytruda) targeting immune checkpoints (Harris et al., 2016). 
Immune checkpoints such as PD-1 and cytotoxic T lymphocyte antigen (CTLA)-4 
were shown to be effective targets in cancer therapy (Chang et al., 2018; Pardoll, 2012; 
Robert et al., 2014; Topalian, 2017; Topalian et al., 2012). Immune checkpoint 
inhibitors such as Pembrolizumab are monoclonal antibodies that block the PD-1 
receptor located on lymphocytes and inhibit interaction with its ligands PD-L1 and 
PD-L2. This then results in the activation of T-cell mediated immune responses 
towards cancer cells (McDermott and Jimeno, 2015; Raedler, 2015). However, long 
term data are still awaited to confirm the benefits of combinatorial use of drugs 
targeting different pathways. Investigations into neuroblastoma and glioma, amongst 
others, suggest the use of MK2206 (an AKT inhibitor) together with other small 
molecule inhibitors and chemotherapeutics, indicating an advantage in causing 
cancer cell death (Agarwal et al., 2013; Cheng et al., 2012; Li et al., 2012). The use of 
multiple small molecule compounds targeting specific oncogenic pathways, together 
with checkpoint inhibitors to re-awaken the immune response could represent a 
viable method to overcome drug resistance in FGFR-driven cancers.  
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8.1 Appendix Chapter III Results Part I 
 
 
 
Appendix Figure 8.1. FGFR2-amplified gastric cancer cell line SNU-16 treated with AZD. 
SNU-16 cells were seeded into 96-well plates and treated with increasing dosages of AZD ranging from 
0.006nM to 50µM and control cells were treated with DMSO and as a background control 1% 
Staurosporine was added to wells containing cells. After 72h incubation, MTS reagent was added and 
cell viability was measured colorimetrically after 2h. An average of three biological MTS experiments in 
technical triplicate is shown with error bars indicating SEM. Log IC50 and IC50 values were calculated 
with GraphPad Prism 5. 
 
 
 
 
Appendix Figure 8.2. Dose response curves of further gastric cancer cell lines treated with BGJ. 
Gastric cancer cell lines were seeded into 96-well plates and exposed to increasing dosages of BGJ 
ranging from 0.006nM to 50µM and control cells were treated with DMSO and as a background control 
1% Staurosporine was added to wells containing cells. After 72h incubation, MTS reagent was added 
and cell viability was measured colorimetrically after 2h. An average of three biological MTT and MTS 
experiments in technical triplicate is shown with error bars indicating SEM. Log IC50 and IC50 values 
were calculated with GraphPad Prism 5. 
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Appendix Figure 8.3. Cell survival of lung cancer cell lines upon FGFR inhibition with AZD or BGJ. 
Lung cancer cell lines H520 (FGFR1-amplified) and A549 (FGFR1-wt) were seeded into 96-well plates 
and treated with increasing dosages of AZD or BGJ ranging from 0.006nM to 50µM and control cells 
were treated with DMSO and as a background control 1% Staurosporine was added to wells containing 
cells. After 72h incubation, MTS reagent was added and cell viability was measured colorimetrically 
after 2h. An average of three biological MTS experiments in technical triplicate is shown with error bars 
indicating SEM. Log IC50 and IC50 values were calculated with GraphPad Prism 5. 
 
 
 
Appendix Figure 8.4. Comparison of lung cancer cell lines and lung fibroblasts. 
Additional replicates of cells seeded into 6-well plates and harvested the next day and subjected to 
Western blot analysis. 1: H520, 2: H1299, 3: A549, 4: MRC-5. H520 cells harbour FGFR1-amplifications as 
shown with the increased FGFR1 expression as compared to other cell lines with wildtype receptor 
expression. HSC70 and GAPDH served as internal controls. 
 
 
Appendix Figure 8.5. Drug treatments of SNU-16 cells. 
Additional replicates of SNU-16 cells treated with increasing concentrations of BGJ. Cells were seeded 
into 6-well plates and treated with 500nM, 1 or 5µM BGJ. After 72h incubation, cells were harvested and 
protein was extracted and probed for p-ERK and as an internal control for t-ERK. 
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Appendix Figure 8.6. FGFR1-amplified lung cancer cells treated with FGFR inhibitors. 
Additional replicates of FGFR1-amplified lung cancer cells H520 that were seeded into 6-well plates and 
treated with vehicle or 1µM PD, AZD or 1.5µM BGJ. After 72h, protein was extracted and signalling 
analysed with Western blot probing for p-AKT, t-AKT, p-ERK, t-ERK and HSC70 as a control. 
 
 
.  
 
Appendix Figure 8.7. FGFR1 wildtype lung cancer cells treated with FGFR inhibitors. 
Additional replicate of FGFR1-wt lung cancer cells H1299 that were seeded into 6-well plates and treated 
with vehicle or 1µM PD, AZD or 1.5µM BGJ. After 72h, protein was extracted and signalling analysed 
with Western blot probing for p-AKT, t-AKT, p-ERK, t-ERK and HSC70 as a control. 
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Appendix Figure 8.8. Protein expression levels of MRC-5 cells treated with FGFR inhibitors. 
Additional replicates of MRC-5 cells were seeded into 6-well plates and treated with 1µM AZD or PD 
or 1.5µM BGJ vehicle for 72h. Protein was extracted and Western blot analysis was performed probing 
for p-AKT, t-AKT, p-ERK, t-ERK and loading control HSC70. 
 
 
 
 
Appendix Figure 8.9. Cell survival of HFF2 cells upon FGFR inhibition with AZD. 
HFF2 cells were seeded into 96-well plates and treated with increasing dosages of AZD ranging from 
0.006nM to 50µM and control cells were treated with DMSO and as a background control 1% 
Staurosporine was added to wells containing cells. After 72h incubation, MTT was added to the medium 
and cell viability was measured colorimetrically after 2h. An average of three biological MTT 
experiments in technical triplicate is shown with error bars indicating SEM. Log IC50 and IC50 values 
were calculated with GraphPad Prism 5. 
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Appendix Figure 8.10. Protein expression levels of HFF2 cells treated with AZD. 
HFF2 cells were seeded into 6-well plates and treated with 1µM AZD or vehicle for 72h. Protein was 
extracted and Western blot analysis was performed probing for p-AKT, t-AKT, p-ERK, t-ERK and 
loading controls GAPDH and HSC70. The blots represent three biological replicates. 
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Appendix Figure 8.11. Comparison of cell survival of gastric, endometrial and lung cancer cells grown 
with and without stromal support and either in 2D or 3D. 
Cells were seeded into 96-well plates and treated with increasing dosages of AZD or BGJ ranging from 
0.006nM to 50µM and control cells were treated with DMSO and as a background control 1% 
Staurosporine was added to wells containing cells. After 72h incubation, MTS reagent was added and 
cell viability was measured colorimetrically after 2h. An average of three biological MTS experiments in 
technical triplicate is shown with error bars indicating SEM. Cell survival of gastric cancer cells SNU-16 
(A) were compared to SNU-16 cells co-cultured with HFF2 cells (i) and to SNU-16 cells grown in 3D in 
Alvetex® 96-well plates (ii). Cell survival of lung cancer cells H520 (A) were compared to H520cells co-
cultured with MRC-5 cells (i) and to H520 cells grown in 3D in Alvetex® 96-well plates (ii). Cell survival 
of co-cultured MFE-296 cells with HFF2 cells in 2D and 3D was compared (C). 
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Appendix Figure 8.12. Cell confluence and area measured with IncuCyte™ ZOOM®. 
H520 cells were grown alone (A) or in co-culture with MRC-5 fibroblasts (B) and imaged with 
IncuCyte™ ZOOM®. Comparison of cell confluence and average area of H520 cells alone, and H520 
grown with MRC-5 cells (C). Bright-field and fluorescence microscopy of co-cultured H520 and HFF2 
cells (D). 
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Appendix Figure 8.13. H&E staining of an uncoated 12 well insert Alvetex® Strata scaffold.  
MFE-296 cells were seeded into a 12-well Alvetex® Strata insert and grown for one week. The whole 
scaffold scale bar indicates 2000μm and magnification scale bar indicates 100μm. 
 
 
 
 
Appendix Figure 8.14. SNU-16 cells co-cultured with HFF2 cells in Alvetex® and treated with BGJ. 
Additional replicate of H&E staining of SNU-16 cells co-cultured with HFF2 cells in Alvetex® scaffolds. 
The whole scaffold scale bar indicates 2000µm and the magnified image scale bar 100µm. 
 
 
 
Appendix Figure 8.15. Fibroblasts cultured in Alvetex® and treated with BGJ. 
Additional replicate of H&E staining of HFF2 cells in Alvetex® scaffolds. The whole scaffold scale bar 
indicates 2000µm and the magnified image scale bar 100µm. 
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Appendix Figure 8.16. SNU-16 morphology or untreated and fluorescently-tagged SNU-16 cells using 
H2B-RFP. 
SNU-16 cells were transduced with lentiviral particles containing an H2B-RFP tag and imaged with 
phase and fluorescence microscopy. The scale bar indicates 25µm. 
 
 
 
 
 
Appendix Figure 8.17. Cell sorting of H2B-positive SNU-16 cells. 
H2B-RFP transduced SNU-16 cells were grown for 8 passages followed by cell sorting using FACS. P1 
displays the selection of live cells and P2 and P3 were used to discriminate cell doublets. Then H2B-RFP 
positive cells were selected using channel YG610/20-A to detect RFP signal.  
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Cell morphology and fluorescence 
 
Appendix Figure 8.18. Fluorescent cells used in this thesis. 
Cells were transduced with lentiviral supernatant containing the plasmid with the fluorescent markers (see section 2.2.17). For SNU-16 and H520 H2B-RFP and for MRC-5 H2B-
GFP was used. For HFF2 cells, EGFP was used to generate fluorescent cells. 
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Appendix Figure 8.19. Co-culturing of SNU-16-H2B-RFP and HFF2-EGFP cells in Alvetex®. 
SNU-16 and HFF2 cells were seeded into 12-well Alvetex® scaffold inserts either 1:1, 1:2 or 2:1 and 
grown for one week, followed by microscopic image acquisition and 3D image rendering with Imaris 
(A). The scale bar indicates 100µm. Simultaneouly, scaffolds were also fixed, paraffin-embedded and 
H&E stained (B). The whole scaffold scale bar indicates 2000µm and the the scale bar in the enlarged 
image indicates 100µm. 
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8.2 Appendix Chapter IV Results Part II 
 
 
Appendix Figure 8.20. Morphology of parental SNU-16 and SNU-16BGJR cells grown in 2D. 
Bright-field acquisition of SNU-16 parental and SNU-16BGJR cells. The scale bar indicates 25µm. 
 
 
 
Appendix Figure 8.21. SNU-16BGJR treated with AZD. 
SNU-16BGJR cells were seeded into 96-well plates and treated with increasing dosages of AZD ranging 
from 0.006nM to 50µM and control cells were treated with DMSO and as a background control 1% 
Staurosporine was added to wells containing cells. After 72h incubation, MTS reagent was added and 
cell viability was measured colorimetrically after 2h. An average of three biological MTS experiments in 
technical triplicate is shown with error bars indicating SEM. Log IC50 and IC50 values were calculated 
with GraphPad Prism 5. 
 
 
 
Appendix Figure 8.22. Removing drug from drug-resistant SNU-16 cells suggests cross-talk between 
ERK and AKT. 
Additional replicate of SNU-16BGJR cells were seeded into 6-well plates and drug was removed and cells 
were harvested after 1, 2, 4, 8, 16 and 24h. As a control cells were kept in medium containing BGJ. Protein 
was extracted and Western blot analysis was performed probing for p-AKT, t-AKT, p-ERK, and t-ERK. 
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Appendix Figure 8.23. SNU-16BGJR cells alone in Alvetex grown for 7 days. 
Additional replicate of drug-resistant SNU-16 cells seeded into a 12-well Alvetex® scaffolds and treated 
with 1.5µM BGJ for one week followed by formalin-fixation, paraffin-embedding and H&E staining. 
Scale bar indicates 1000µm in the left panel and 100µm in the enlarged panel. 
 
 
 
Appendix Figure 8.24. SNU-16BGJR cells alone in Alvetex grown for 7 days. 
Additional replicate of drug-resistant SNU-16 cells seeded into a 12-well Alvetex® scaffolds and treated 
with 1.5µM BGJ for one week followed by formalin-fixation, paraffin-embedding and H&E staining. 
Scale bar indicates 1000µm in the left panel and 100µm in the enlarged panel. 
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Appendix Figure 8.25. BGJ-resistant cells with fibroblasts. 
SNU-16BGJR cells and HFF2 cells were mixed 2:1 and were seeded into 12-well insert Alvetex® scaffolds 
and incubated overnight. The cells were grown in the scaffolds for 1 week. Medium containing 1.5µM 
BGJ was fed from below and exchanged every 2 days. The experiment was performed in triplicate. Scale 
bar indicates 1000µm in the left panel and 100µm in the enlarged panel. 
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Appendix Figure 8.26. Imaris rendered images of 3D resistance assay in Alvetex of week 1. 
The experiment was performed in biological and technical triplicate. Per condition three images were taken using a confocal microscope. Scale bar indicates 100µm. 
 
Appendix Figures and Tables Results Part II 
376 
 
 
 
 
Appendix Figure 8.27. Imaris rendered images of 3D resistance assay in Alvetex of week 2.  
The experiment was performed in biological and technical triplicate. Per condition three images were taken using a confocal microscope. Scale bar indicates 100µm. 
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Appendix Figure 8.28. Imaris rendered images of 3D resistance assay in Alvetex of week 3. 
The experiment was performed in biological and technical triplicate. Per condition three images were taken using a confocal microscope. Scale bar indicates 100µm. 
 
Appendix Figures and Tables Results Part II 
378 
 
 
 
 
Appendix Figure 8.29. Imaris rendered images of 3D resistance assay in Alvetex of week 4. 
The experiment was performed in biological and technical triplicate. Per condition three images were taken using a confocal microscope. Scale bar indicates 100µm. 
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Appendix Figure 8.30. Cell volume measurements of HFF2 cells in co-culture with SNU-16 cells rendered resistant in Alvetex®. 
Volume changes of HFF2 cells grown together in co-culture with SNU-16 cells in Alvetex® were measured over four weeks. 
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Appendix Figure 8.31. Imaris rendered images of 3D resistance assay in Alvetex of week 5, 6, 7 and 8.  
The experiment was performed in biological and technical triplicate. Per condition three images were taken using a confocal microscope. Scale bar indicates 100µm. 
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Appendix Figure 8.32. STRING networks ofSNU-16 (SdvsSb) and Co-culture cells (FdvsFb), 
Significantly regulated genes (Log fold change >2, <-2) were analysed and network interactions displayed. 
Appendix Figures and Tables Results Part II 
382 
 
 
Appendix Figure 8.33. STRING networks.  
STRING networks of top 20 up and downregulated genes in SNU-16BGJR compared to parental SNU-16 and Co-cultureBGJR compared to parental co-culture cells. 
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Appendix Figure 8.34. Top 20 targets upregulated in BGJ-resistant co-culture cells compared to BGJ-
resistant SNU-16 in Alvetex (other comparison).  
Top 20 targets downregulated in BGJ398-resistant co-culture cells compared to BGJ-resistant SNU-16 in 
Alvetex. Among the 2480 genes, 1591 genes were upregulated in SNU16d and 889 genes were 
upregulated in FIBROd. 
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Appendix Figure 8.35. Top 20 target upregulated in SNU-16 gastric cancer cells treated with BGJ over 
8 weeks in Alvetex.  
Top 20 targets Downregulated in SNU-16 gastric cancer cells treated with BGJ over 8 weeks in Alvetex. 
Among the 3413 genes, 2028 genes were upregulated in SNU16b and 1385 genes were upregulated in 
FIBROb. 
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Appendix Figure 8.36. Comparison of all datasets from differential gene expression analysis. 
(A) Comparison of all genes from all datasets that were compared to each other, where 78 genes where 
shared between all datasets. (B) Comparison of all significantly regulated genes from all datasets that 
were compared to each other, where 13 genes where shared between all datasets. SdvsSb = DMSO-
treated SNU-16 cells compared to BGJ-treated SNU-16 cells, SdvsFb = DMSO-treated SNU-16 cells 
compared to BGJ-treated co-culture cells, SbvsFb = BGJ-treated SNU-16 compared to BGJ-treated co-
culture cells, FdvsFb = DMSO-treated co-culture cells compared to BGJ-treated co-culture cells. 
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Appendix Figure 8.37. Spatial information of up- and downregulated genes. 
(A) Location of significantly regulated genes of SNU-16BGJR cells compared to parental cells. (B) Location 
of significantly regulated genes of co-cultureBGJR cells compared to parental cells. Red indicates 
upregulation and green downregulation. The intensity of the colour represents the extent of regulation. 
The shape of the protein depicts the different classes of proteins to which the genes belong. 
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Appendix Figure 8.38. SPIA plot of regulated pathways and differential gene expression analysis. 
Pathway analysis was also performed with Signaling Pathway Impact Analysis (SPIA) using a Bioconductor package in R, showing significantly regulated pathways (p<0.05, red 
line). This method combines the evidence obtained from classical enrichment analysis with a novel type of evidence, which includes the actual perturbation on a given pathway 
under a given condition (Tarca et al., 2009). 
 
 
Appendix Figures and Tables Results Part II 
388 
 
 
 
 
 
 
 
 
Appendix Figure 8.39. Serotonin degradation in SNU-16 and co-culture cells. 
The serotonin pathway is driven by the upregulation of aryl sulfotransferase, amine oxidase, aldehyde 
dehydrogenase and glucuronyltransferase. 
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Appendix Figure 8.40. SI interaction network in SNU-16BGJR cells compared to parental SNU-16 cells. 
From the significantly regulated genes in the gene expression analysis of SNU-16 cells against SNU-16BGJR generated in Alvetex, SI was isolated and an interaction map created 
using IPA. The shape of the protein categorises the gene into functional classes and the strength of the colour indicates up- (red) or downregulation (green). 
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Appendix Figure 8.41. PIWIL1 interaction network in SNU-16BGJR cells compared to parental SNU-16 cells. 
From the significantly regulated genes in the gene expression analysis of SNU-16 cells against SNU-16BGJR generated in Alvetex, PIWIL1 was isolated and an interaction map 
created using IPA. The shape of the protein categorises the gene into functional classes and the strength of the colour indicates up- (red) or downregulation (green). 
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Appendix Figure 8.42. REG1A interaction network in co-culture cells.  
From the significantly regulated genes in the gene expression analysis of SNU-16 cells against SNU-
16BGJR generated in Alvetex, REG1A was isolated and an interaction map created using IPA. The shape 
of the protein categorises the gene into functional classes and the strength of the colour indicates up- 
(red) or downregulation (green). 
 
 
 
 
Appendix Figure 8.43. FGFR1-amplified lung cancer. 
Phase contrast image of H520 cells untreated, with lentiviral transfection and BGJ-resistant H520 cells. 
The scale bar indicates 25µm. 
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Appendix Table 8.1. Count files of RNA-Seq reads mapped to hg38. 
Paired end reads and alignment and percentage of reads for gene quantification. 
FIBROb=Co-culture treated with BGJ, FIBROd=Co-culture treated with DMSO, SNU16b=SNU-16 treated 
with BGJ, SNU16d=SNU-16 treated with DMSO. 
 
 Total number paired end 
reads 
Number of paired-end reads 
uniquely aligned to gene 
features 
Percentage of reads used for 
gene quantification 
FIBRObr1 32249015 24296659 75.34 
FIBRObr2 31648117 20705563 65.42 
FIBRObr3 28494183 18771410 65.88 
FIBROdr1 39770923 26322042 66.18 
FIBROdr2 36439322 23520509 64.55 
FIBROdr3 40377416 26462316 65.54 
SNU16br1 37497647 24093113 64.25 
SNU16br2 36080060 21702294 60.15 
SNU16br3 31914026 21417907 67.11 
SNU16dr1 32216061 21156983 65.67 
SNU16dr2 32371589 22055306 68.13 
SNU16dr3 35026685 23163878 66.13 
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Appendix Table 8.2. Gene names, aliases and function of the top 5 upregulated targets of SNU-16 cells treated with BGJ. 
Gene name Aliases Function 
SI Sucrase isomaltase 
 Expressed in foetal life 
 Glucosidase enzyme (breaking down carbohydrates) ultimately leading to ATP 
 Type II transmembrane glycoprotein (C-term in lumen) 
 Intestinal enzyme located on brush border of small intestine 
 Not expressed in normal gastric mucosa, SI mutations in CLL 
 Colon oncofoetal antigen  enterocytic differentiation 
(Cross and Quaroni, 1991; Ellis et al., 1992; Iannettoni et al., 1996; Lojda and Fric, 1996; Mehdawi et al., 2016) 
ALDOB 
Aldolase, Fructose-
Bisphosphate B 
 Conversion of fructose-1,6-bisphosphate to glyceraldehydes-3-phosphate 
 Plays a key role in both glycolysis and gluconeogenesis. 
(Glucose  pyruvate) 
 Cancer 200 fold glycolytic rates 
(He et al., 2016; Peng et al., 2008; Tao et al., 2015) 
BMX 
Cytoplasmic 
tyrosine-protein 
kinase BMX 
 Non‐receptor tyrosine kinase, which may play a role in the growth and differentiation of hematopoietic cells 
 Transfer a phosphate group from ATP to a protein 
 Induce activation of the Stat signalling pathway 
 Anti-apoptotic downstream effector of PI3K 
(Peng et al., 2016; Potter et al., 2016, 2014; Wei et al., 2017) 
UGT2A3 
UDP 
glucuronosyltransferase 
family 2 member A3 
 Catalyse phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to 
increase water solubility and enhance excretion 
 Elimination of potentially toxic xenobiotics and endogenous compounds 
(Kurita et al., 2017) 
RGS13 Regulator of G-Protein 13 
 Suppresses the immunoglobulin E-mediated allergic responses 
 Accelerate GTPase activity of G protein alpha-subunits, thereby driving G protein into their inactive GDP-bound form, 
thus negatively regulating G protein signalling 
 Nuclear repressor of CREB 
(Han et al., 2006; Sethakorn and Dulin, 2013; Wang et al., 2010; Xie et al., 2008) 
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Appendix Table 8.3. Gene names, aliases and function of the top 5 downregulated targets of SNU-16 cells treated with BGJ. 
Gene name Full name Function 
PIWIL1 
Piwi-like RNA-mediated gene 
silencing 1 
 PIWI subfamily of Argonaute proteins 
 Containing both PAZ and Piwi motifs that play important roles in stem cell self-renewal, RNA silencing, 
and translational regulation in diverse organisms 
 Intrinsic regulator of the self-renewal capacity of germline and hematopoietic stem cells 
(Cao et al., 2016; Chen et al., 2015; Iliev et al., 2016; Van Tongelen et al., 2017) 
H19 
Imprinted maternally expressed 
transcript 
 Long non-coding RNA 
 Role in negative regulation of body weight and cell proliferation 
 Only transcribed from maternally inherited allele 
(Lv et al., 2017; Zhang et al., 2017; Zhao et al., 2017) 
AFP Alpha-fetoprotein 
 Glycoprotein, plasma protein in yolk sac and liver 
 Foetal form of serum albumin 
 Binds copper, nickel, fatty acids, bilirubin 
(D’Ambrosio et al., 2017; Sasaki et al., 2011)  
STARD8 
StAR related lipid transfer domain 
containing 8 
 Rho GTPase-activating protein (GAP) 
 Expression inhibits the growth of human breast and prostate cancer cells in culture 
 Protein is expressed in tissues throughout the body, but is absent or reduced in many kinds of tumour 
cells 
(Braun and Olayioye, 2015; Durkin et al., 2007; Mokarram et al., 2009) 
FGF12 Fibroblast growth factor 12 
 Broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including 
embryonic development, cell growth, morphogenesis, tissue repair, tumour growth, and invasion 
(Volkomorov et al., 2013) 
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Appendix Table 8.4. Gene names, aliases and function of the top 5 upregulated targets of co-culture cells treated with BGJ. 
Gene name Full name Function 
REG1A 
Lithostathine-1-alpha also known as islet cells 
regeneration factor (ICRF) or islet of Langerhans 
regenerating protein (REG) 
 multi protein family grouped into four subclasses, types I, II, III and IV based on the primary 
structures of the proteins 
 secreted by exocrine pancreas 
 contain a C-lectin domain 
(Aboshanif et al., 2016; Geng et al., 2017; Hara et al., 2015; Wakita et al., 2015) 
REG1B 
Lithostathine-1-alpha also known as islet cells 
regeneration factor (ICRF) or islet of Langerhans 
regenerating protein (REG) 
type I subclass of the REG family of genes 
(Liu et al., 2015; Usami et al., 2010) 
ALDOB See above  
COL3A1 Collagen alpha-1(III) chain 
 precursor to collagen III 
 connected to Ehlers-Danlos syndrome and aortic arterial aneruysms 
(Januchowski et al., 2016; Wang et al., 2016) 
POSTN Periostin 
 ligand for alpha-V/beta-3 and alpha-V/beta-5 integrins to support adhesion and migration 
of epithelial cells 
 secreted extracellular matrix protein 
 from the mesenchymal lineage 
 EMT 
 binds to integrins on cancer cells, activating the AKT/PKB-and FAK-mediated signalling 
pathways 
(Liu et al., 2017; Nitsche et al., 2016; Oh et al., 2017) 
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Appendix Table 8.5 Gene names, aliases and function of the top 5 downregulated targets of co-culture cells treated with BGJ. 
Gene name Full name Function 
AFP 
alpha-fetoprotein 
 
See above 
 
ALB Albumin 
 in human blood 
 produced in liver 
 transports hormones, fatty acids and other compounds, buffer pH and maintains oncotic 
pressure 
 transports drugs as well 
 down-regulated in inflammatory state 
(Alfarouk et al., 2015; Merlot et al., 2014) 
ANXA10 Annexin A10 
 calcium-dependent phospholipid-binding proteins 
 associated with vascular invasion 
(Liu et al., 2002) 
PIWIL1 See above  
UPK1B Uroplakin 1B 
 transmembrane 4 superfamily, also known as the tetraspanin family 
 cell-surface proteins 
(Olsburgh et al., 2003) 
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Appendix Table 8.6. Diseases identified with the DAVID database using OMI. 
 Significantly regulated genes (>-2, >2), (A) SNU-16 cells and (B) co-culture cells. 
 
 
 
Appendix Table 8.7. Diseases identified with the DAVID database using all genes in the datasets. 
SNU-16 cells and (B) co-culture cells. 
 
 
Appendix Table 8.8. KEGG in DAVID looking at all genes of SNU-16 cells alone and co-culture cells. 
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8.3 Appendix chapter IX Results part III 
8.3.1 Retinol pathway 
 
Appendix Figure 8.44. MFE-296 cells treated with ATRA and BGJ.  
Additional replicates and inclusion of all cells in the analysis. The error bars indicate SEM. 
 
 
 
Appendix Figure 8.45. SNU-16 cells treated with ATRA. 
SNU-16 cells were seeded into 6 well-plates and and treated with vehicle, ATRA, BGJ or a combination 
of ATRA and BGJ. After 72h cells were harvested and stained with DAPI and cell cycle was analysed 
using FACS. The error bars indicate SEM. 
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Appendix Figure 8.46. ATRA in SNU-16 potentially induces a decrease in G1 subpopulations.  
Gastric SNU-16 cancer cells were plated into 6-well plates and treated with 1µM ATRA and 1.5µM BGJ 
and corresponding vehicle controls. After 72h cells were fixed in 70% Ethanol, followed by DAPI staining 
and cell cycle analysis using flow cytometry. Typical cell cycle profiles are shown for one of three 
individual biological replicates. The histogram shows the values indicating the average proportion of 
cells in G1 phase with y-axis indicating cell counts and x-axis DAPI staining. The error bars indicate 
SEM. 
 
 
Appendix Figure 8.47. SNU-16BGJR cells treated with ATRA. 
Additonal replicates of drug-resistant cells treated eith ATRA or in combination with BGJ, followed by 
cell cycle analysis with FACS.  
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Appendix Figure 8.48. SNU-16 cells undergo apoptosis upon BGJ treatment. 
SNU-16 and SNU-18BGJR cells were seeded into 6-well plates and treated with 500nM, 1µM, 1.5µM and 
DMSO. After 72h cells were stained with Annexin V and PI to measure apoptosis and necrosis in cells 
using flow cytometry in SNU-16 (A) and SNU-16BGJR (B) cells with the corresponding analysis (C). The 
experiment was performed once.  
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8.3.2 Sucrose and starch pathway 
 
Appendix Figure 8.49. SNU-16 cells are highly heterogeneous in cell populations.  
SNU-16 cells were seeded into 6 well-plates and grown in medium with either no glucose, 1, 2 or 4g/L 
glucose and either 500nM, 1µM and 1.5µM BGJ or vehicle control DMSO. After 72h cells were fixed in 
70% Ethanol, followed by PI staining and cell cycle analysis using flow cytometry. 
 
 
Appendix Figure 8.50. SNU-16BGJR cell cycle analysis treated with different glucose concentrations. 
Additional replicates. 
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Appendix Figure 8.51. SNU-16 cells have a reduced AKT phosphorylation with higher sucrose 
concentrations. 
SNU-16 cells were exposed to medium containing 0, 1, 2 and 4g/L sucrose and grown for 72h followed 
by Western blot analysis. Protein expression of p-AKT, t-AKT, p-ERK, t-ERK and housekeeping gene 
HSC70 was analysed. This blot is representative of two individual experiments. 
 
 
 
 
Appendix Figure 8.52. SNU-16 cells and SNU-16BGJR cells treated with Acarbose. 
SNU-16 and SNU-16BGJR cells were seeded into 96-well plates and treated with increasing dosages of 
acarbose ranging from 0.006nM to 50µM and control cells were treated with DMSO and as a background 
control 1% Staurosporine was added to wells containing cells. After 72h incubation, MTS reagent was 
added and cell viability was measured colorimetrically after 2h. An average of three biological MTS 
experiments in technical triplicate is shown with error bars indicating SEM. 
 
 
Appendix Figure 8.53. BGJ, Acarbose and TDZD-8 treatment of H520 cells. 
H520 cells were seeded into 96-well plates and treated with increasing dosages of acarbose and TDZD-
8 ranging from 0.006nM to 50µM and control cells were treated with DMSO and as a background control 
1% Staurosporine was added to wells containing cells. After 72h incubation, MTS reagent was added 
and cell viability was measured colorimetrically after 2h. An average of three biological MTS 
experiments in technical triplicate is shown with error bars indicating SEM. 
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Appendix Figure 8.54. SI expression in SNU-16 and SNU-16BGJR cells grown in medium with altered 
Sucrose levels and treated with Acarbose. 
As a positive control, protein lysates from Caco-2 cells were used, which express high SI levels. 
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Appendix Figure 8.55. Acarbose treatment of BGJ-resistant SNU-16 cells.  
Additional replicates. 
 
 
 
Appendix Figure 8.56. Additonal sucrose concentrations of parental SNU-16 cells treated with sucrose 
and acarbose. 
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Appendix Figure 8.57. Additonal replicates of parental SNU-16 cells treated with sucrose and 
acarbose. 
 
Appendix Figure 8.58. Additonal replicates of parental SNU-16 cells treated with sucrose and 
acarbose. 
Appendix Figures and Tables Results Part III 
406 
 
 
 
 
Appendix Figure 8.59. Additional sucrose concentrations for Annexin V staining of SNU-16BGJR cells. 
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Appendix Figure 8.60. TDZD-8 treatment of parental and BGJ-resistant cells does not affect apoptosis 
or necrosis. 
Parental and drug-resistant SNU-16 cells were plated into 6-well plates and grown in presence of 1.6, 3 
and 6.3µM TDZD-8 for 72h followed by fixation in 70% Ethanol. Apoptotic and necrotic cells were 
identified by staining with Annexin V and PI. Error bars indicate SEM. The experiment was performed 
in biological triplicate. 
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Appendix Figure 8.61. Additonal replicates of gastric cancer cells treated with TDZD-8. 
  
Appendix Figures and Tables Results Part III 
409 
 
 
 
Appendix Figure 8.62. Additional replicates of BGJ-resistant cells treated with Acarbose or Sucrose 
and TDZD-8. 
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Appendix Figure 8.63. Plasmid sequence map with KOZAK cassette containing PIWIL1. 
 
 
Appendix Figure 8.64. PIWIL1 overexpression in SNU-16 and SNU-16BGJR cells with Lipofectamine®. 
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Appendix Figure 8.65. REG1A staining of Alvetex® sections. 
Alvetex® scaffold sections of SNU-16 cells and SNU-16 cells co-cultured with HFF2 cells and either 
treated with vehicle or rendered resistant to BGJ were stained with REG1A antibody and the slides were 
imaged. Scale bar on the left indicates 1000µm and on the right 100µm. 
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Appendix Figure 8.66. REG1A knockdown of SNU-16BGJR cells. 
Cells were seeded into 30mm dishes and transfected with lentiviral particles containing plasmids with 
REG1A shRNAs and grown in puromycin to select for cells containing the plasmid. Cells were then 
seeded into 6-well plates protein was extracted to perform Western blot analysis loading 20µM protein 
in each lane.  
 
 
 
 
Appendix Figure 8.67. REG1A knockdown in SNU-16BGJR cells.  
Cells were seeded into 30mm dishes and transfected with lentiviral particles containing plasmids with 
REG1A shRNAs and grown in puromycin to select for cells containing the plasmid. Cells were then 
seeded into 6-well plates protein was extracted to perform Western blot analysis loading 20µM protein 
in each lane. The blots were tested with a REG1A antibody from Tanja Crnogorac-Jurcevic’s group. 
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Appendix Figure 8.68. FACS sorting of drug-resistant cells with REG1A knock-down. 
Drug-resistant gastric cancer cells and fibroblasts treated with different shRNAs were seeded into 
Alvetex® scaffolds and grown for one week following cell extraction from scaffolds. Cells were the sorted 
into RFP and GFP-positive cells and percentages of cells in the samples of untreated and shRNA treated 
cells were compared. 
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Appendix Figure 8.69. REG1A shRNA knockdown in SNU-16BGJR cells and HFF2. 
SNU-16BGJR and HFF2 cells were transfected with three different shRNAs for REG1A and grown in 
Alvetex® scaffolds, followed by H&E staining prior to scanning of the sections. Scale bar indicates 100µm. 
 
 
 
Appendix Figure 8.70. REG1A staining of SNU-16BGJR cells together with fibroblasts REG1A shRNA 
knockdown. 
SNU-16BGJR and HFF2 cells were transfected with three different shRNAs for REG1A and grown in 
Alvetex® scaffolds, followed by REG1A staining prior to scanning of the sections. Scale bar indicates 
100µm. 
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Appendix Figure 8.71. REG1A knockdown in SNU-16BGJR and HFF2 cells in Alvetex®. 
SNU-16BGJR and HFF2 cells with three different shRNA knockdowns were seeded into Alvetex® scaffolds 
2:1 and grown with microscopic acquisition and Imaris analysis at week 1 (A) and week 2 (B). Three 
microscopic images per scaffold were acquired with 50 Z-stacks per image. Scale bar indicates 100µm. 
From the Imaris images, cell volumes were plotted and SNU-16 cell volume values were compared from 
week 1 (Ci) to values from week 2 (Cii). Additionally cell volumes of HFF2 cells at week 2 were plotted 
(Cii). Error bars indicate SEM. The scale bar indicates 100µm. 
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Appendix Figure 8.72. Drug-resistant co-culture cells do not show increased lipid deposits. 
SNU-16 cells were grown alone (A) or in co-culture with HFF2 cells (B) and either treated with vehicle 
or made resistant to BGJ. Once resistant cell populations were observed with live cell imaging, scaffolds 
were fixed, paraffin-embedded and sectioned. The sections were then stained with Oil red O to stain 
lipid deposits. Scale bar on the left indicates 2000µm and on the right 100µm. 
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8.3.3 Additonal regulated genes in mono- and co-culture cells 
 
 
 
Appendix Figure 8.73. PHLDA1 expression is decreased in AZD-resistant endometrial cancer cells.  
MFE-296 or MFE-296AZDR cells were seeded into 6-well plates and incubated for 72h. Protein was 
extracted and Western blot analysis was performed probing for PHLDA1, p-AKT, t-AKT, p-ERK, t-ERK 
and GAPDH and HSC70 as loading controls. The blots represent three biological replicates. 
 
 
 
Appendix Figure 8.74. Protein expression levels of parental and drug-resistant SNU-16 cells. 
Protein of parental and drug-resistant SNU-16 cells was extracted and probed for, FGFR2, p-AKT, t-
AKT, DUSP6, PHLDA1, p-ERK, t-ERK and HSC70 as a loading control. The blots represent three 
individual experiments. 
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Appendix Figure 8.75. ERK and PI3K inhibitor treatment of MFE-296 cells. 
Additional replicates of Western blots of endometrial MFE-296 cells treated with PI3K inhibitor ZSTK, 
ERK inhibitor U0126 or vehicle for 72h. Protein was extracted and probed for PHLDA1, p-AKT, t-AKT, 
p-ERK, t-ERK and HSC70 as a loading control. 
 
 
Appendix Figure 8.76. AN3CA 24h AZD. 
AN3CA cells were seeded into 6-well plates and treated with vehicle or AZD. Cells were harvested after 
1, 4, 8, or 24 hours. Protein was extracted and expression levels were measured for p-AKT, PHLDA1, p-
ERK and HSC70 as a loading control. 
 
 
Appendix Figure 8.77. Time course of MFE-296 cells treated with PD. 
MFE-296 cells were seeded into 6-well plates and treated with vehicle or PD. Cells were harvested after 
1, 4, 8, 24 and 48 hours. Protein was extracted and expression levels were measured for p-AKT, PHLDA1, 
p-ERK and HSC70 as a loading control. 
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Appendix Figure 8.78. Time course of MFE-296 cells treated with AZD. 
MFE-296 cells were seeded into 6-well plates and treated with vehicle or AZD. Cells were harvested after 
1, 4, 8 or 24 hours. Protein was extracted and expression levels were measured for p-AKT, PHLDA1, p-
ERK and HSC70 as a loading control. 
 
 
Appendix Figure 8.79. PHLDA1 reappears after one week FGFR inhibition. 
Additional replicates of endometrial AN3CA cancer cells treated with FGFR inhibitor PD for one week. 
Protein was extracted and probed for p-AKT, PHLDA1, p-ERK or HSC70 as a loading control. 
 
 
 
Appendix Figure 8.80. PHLDA1 knockdown in MFE-296 cells 
PHLDA1 was knocked down in FGFR2-mutated lung cancer cells MFE-296 using three different shRNAs 
towards PHLDA1. As a control, cells were transduced with a scrambled shRNA (UT). Protein was 
extracted and expression levels of PHLDA1, and HSC70 as a control, were measured. 
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Appendix Figure 8.81. PHLDA1 knockdown in MFE-296 cells confers resistance towards kinase 
inhibitors. 
MFE-296 cells with PHLDA1 scrambled treated with 1µM AZD and vehicle. (B) MFE-296 cells with 
PHLDA1 shRNA knockdown treated with 1µM AZD and vehicle. (C) MFE-296 and HFF2 cells with 
PHLDA1 scrambled treated with 1µM AZD and vehicle. (D) MFE-296 and HFF2 cells with PHLDA1 
knockdown treated with 1µM AZD and vehicle. (E) HFF2 cells treated with vehicle and AZD. (F) MFE-
296 cells with PHLDA1 scrambled or PHLDA1 knockdown and treated with 1µM PD. (G) MFE-296 and 
HFF2 cells with PHLDA1 scrambled or PHLDA1 knockdown and treated with 1µM PD. (H) HFF2 cells 
treated with vehicle and PD. Scale bar on the whole scaffold image indicates 2000µm and on the 
magnified image 100µm. 
